
<html lang="en"     class="pb-page"  data-request-id="0d35142e-7ae1-4a13-9877-6e5df98b3921"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2020.63.issue-3;article:article:10.1021/acs.jmedchem.9b01886;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B" /></meta><meta name="dc.Creator" content="Damijan  Knez" /></meta><meta name="dc.Creator" content="Natalia  Colettis" /></meta><meta name="dc.Creator" content="Luca G.  Iacovino" /></meta><meta name="dc.Creator" content="Matej  Sova" /></meta><meta name="dc.Creator" content="Anja  Pišlar" /></meta><meta name="dc.Creator" content="Janez  Konc" /></meta><meta name="dc.Creator" content="Samo  Lešnik" /></meta><meta name="dc.Creator" content="Josefina  Higgs" /></meta><meta name="dc.Creator" content="Fabiola  Kamecki" /></meta><meta name="dc.Creator" content="Irene  Mangialavori" /></meta><meta name="dc.Creator" content="Ana  Dolšak" /></meta><meta name="dc.Creator" content="Simon  Žakelj" /></meta><meta name="dc.Creator" content="Jurij  Trontelj" /></meta><meta name="dc.Creator" content="Janko  Kos" /></meta><meta name="dc.Creator" content="Claudia  Binda" /></meta><meta name="dc.Creator" content="Mariel  Marder" /></meta><meta name="dc.Creator" content="Stanislav  Gobec" /></meta><meta name="dc.Description" content="The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent correlations of this enzymatic activity with cardiovascular, neurological, and oncological disorders. This has prom..." /></meta><meta name="Description" content="The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent correlations of this enzymatic activity with cardiovascular, neurological, and oncological disorders. This has prom..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 9, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01886" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01886" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01886" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01886" /></link>
        
    
    

<title>Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01886" /></meta><meta property="og:title" content="Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0014.jpeg" /></meta><meta property="og:description" content="The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent correlations of this enzymatic activity with cardiovascular, neurological, and oncological disorders. This has promoted increased research into selective MAO-A and MAO-B inhibitors. Here, we shed light on how selective inhibition of MAO-A and MAO-B can be achieved by geometric isomers of cis- and trans-1-propargyl-4-styrylpiperidines. While the cis isomers are potent human MAO-A inhibitors, the trans analogues selectively target only the MAO-B isoform. The inhibition was studied by kinetic analysis, UV–vis spectrum measurements, and X-ray crystallography. The selective inhibition of the MAO-A and MAO-B isoforms was confirmed ex vivo in mouse brain homogenates, and additional in vivo studies in mice show the therapeutic potential of 1-propargyl-4-styrylpiperidines for central nervous system disorders. This study represents a unique case of stereoselective activity of cis/trans isomers that can discriminate between structurally related enzyme isoforms." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01886"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01886">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01886&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01886&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01886&amp;href=/doi/10.1021/acs.jmedchem.9b01886" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 1361-1387</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01721" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01931" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Damijan Knez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Damijan Knez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Damijan++Knez">Damijan Knez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Natalia Colettis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Natalia Colettis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, and Instituto de Química y Fisicoquímica Biológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Natalia++Colettis">Natalia Colettis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luca G. Iacovino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luca G. Iacovino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biology and Biotechnology, University of Pavia, Via Ferrata 1, 27100 Pavia, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luca+G.++Iacovino">Luca G. Iacovino</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matej Sova</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matej Sova</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matej++Sova">Matej Sova</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anja Pišlar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anja Pišlar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anja++Pi%C5%A1lar">Anja Pišlar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Janez Konc</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Janez Konc</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Chemistry, Hajdrihova 19, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Janez++Konc">Janez Konc</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samo Lešnik</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samo Lešnik</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Institute of Chemistry, Hajdrihova 19, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samo++Le%C5%A1nik">Samo Lešnik</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Josefina Higgs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Josefina Higgs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, and Instituto de Química y Fisicoquímica Biológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Josefina++Higgs">Josefina Higgs</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fabiola Kamecki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fabiola Kamecki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, and Instituto de Química y Fisicoquímica Biológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fabiola++Kamecki">Fabiola Kamecki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Irene Mangialavori</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Irene Mangialavori</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, and Instituto de Química y Fisicoquímica Biológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Irene++Mangialavori">Irene Mangialavori</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ana Dolšak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ana Dolšak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ana++Dol%C5%A1ak">Ana Dolšak</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon Žakelj</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon Žakelj</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon++%C5%BDakelj">Simon Žakelj</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jurij Trontelj</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jurij Trontelj</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jurij++Trontelj">Jurij Trontelj</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Janko Kos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Janko Kos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Janko++Kos">Janko Kos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claudia Binda</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claudia Binda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biology and Biotechnology, University of Pavia, Via Ferrata 1, 27100 Pavia, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>C.B.: e-mail, <a href="/cdn-cgi/l/email-protection#6407080511000d054a060d0a000524110a0d14124a0d10"><span class="__cf_email__" data-cfemail="e3808f8296878a82cd818a8d8782a3968d8a9395cd8a97">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claudia++Binda">Claudia Binda</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2038-9845" title="Orcid link">http://orcid.org/0000-0003-2038-9845</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mariel Marder</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mariel Marder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, and Instituto de Química y Fisicoquímica Biológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina</div></div><span class="conrtib-corresp"><strong>*</strong>M.M.: e-mail, <a href="/cdn-cgi/l/email-protection#bdd0d0dccfd9d8cffdccdf93dbdbc4df93c8dfdc93dccf"><span class="__cf_email__" data-cfemail="096464687b6d6c7b49786b276f6f706b277c6b6827687b">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mariel++Marder">Mariel Marder</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Stanislav Gobec</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stanislav Gobec</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</div></div><span class="conrtib-corresp"><strong>*</strong>S.G.: e-mail, <a href="/cdn-cgi/l/email-protection#e49790858a8d97888592ca838b868187a4828285ca918a8dc9888eca978d"><span class="__cf_email__" data-cfemail="f28186939c9b819e9384dc959d909791b2949493dc879c9bdf9e98dc819b">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stanislav++Gobec">Stanislav Gobec</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9678-3083" title="Orcid link">http://orcid.org/0000-0002-9678-3083</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01886&amp;href=/doi/10.1021%2Facs.jmedchem.9b01886" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 1361–1387</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 9, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 November 2019</li><li><span class="item_label"><b>Published</b> online</span>9 January 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 February 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01886" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01886</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01886"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2400</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">11</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01886" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Damijan&quot;,&quot;last_name&quot;:&quot;Knez&quot;},{&quot;first_name&quot;:&quot;Natalia&quot;,&quot;last_name&quot;:&quot;Colettis&quot;},{&quot;first_name&quot;:&quot;Luca&quot;,&quot;last_name&quot;:&quot;G. Iacovino&quot;},{&quot;first_name&quot;:&quot;Matej&quot;,&quot;last_name&quot;:&quot;Sova&quot;},{&quot;first_name&quot;:&quot;Anja&quot;,&quot;last_name&quot;:&quot;Pišlar&quot;},{&quot;first_name&quot;:&quot;Janez&quot;,&quot;last_name&quot;:&quot;Konc&quot;},{&quot;first_name&quot;:&quot;Samo&quot;,&quot;last_name&quot;:&quot;Lešnik&quot;},{&quot;first_name&quot;:&quot;Josefina&quot;,&quot;last_name&quot;:&quot;Higgs&quot;},{&quot;first_name&quot;:&quot;Fabiola&quot;,&quot;last_name&quot;:&quot;Kamecki&quot;},{&quot;first_name&quot;:&quot;Irene&quot;,&quot;last_name&quot;:&quot;Mangialavori&quot;},{&quot;first_name&quot;:&quot;Ana&quot;,&quot;last_name&quot;:&quot;Dolšak&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Žakelj&quot;},{&quot;first_name&quot;:&quot;Jurij&quot;,&quot;last_name&quot;:&quot;Trontelj&quot;},{&quot;first_name&quot;:&quot;Janko&quot;,&quot;last_name&quot;:&quot;Kos&quot;},{&quot;first_name&quot;:&quot;Claudia&quot;,&quot;last_name&quot;:&quot;Binda&quot;},{&quot;first_name&quot;:&quot;Mariel&quot;,&quot;last_name&quot;:&quot;Marder&quot;},{&quot;first_name&quot;:&quot;Stanislav&quot;,&quot;last_name&quot;:&quot;Gobec&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;1361-1387&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01886&quot;},&quot;abstract&quot;:&quot;The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent correlations of this enzymatic activity with cardiovascular, neurological, and oncological disorders. This has promoted increased research into selective MAO-A and MAO-B inhibitors. Here, we shed light on how selective inhibition of MAO-A and MAO-B can be achieved by geometric isomers of cis- and trans-1-propargyl-4-styrylpiperidines. While the cis isomers are potent human MAO-A inhibitors, the trans analogues selectively target only the MAO-B isoform. The inhibition was studied by kinetic analysis, UV–vis spectrum measurements, and X-ray crystallography. The selective inhibition of the MAO-A and MAO-B isoforms was confirmed ex vivo in mouse brain homogenates, and additional in vivo studies in mice show the therapeutic potential of 1-propargyl-4-styrylpiperidines for central nervous system disorders. This study represents a unique case of stereoselective activity of cis/trans isomers that can discriminate between structurally re&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01886&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01886" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01886&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01886" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01886&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01886" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01886&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01886&amp;href=/doi/10.1021/acs.jmedchem.9b01886" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01886" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01886" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01886%26sid%3Dliteratum%253Aachs%26pmid%3D31917923%26genre%3Darticle%26aulast%3DKnez%26date%3D2020%26atitle%3DStereoselective%2BActivity%2Bof%2B1-Propargyl-4-styrylpiperidine-like%2BAnalogues%2BThat%2BCan%2BDiscriminate%2Bbetween%2BMonoamine%2BOxidase%2BIsoforms%2BA%2Band%2BB%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D3%26spage%3D1361%26epage%3D1387%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (8)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/jmcmar.2020.63.issue-3/20200213/jmcmar.2020.63.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent correlations of this enzymatic activity with cardiovascular, neurological, and oncological disorders. This has promoted increased research into selective MAO-A and MAO-B inhibitors. Here, we shed light on how selective inhibition of MAO-A and MAO-B can be achieved by geometric isomers of <i>cis-</i> and <i>trans</i>-1-propargyl-4-styrylpiperidines. While the <i>cis</i> isomers are potent human MAO-A inhibitors, the <i>trans</i> analogues selectively target only the MAO-B isoform. The inhibition was studied by kinetic analysis, UV–vis spectrum measurements, and X-ray crystallography. The selective inhibition of the MAO-A and MAO-B isoforms was confirmed <i>ex vivo</i> in mouse brain homogenates, and additional <i>in vivo</i> studies in mice show the therapeutic potential of 1-propargyl-4-styrylpiperidines for central nervous system disorders. This study represents a unique case of stereoselective activity of <i>cis</i>/<i>trans</i> isomers that can discriminate between structurally related enzyme isoforms.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60857" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60857" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Specific interaction patterns and molecular geometry are critical factors that influence ligand binding affinity and ligand selectivity toward a target.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Numerous examples of “chiral switching” in drug development have highlighted the effects of spatial geometry on not only pharmacodynamics but also pharmacokinetics and toxicology of drugs.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> In addition to optical isomers, <i>cis</i> and <i>trans</i> isomers can have different pharmacological activities, as demonstrated by the well-known cases of cisplatin,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> tamoxifen,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and combretastatin A4 (CA-4).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> This last includes a stilbene motif in the <i>cis</i> conformation (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A), which efficiently binds to the colchicine binding site of tubulin and acts as a microtubule-destabilizing agent.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The binding of <i>trans</i>-combretastatin A4 (<i>trans</i>-CA-4, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A) to this site is thermodynamically less stable than that of <i>cis</i>-combretastatin A4 (<i>cis</i>-CA-4), and consequently the <i>trans</i> conformation does not prevent microtubule assembly.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> However, examples of stereoselective activities of <i>cis</i>/<i>trans</i> isomers are rare in comparison with optical isomers.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Stilbene derivatives and MAO inhibitory potencies. Chemical structures of <i>cis</i>/<i>trans</i>-combretastatin A4 (CA-4) (A) and hit inhibitor <b>1</b> (B) and <i>cis</i> isomer <b>6</b> (B). The stilbene core is blue, and the stilbene-like moiety of inhibitor <b>1</b> is red. (C) <sup>a</sup>IC<sub>50</sub> values are mean ± SEM values (<i>n</i> = 2, 3). <sup>b</sup>Selectivity ratio is defined as IC<sub>50</sub>(hMAO-A)/IC<sub>50</sub>(hMAO-B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Human monoamine oxidase A (hMAO-A) and human monoamine oxidase B (hMAO-B) are flavoenzymes that are encoded by separate genes on the X chromosome, and they share 70% sequence identity.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> They are differentiated by their substrate specificities and inhibitor sensitivities. This arises from the differences in the active site size and shape, and the altered amino acid residues between these isoforms. The hMAO-A and hMAO-B active sites are hydrophobic cavities with volumes of about 550 Å<sup>3</sup> and 700 Å<sup>3</sup>, respectively.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The active site of hMAO-B is flat and elongated, with a bipartite configuration, where Ile199 and Tyr326 are the gating residues that determine the shape of the cavity and the specificity of substrate/inhibitor binding.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> hMAO-A has a monopartite and more spherical active site, with Ile335 and Phe208 as the gating residues. MAOs catalyze the oxidative deamination of primary and some secondary amines, and they are responsible for neurotransmitter metabolism in peripheral tissues and in the central nervous system.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> This reaction produces an imino intermediate, which is spontaneously hydrolyzed to the corresponding aldehyde, with ammonia and hydrogen peroxide as side-products.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Reduced levels of neurotransmitters, increased activity and levels of MAOs, and the production of toxic metabolites are linked with various neurological,<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> psychological,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and cardiovascular disorders<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and cancers.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">MAO-A inhibitors have been widely used for several decades in the therapy of depression and affective disorders.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> On the other hand, selective MAO-B inhibitors are used as monotherapies in the early stages of Parkinson’s disease and as add-on therapy to levodopa in advanced forms of Parkinson’s disease.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> MAO-A and MAO-B are recognized as validated targets. In terms of their contribution to increased cellular oxidative stress,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> novel inhibitors are emerging as important disease-modifying therapeutic agents in such devastating neurodegenerative diseases as Alzheimer’s disease and a number of others.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p last">To the best of our knowledge, <i>cis</i>/<i>trans</i> isomerisms of double bonds have never been used to achieve stereoselective inhibition of MAO isoforms. Here, we demonstrate a unique case study whereby configuration of the double bond in stilbene-like derivatives can define the selectivity for either MAO-A or MAO-B. We identify 1-propargyl-4-((<i>E</i>)-styryl)-piperidines as potent, selective, and irreversible hMAO-B inhibitors. <i>Cis</i> analogues with small substituents on the phenyl ring selectively inhibit hMAO-A. These inhibitors were evaluated for their MAO inhibitory activities and pharmacological properties.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02373" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02373" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="secz" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Identification, Design, Synthesis, and Selectivity Profile of Potent and Selective hMAO-A and hMAO-B Inhibitors</h3><div class="NLM_p">Compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B) contains a stilbene-like motif, and it was identified as a hit inhibitor in an in-house library screening campaign. Indeed, compound <b>1</b> is a potent selective hMAO-B inhibitor, with no significant inhibition of hMAO-A at 100 μM (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C).</div><div class="NLM_p">This hit inhibitor was resynthesised using an efficient and straightforward synthesis (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) that started from readily available isonipecotic acid, which was transformed into Weinreb’s amide <b>2</b> and subsequently reduced to obtain aldehyde <b>3</b>. The aldehyde then underwent the Wittig reaction with phosphonium ylide to yield a mixture of <i>cis</i> (<b>4</b>) and <i>trans</i> (<b>5</b>) Boc-protected piperidines, which were separated using column chromatography. Following acidolysis, the corresponding secondary amine was reacted with propargyl bromide to obtain hit compound <b>1</b> and the <i>cis</i> isomer <b>6</b>. Compound <b>6</b> showed preferential inhibition of hMAO-A over hMAO-B (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Resynthesis of Hit Inhibitor <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 1) Boc<sub>2</sub>O, 1.0 M NaOH, 1,4-dioxane, 0 °C, rt, 1 h (91%); 2) <i>N</i>,<i>O</i>-dimethyhydroxylamine hydrochloride, Et<sub>3</sub>N, TBTU, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, overnight (76%); (ii) LiAlH<sub>4</sub>, anh THF, 0 °C, 1 h (crude product, 83%); (iii) (4-fluorobenzyl)triphenylphosphonium bromide, sodium bis(trimethylsilyl)amide (NaHMDS, 2 N in THF), anh THF, Ar(g), rt, overnight (52%); (iv) (1) 4.0 M HCl in 1,4-dioxane, 80 °C, 2 h (100%); (2) propargyl bromide (80% solution in toluene), Cs<sub>2</sub>CO<sub>3</sub>, DMF, Ar(g), 0 °C, rt, overnight (yield, <b>1</b>, 26%; <b>6</b>, 72%).</p></p></figure><div class="NLM_p">The selectivity profile was explained through analysis of the binding cavity using the Caver tool.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Human (h)MAO-A (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) has a wide cavity at the active site near the FAD cofactor (<i>r</i> = 2.1 Å), which is lined with Tyr407, Phe352, and Gly215. In the direction toward the entrance, the cavity widens (<i>r</i> ≃ 2.5 Å) and remains wide to Val210, Gln215, and Ile335, and then it narrows to Val210, Cys323, and Ile335 (<i>r</i> = 1.9 Å) and remains narrow to the entrance, which is also the narrowest part of the active site (<i>r</i> = 1.9 Å) and is composed of Leu97, Gly110, and Val210. In hMAO-B (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B), the entrance is even wider in the active site near the FAD cofactor (<i>r</i> = 2.3 Å), with Gln206, Tyr398, and Tyr435, but then narrows in the direction of the entrance (<i>r</i> = 1.9 Å) at Leu171 and Ile199 and then widens again (<i>r</i> = 2.5 Å) to Ile199, Ile316, and Tyr326. The narrowest part is at the entrance (<i>r</i> = 1.6 Å), and it is composed of Glu84, Pro102, and Ser200. The hMAO-A active site entrance is thus significantly wider (<i>r</i> = 1.9 Å) than the hMAO-B active site entrance (<i>r</i> = 1.6 Å). Both entrances are also the bottlenecks, which indicates that the active site of hMAO-B might be more difficult to reach by wider ligands.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Active sites of hMAO-A (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z5X">2Z5X</a>) and hMAO-B (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FVZ">6FVZ</a>). (A) MAO-A; FAD cofactor (green sticks); active site (red surface) spans from FAD to the entrance; bottleneck residues Leu97, Gly110, and Val210 at the entrance (salmon sticks). (B) MAO-B; FAD cofactor (green sticks); active site (violet surface) spans from FAD to the entrance; bottleneck residues Glu84, Pro102, and Ser200 at the entrance (purple sticks).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The active site of hMAO-B is also significantly more curved than the active site of hMAO-A, with a bend of 90°, while in hMAO-A, the cavity bends at an angle of ∼60° (compare <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A,B). The narrow entrance of hMAO-B and the higher curvature might prevent the relatively wider <i>cis</i> isomer <b>6</b> from entering the hMAO-B binding site. Indeed, <b>6</b> has a maximum width of 4.1 Å when measured as the height of the triangle composed of the fluorine atom, one of the sp<sup>2</sup> carbons, and the carbon bonded to the nitrogen, while the maximum width of the <i>trans</i> isomer <b>1</b> is only 2.5 Å when measured as the distance between two opposing carbon atoms in the piperidine ring. The <i>cis</i> isomer thus appears to inhibit hMAO-A but not hMAO-B because it is too wide to enter the narrower hMAO-B entrance. Its maximum width is only slightly greater than the 3.8 Å diameter of the hMAO-A entrance, while it is significantly greater than the 3.2 Å diameter of the hMAO-B entrance, which suggests that the hMAO-B entrance would need to undergo more substantial conformational changes to accommodate the <i>cis</i> isomer <b>6</b>. The active site loop in hMAO-A contains Gly (i.e., Gly110), which is replaced by Pro102 in hMAO-B. This produces much higher rigidity in comparison to hMAO-A, where the active site loop is more flexible. This lack of flexibility of hMAO-B adds to the restricted access of the <i>cis</i> isomer to the hMAO-B active site. The <i>cis</i> isomer <b>6</b> inactivity against hMAO-B thus appears to be caused by steric hindrance in the active site, compound <b>6</b> being unable to fit into the elongated and rigid cavity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><div class="NLM_p">However, the selectivity of the <i>trans</i> isomer <b>1</b> is not explained only by the analysis of its access to the active site, as <i>trans</i> isomer <b>1</b> can bind to both hMAO-A and hMAO-B. To simulate the transport process of the inhibitor from the active site to the surface of the protein, these two isomers were undocked from hMAO-A and hMAO-B using the CaverDock software.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Starting from the docked conformations of both ligands at the active sites, the energetically most favorable trajectories of the ligands to the protein surfaces were investigated (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). In hMAO-A, <i>cis</i> isomer <b>6</b> is oriented with the propargyl group facing the FAD cofactor, with a binding energy of −8.3 kcal/mol (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_002.mp4" class="ext-link">movie file jm9b01886_si_002.mp4 in Supporting Information</a> ). As <i>cis</i> isomer <b>6</b> moves toward the entrance, its energy peaks at 0.4 kcal/mol and then falls to −3.8 kcal/mol at the entrance (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). <i>Trans</i> isomer <b>1</b> in the correct orientation has a binding energy of −6.2 kcal/mol (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C), which is higher than for <b>6</b>. As the <i>trans</i> isomer is undocked, its binding energy peaks at −3.4 kcal/mol and then falls to −4.1 kcal/mol at the entrance (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). Further, the <i>trans</i> ligand in the “wrong” orientation in the active site (i.e., with the fluorophenyl group facing the FAD cofactor) has a much lower energy of −10.1 kcal/mol (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D; lower-bounds energy curve). However, in this orientation, the <i>trans</i> ligand cannot form the covalent bond with FAD. Thus, in agreement with the experimental findings, the computational undocking simulation of hMAO-A showed that <i>cis</i> isomer <b>6</b> has lower binding energy at the active site than <i>trans</i> isomer <b>1</b>, which indicates that the <i>cis</i> isomer is more likely to bind to hMAO-A than the <i>trans</i> isomer. In addition, the <i>trans</i> isomer might preferentially access the active site in an orientation that does not allow formation of the covalent bond, as can be seen by the lower binding energy of the “wrong” conformation compared to the energy of the correctly oriented <i>trans</i> isomer. This noncovalent only binding of the <i>trans</i> isomer might lead to the worse performance observed experimentally of this inhibitor with hMAO-A.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Undocking of <i>trans</i> (<b>1</b>) and <i>cis</i> (<b>6</b>) isomers in hMAO-A and hMAO-B. (A) Docked <b>6</b> in hMAO-A: <i>cis</i> isomer (yellow sticks) with propargyl group facing the FAD cofactor (green sticks), with binding energy of −8.3 kcal/mol; bottleneck residues at the active site entrance at the back (salmon sticks). (B) Energy profile for undocking of <b>6</b> from active site of hMAO-A in the correct conformation (propargyl facing FAD). (C) Docked <b>1</b> in hMAO-A: <i>trans</i> isomer (violet sticks) with propargyl group facing the FAD cofactor (green sticks), with binding energy of −6.2 kcal/mol; bottleneck residues at active site entrance at the back (salmon sticks). (D) Energy profile for undocking of <b>1</b> from active site of hMAO-A. (E) Docked <b>6</b> in hMAO-B: <i>cis</i> isomer (gray sticks) with propargyl group facing FAD cofactor (green sticks), with binding energy of −6.5 kcal/mol; bottleneck residues at entrance at the back (violet sticks). (F) Energy profile for undocking of <b>6</b> from active site of hMAO-B. (G) Docked <b>1</b> in hMAO-B: <i>trans</i> isomer (purple sticks) with propargyl group facing FAD cofactor (green sticks), with binding energy of −7.4 kcal/mol; bottleneck residues at entrance at the back (violet sticks). (H) Energy profile for undocking of <b>1</b> from active site of hMAO-B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In hMAO-B, the docked <i>cis</i> ligand <b>6</b> in the correct orientation in the active site has energy of −6.5 kcal/mol (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>E; <a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_003.mp4" class="ext-link">movie file jm9b01886_si_003.mp4 in Supporting Information</a>). No energy peaks were observed along the active site for this isomer, whereby the energy reaches a plateau of 4.6 kcal/mol near the active site entrance (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>F). <i>Trans</i> isomer <b>1</b> in the correct orientation has the energy of −7.4 kcal/mol (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>G; <a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_003.mp4" class="ext-link">movie file jm9b01886_si_003.mp4 in Supporting Information</a>), which is lower than the energy of the <i>cis</i> isomer, and then this falls further to −8.2 kcal/mol at the lowest point on the way out of the entrance (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>H). The energy barrier to reach the active site is lower for the <i>trans</i> isomer than it is for the <i>cis</i> isomer, with the highest peak of 1.5 kcal/mol near the entrance, which is lower than the 4.6 kcal/mol energy barrier for the <i>cis</i> isomer. This lower energy barrier of the <i>trans</i> isomer at the entrance might be explained by the smaller maximum width of the <i>trans</i> isomer compared to the <i>cis</i> isomer, as discussed above. We also note that the docked <i>trans</i> inhibitor position in the active site has a root-mean-square deviation of 2.1 Å, compared to the cocrystal structure of inhibitor <b>1</b> in hMAO-B reported in the present study (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKB">6RKB</a>). This indicates that the docking successfully predicted the positioning of this inhibitor in the active site. In agreement with the experimental findings, the lower binding energies at the active site for the <i>trans</i> isomer and the lower energy barrier to reach the active site for the <i>trans</i> isomer indicate that the binding of <i>trans</i> isomer <b>1</b> to hMAO-B is favored compared to the binding of <i>cis</i> isomer <b>6</b>.</div><div class="NLM_p">The distinct activity of this geometric isomer pair prompted us to study the structure–activity relationships (SARs) through the construction of a focused library of substituted piperidines (<b>19</b>–<b>26</b>; <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) to probe the effect of piperidine disubstitution pattern on the inhibitory potency. 1,4-Disubstituted piperidines were the most tolerated and showed the highest selectivity for both hMAO-A and hMAO-B, and thus several analogues with various substituents on the phenyl ring were synthesized (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, compounds <b>67</b>–<b>107</b>).</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Inhibitors <b>19</b>–<b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 1) Boc<sub>2</sub>O, 1.0 M NaOH, 1,4-dioxane, 0 °C, rt, 1–3 h (86–91%); (2) <i>N</i>,<i>O</i>-dimethyhydroxylamine hydrochloride, Et<sub>3</sub>N, TBTU, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, overnight (76–82%); (ii) LiAlH<sub>4</sub>, anh THF, 0 °C, 1–2 h (crude products, 79–83%); (iii) corresponding Wittig salts ((4-fluorobenzyl)triphenylphosphonium bromide or (2,4,5-trifluorobenzyl)triphenylphosphonium bromide), NaHMDS (2 N in THF), anh THF, Ar(g), rt, overnight (overall yield for both isomers combined, 47–56%); (iv) corresponding mixture of <i>cis</i> and <i>trans</i> isomer (<b>9</b>–<b>14</b>), H<sub>2</sub>(g), Pd/C, EtOH, rt, overnight (97–100%); (v) (1) 4.0 M HCl in 1,4-dioxane, 80 °C, 2 h (100%); (2) propargyl bromide (80% solution in toluene), Cs<sub>2</sub>CO<sub>3</sub>, DMF, Ar(g), 0 °C, rt, overnight (26–85%).</p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Inhibitors <b>67</b>–<b>107</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) benzyl halide, PPh<sub>3</sub>, MeCN, 85 °C, overnight (80–97%); (ii) corresponding Wittig salts (<b>27a</b>–<b>l</b>), NaHMDS (2 N in THF)/KHMDS (0.5 M in toluene), anh THF, Ar(g), rt, overnight (overall yield, 30–66%); (iii) mixture of <i>cis</i> and <i>trans</i> isomers (<b>28</b>–<b>55</b>), H<sub>2</sub>(g), Pd/C, EtOH, rt, overnight (83–100%); (iv) (1) 4.0 M HCl in 1,4-dioxane (or HCl in EtOH), 80 °C, 2 h (100%); (2) propargyl bromide (80% in toluene), K<sub>2</sub>CO<sub>3</sub>, MeCN, Ar(g), 0 °C, rt, overnight (6–89%); (v) cyclopropylboronic acid, K<sub>3</sub>PO<sub>4</sub>, tricyclohexylphosphine (20% in toluene), Pd(OAc)<sub>2</sub>, toluene, water, Ar(g), 100 °C, 3 h (78%); (vi) KOH, <i>t</i>BuOH, 90 °C, 12–24 h (42–63%); (vii) BBr<sub>3</sub> (1 M in CH<sub>2</sub>Cl<sub>2</sub>), toluene, Ar(g), – 20 °C, 1 h, rt, 1 h (57%).</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Potencies and Structures of Hit Compound <b>1</b> and All of the Synthesized Inhibitors and Positive Controls<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0013.gif" alt="" id="GRAPHIC-d7e1176-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">structure</th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> ± SEM [nM] or % RA ± SD at 100 μM</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">Pdp<a class="ref internalNav" href="#t1fn3" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">linker</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">hMAO-A</th><th class="colsep0 rowsep0" align="center">hMAO-B</th><th class="colsep0 rowsep0" align="center">selectivity ratio<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">60.2 ± 1.6%</td><td class="colsep0 rowsep0" align="left"><b>342.2 ± 22.4</b></td><td class="colsep0 rowsep0" align="left">>292</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left"><b>726.1 ± 26.9</b></td><td class="colsep0 rowsep0" align="left"><b>6221.5 ± 726.8</b></td><td class="colsep0 rowsep0" align="left">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>ethyl</i></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">76.9 ± 2.2%</td><td class="colsep0 rowsep0" align="left"><b>370.1 ± 37.3</b></td><td class="colsep0 rowsep0" align="left">>270</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">2,4,5-F</td><td class="colsep0 rowsep0" align="left"><b>5243.7 ± 323.4</b></td><td class="colsep0 rowsep0" align="left">66.5 ± 3.9%</td><td class="colsep0 rowsep0" align="left"><0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">2,4,5-F</td><td class="colsep0 rowsep0" align="left">81.2 ± 3.1%</td><td class="colsep0 rowsep0" align="left"><b>436.2 ± 11.7</b></td><td class="colsep0 rowsep0" align="left">>229</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">2,4,5-F</td><td class="colsep0 rowsep0" align="left">65.6 ± 4.4%</td><td class="colsep0 rowsep0" align="left"><b>216.4 ± 14.2</b></td><td class="colsep0 rowsep0" align="left">>462</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">1,3</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">91.0 ± 3.1%</td><td class="colsep0 rowsep0" align="left"><b>1469.5 ± 233.2</b></td><td class="colsep0 rowsep0" align="left">>68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">1,3</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">93.1 ± 3.2%</td><td class="colsep0 rowsep0" align="left"><b>7411.6 ± 1190.0</b></td><td class="colsep0 rowsep0" align="left">>13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">1,3</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">2,4,5-F</td><td class="colsep0 rowsep0" align="left">102.5 ± 5.2%</td><td class="colsep0 rowsep0" align="left"><b>2195.6 ± 228.3</b></td><td class="colsep0 rowsep0" align="left">>46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">1,3</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">2,4,5-F</td><td class="colsep0 rowsep0" align="left">86.0 ± 5.2%</td><td class="colsep0 rowsep0" align="left"><b>11229.4 ± 974.7</b></td><td class="colsep0 rowsep0" align="left">>9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><b>168.8 ± 8.5</b></td><td class="colsep0 rowsep0" align="left">79.1 ± 4.0%</td><td class="colsep0 rowsep0" align="left"><0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><b>32960.7 ± 3476.5</b></td><td class="colsep0 rowsep0" align="left"><b>3540.2 ± 611.8</b></td><td class="colsep0 rowsep0" align="left">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>93</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><b>75779.6 ± 7566.0</b><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"><b>4603.4 ± 371.1</b></td><td class="colsep0 rowsep0" align="left">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left"><b>68.4 ± 4.3</b></td><td class="colsep0 rowsep0" align="left"><b>48912.0 ± 2525.4</b></td><td class="colsep0 rowsep0" align="left">0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left"><b>6906.8 ± 860.2</b></td><td class="colsep0 rowsep0" align="left"><b>5048.7 ± 1224.6</b></td><td class="colsep0 rowsep0" align="left">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>94</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left"><b>19927.3 ± 1608.5</b></td><td class="colsep0 rowsep0" align="left"><b>3363.5 ± 310.5</b></td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left"><b>3013.7 ± 207.3</b></td><td class="colsep0 rowsep0" align="left">65.5 ± 0.3%</td><td class="colsep0 rowsep0" align="left"><0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left"><b>27293.2 ± 1758.4</b></td><td class="colsep0 rowsep0" align="left"><b>11830.4 ± 766.5</b></td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left"><b>5927.3 ± 223.8</b></td><td class="colsep0 rowsep0" align="left"><b>14159.5 ± 708.9</b></td><td class="colsep0 rowsep0" align="left">0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">2-Cl-4-F</td><td class="colsep0 rowsep0" align="left"><b>46121.5 ± 10141.6</b></td><td class="colsep0 rowsep0" align="left"><b>53000.5 ± 2662.5</b></td><td class="colsep0 rowsep0" align="left">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>74</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">2-Cl-4-F</td><td class="colsep0 rowsep0" align="left"><b>66028.4 ± 8419.0</b></td><td class="colsep0 rowsep0" align="left"><b>417.6 ± 46.9</b></td><td class="colsep0 rowsep0" align="left">158</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>75</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-Me</td><td class="colsep0 rowsep0" align="left">62.2 ± 4.4%</td><td class="colsep0 rowsep0" align="left"><b>19162.8 ± 5139.7</b></td><td class="colsep0 rowsep0" align="left">>5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>76</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-Me</td><td class="colsep0 rowsep0" align="left">57.3 ± 2.9%</td><td class="colsep0 rowsep0" align="left"><b>147.0 ± 13.8</b></td><td class="colsep0 rowsep0" align="left">>680</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>96</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">4-Me</td><td class="colsep0 rowsep0" align="left">68.1 ± 1.6%</td><td class="colsep0 rowsep0" align="left"><b>159.0 ± 13.3</b></td><td class="colsep0 rowsep0" align="left">>630</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>77</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-<i>i</i>Pr</td><td class="colsep0 rowsep0" align="left">83.2 ± 0.5%</td><td class="colsep0 rowsep0" align="left"><b>1883.9 ± 278.6</b></td><td class="colsep0 rowsep0" align="left">>53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-<i>i</i>Pr</td><td class="colsep0 rowsep0" align="left"><b>73638.2 ± 11010.1</b><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"><b>44.4 ± 8.2</b></td><td class="colsep0 rowsep0" align="left">1658</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>97</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">4-<i>i</i>Pr</td><td class="colsep0 rowsep0" align="left"><b>162399.3 ± 9715.9</b><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"><b>7.0 ± 2.2</b></td><td class="colsep0 rowsep0" align="left">23200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left"><b>118844.3 ± 26412.7</b><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"><b>11745.1 ± 555.9</b></td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>80</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">71.7 ± 0.2%</td><td class="colsep0 rowsep0" align="left"><b>50.4 ± 4.7</b></td><td class="colsep0 rowsep0" align="left">>1984</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>98</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">67.7 ± 0.0%</td><td class="colsep0 rowsep0" align="left"><b>38.1 ± 6.8</b></td><td class="colsep0 rowsep0" align="left">>2625</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>81</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-Br</td><td class="colsep0 rowsep0" align="left">54.5 ± 1.2%</td><td class="colsep0 rowsep0" align="left"><b>21.2 ± 4.2</b></td><td class="colsep0 rowsep0" align="left">>4717</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="left">56.1 ± 1.6%</td><td class="colsep0 rowsep0" align="left"><b>68.1 ± 11.1</b></td><td class="colsep0 rowsep0" align="left">>1468</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>99</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="left">62.2 ± 1.9%</td><td class="colsep0 rowsep0" align="left"><b>67.0 ± 11.4</b></td><td class="colsep0 rowsep0" align="left">>1493</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>83</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">80.1 ± 4.5%</td><td class="colsep0 rowsep0" align="left"><b>1506.6 ± 216.3</b></td><td class="colsep0 rowsep0" align="left">>66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>84</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">64.9 ± 0.5%</td><td class="colsep0 rowsep0" align="left"><b>18.6 ± 3.3</b></td><td class="colsep0 rowsep0" align="left">>5376</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>100</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">62.3 ± 0.7%</td><td class="colsep0 rowsep0" align="left"><b>10.9 ± 3.0</b></td><td class="colsep0 rowsep0" align="left">>9174</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left"><b>858.0 ± 29.2</b></td><td class="colsep0 rowsep0" align="left"><b>9352.5 ± 1512.9</b></td><td class="colsep0 rowsep0" align="left">0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>86</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">64.8 ± 4.0%</td><td class="colsep0 rowsep0" align="left"><b>549.7 ± 127.5</b></td><td class="colsep0 rowsep0" align="left">>182</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>101</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">71.6 ± 2.2%</td><td class="colsep0 rowsep0" align="left"><b>501.8 ± 107.1</b></td><td class="colsep0 rowsep0" align="left">>199</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>87</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-CN</td><td class="colsep0 rowsep0" align="left">68.1 ± 2.7%</td><td class="colsep0 rowsep0" align="left"><b>1745.3 ± 315.4</b></td><td class="colsep0 rowsep0" align="left">>57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>88</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-CN</td><td class="colsep0 rowsep0" align="left"><b>129064.0 ± 8079.7</b><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"><b>57.0 ± 7.1</b></td><td class="colsep0 rowsep0" align="left">2264</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>102</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">4-CN</td><td class="colsep0 rowsep0" align="left"><b>21478.3 ± 6280.3</b></td><td class="colsep0 rowsep0" align="left"><b>56.6 ± 8.7</b></td><td class="colsep0 rowsep0" align="left">379</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>89</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">70.6 ± 5.8%</td><td class="colsep0 rowsep0" align="left"><b>8444.7 ± 627.1</b></td><td class="colsep0 rowsep0" align="left">>12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>90</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">68.7 ± 0.2%</td><td class="colsep0 rowsep0" align="left"><b>32.7 ± 2.5</b></td><td class="colsep0 rowsep0" align="left">>3058</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>91</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-cyclopropyl</td><td class="colsep0 rowsep0" align="left"><b>7398.7 ± 661.8</b></td><td class="colsep0 rowsep0" align="left"><b>2640.1 ± 342.8</b></td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>92</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-cyclopropyl</td><td class="colsep0 rowsep0" align="left"><b>20564.5 ± 2315.8</b></td><td class="colsep0 rowsep0" align="left"><b>43.7 ± 6.4</b></td><td class="colsep0 rowsep0" align="left">471</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>103</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">4-propyl</td><td class="colsep0 rowsep0" align="left"><b>80305.3 ± 9033.0</b></td><td class="colsep0 rowsep0" align="left"><b>36.1 ± 4.1</b></td><td class="colsep0 rowsep0" align="left">2225</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>104</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>cis</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">89.5 ± 0.6%</td><td class="colsep0 rowsep0" align="left"><b>51019.0 ± 6046.5</b></td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>105</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left"><i>trans</i>-vinyl</td><td class="colsep0 rowsep0" align="left">4-CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">64.8 ± 1.1%</td><td class="colsep0 rowsep0" align="left"><b>1737.0 ± 691.0</b></td><td class="colsep0 rowsep0" align="left">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>106</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">4-CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">75.1 ± 2.2%</td><td class="colsep0 rowsep0" align="left"><b>5554.5 ± 1778.9</b></td><td class="colsep0 rowsep0" align="left">>18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>107</b></td><td class="colsep0 rowsep0" align="left">1,4</td><td class="colsep0 rowsep0" align="left">ethyl</td><td class="colsep0 rowsep0" align="left">4-OH</td><td class="colsep0 rowsep0" align="left">67.7 ± 0.5%</td><td class="colsep0 rowsep0" align="left"><b>7440.7 ± 1291.3</b></td><td class="colsep0 rowsep0" align="left">>13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pargyline</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>3967.9 ± 275.1</b></td><td class="colsep0 rowsep0" align="left"><b>195.5 ± 19.1</b></td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-deprenyl</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>62663.8 ± 4113.6</b></td><td class="colsep0 rowsep0" align="left"><b>12.1 ± 4.2</b></td><td class="colsep0 rowsep0" align="left">5179</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rasagiline</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>29520 ± 8597</b></td><td class="colsep0 rowsep0" align="left"><b>36.0 ± 4.1</b></td><td class="colsep0 rowsep0" align="left">820</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">clorgiline</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>3.4 ± 0.3</b></td><td class="colsep0 rowsep0" align="left"><b>13568.4 ± 1157.3</b></td><td class="colsep0 rowsep0" align="left">0.0003</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Data are mean values ± SEM: IC<sub>50</sub> (in boldface), <i>n</i> = 2, 3; residual activity (RA), <i>n</i> = 2.</p></div><div class="footnote" id="t1fn3"><sup><sup>b</sup></sup><p class="last">Pdn: piperidine disubstitution pattern.</p></div><div class="footnote" id="t1fn2"><sup><sup>c</sup></sup><p class="last">Selectivity ratio is defined as IC<sub>50</sub>(hMAO-A)/IC<sub>50</sub>(hMAO-B).</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Estimated IC<sub>50</sub> values from the RAs below 100 μM. Compounds showed precipitation in the assay buffer at concentrations above 100 μM.</p></div></div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Structure–Activity Relationships and Stability of Compounds</h3><div class="NLM_p">Hit inhibitor <b>1</b> and the synthesized analogues <b>6</b>, <b>19</b>–<b>26</b>, and <b>67</b>–<b>107</b> were evaluated for their inhibition of both hMAO-A and hMAO-B using a horseradish peroxidase (HRP)–Amplex Red coupled assay (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The most important findings regarding the SARs are summarized in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Scanning the 1,3- and 1,4-disubstitution patterns of piperidine derivatives with the <i>trans</i> configuration of the double bond revealed at least 5-fold superior inhibition of hMAO-B for the 1,4-disubstitution (e.g., <b>19</b> IC<sub>50</sub> = 1470 nM vs <b>1</b> IC<sub>50</sub> = 342 nM). Interestingly, reduction of the double bond retained this selective hMAO-B inhibition (IC<sub>50</sub> of 243 nM and 370 nM for hit compound <b>1</b> and analogue <b>25</b>, respectively. Broadening the series of 1,4-disubsituted piperidines showcased selective inhibition of hMAO-A by <i>cis</i> analogues with small substituents on the phenyl ring (e.g., fluorine). The most potent was <b>69</b>, a 3-fluorophenyl derivative, with an IC<sub>50</sub> of 68.4 nM and almost a 3-log unit selectivity over hMAO-B. On the other hand, the <i>trans</i> derivatives preferentially inhibited hMAO-B, with a general trend of improved inhibitory potencies with increasing hydrophobicity/size of the substituents on phenyl ring position 4 (−H < −F < −Cl < −Br and −H < −Me < −<i>i</i>Pr ∼ −cyclopropyl). Double-digit nanomolar inhibition of hMAO-B was also obtained for <b>82</b>, <b>84</b>, <b>88</b>, and <b>90</b> with −OMe, −CF<sub>3</sub>, −CN, −SO<sub>2</sub>Me substituents, respectively, on position 4 of the phenyl ring. Compounds with an ethyl moiety that connected the rings showed comparable selective inhibition of hMAO-B as their <i>trans</i> congeners. All the <i>N</i>-propargylpiperidine derivatives inhibited corresponding isoenzyme in an irreversible manner as demonstrated by the 100-fold dilution assay.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crucial observations regarding SARs of the stilbene-like MAO inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For additional experiments, compounds <b>1</b>, <b>6</b>, <b>67</b>, <b>69</b>, <b>84</b>, <b>97</b>, and <b>100</b> were used in the form of hydrochloride salts to avoid possible solubility issues. The thermodynamic solubility of the compounds in PBS (pH 7.4) was at least 17.6 g/250 mL, 10.5 g/250 mL, 8.6 g/250 mL, 12.5 g/250 mL, 14.5 g/250 mL, and 16.3 g/250 mL for <b>6</b>, <b>67</b>, <b>69</b>, <b>84</b>, <b>97</b>, and <b>100</b>, respectively, which is good solubility according to biopharmaceutical classification for any realistically expected dose of investigated compounds.</div><div class="NLM_p last">Possible chemical instability and photoisomerization of <i>E</i>/<i>Z</i> isomers were also addressed as these are known liabilities of stilbene derivatives.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Proton NMRs of <b>69</b> (<i>cis</i> derivative), <b>84</b> (<i>trans</i> derivative), and <b>100</b> (ethyl analogue) in the form of hydrochloride salts were recorded in D<sub>2</sub>O (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Figures S1–S3</a>). Inspection of the spectra confirmed that these compounds are relatively stable after more than 1 year of storage at room temperature (protected from sunlight) as only smaller amounts of impurities were detected for <b>84</b> (in the aromatic area), whereas compounds <b>69</b> and <b>100</b> showed no signs of chemical instability. The samples dissolved in the NMR tubes were then left on the benchtop exposed to natural daylight for 7 days, which could induce photoisomerization. No spectral changes were observed in comparison to spectra of freshly prepared samples. Altogether, these studies imply reasonable stability of the compounds.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Kinetic Evaluation</h3><div class="NLM_p">The exploration of SARs allowed the identification of a few compounds for more in-depth kinetic analysis with the purified enzyme samples, which allowed their inhibition mechanism to be better defined. On the basis of their inhibitory potencies and molecular features, compounds <b>1</b>, <b>84</b>, and <b>97</b> were selected for hMAO-B, whereas for hMAO-A the analysis was restricted to <b>69</b>. The inhibitors were tested using UV–vis spectrum measurements (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) and steady-state enzymatic assays (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The propargyl unit is known to react covalently with the <i>N5</i> atom of the flavin cofactor by rapidly forming a stable covalent adduct that produces a typical modification of the spectrum; this is seen as bleaching of the peak at 450 nm and appearance of a stronger peak at 415 nm.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> All of these selected compounds were tested by adding them in 10-fold excess to the protein solution in the spectrophotometer cuvette and measuring the spectra over time until no further modification was detected. All of the irreversible inhibitors produced a clear change in the enzyme spectra (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), similar to other classic acetylenic inhibitors, like <span class="smallcaps smallerCapital">l</span>-deprenyl and clorgyline.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> However, there were differences in the times required to complete the reactions for the adduct formation, i.e., to reach the final spectrum with no further modification. While <b>69</b> fully inactivated hMAO-A almost instantaneously (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A), similar to clorgyline, the hMAO-B selective compounds were slower. In particular, <b>84</b> initiated the reaction with the flavin within 1 min, showing an intermediate spectrum profile that evolved into the final 415 nm peak in 30 min (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Instead, <b>1</b> and <b>97</b> did not show any spectral modifications in the first few minutes and required half an hour to obtain an intermediate profile and more than 2 h to complete the reaction (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D, respectively).</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. UV–vis absorption spectra of the hMAO enzymes after FAD cofactor modification by irreversible covalent inhibitors. The oxidized enzyme (10 μM) before inhibitor addition (100 μM) is shown as the continuous black line, whereas the gray profile indicates the final spectrum (i.e., no further changes were observed), which was reached at different times depending on the inhibitor. The intermediate spectra are shown as either dotted or dashed lines. (A) hMAO-A and <b>69</b>; (B) hMAO-B and <b>84</b>; (C) hMAO-B and <b>1</b>; (D) hMAO-B and <b>97</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Kinetic Parameters for the Reversible and Irreversible Inhibition of the hMAOs by the Selected 4-Styrylpiperidine Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">reversible inhibition</th><th class="rowsep1 colsep0" colspan="2" align="center">irreversible inhibition</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">MAO</th><th class="colsep0 rowsep0" align="center">inhibitor</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>I</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>inact</sub> (min<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> (min<sup>–1</sup> μM<sup>–1</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hMAO-A</td><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="left">0.23 ± 0.02</td><td class="colsep0 rowsep0" align="left">1.01 ± 0.76</td><td class="colsep0 rowsep0" align="left">1.25 ± 0.25</td><td class="colsep0 rowsep0" align="left">1.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">clorgyline<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.040 ± 0.004<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.22 ± 0.08<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.12 ± 0.05<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.55<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hMAO-B</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">1.92 ± 0.32</td><td class="colsep0 rowsep0" align="left">1.38 ± 0.29</td><td class="colsep0 rowsep0" align="left">0.66 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>84</b></td><td class="colsep0 rowsep0" align="left">1.25 ± 0.23</td><td class="colsep0 rowsep0" align="left">17.25 ± 4.38</td><td class="colsep0 rowsep0" align="left">2.03 ± 0.38</td><td class="colsep0 rowsep0" align="left">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>97</b></td><td class="colsep0 rowsep0" align="left">1.36 ± 0.31</td><td class="colsep0 rowsep0" align="left">6.55 ± 1.62</td><td class="colsep0 rowsep0" align="left">1.04 ± 0.12</td><td class="colsep0 rowsep0" align="left">0.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-deprenyl<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.97 ± 0.11</td><td class="colsep0 rowsep0" align="left">5.68 ± 0.78</td><td class="colsep0 rowsep0" align="left">2.56 ± 0.24</td><td class="colsep0 rowsep0" align="left">0.45</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Kinetic parameters were compared to clorgyline and <span class="smallcaps smallerCapital">l</span>-deprenyl in the cases of hMAO-A and hMAO-B selective inhibitors, respectively.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Data from Esteban et al. (2014).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></p></div></div></div><div class="NLM_p last">Full kinetic analysis was then undertaken for hMAO-A and hMAO-B inhibition by the selected compounds, using purified enzyme samples and the spectrophotometric version of the assay coupled to HRP that was used for IC<sub>50</sub> determination, as described above. As enzyme inhibition by propargyl-based inhibitors involves a first step in which the ligand is accommodated into the protein active site to be correctly oriented for flavin adduct formation, competitive inhibition can be measured under steady-state conditions using kynuramine and benzylamine as substrates for hMAO-A and hMAO-B, respectively. Thus, both the reversible and irreversible inhibition parameters were determined (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compound <b>69</b> is a potent hMAO-A inhibitor with a reversible <i>K</i><sub>i</sub> of 0.23 μM, which is 5-fold higher than that reported for clorgyline. This difference is in line with the irreversible constant <i>K</i><sub>I</sub>, and it is balanced by the irreversible inactivation velocity that is 10-fold higher that for clorgyline. Overall, <b>69</b> is a very potent hMAO-A inhibitor with comparable activity to clorgyline. Similar to <span class="smallcaps smallerCapital">l</span>-deprenyl, in the case of hMAO-B selective ligands, the reversible <i>K</i><sub>i</sub> values are all in the micromolar range. The irreversible constant <i>K</i><sub>I</sub> for covalent hMAO-B inhibitors is in general 5-fold the reversible <i>K</i><sub>i</sub>; however, the <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> indicated comparable inhibitory potencies of the hMAO-B inhibitors to <span class="smallcaps smallerCapital">l</span>-deprenyl.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Structure of hMAO-B in Complex with Inhibitors</h3><div class="NLM_p">Structural studies were performed by cocrystallization of hMAO-B with the inhibitors selected for the kinetic analyses, using previously published procedures.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Structures for inhibitors <b>1</b>, <b>84</b>, and <b>97</b> were solved at resolution ranging from 2.3 to1.7 Å (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The crystallographic statistics are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Table S1</a>. Crystallographic studies on hMAO-B in complex with <b>1</b>, <b>84</b>, and <b>97</b> showed that these inhibitor molecules are certain to be bound to the enzyme active site (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Ligand binding does not cause any major conformational changes to the overall protein dimeric structure (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Figure S4</a>). As for all of the inhibitors, the structure of the active site is identical in the two monomers present in the asymmetric unit that forms the protein dimer, and here we will refer to chain A of each structure in the following discussion. The electron density map clearly showed that all of these inhibitors form a covalent adduct with the flavin (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Crystal structures of the active site of hMAO-B-inhibitor complexes. The hMAO-B active site cavity is shown as a gray semitransparent surface, which is lined by the protein residues (represented in cyan). Water molecules are red spheres, and hydrogen bonds are dashed lines. The FAD cofactor is in yellow stick representation. The inhibitor molecule bound in the hMAO-B active site cavity is shown as sticks, with carbon, nitrogen, and fluorine in magenta, blue, and black, respectively. The refined 2<i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> electron density map contoured at 1.2σ is shown in blue for the inhibitor and the FAD molecules. (A) Active site of hMAO-B in complex with <b>1</b> (2.3 Å resolution; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKB">6RKB</a>). (B) Active site of hMAO-B in complex with <b>84</b> (1.7 Å resolution; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKP">6RKP</a>). (C) Active site of hMAO-B in complex with <b>97</b> (2.3 Å resolution; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RLE">6RLE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All of these inhibitors bind to the hMAO-B active site in a similar fashion, from the covalent adduct with the flavin to the 4-substituted phenyl ring at the other end of the molecule (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). They adopt an extended conformation, as they occupy both the substrate and the cavity spaces (Ile199 in the open conformation). The 4-substituted phenyl ring is constrained by the flat hydrophobic shape of the hMAO-B cavity in a position perpendicular to the flavin plane, as for other well-known inhibitors, such as <span class="smallcaps smallerCapital">l</span>-deprenyl and safinamide (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). The site occupied by the halogen substituent on the aromatic ring of <b>1</b> is also conserved, which is a common feature of many hMAO-B inhibitors.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The more polar substituents that have lower inhibitory activities (e.g., <b>82</b>, <b>105</b>) would be much less favored in their binding to this highly hydrophobic site. The enzyme active site architecture does not undergo any conformational change with respect to that of other hMAO-B structures except for minor modifications to the side chains of Cys172 and Tyr188 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). This is due to the position adopted by the piperidine ring that represents the hallmark of this series of inhibitors. Despite the flat shape of the hMAO-B cavity, the nonplanar conformation of the piperidine and its pyramidal nitrogen that is involved in the covalent adduct constrain the piperidine ring to bind perpendicular to the plane of the cavity (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Instead, with other inhibitors such as <span class="smallcaps smallerCapital">l</span>-deprenyl and safinamide, there is an aromatic ring that binds coplanar with the cavity plane and with any substituted aromatic at the other end of the molecule, if present (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Therefore, the position of the piperidine in the upper part of the cavity allows Cys172 and Tyr188 to move slightly upward. In the structure of the complex with <b>97</b>, the conformation of the Cys172 and Tyr188 is conserved to some extent with respect to the previous structures. This is due to the linker that is devoid of the double bond, and the consequent tetrahedral conformation of its carbon atoms results in a more contracted conformation of the inhibitor molecule with respect to <b>84</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B) and <b>1</b>. As a result, the piperidine collapses toward the bottom of the cavity, and the covalent linkage is forced to adopt a slightly different conformation with respect to the other propargyl inhibitors (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structural superposition to highlight differences and common features in the binding modes of the hMAO-B inhibitors. The protein, inhibitor, and cofactor atoms are represented as sticks (color code as in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> except for the carbon atoms of protein and inhibitor molecules, which are depicted accordingly to distinguish the different structures). For clarity, only Cys172 and Tyr188 of the protein active site residues are shown, which undergo some conformational changes. (A) Superposition of structures in complex with <b>84</b> (green), safinamide (gray) and <span class="smallcaps smallerCapital">l</span>-deprenyl (pink). (B) Superposition of structures in complex with <b>84</b> (green) and <b>97</b> (light gray).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Cell-Based Assays</h3><div class="NLM_p">Following the chemical-space exploration and kinetic and structural evaluations, several of these structurally diverse hMAO-A and hMAO-B inhibitors were also tested <i>in vitro</i> in cell models. First, their cytotoxicity profiles were defined using the SH-SY5Y human neuroblastoma cell line. By use of the MTS assay, no significant cytotoxic effects were seen for 24 h treatments of these cells with the compounds <b>1</b>, <b>6</b>, <b>67</b>, <b>69</b>, <b>84</b>, <b>97</b>, <b>100</b>, and <b>102</b> at concentrations of 5 μM and 10 μM (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Figure S5</a>). Indeed, at 50 μM, the cell viabilities remained >80% for almost all of the compounds, which is roughly 3 log units higher than the concentrations needed to achieve 50% <i>in vitro</i> inhibition of either of the two MAO isoforms.</div><div class="NLM_p">The experimental <i>in vitro</i> cell model with the neurotoxin 6-hydroxydopamine (6-OHDA) is commonly used to study neurodegenerative processes, as it induces toxicity that mimics the biochemistry and neuropathology of Parkinson’s disease.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> To determine the possibility that MAO inhibitors can abrogate 6-OHDA-induced toxicity, we examined lactate dehydrogenase (LDH) release and propidium iodide (PI) staining in the SH-SY5Y cells after 30 min pretreatment with the compounds at the noncytotoxic concentration of 5 μM, followed by 6-OHDA treatment for 24 h (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The active treatment with 6-OHDA significantly increased LDH release (135% vs control), while pretreatment with compounds <b>1</b>, <b>84</b>, <b>97</b>, and <b>102</b> protected against this increased LDH release (76%, 87%, 82%, 82% vs 6-OHDA, respectively), thus indicating improved cell viability. In the confirmation using flow cytometry, the proportion of PI-positive cells increased after the active 24 h treatment with 6-OHDA and was significantly reduced following the pretreatments with the hMAO-B inhibitors <b>84</b> and <b>97</b> (0.65 and 0.68, respectively), compared to the 6-OHDA-treated cells. Altogether, this indicates that the selective hMAO-B inhibitors <b>84</b> and <b>97</b> reduced the 6-OHDA-induced cytotoxicity and increased the viability of these SH-SY5Y neuronal-like cells.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of inhibitors on 6-OHDA-induced cell death in SH-SY5Y cells. (A, B) SH-SY5Y cells were pretreated with the compounds (5 μM) for 30 min (as indicated) and then treated with 6-OHDA (100 μM). After 24 h, LDH assays (A) and PI staining (B) were performed. Data are mean values ± standard deviation (<i>n</i> ≥ 2; each in duplicate): ∗, <i>p</i> < 0.05 (one-way ANOVA, with Bonferroni correction, followed by <i>t</i>-tests).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>In Vivo</i> MAO Inhibition in Mouse Brain Homogenates and <i>in Vitro</i> Permeability</h3><div class="NLM_p">The inhibition of the MAOs in mouse brain homogenates was also investigated both <i>in vitro</i> and <i>ex vivo</i> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Here, the more potent of the inhibitors against hMAO-A (i.e., <b>69</b>) and hMAO-B (i.e., <b>100</b>) were tested based on their IC<sub>50</sub> values and structural features. Brain homogenates from male Swiss mice were first characterized in terms of their MAOs activity and substrate specificity (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Table S2</a>, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Figure S6</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. <i>In Vitro</i> and <i>ex Vivo</i> Mouse Brain Homogenate Residual Activities of <b>69</b> and <b>100</b> at 60 mg/kg ip on MAO-A and MAO-B According to Substrate<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">residual activity (%)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center">MAO-A substrate</th><th class="colsep0 rowsep0" colspan="2" align="center">MAO-A/B substrate</th><th class="colsep0 rowsep0" colspan="2" align="center">MAO-B substrate</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center">5-HT (0.25 mM)</th><th class="colsep0 rowsep0" colspan="2" align="center"><i>p</i>-tyramine (0.5 mM)</th><th class="colsep0 rowsep0" colspan="2" align="center">benzylamine (0.5 mM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center"><i>in vitro</i><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>ex vivo</i><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"><i>in vitro</i><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>ex vivo</i><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"><i>in vitro</i><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>ex vivo</i><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="left">–1.3 ± 0.1</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.02</td><td class="colsep0 rowsep0" align="left">31.3 ± 0.2</td><td class="colsep0 rowsep0" align="left">14.2 ± 0.2</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>100</b></td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">59.4 ± 0.2</td><td class="colsep0 rowsep0" align="left">77.2 ± 0.2</td><td class="colsep0 rowsep0" align="left">–7.7 ± 0.2</td><td class="colsep0 rowsep0" align="left">24.3 ± 0.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Data are mean values ± SD (<i>n</i> = 1, in triplicate). nd, not determined.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last"><i>In vitro</i>: 50 μM compounds (final concentrations) versus 0.9% saline with mouse brain homogenate from nontreated mice.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last"><i>Ex vivo</i>: brain homogenates from mice treated (<i>n</i> = 3, per group) with 60 mg/kg ip compounds or 0.9% saline 30 min before brain homogenate preparation.</p></div></div></div><div class="NLM_p">Compound <b>69</b> completely abolished MAO-A activity <i>in vitro</i> at 50 μM when 5-HT was used as the selective MAO-A substrate. Compound <b>100</b> at 50 μM inhibited mice MAO-B when benzylamine was used as the selective MAO-B substrate (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). When the dual hMAO-A/B substrate <i>p</i>-tyramine was used, the inhibition was lower (i.e., higher residual activities; RAs). The same profile of inhibition was established <i>ex vivo</i> for brain homogenates from mice treated with these compounds, which were injected intraperitoneally (ip) 30 min before preparation of the brain homogenates. Again, more potent inhibition was seen in these brain homogenates when the isoenzyme-selective substrates were used. Selective MAO-A inhibitor <b>69</b> was the most active compound when administered at 60 mg/kg ip (RA, 1.6% ± 0.02%), while 60 mg/kg ip <b>100</b> resulted in similar MAO-B inhibition (RA, 24.3% ± 0.5%). Compounds <b>69</b> and <b>100</b> showed dose-dependent inhibition of these corresponding MAO isoforms (ED<sub>50</sub> of 0.43 ± 0.26 mg/kg and 1.38 ± 0.87 mg/kg, respectively).</div><div class="NLM_p">MAO inhibitors are in clinical use for treatment of psychiatric and neurological disorders, where they are used in chronic, low-dose regimes.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> These MAO-A and MAO-B activities in <i>ex vivo</i> mouse brain homogenates were therefore studied after chronic 10-day administration to the mice of <b>69</b> and <b>100</b> at the low dose of 0.3 mg/kg ip. This chronic administration of selective MAO-A inhibitor <b>69</b> significantly reduced MAO-A activity compared to 0.9% saline ip in the control mice. After the single administration of <b>69</b> at 0.3 mg/kg ip, the <i>ex vivo</i> MAO-A RA was reduced to 67.8% ± 31.2% (i.e., compared to 0.9% saline), whereas the 10-day treatment resulted in MAO-A RA of 9.5% ± 23.4%. Similar to <b>69</b>, one single ip injection of <b>100</b> at 0.3 mg/kg showed MAO-B RA of 83.4% ± 19.2%, while chronic 10-day treatment resulted in RA of 28.3% ± 13.8%, which demonstrated accumulation of inhibition over time.</div><div class="NLM_p last">The <i>ex vivo</i> inhibitory activity of inhibitors <b>69</b> and <b>100</b> was also demonstrated in the mouse brain homogenates prepared 90 min after acute oral administration to the mice, via oral gavage at 30 mg/kg. Inhibitors <b>69</b> and <b>100</b> showed RAs of 45.3% ± 14.6% (vs 0.9% saline-treated mice) and 30.5% ± 10.4% (vs 0.9% saline treated mice), respectively. This prompted us to also study gut permeability of these representative inhibitors (i.e., <b>69</b>, <b>84</b>, and <b>100</b>) <i>in vitro</i> on rat intestine. The apparent bidirectional permeability coefficient for the rat intestine <i>in vitro</i> was determined for <b>69</b>. This was 108 ± 13 nm/s (as mean ± SEM) in the absorptive direction and 354 ± 99 nm/s in the eliminatory direction. For comparison, the apparent permeability coefficients of the internal low- and high-permeability standards furosemide and metoprolol in the absorptive direction were 64 ± 11 nm/s and 140 ± 18 nm/s, respectively.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Behavioral Studies with the Selective MAO-A and MAO-B Inhibitors</h3><div class="NLM_p">MAO-A inhibitors are currently used in the therapy of treatment-resistant major depressive disorder and some specific types of depression.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Symptoms of depression correlate highly with those of anxiety.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> These have been shown to be associated with 5-HT<sub>1A</sub> receptors,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> which are presynaptic and postsynaptic G-protein-coupled receptors that are involved in neuromodulation. 5-HT<sub>1A</sub> receptor agonists, such as buspirone, show efficacy for the relief of anxiety and depression.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The binding affinities (<i>K</i><sub>i</sub> values) for this 5-HT<sub>1A</sub> receptor subtype were thus determined for these MAO inhibitors to potentially further explain their behavioral effects. These ranged from low micromolar to submicromolar <i>K</i><sub>i</sub> values (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Table S3</a>). Following treatments with the selective irreversible MAO-A inhibitors <b>6</b>, <b>67</b>, and <b>69</b>, the Swiss mice were subjected to the different behavioral tasks to determine whether these compounds have any antidepressant-like activity, any activity in an anxiety model and whether they affect locomotor activity.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">The antidepressant-like activity was screened with the widely used tail suspension test. At 30 min before the behavioral assays, the mice were treated with <b>6</b>, <b>67</b>, and <b>69</b> at 3 mg/kg and 10 mg/kg ip, with <b>69</b> also at 1 mg/kg and 30 mg/kg ip, or were injected with 0.9% saline as control. Imipramine (30 mg/kg ip) was used as the reference drug. Compounds <b>67</b> and <b>69</b> did not decrease the immobility time, whereas selective MAO-A inhibitor <b>6</b> and imipramine significantly reduced it, which demonstrated the antidepressant-like effects of these compounds under acute treatment (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A).</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <i>In vivo</i> evaluation in mice of antidepressant-like activity of the selective MAO-A inhibitors <b>6</b>, <b>67</b>, and <b>69</b>. (A) Effects of acute ip treatment with <b>6</b> (3, 10 mg/kg, <i>n</i> = 13, 9), <b>67</b> (3, 10 mg/kg, <i>n</i> = 6, 10), and <b>69</b> (1, 3, 10, 30 mg/kg, <i>n</i> = 8, 7, 8, 6) and imipramine (30 mg/kg, <i>n</i> = 8) in the tail suspension test. Data are mean values ± SEM of immobility time in comparison to control mice (SAL, <i>n</i> = 23): ∗, <i>p</i> < 0.05; ∗∗∗, <i>p</i> < 0.001 (one-way ANOVA, followed by Dunnett’s tests). (B) Effects of acute ip treatment with <b>6</b> (3, 10 mg/kg, <i>n</i> = 8, 8), <b>67</b> (1, 3, 6 mg/kg; <i>n</i> = 5, 5, 5), and <b>69</b> (1, 3, 6 mg/kg, <i>n</i> = 10, 5, 5) on locomotor activity of the mice. Data are mean values ± SEM of spontaneous locomotor activity counts recorded in 5 min sessions: ∗∗∗, <i>p</i> < 0.001 (one-way ANOVA, followed by Dunnett’s tests). (C) Effects of 10-day chronic ip treatment with <b>69</b> (0.3 mg/kg, daily; <i>n</i> = 10) in the tail suspension test. Data are mean values ± SEM of the immobility time, compared to control mice (<i>n</i> = 8): ∗∗, <i>p</i> < 0.01 (unpaired <i>t</i>-test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The performance of mice in the “elevated plus maze test” was used here as a rodent model of anxiety, which was carried out 30 min after the ip treatments with <b>6</b>, <b>67</b>, and <b>69</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Table S4</a>). Compound <b>6</b> at the dose of 10 mg/kg ip induced a significant decrease compared to mice injected with 0.9% saline, for both the number of total arm entries (9.7 ± 2.9 vs 22.0 ± 1.5; <i>p</i> < 0.001) and the proportion of time spent in the center of the apparatus (13.4 ± 2.3 vs 43.5 ± 2.8; <i>p</i> < 0.001), and also an increase in the proportion of open-arm entries (2.0-fold; <i>p</i> < 0.001). Meanwhile, <b>69</b> at 3 mg/kg ip produced a significant increase in the proportion of open-arm entries (2.0-fold; <i>p</i> < 0.001) and in the time spent in those entries (2.1-fold; <i>p</i> < 0.001), similar to diazepam (reference drug) at 1 mg/kg ip (2.1-fold, 2.4-fold, respectively; <i>p</i> < 0.001 for both).</div><div class="NLM_p">The locomotor activity of the mice was also determined, as it can affect the data obtained in these behavioral assays. It was shown that <b>6</b> at 10 mg/kg ip significantly decreased spontaneous locomotor activity (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B), which is correlated with the decrease in the total arm entries in the elevated plus maze test. This indicates that the effects of <b>6</b> after acute 10 mg/kg ip treatment are not associated with antidepressant-like or anxiolytic effects but rather with a decrease in the locomotion of the mice. On the other hand, the increased open arm parameters in the elevated plus maze for <b>69</b> (3 mg/kg ip) appear to be correlated with an anxiolytic-like effect, which would be mediated through the 5-HT<sub>1A</sub> receptor, as locomotion was not altered at this dose of <b>69</b>. Importantly, chronic 10-day treatment with <b>69</b> at a low dose (i.e., 0.3 mg/kg ip, daily) significantly decreased the immobility time in the treated group (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C). No significant effects were seen for this chronic low dose of <b>69</b> in the elevated plus maze and locomotor activity tests (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Table S5</a>). This confirmed the antidepressant-like effects of <b>69</b> when administered chronically, which were not seen for the acute treatment regime.</div><div class="NLM_p">Behavioral studies of the selective hMAO-B inhibitors were performed with compound <b>100</b> (irreversible MAO-B inhibitor). Although <i>trans</i> derivative <b>84</b> also showed potent irreversible MAO-B inhibition (IC<sub>50</sub> = 18.6 ± 3.3 nM; equipotent to <b>100</b>), it was not studied here <i>in vivo</i> due to its poor permeability in the rat gut (see above) and its low binding potential for the 5-HT<sub>1A</sub> receptor (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Table S3</a>).</div><div class="NLM_p last">The hole–board test is commonly used to study stress-related changes in exploratory behavior of animals.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This was combined here with the locomotor activity test. At acute ip doses of ≥10 mg/kg of <b>100</b> in the mice, the hole–board test parameters and locomotor activities were reduced (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Table S6</a>, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Figure S7A–C</a>). Due to the locomotor impairment at high doses, compound <b>100</b> was further studied in the haloperidol-induced catalepsy test at lower doses (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Supplementary Results and Discussion</a>). Compound <b>100</b> was also tested in the same battery of behavioral tests after 10 days of low-dose ip treatment (0.3 mg/kg, daily), where it did not affect the locomotor activity of the mice (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Figure S7D</a>) or the parameters of the hole–board test (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Figure S8</a>). During these 10-day treatments (i.e., <b>69</b>, <b>100</b> at 0.3 mg/kg ip, daily), the body mass of the mice was also monitored (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Figure S9</a>). No significant differences were seen for the proportions of body mass variations versus the control mice (0.9% saline treated). Also, all of these mice survived these 10-day treatments without any apparent signs of changes in behavior, which supports the general safety of these compounds.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38653" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38653" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Biological receptors differ greatly in shape, polarity, and conformational dynamics.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, it is a challenging task to obtain selectivity between structurally related targets such as isoenzymes, which requires different ligand-design approaches. MAO-A and MAO-B are two closely related isoenzymes where numerous selective inhibitors have been described in the literature, with some now used in the clinical setting for treatment of neurological disorders.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p">Selective hMAO-B inhibitor <b>6</b> was identified in a screening campaign, and chemistry-driven exploration of the chemical space revealed that the <i>trans</i> isomers selectively inhibit hMAO-B over hMAO-A. On the other hand, <i>cis</i> isomers were identified as selective hMAO-A inhibitors. The inhibitory potencies in the SARs exploration phase are generally expressed as IC<sub>50</sub> values (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), although these derivatives are irreversible. The IC<sub>50</sub> values are thus dependent on the assay conditions and particularly on the preincubation period.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Despite these limitations, the measured IC<sub>50</sub> values still allow relatively simple, yet not the most precise, comparisons between such compounds in a series.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The inhibitory activity against hMAO-B was increased by introducing bulkier and more lipophilic substituents onto position 4 of the phenyl ring, as previously reported in the literature.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> A similar trend was also observed for the turnover of variously substituted substrates of the benzylamine and phenethylamine classes,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> where the binding affinity improved with increasing hydrophobicity of the substituent.</div><div class="NLM_p">Further examination of the binding kinetics for the selected compounds here using purified enzyme samples confirmed the variable nature of these IC<sub>50</sub> values. The overall higher affinity inferred from the IC<sub>50</sub> values (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) compared to <i>K</i><sub>i</sub> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) is related to the covalent nature of these inhibitors, which fully inactivate the enzyme during the preincubation step in the absence of substrate (not included in competitive steady-state experiments used to determine IC<sub>50</sub>). For the same reason, the variability of the IC<sub>50</sub> values among the different inhibitors that was not seen for <i>K</i><sub>i</sub> has to be interpreted in light of the time-dependent inactivation process that showed different kinetics depending on the inhibitor (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). For example, <b>84</b> showed an IC<sub>50</sub> that is 0.05-fold that of <b>1</b> and a similar reversible <i>K</i><sub>i</sub>, while its inactivation rate was 4-fold that of <b>1</b>, which results in a <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> ratio that is comparable between these two inhibitors. Similar observations can be reasoned for the other covalent analogues and for <span class="smallcaps smallerCapital">l</span>-deprenyl.</div><div class="NLM_p">Crystallographic studies confirmed the covalent adduct formation with flavin for the inhibitors investigated here. A similar binding mode for all of these inhibitors was seen, with only minor modifications of the active site arrangements in comparison to other hMAO-B structures reported in the literature. These changes were most prominent with the <i>trans</i> inhibitors <b>1</b> and <b>84</b>, which imposed a slight upward shift of Cys172 and Tyr188. This is related to the conformation adopted by the piperidine ring, which represents the hallmark of this class of inhibitors, as a novel element with respect to previous propargyl inhibitors (i.e., where the nitrogen atom is within a linear molecular structure rather than part of a ring).</div><div class="NLM_p">The inhibitor series studied here were not cytotoxic to SH-SY5Y cells up to treatments of 50 μM. Remarkably, only the selective hMAO-B inhibitors decreased the LDH release induced by the neurotoxin 6-OHDA. The reduced proportion of PI-positive SH-SY5Y cells was also confirmed for the two MAO-B-selective ligands during 6-OHDA-induced toxicity. This indicated their neuroprotective nature, which might also be attributed, among others possibilities, to their selective MAO-B inhibition. Following ip and peroral administration, these compounds inhibited MAO-A and MAO-B activities <i>ex vivo</i> in the mouse brain homogenates. The extent of their inhibition varied depending on the inhibitor selectivity and the substrate used. Selective MAO-A inhibitor <b>69</b> completely inhibited MAO-A <i>ex vivo</i> when the MAO-A substrate 5-HT was used (RA, 1.6%), while its inhibition was lower when using <i>p</i>-tyramine (RA, 14.2%), which is a dual MAO-A/B substrate. The difference is even more evident for the MAO-B inhibitors, with decreased inhibition when switching from the MAO-B substrate benzylamine to dual substrate <i>p</i>-tyramine. Both MAO-A and MAO-B can metabolize <i>p</i>-tyramine; however, only one of them was inhibited by the selective inhibitor, which explained the impaired inhibition. This additionally confirmed the <i>in vitro</i> selectivity of these inhibitors not only on the isolated human enzymes but also in complex matrices, such as mouse brain homogenates. The MAO inhibition in these mouse brain homogenates after peroral single-dose administration also indicated the oral bioavailability of these analogues. The <i>in vitro</i> permeability of <b>69</b> studied for rat intestine was between that of the low-permeability and high-permeability standards, and as such, <b>69</b> should be classified with an intermediate/moderate permeability, with the possibility of interference by the intestinal efflux mechanisms, as seen by the higher apparent permeability coefficient determined for the eliminatory direction. The permeabilities of <b>84</b> and <b>100</b> were not determinable <i>in vitro</i> due to their high tissue binding. These findings do not correlate directly with the <i>ex vivo</i> effects; however, the <i>ex vivo</i> effects show that both <b>69</b> and <b>100</b> reached the brain tissue and inhibited the MAO activity after their oral administration.</div><div class="NLM_p">Under the acute treatment regime in these mice, the selective MAO-A inhibitor <b>69</b> did not affect the immobility time of the mice in the tail suspension test. The observed anxiolytic-like activity with acute treatment with <b>69</b>, which can be attributed to 5-HT<sub>1A</sub> binding, prompted us to also study <b>69</b> in a 10-day treatment regime. The antidepressant-like effects of <b>69</b> in this setup, together with no significant toxic effects, confirmed the therapeutic potential for this class of selective hMAO-A inhibitors. On the other hand, the selective MAO-B inhibitor <b>100</b> did not produce the expected results for haloperidol-induced catalepsy, in terms of what would be expected for a MAO-B inhibitor.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Nonetheless, the general safety of these compounds has been established in the chronic low-dose treatment regime.</div><div class="NLM_p last">In summary, we have generated the first example of selective hMAO-A and hMAO-B inhibitors where this selectivity is conferred by the configurational <i>cis</i>/<i>trans</i> isomerism of a double bond. <i>Cis</i> isomers with fluorine or unsubstituted benzene ring selectively inhibit hMAO-A. On the other hand, <i>trans</i> derivatives and their corresponding reduced ethyl analogues with small lipophilic substituents on benzene ring selectively inhibit hMAO-B. In addition, we provide the first in depth, and we believe critical, kinetic and structural characterization of these 1-propargyl-4-styrylpiperidines as potential fragments in the design of pharmaceuticals that can be used to target the MAOs.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry. General Information</h3><div class="NLM_p last">The reagents and solvents used were obtained from commercial sources (i.e., Acros Organics, Sigma-Aldrich, TCI Europe, Merck, Carlo Erba, Apollo Scientific) and were used as provided. Anhydrous THF was prepared by distillation over sodium and benzophenone under Ar(g). Analytical thin-layer chromatography was performed on silica gel aluminum sheets (60 F254, 0.20 mm; Merck). Flash column chromatography was performed on silica gel 60 (particle size 0.040–0.063 mm, Merck). <sup>1</sup>H NMR and <sup>13</sup>C spectra were recorded at 400 and 100 MHz, respectively, on a Bruker Avance III NMR spectrometer (Bruker, MA, USA) at 295 K. The chemical shifts (δ) are reported in ppm and are referenced to the deuterated solvent used. HRMS measurements were performed (Autospec Q Micromass MS; Fisons, VG Analytical, Manchester, U.K.) at the Jozef Stefan Institute, Ljubljana, Slovenia, and on a LC–MS/MS system (Q Executive Plus; Thermo Scientific, MA, USA). MS measurements were performed on an Expression CMS mass spectrometer (Advion, NY, USA). Infrared spectra were obtained on a Thermo Nicolet FT-IR spectrometer using the ATR technique. Analytical reversed-phase HPLC analyses were performed on a modular system (1100LC; Agilent Technologies, CA, USA, and Thermo Scientific Dionex UltiMate 3000; Thermo Fisher Scientific Inc., MA, USA). Method: C18 column (Eclipse Plus; 5 μm, 4.6 mm × 150 mm; Agilent), <i>T</i> = 25 °C; sample 0.2 mg/mL in MeCN; flow rate = 1.0 mL/min; detector λ = 220 nm; mobile phase A (0.1% TFA [v/v] in water), mobile phase B (MeCN). Gradient (for mobile phase B): 0–12 min, 10–90%; 12–14 min, 90%; 14–15 min, 90–10%. Purities of the tested compounds were established to be ≥95%, as determined by HPLC. All compounds described in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were checked by SwissADME<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> for the presence of PAINS substructures,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and no PAINS substructures were identified.</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Synthetic Chemistry Experimental Protocols. General Procedure A: Synthesis of Wittig Reagents</h3><div class="NLM_p last">Appropriate benzyl halide (25.0 mmol, 1.0 equiv) was dissolved in MeCN (25–50 mL), and triphenylphosphine (6.56 g, 25.0 mmol, 1.0 equiv) was added at room temperature. The reaction mixture was stirred at 85 °C for 16–24 h. The solvent was evaporated, and CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and Et<sub>2</sub>O (50 mL) were added to the residue. The precipitated solid was filtered off, washed with Et<sub>2</sub>O (20 mL), and dried overnight at room temperature. The crude product was used in the following reaction step without further purification.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure B: Wittig Reaction</h3><div class="NLM_p last">Appropriate Witting reagent synthesized according to general procedure A (1.1 equiv) was dissolved in anhydrous THF (30 mL) under argon atmosphere. NaHMDS (2 N in THF, 1.2 equiv) or KHMDS (0.5 M in toluene, 1.1 equiv) was added to the resulting suspension at room temperature. The orange-red colored reaction mixture was then stirred for 30 min under argon, followed by a dropwise addition of <i>N-</i>Boc protected 3- or 4- formylpiperidine (1.0 equiv) solution in anhydrous THF (10 mL). The reaction mixture was stirred at room temperature overnight (16–24 h) and then quenched by adding saturated aqueous NaHCO<sub>3</sub> solution (10–15 mL). The solvent was evaporated, and the white residue was resuspended in EtOAc (50 mL) and saturated aqueous NaHCO<sub>3</sub> solution (50 mL) and transferred into a separating funnel. The phases were separated, and the aqueous phase was additionally extracted with EtOAc (2 × 50 mL). Combined organic phases were washed with saturated brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The crude product was purified by flash column chromatography to yield (in a majority of cases) both pure <i>cis</i> and <i>trans</i> isomers.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Procedure C: Reduction of the Double Bond</h3><div class="NLM_p last">Alkene derivative (Wittig reaction product-mixture of <i>cis</i> and <i>trans</i> isomer, 1.0 equiv) was dissolved in EtOH (50 mL) and purged under a stream of argon for 10 min. Catalytic amount of Pd/C (10% load on carbon, 10–20% [w/w] calculated to the starting material) was added, and the resulting suspension mixture was stirred under H<sub>2</sub>(g) atmosphere at room temperature for 16–24 h. The catalyst was removed by filtration through Celite and evaporated to obtain crude product. The product was used without further purification unless stated otherwise.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure D: Boc Protection Removal (HCl Method)</h3><div class="NLM_p last">To the solution of Boc-protected derivative (1.0 equiv) in 1,4-dioxane or EtOH (30 mL), concentrated HCl (10.0 equiv) was added at room temperature. The reaction mixture was stirred at 80 °C for 2 h. The solvent was evaporated under reduced pressure, and the crude product was used in the next step without further purification.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure E: Alkylation of Piperidine</h3><div class="NLM_p last">Piperidine intermediate (in the form of the salt with HCl) was dissolved in MeCN (20–30 mL) or DMF (5–10 mL) at 0 °C under an argon atmosphere. K<sub>2</sub>CO<sub>3</sub> or Cs<sub>2</sub>CO<sub>3</sub> (3.0 equiv) was added, followed by dropwise addition of propargyl bromide (80% solution in toluene, 1.2 equiv). The resulting suspension was stirred at room temperature (unless specified otherwise) for 16–72 h. The solvent was evaporated, the residue dissolved in a mixture of CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and saturated aqueous NaHCO<sub>3</sub> solution (50 mL) and transferred into a separating funnel. The organic phase was further washed with saturated brine solution (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The crude product was purified by flash column chromatography.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure F: Hydrolysis of Nitrile</h3><div class="NLM_p last">The starting nitrile (1.0 equiv) was dissolved in <i>tert</i>-butanol (20–50 mL), followed by the addition of powdered KOH (3.0 equiv). The resulting suspension was stirred at 90 °C for 12–24 h, and then the solvent was evaporated. The residue was dissolved in a mixture of CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and saturated aqueous NaHCO<sub>3</sub> (50 mL) and transferred into a separating funnel. The water layer was additionally extracted with CH<sub>2</sub>Cl<sub>2</sub> (50 mL). The combined organic layers were washed with saturated brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The crude product was purified by flash column chromatography.</div></div><div id="sec4_2_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Synthesis of Intermediates and Inhibitors. (<i>E</i>)-4-(4-Fluorostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>1</b>)</h3><div class="NLM_p last">Synthesized from <b>5</b> (0.157 g, 0.514 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 26% (33 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.57 (dt, <i>J</i> = 12.3, 3.4 Hz, 1H), 1.60 (dt, <i>J</i> = 12.0, 3.7 Hz, 1H), 1.77–1.83 (m, 2H), 2.08–2.18 (m, 1H), 2.27 (t, <i>J</i> = 2.4 Hz, 1H), 2.30 (dd, <i>J</i> = 11.7, 2.0 Hz, 2H), 2.95 (td, <i>J</i> = 11.1, 2.8 Hz, 2H), 3.34 (d, <i>J</i> = 2.4 Hz, 2H), 6.07 (dd, <i>J</i> = 16.0, 7.0 Hz, 1H), 6.34 (d, <i>J</i> = 16.0 Hz, 1H), 6.95–7.00 (m, 2H), 7.28–7.33 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.89, 38.71, 47.20, 52.19, 73.26, 78.73, 115.31 (d, <i>J</i><sub>C,F</sub> = 21.4 Hz), 127.14, 127.41 (d, <i>J</i><sub>C,F</sub> = 7.7 Hz), 133.70 (d, <i>J</i><sub>C,F</sub> = 3.3 Hz), 134.49, 161.94 (d, <i>J</i><sub>C,F</sub> = 245.9 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>FN [M + H]<sup>+</sup> 244.1502; found 244.1508. IR (ATR): 3287, 2925, 2804, 1599, 1507, 1425, 1314, 1222, 1124, 966, 855, 669, 631 cm<sup>–1</sup>. HPLC purity, 96.2% (<i>t</i><sub>R</sub> = 9.11 min).</div></div><div id="sec4_2_7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>tert</i>-Butyl 4-(Methoxy(methyl)carbamoyl)piperidine-1-carboxylate (<b>2</b>)</h3><div class="NLM_p">Piperidine-4-carboxylic acid (15.00 g, 116.1 mmol, 1.0 equiv) was dissolved in a mixture of 1,4-dioxane (75 mL) and 1 M NaOH (116.1 mL, 116.1 mmol, 1.0 equiv) and cooled to 0 °C. A solution of Boc<sub>2</sub>O (30.41 g, 139.3 mmol, 1.2 equiv) in 1,4-dioxane (100 mL) was added dropwise over 30 min. The resulting suspension was stirred at room temperature for 1 h. The organic solvent was evaporated, and the aqueous residue was transferred into a separating funnel and extracted with Et<sub>2</sub>O (2 × 100 mL). The aqueous layer was acidified with 2 M HCl to pH 2–3. The precipitated solid was filtered under suction, washed with cold water (100 mL), and dried at 50 °C overnight to obtain 1-(<i>tert</i>-butoxycarbonyl)piperidine-4-carboxylic acid. Yield: 91% (24.22 g); white crystals, mp 158–160 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.46 (s, 9H), 1.62–1.69 (m, 2H), 1.88–1.94 (m, 2H), 2.48 (tt, <i>J</i> = 10.9, 3.9 Hz, 1H), 2.82–2.89 (m, 2H), 4.03 (td, <i>J</i> = 13.6, 3.7 Hz, 2H), 9.13 (bs, 1H).</div><div class="NLM_p last">1-(<i>tert</i>-Butoxycarbonyl)piperidine-4-carboxylic acid (10.00 g, 43.61 mmol, 1.0 equiv) was suspended in CH<sub>2</sub>Cl<sub>2</sub> (150 mL) and cooled to 0 °C. Then Et<sub>3</sub>N (15.11 mL, 109.03 mmol, 2.5 equiv) was added, followed by TBTU (14.70 g, 45.78 mmol, 1.05 equiv). After stirring for 30 min at 0 °C, <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (5.10 g, 52.32 mmol, 1.2 equiv) was added, and the mixture was stirred overnight at room temperature. The resulting solution was transferred into a separating funnel and washed with saturated aqueous NaHCO<sub>3</sub> solution (2 × 100 mL), 1 M HCl (100 mL), saturated brine solution (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 76% (9.03 g); white crystals, mp 68–72 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.45 (s, 9H), 1.61–1.74 (m, 4H), 2.72–2.83 (m, 3H), 3.17 (s, 3H), 3.70 (s, 3H), 4.17 (td, <i>J</i> = 13.4, 2.9 Hz, 2H).</div></div><div id="sec4_2_7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>tert</i>-Butyl 4-Formylpiperidine-1-carboxylate (<b>3</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate <b>2</b> (9.03 g, 33.16 mmol, 1.0 equiv) was dissolved in anhydrous THF (75 mL) and cooled to 0 °C. After stirring 10 min under an argon atmosphere, LiAlH<sub>4</sub> (1.89 g, 49.73 mmol, 1.5 equiv) was added. The mixture was stirred at 0 °C for 2 h and afterward quenched by adding saturated aqueous NaHCO<sub>3</sub> solution (30 mL). The suspension formed was transferred into a separating funnel and extracted with EtOAc (3 × 100 mL). Combined organic phases were washed with saturated aqueous NaHCO<sub>3</sub> solution (100 mL), 1 M HCl (100 mL), saturated brine solution (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The crude product was used without further purification. Yield: 83% (5.87 g); pale yellow oil.</div></div><div id="sec4_2_7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>tert</i>-Butyl 4-(4-Fluorostyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>4</b> and (<i>E</i>)-<b>5</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (2.0 g, 9.38 mmol, 1.0 equiv), (4-fluorobenzyl)triphenylphosphonium bromide (4.66 g, 10.3 mmol, 1.1 equiv) and NaHMDS (2 N in THF, 5.63 mL, 11.26 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 10/1 (v/v). Overall yield of reaction: 52% (mass of both <i>Z</i> and <i>E</i> isomers, 1.5 g); isolated pure <i>Z</i> isomer, 55 mg; isolated pure <i>E</i> isomer, 155 mg; mixture of <i>E</i>/<i>Z</i> isomers, 1.29 g.</div><div class="NLM_p"><b>4</b>: <i>R</i><sub><i>f</i></sub> = 0.82 (EtOAc/n-hex = 1/2, v/v); white crystals, mp 80–82 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.34 (dt, <i>J</i> = 12.4, 4.6 Hz, 1H), 1.37 (dt, <i>J</i> = 12.7, 4.7 Hz, 1H), 1.45 (s, 9H), 1.59–1.66 (m, 2H), 2.58–2.66 (m, 1H), 2.72 (t, <i>J</i> = 11.7 Hz, 2H), 4.08 (d, <i>J</i> = 12.5 Hz, 2H), 5.44 (dd, <i>J</i> = 11.6, 10.1 Hz, 1H), 6.34 (d, <i>J</i> = 11.6 Hz, 1H), 6.99–7.05 (m, 2H), 7.16–7.21 (m, 2H). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>24</sub>FNO<sub>2</sub>Na [M + Na]<sup>+</sup> 328.1689; found 328.1688.</div><div class="NLM_p last"><b>5</b>: <i>R</i><sub><i>f</i></sub> = 0.79 (EtOAc/n-hex = 1/2, v/v); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.30–1.42 (m, 2H), 1.46 (s, 9H), 1.51–1.57 (m, 1H), 1.71–1.77 (m, 2H), 2.77 (dt, <i>J</i> = 13.2, 2.7 Hz, 2H), 4.13 (d, <i>J</i> = 13.0 Hz, 2H), 6.05 (dd, <i>J</i> = 15.9, 6.9 Hz, 1H), 6.34 (d, <i>J</i> = 16.2 Hz, 1H), 6.95–7.01 (m, 2H), 7.27–7.32 (m, 2H). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>24</sub>FNO<sub>2</sub>Na [M + Na]<sup>+</sup> 328.1689; found 328.1686.</div></div><div id="sec4_2_7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>Z</i>)-4-(4-Fluorostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>6</b>)</h3><div class="NLM_p last">Synthesized from <b>4</b> (57 mg, 0.187 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 72% (33 mg); white crystals, mp 45–46 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.51–1.61 (m, 2H), 1.69–1.76 (m, 2H), 2.21–2.28 (m, 3H), 2.45–2.55 (m, 1H), 2.90 (dt, <i>J</i> = 9.0, 2.7 Hz, 2H), 3.32 (d, <i>J</i> = 2.4 Hz, 2H), 5.48 (dd, <i>J</i> = 11.5, 10.1 Hz, 1H), 6.33 (d, <i>J</i> = 11.6 Hz, 1H), 6.99–7.05 (m, 2H), 7.17–7.21 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.16, 34.31, 47.22, 51.85, 73.21, 78.77, 115.12 (d, <i>J</i><sub>C,F</sub> = 21.3 Hz), 127.07, 130.00 (d, <i>J</i><sub>C,F</sub> = 7.9 Hz), 133.58 (d, <i>J</i><sub>C,F</sub> = 3.3 Hz), 137.05, 161.52 (d, <i>J</i><sub>C,F</sub> = 246.1 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>FN [M + H]<sup>+</sup> 244.1502; found 244.1503. IR (ATR): 3299, 2930, 1601, 1508, 1446, 1225, 1157, 972, 845, 657 cm<sup>–1</sup>. HPLC purity, 99.5% (<i>t</i><sub>R</sub> = 9.03 min).</div></div><div id="sec4_2_7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (±)-<i>tert</i>-Butyl 3-(Methoxy(methyl)carbamoyl)piperidine-1-carboxylate (<b>7</b>)</h3><div class="NLM_p">Synthesis of (±)-1-(<i>tert</i>-butoxycarbonyl)piperidine-3-carboxylic acid was carried out following the procedure described for the synthesis of compound <b>2</b>, starting from (±)-piperidine-3-carboxylic acid (7.75 g, 60.0 mmol, 1.0 equiv). Yield: 86% (11.83 g); white crystals, mp 164–165 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.43–1.53 (m, 1H), 1.45 (s, 9H), 1.59–1.75 (m, 2H), 2.03–2.09 (m, 1H), 2.48 (tt, <i>J</i> = 10.2, 4.0 Hz, 1H), 2.82–2.89 (m, 1H), 3.03 (dd, <i>J</i> = 12.7, 10.6 Hz, 1H), 3.88 (td, <i>J</i> = 13.3, 4.0 Hz, 1H), 4.08–4.15 (m, 1H), 8.67 (bs, 1H).</div><div class="NLM_p last">(±)1-(<i>Tert</i>-butoxycarbonyl)piperidine-3-carboxylic acid (10.00 g, 43.61 mmol, 1.0 equiv) was transformed to Weinreb amide <b>7</b> following the procedure described for compound <b>2</b>. Yield: 82% (9.74 g); white crystals, mp 89–91 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.41–1.52 (m, 1H), 1.44 (s, 9H), 1.58–1.73 (m, 2H), 1.87–1.94 (m, 1H), 2.68 (tt, <i>J</i> = 12.8, 2.9 Hz, 1H), 2.72–2.82 (m, 1H), 2.86 (t, <i>J</i> = 11.7 Hz, 1H), 3.17 (s, 3H), 3.72 (s, 3H), 4.05–4.15 (m, 2H).</div></div><div id="sec4_2_7_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (±)-<i>tert</i>-Butyl 3-Formylpiperidine-1-carboxylate (<b>8</b>)</h3><div class="NLM_p last">Synthesis of aldehyde <b>8</b> was carried out following the procedure described for compound <b>3</b>, starting from amide <b>7</b> (9.74 g, 35.76 mmol, 1.0 equiv). Yield: 79% (6.03 g); pale yellow oil.</div></div><div id="sec4_2_7_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (±)-<i>tert</i>-Butyl 3-(4-Fluorostyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>9</b> and (<i>E</i>)-<b>10</b>]</h3><div class="NLM_p">Synthesized from <b>8</b> (1.02 g, 4.78 mmol, 1.0 equiv), (4-fluorobenzyl)triphenylphosphonium bromide (2.59 g, 5.74 mmol, 1.2 equiv), and NaHMDS (2 N in THF, 2.87 mL, 5.74 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 10/1 (v/v) yielding pure <i>trans</i> isomer <b>10</b> (<8% <i>cis</i> isomer <b>9</b> was present in the mixture as estimated from <sup>1</sup>H NMR). Overall yield of reaction (mixture of <i>E</i>/<i>Z</i> isomers): 56% (0.817 g).</div><div class="NLM_p last"><b>10</b>: <i>R</i><sub><i>f</i></sub> = 0.38 (Et<sub>2</sub>O/petroleum ether = 1/10, v/v); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, <i>E</i> isomer): δ 1.31–1.41 (m, 1H), 1.47 (s, 9H), 1.68–1.73 (m, 1H), 1.90–1.94 (m, 1H), 2.26–2.34 (m, 1H), 2.60–2.71 (m, 1H), 2.78 (dd, <i>J</i> = 13.2, 11.5 Hz, 2H), 3.97 (d, <i>J</i> = 13.1 Hz, 2H), 5.99 (dd, <i>J</i> = 16.0, 7.0 Hz, 1H), 6.40 (d, <i>J</i> = 16.0 Hz, 1H), 6.95–7.02 (m, 2H), 7.27–7.32 (m, 2H). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>24</sub>FNO<sub>2</sub>Na [M + Na]<sup>+</sup> 328.1689; found 328.1682.</div></div><div id="sec4_2_7_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (±)-<i>tert</i>-Butyl 3-(2,4,5-Trifluorostyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>11</b> and (<i>E</i>)-<b>12</b>]</h3><div class="NLM_p">Synthesized from <b>8</b> (0.79 g, 3.71 mmol, 1.0 equiv), (2,4,5-trifluorobenzyl)triphenylphosphonium bromide (2.23 g, 4.58 mmol, 1.2 equiv), and NaHMDS (2 N in THF, 2.29 mL, 4.58 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 10/1 (v/v) to obtain a mixture of <i>cis</i>/<i>trans</i> isomers (ratio ∼40/60, estimated from <sup>1</sup>H NMR). Overall yield of reaction: 47% (mass of both <i>Z</i> and <i>E</i> isomers, 0.595 g).</div><div class="NLM_p last"><b>11</b> and <b>12</b> (mixture of both isomers): <i>R</i><sub><i>f</i></sub> = 0.34 (petroleum ether/Et<sub>2</sub>O = 10/1, v/v); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.30–1.40 (m, 3.4H), 1.45 (1.46) (s + s, 15.3H), 1.62–1.73 (m, 1.7H), 1.88–1.94 (m, 0.7H), 2.30–2.38 (m, 0.7H), 2.43–2.53 (m, 1H), 2.62–2.84 (m, 3.4H), 3.92–4.08 (m, 3.4H), 5.58 (dd, <i>J</i> = 11.5, 10.4 Hz, 0.7H), 6.07 (dd, <i>J</i> = 16.2, 7.1 Hz, 1H), 6.32 (d, <i>J</i> = 11.5 Hz, 0.7H), 6.49 (d, <i>J</i> = 16.3 Hz, 1H), 6.85–6.96 (m, 1.7H), 7.11 (ddd, <i>J</i> = 10.6, 8.8, 6.9 Hz, 1H), 7.21 (ddd, <i>J</i> = 11.2, 8.7, 7.0 Hz, 0.7H). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>22</sub>F<sub>3</sub>NO<sub>2</sub>Na [M + Na]<sup>+</sup> 364.1500; found 364.1491.</div></div><div id="sec4_2_7_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>tert</i>-Butyl 4-(2,4,5-Trifluorostyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>13</b> and (<i>E</i>)-<b>14</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (0.575 g, 2.70 mmol, 1.0 equiv), (2,4,5-trifluorobenzyl)triphenylphosphonium bromide (1.59 g, 3.25 mmol, 1.2 equiv) and NaHMDS (2 N solution in THF, 1.63 mL, 3.25 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 10/1 (v/v). Overall yield of reaction: 52% (mass of both <i>Z</i> and <i>E</i> isomers, 0.48 g); isolated pure <i>Z</i> isomer, 165 mg; isolated pure <i>E</i> isomer, 135 mg; mixture of <i>E</i>/<i>Z</i> isomers, 180 mg.</div><div class="NLM_p"><b>13</b>: <i>R</i><sub><i>f</i></sub> = 0.80 (EtOAc/n-hex = 1/2, v/v); yellow crystals, mp 86–87 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.30–1.40 (m, 2H), 1.46 (s, 9H), 1.58–1.64 (m, 2H), 2.37–2.48 (m, 1H), 2.70 (dt, <i>J</i> = 13.4, 2.7 Hz, 2H), 4.08 (td, <i>J</i> = 13.4, 2.7 Hz, 2H), 5.55 (dd, <i>J</i> = 11.4, 10.3 Hz, 1H), 6.17 (d, <i>J</i> = 11.6 Hz, 1H), 6.93 (ddd, <i>J</i> = 10.1, 9.2, 6.7 Hz, 1H), 7.01 (ddd, <i>J</i> = 10.6, 8.7, 6.9 Hz, 1H). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>22</sub>F<sub>3</sub>NO<sub>2</sub>Na [M + Na]<sup>+</sup> 364.1500; found 364.1503.</div><div class="NLM_p last"><b>14</b>: <i>R</i><sub><i>f</i></sub> = 0.78 (EtOAc/n-hex = 1/2, v/v); pale yellow crystals, mp 60–63 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.36 (dt, <i>J</i> = 12.4, 4.2 Hz, 1H), 1.39 (dt, <i>J</i> = 12.3, 4.3 Hz, 1H), 1.47 (s, 9H), 1.71–1.79 (m, 2H), 2.25–2.36 (m, 1H), 2.78 (t, <i>J</i> = 12.0 Hz, 2H), 4.14 (bs, 2H), 6.13 (dd, <i>J</i> = 16.1, 6.9 Hz, 1H), 6.44 (d, <i>J</i> = 16.1 Hz, 1H), 6.88 (dt, <i>J</i> = 9.9, 6.6 Hz, 1H), 7.01 (ddd, <i>J</i> = 11.1, 8.8, 7.0 Hz, 1H). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>22</sub>F<sub>3</sub>NO<sub>2</sub>Na [M + Na]<sup>+</sup> 364.1500; found 364.1497.</div></div><div id="sec4_2_7_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (±)-<i>tert</i>-Butyl 3-(4-Fluorophenethyl)piperidine-1-carboxylate (<b>15</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>9</b> and <b>10</b> (0.55 g, 1.80 mmol, 1.0 equiv) via general procedure C. Yield: quantitative (0.55 g); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.08–1.13 (m, 1H), 1.35–1.56 (m, 3H), 1.45 (s, 9H), 1.59–1.66 (m, 1H), 1.80–1.87 (m, 1H), 2.41–2.56 (m, 1H), 2.61 (t, <i>J</i> = 12.2 Hz, 2H), 2.79 (dt, <i>J</i> = 12.2, 2.5 Hz, 2H), 3.89 (td, <i>J</i> = 13.1, 3.9 Hz, 1H), 4.04 (bs, 1H), 6.92–6.98 (m, 2H), 7.09–7.14 (m, 2H). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>26</sub>FNO<sub>2</sub>Na [M + Na]<sup>+</sup> 330.1845; found 330.1842.</div></div><div id="sec4_2_7_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (±)-<i>tert</i>-Butyl 3-(2,4,5-Trifluorophenethyl)piperidine-1-carboxylate (<b>16</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>11</b> and <b>12</b> (0.30 g, 0.88 mmol, 1.0 equiv) via general procedure C. Yield: 97% (0.29 g); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.09–1.18 (m, 1H), 1.37–1.55 (m, 4H), 1.47 (s, 9H), 1.62–1.69 (m, 1H), 1.83–1.90 (m, 1H), 2.55 (dd, <i>J</i> = 13.0, 9.3 Hz, 1H), 2.62 (t, <i>J</i> = 7.6 Hz, 2H), 2.82 (ddd, <i>J</i> = 13.2, 11.2, 3.2 Hz, 1H), 3.89 (td, <i>J</i> = 13.2, 4.1 Hz, 1H), 3.97 (d, <i>J</i> = 12.6 Hz, 1H), 6.88 (ddd, <i>J</i> = 10.1, 9.3, 6.7 Hz, 1H), 7.00 (ddd, <i>J</i> = 10.6, 8.7, 6.9 Hz, 1H). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>24</sub>F<sub>3</sub>NO<sub>2</sub>Na [M + Na]<sup>+</sup> 366.1657; found 366.1653.</div></div><div id="sec4_2_7_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>tert</i>-Butyl 4-(4-Fluorophenethyl)piperidine-1-carboxylate (<b>17</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>4</b> and <b>5</b> (0.152 g, 0.50 mmol, 1.0 equiv) via general procedure C. Yield: quantitative (0.155 g); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.11 (dt, <i>J</i> = 12.4, 4.2 Hz, 1H), 1.14 (dt, <i>J</i> = 12.5, 4.2 Hz, 1H), 1.35–1.44 (m, 1H), 1.45 (s, 9H), 1.51–1.56 (m, 2H), 1.60–1.62 (m, 1H), 1.65–1.72 (m, 2H), 2.57–2.62 (m, 1H), 2.66 (t, <i>J</i> = 11.5 Hz, 2H), 4.07 (bs, 2H), 6.93–6.99 (m, 2H), 7.09–7.14 (m, 2H). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>26</sub>FNO<sub>2</sub>Na [M + Na]<sup>+</sup> 330.1845; found 330.1848.</div></div><div id="sec4_2_7_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>tert</i>-Butyl 4-(2,4,5-Trifluorophenethyl)piperidine-1-carboxylate (<b>18</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>13</b> and <b>14</b> (0.152 g, 0.45 mmol, 1.0 equiv) via general procedure C. Yield: quantitative (0.155 g); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.11 (dt, <i>J</i> = 12.4, 4.3 Hz, 1H), 1.14 (dt, <i>J</i> = 12.7, 4.2 Hz, 1H), 1.35–1.44 (m, 1H), 1.45 (s, 9H), 1.49–1.54 (m, 2H), 1.66–1.73 (m, 2H), 2.59 (t, <i>J</i> = 8.0 Hz, 2H), 2.66 (dt, <i>J</i> = 13.2, 2.5 Hz, 2H), 4.09 (d, <i>J</i> = 13.2 Hz, 2H), 6.87 (ddd, <i>J</i> = 10.0, 9.4, 6.7 Hz, 1H), 6.97 (ddd, <i>J</i> = 10.6, 8.8, 7.1 Hz, 1H). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>24</sub>F<sub>3</sub>NO<sub>2</sub>Na [M + Na]<sup>+</sup> 366.1657; found 366.1652.</div></div><div id="sec4_2_7_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (±)-(<i>E</i>)-3-(4-Fluorostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>19</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>9</b> and <b>10</b> (0.190 g, 2.11 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v) yielding pure <i>trans</i> isomer <b>19</b>. Yield: 45% (68 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.17 (dt, <i>J</i> = 12.3, 4.1 Hz, 1H), 1.61–1.72 (m, 1H), 1.74–1.80 (m, 1H), 1.81–1.87 (m, 1H), 2.09 (t, <i>J</i> = 10.8 Hz, 1H), 2.19 (dt, <i>J</i> = 11.4, 3.0 Hz, 1H), 2.25 (t, <i>J</i> = 2.4 Hz, 1H), 2.41–2.50 (m, 1H), 2.82–2.87 (m, 1H), 2.89–2.93 (m, 1H), 3.34 (d, <i>J</i> = 2.5 Hz, 2H), 6.04 (dd, <i>J</i> = 16.0, 7.2 Hz, 1H), 6.38 (d, <i>J</i> = 16.0 Hz, 1H), 6.95–7.01 (m, 2H), 7.28–7.33 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 24.64, 29.94, 39.41, 47.18, 52.23, 57.76, 73.97, 77.87, 115.34 (d, <i>J</i><sub>C,F</sub> = 21.7 Hz), 127.47 (d, <i>J</i><sub>C,F</sub> = 8.0 Hz), 128.41, 131.95, 133.50 (d, <i>J</i><sub>C,F</sub> = 3.3 Hz), 162.03 (d, <i>J</i><sub>C,F</sub> = 246.0 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>FN [M + H]<sup>+</sup> 244.1502; found 244.1509. IR (ATR): 3433, 3196, 2934, 2544, 2124, 1507, 1225, 1159, 1012, 858, 750, 647 cm<sup>–1</sup>. HPLC purity, 99.4% (<i>t</i><sub>R</sub> = 9.10 min).</div></div><div id="sec4_2_7_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (±)-(<i>E</i>)-1-(Prop-2-yn-1-yl)-3-(2,4,5-trifluorostyryl)piperidine (<b>20</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>11</b> and <b>12</b> (0.219 g, 0.64 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v) to obtain pure <i>trans</i> isomer <b>20</b>. Yield: 34% (61 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.21 (ddd, <i>J</i> = 15.8, 12.1, 4.1 Hz, 1H), 1.63–1.87 (m, 3H), 2.13 (t, <i>J</i> = 10.7 Hz, 1H), 2.24 (dt, <i>J</i> = 11.2, 2.6 Hz, 1H), 2.27 (t, <i>J</i> = 2.4 Hz, 1H), 2.47–2.56 (m, 1H), 2.84–2.87 (m, 1H), 2.90–2.94 (m, 1H), 3.36 (d, <i>J</i> = 2.4 Hz, 2H), 6.12 (dd, <i>J</i> = 16.1, 7.2 Hz, 1H), 6.46 (d, <i>J</i> = 16.2 Hz, 1H), 6.88 (dt, <i>J</i> = 9.9, 6.7 Hz, 1H), 7.22 (ddd, <i>J</i> = 11.1, 8.8, 7.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 24.77, 29.89, 39.90, 47.28, 52.32, 57.64, 73.44, 78.51, 105.56 (dd, <i>J</i><sub>C,F</sub> = 28.4, 21.0 Hz), 114.14 (dd, <i>J</i><sub>C,F</sub> = 19.8, 5.1 Hz), 120.01–120.02 (m), 121.74–121.93 (m), 136.12–136.16 (m), 146.93 (ddd, <i>J</i><sub>C,F</sub> = 243.9, 13.2, 3.6 Hz), 148.83 (ddd, <i>J</i><sub>C,F</sub> = 251.2, 14.8, 12.4 Hz), 154.78 (ddd, <i>J</i><sub>C,F</sub> = 248.0, 9.0, 2.1 Hz). IR (ATR): 3304, 2932, 2798, 1621, 1512, 1427, 1336, 1154, 1106, 969, 879, 850, 665 cm<sup>–1</sup>. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>17</sub>F<sub>3</sub>N [M + H]<sup>+</sup> 280.1313; found 280.1316. HPLC purity, 99.1% (<i>t</i><sub>R</sub> = 9.57 min).</div></div><div id="sec4_2_7_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>Z</i>)-1-(Prop-2-yn-1-yl)-4-(2,4,5-trifluorostyryl)piperidine (<b>21</b>)</h3><div class="NLM_p last">Synthesized from <b>13</b> (165 mg, 0.483 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 68% (92 mg); white crystals, mp 72–74 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.55 (dt, <i>J</i> = 12.5, 3.8 Hz, 1H), 1.58 (dt, <i>J</i> = 11.7, 3.8 Hz, 1H), 1.66–1.71 (m, 2H), 2.20–2.35 (m, 3H), 2.25 (t, <i>J</i> = 2.5 Hz, 1H) 2.90 (dt, <i>J</i> = 11.6, 2.8 Hz, 2H), 3.32 (d, <i>J</i> = 2.4 Hz, 2H), 5.64 (dd, <i>J</i> = 11.3, 10.4 Hz, 1H), 6.23 (d, <i>J</i> = 11.6 Hz, 1H), 6.92 (ddd, <i>J</i> = 10.0, 9.3, 6.7 Hz, 1H), 7.01 (ddd, <i>J</i> = 10.6, 8.8, 6.9 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.77, 34.96, 47.19, 51.71, 73.33, 78.62, 105.51 (dd, <i>J</i><sub>C,F</sub> = 28.7, 20.7 Hz), 117.62 (dd, <i>J</i><sub>C,F</sub> = 19.4, 4.6 Hz), 119.00, 121.36 (ddd, <i>J</i><sub>C,F</sub> = 17.7, 5.8, 4.4 Hz), 140.20, 146.36 (ddd, <i>J</i><sub>C,F</sub> = 243.7, 12.6, 3.6 Hz), 148.88 (ddd, <i>J</i><sub>C,F</sub> = 248.8, 14.4, 12.6 Hz); 154.97 (ddd, <i>J</i><sub>C,F</sub> = 246.8, 9.0, 2.7 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>17</sub>F<sub>3</sub>N [M + H]<sup>+</sup> 280.1313; found 280.1317. IR (ATR): 3293, 2905, 2824, 1618, 1503, 1423, 1310, 1192, 1151, 1133, 972, 882, 779, 679, 653 cm<sup>–1</sup>. HPLC purity, 100% (<i>t</i><sub>R</sub> = 9.47 min).</div></div><div id="sec4_2_7_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>E</i>)-1-(Prop-2-yn-1-yl)-4-(2,4,5-trifluorostyryl)piperidine (<b>22</b>)</h3><div class="NLM_p last">Synthesized from <b>14</b> (0.135 g, 0.395 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 74% (82 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.56 (dt, <i>J</i> = 12.4, 3.4 Hz, 1H), 1.59 (dt, <i>J</i> = 12.0, 3.7 Hz, 1H), 1.78–1.84 (m, 2H), 2.11–2.20 (m, 1H), 2.26 (t, <i>J</i> = 2.4 Hz, 1H), 2.30 (dt, <i>J</i> = 11.7, 2.3 Hz, 2H), 2.95 (dt, <i>J</i> = 11.6, 2.8 Hz, 2H), 3.34 (d, <i>J</i> = 2.4 Hz, 2H), 6.13 (dd, <i>J</i> = 16.1, 7.0 Hz, 1H), 6.43 (d, <i>J</i> = 16.1 Hz, 1H), 6.87 (dt, <i>J</i> = 9.9, 6.7 Hz, 1H), 7.23 (ddd, <i>J</i> = 11.1, 8.8, 7.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.69, 39.02, 47.17, 52.07, 73.23, 78.73, 105.51 (dd, <i>J</i><sub>C,F</sub> = 28.5, 20.9 Hz), 114.06 (dd, <i>J</i><sub>C,F</sub> = 19.6, 5.2 Hz), 118.96–119.03 (m), 121.95 (ddd, <i>J</i><sub>C,F</sub> = 14.8, 5.8, 4.4 Hz), 138.10–138.17 (m), 146.93 (ddd, <i>J</i><sub>C,F</sub> = 243.5, 12.9, 3.4 Hz), 148.76 (ddd, <i>J</i><sub>C,F</sub> = 251.1, 14.9, 12.6 Hz); 154.73 (ddd, <i>J</i><sub>C,F</sub> = 247.4, 9.1, 2.3 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>17</sub>F<sub>3</sub>N [M + H]<sup>+</sup> 280.1313; found 280.1318. IR (ATR): 3305, 3180, 2931, 2804, 2513, 1619, 1510, 1426, 1335, 1150, 1107, 970, 878, 706, 630 cm<sup>–1</sup>. HPLC purity, 100% (<i>t</i><sub>R</sub> = 9.57 min).</div></div><div id="sec4_2_7_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (±)-3-(4-Fluorophenethyl)-1-(prop-2-yn-1-yl)piperidine (<b>23</b>)</h3><div class="NLM_p last">Synthesized from <b>15</b> (0.193 g, 0.628 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 33% (51 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.85–0.95 (m, 1H), 1.46–1.54 (m, 2H), 1.55–1.65 (m, 2H), 1.66–1.74 (m, 1H), 1.75–1.82 (m, 1H), 1.88 (t, <i>J</i> = 10.6 Hz, 1H), 2.14 (dt, <i>J</i> = 11.4, 3.0 Hz, 1H), 2.24 (t, <i>J</i> = 2.4 Hz, 1H), 2.60 (t, <i>J</i> = 7.9 Hz, 2H), 2.79–2.83 (m, 1H), 2.84–2.89 (m, 1H), 3.30 (d, <i>J</i> = 2.4 Hz, 2H), 6.91–6.97 (m, 2H), 7.09–7.14 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 25.03, 30.25, 32.26, 35.55, 36.44, 47.29, 52.72, 58.53, 73.49, 78.45, 115.00 (d, <i>J</i><sub>C,F</sub> = 21.0 Hz), 129.54 (d, <i>J</i><sub>C,F</sub> = 7.9 Hz), 138.00 (d, <i>J</i><sub>C,F</sub> = 3.2 Hz), 161.13 (d, <i>J</i><sub>C,F</sub> = 243.3 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>21</sub>FN [M + H]<sup>+</sup> 246.1658; found 246.1652. IR (ATR): 3302, 2929, 2853, 2797, 1601, 1509, 1452, 1222, 1157, 1106, 828, 661 cm<sup>–1</sup>. HPLC purity, 98.5% (<i>t</i><sub>R</sub> = 9.16 min).</div></div><div id="sec4_2_7_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (±)-3-(2,4,5-Trifluorophenethyl)-1-(prop-2-yn-1-yl)piperidine (<b>24</b>)</h3><div class="NLM_p last">Synthesized from <b>16</b> (0.181 g, 0.527 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 26% (39 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.88–0.98 (m, 1H), 1.45–1.56 (m, 2H), 1.58–1.77 (m, 3H), 1.78–1.85 (m, 1H), 1.91–2.00 (m, 1H), 2.17–2.25 (m, 1H), 2.26–2.29 (m, 1H), 2.54–2.66 (m, 2H), 2.88 (t, <i>J</i> = 12.6 Hz, 2H), 3.35 (d, <i>J</i> = 2.5 Hz, 2H), 6.86 (ddd, <i>J</i> = 10.0, 9.5, 6.7 Hz, 1H), 6.98 (ddd, <i>J</i> = 10.6, 8.8, 6.9 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 25.08, 25.67, 30.21, 34.61, 35.62, 47.33, 52.76, 58.46, 73.28, 78.69, 105.20 (dd, <i>J</i><sub>C,F</sub> = 28.6, 20.6 Hz), 117.71 (dd, <i>J</i><sub>C,F</sub> = 18.7, 6.2 Hz), 125.50 (td, <i>J</i><sub>C,F</sub> = 18.1, 4.4 Hz), 146.57 (ddd, <i>J</i><sub>C,F</sub> = 243.7, 12.4, 3.7 Hz), 148.14 (ddd, <i>J</i><sub>C,F</sub> = 248.6, 14.3, 12.5 Hz), 155.73 (ddd, <i>J</i><sub>C,F</sub> = 243.8, 9.2, 2.7 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>F<sub>3</sub>N [M + H]<sup>+</sup> 282.1470; found 282.1464. IR (ATR): 3306, 2931, 2798, 1515, 1422, 1331, 1209, 1150, 1100, 843, 659 cm<sup>–1</sup>. HPLC purity, 100% (<i>t</i><sub>R</sub> = 9.57 min).</div></div><div id="sec4_2_7_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 4-(4-Fluorophenethyl)-1-(prop-2-yn-1-yl)piperidine (<b>25</b>)</h3><div class="NLM_p last">Synthesized from <b>17</b> (0.130 g, 0.423 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 85% (88 mg); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.21–1.40 (m, 3H), 1.52–1.57 (m, 2H), 1.73–1.79 (m, 2H), 2.19–2.24 (m, 2H), 2.25 (t, <i>J</i> = 2.4 Hz, 1H), 2.57–2.61 (m, 2H), 2.89–2.93 (m, 2H), 3.33 (d, <i>J</i> = 2.4 Hz, 2H), 6.92–6.98 (m, 2H), 7.09–7.14 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.07, 32.21, 34.61, 38.35, 47.16, 52.48, 73.09, 78.90, 114.99 (d, <i>J</i><sub>C,F</sub> = 21.1 Hz), 129.54 (d, <i>J</i><sub>C,F</sub> = 7.9 Hz), 138.16 (d, <i>J</i><sub>C,F</sub> = 3.1 Hz), 161.11 (d, <i>J</i><sub>C,F</sub> = 243.2 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>21</sub>FN [M + H]<sup>+</sup> 246.1658; found 246.1657. IR (ATR): 3300, 2923, 1601, 1508, 1453, 1218, 1156, 824, 642 cm<sup>–1</sup>. HPLC purity, 97.5% (<i>t</i><sub>R</sub> = 9.15 min).</div></div><div id="sec4_2_7_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 1-(Prop-2-yn-1-yl)-4-(2,4,5-trifluorophenethyl)piperidine (<b>26</b>)</h3><div class="NLM_p last">Synthesized from <b>18</b> (0.175 g, 0.509 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 32% (45 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.22–1.39 (m, 3H), 1.49–1.55 (m, 2H), 1.72–1.79 (m, 2H), 2.17–2.23 (m, 2H), 2.23–2.25 (m, 1H), 2.59 (t, <i>J</i> = 7.8 Hz, 2H), 2.88–2.93 (m, 2H), 3.30–3.32 (m, 2H), 6.86 (ddd, <i>J</i> = 10.0, 9.5, 6.7 Hz, 1H), 6.97 (ddd, <i>J</i> = 10.7, 8.8, 6.5 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 25.56, 31.94, 34.68, 36.55, 47.13, 52.40, 73.16, 78.81, 105.18 (dd, <i>J</i><sub>C,F</sub> = 28.7, 20.6 Hz), 117.66 (dd, <i>J</i><sub>C,F</sub> = 19.1, 6.5 Hz), 125.50–125.82 (m), 146.57 (ddd, <i>J</i><sub>C,F</sub> = 243.6, 12.6, 3.2 Hz), 148.09 (ddd, <i>J</i><sub>C,F</sub> = 249.2, 13.4, 11.5 Hz); 155.72 (ddd, <i>J</i><sub>C,F</sub> = 243.4, 9.3, 2.7 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>F<sub>3</sub>N [M + H]<sup>+</sup> 282.1470; found 282.1471. IR (ATR): 3306, 2920, 2803, 1517, 1423, 1334, 1210, 1151, 1108, 876, 660 cm<sup>–1</sup>. HPLC purity, 100% (<i>t</i><sub>R</sub> = 9.63 min).</div></div><div id="sec4_2_7_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Wittig Salts (<b>27a</b>–<b>l</b>)</h3><div class="NLM_p last">Synthesized according to general procedure A. The product was used in next reaction step without purification.</div></div><div id="sec4_2_7_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>tert</i>-Butyl 4-Styrylpiperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>28</b> and (<i>E</i>)-<b>29</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (2.00 g, 9.38 mmol, 1.0 equiv), benzyltriphenylphosphonium chloride (4.01 g, 10.32 mmol, 1.1 equiv), and NaHMDS (2 N in THF, 5.63 mL, 11.26 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 9/1 (v/v). Overall yield of reaction: 66% (mass of both <i>Z</i> and <i>E</i> isomers, 1.78 g); isolated pure <i>Z</i> isomer, 95 mg; isolated pure <i>E</i> isomer, 285 mg; mixture of <i>E</i>/<i>Z</i> isomers, 1.4 g.</div><div class="NLM_p"><b>28</b>: <i>R</i><sub><i>f</i></sub> = 0.31 (petroleum ether/Et<sub>2</sub>O = 9/1, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.36 (ddd, <i>J</i> = 17.1, 13.9, 5.3 Hz, 2H), 1.46 (s, 9H), 1.65–1.68 (m, 2H), 2.68–2.76 (m, 3H), 4.08 (bs, 2H), 5.45 (dd, <i>J</i> = 11.7, 10.0 Hz, 1H), 6.39 (d, <i>J</i> = 11.7 Hz, 1H), 7.21–7.25 (m, 3H), 7.31–7.35 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 310.18; found 310.17.</div><div class="NLM_p last"><b>29</b>: <i>R</i><sub><i>f</i></sub> = 0.28 (petroleum ether/Et<sub>2</sub>O = 9/1, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.36 (ddd, <i>J</i> = 16.6, 12.6, 4.5 Hz, 2H), 1.47 (s, 9H), 1.73–1.76 (m, 2H), 2.22–2.31 (m, 1H), 2.77 (t, <i>J</i> = 11.5 Hz, 2H), 4.12 (bs, 2H), 6.13 (dd, <i>J</i> = 17.0, 6.9 Hz, 1H), 6.38 (d, <i>J</i> = 16.0 Hz, 1H), 7.17–7.21 (m, 1H), 7.27–7.35 (m, 4H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 310.18; found 310.12.</div></div><div id="sec4_2_7_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>tert</i>-Butyl 4-(3-Fluorostyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>30</b> and (<i>E</i>)-<b>31</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (2.00 g, 9.38 mmol, 1.0 equiv), <b>27a</b> (4.20 g, 10.32 mmol, 1.1 equiv), and NaHMDS (2 N in THF, 5.63 mL, 11.26 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 10/1 (v/v). Overall yield of reaction: 56% (mass of both <i>Z</i> and <i>E</i> isomers, 1.60 g); isolated pure <i>Z</i> isomer, 120 mg; isolated pure <i>E</i> isomer, 355 mg; mixture of <i>E</i>/<i>Z</i> isomers, 1.125 g.</div><div class="NLM_p"><b>30</b>: <i>R</i><sub><i>f</i></sub> = 0.70 (EtOAc/n-hex = 1/2, v/v); pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.35 (dt, <i>J</i> = 12.4, 3.9 Hz, 1H), 1.38 (dt, <i>J</i> = 12.2, 3.7 Hz, 1H), 1.46 (s, 9H), 1.60–1.69 (m, 2H), 2.62–2.77 (m, 3H), 4.09 (bs, 2H), 5.50 (dd, <i>J</i> = 11.6, 10.2 Hz, 1H), 6.35 (d, <i>J</i> = 11.6 Hz, 1H), 6.91–6.97 (m, 2H), 6.99–7.01 (m, 1H), 7.27–7.32 (m, 1H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 328.17; found 328.42.</div><div class="NLM_p last"><b>31</b>: <i>R</i><sub><i>f</i></sub> = 0.67 (EtOAc/n-hex = 1/2, v/v); white crystals, mp 45–46 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.31–1.44 (m, 2H), 1.47 (s, 9H), 1.71–1.78 (m, 2H), 2.23–2.33 (m, 1H), 2.78 (t, <i>J</i> = 12.2 Hz, 2H), 4.13 (bs, 2H), 6.15 (dd, <i>J</i> = 16.0, 6.8 Hz, 1H), 6.35 (d, <i>J</i> = 16.0 Hz, 1H), 6.89 (ddt, <i>J</i> = 8.4, 2.6, 0.9 Hz, 1H), 7.02–7.06 (m, 1H), 7.07–7.11 (m, 1H), 7.25 (td, <i>J</i> = 8.0, 5.8 Hz, 1H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 328.17; found 328.40.</div></div><div id="sec4_2_7_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>tert</i>-Butyl 4-(2-Fluorostyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>32</b> and (<i>E</i>)-<b>33</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (1.50 g, 7.04 mmol, 1.0 equiv), <b>27b</b> (3.49 g, 7.74 mmol, 1.1 equiv), and NaHMDS (2 N in THF, 4.22 mL, 8.45 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 10/1 (v/v). Overall yield of reaction: 58% (mass of both <i>Z</i> and <i>E</i> isomers, 1.25 g); isolated pure <i>Z</i> isomer, 252 mg; isolated pure <i>E</i> isomer, 194 mg; mixture of <i>E</i>/<i>Z</i> isomers, 0.804 g.</div><div class="NLM_p"><b>32</b>: <i>R</i><sub><i>f</i></sub> = 0.16 (petroleum ether/Et<sub>2</sub>O = 10/1, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.27–1.40 (m, 2H), 1.43 (s, 9H), 1.56–1.62 (m, 2H), 2.44–2.54 (m, 1H), 2.61–2.70 (m, 2H), 4.09 (bs, 2H), 5.53 (dd, <i>J</i> = 11.6, 10.2 Hz, 1H), 6.33 (d, <i>J</i> = 11.6 Hz, 1H), 6.96 (ddd, <i>J</i> = 10.8, 8.2, 1.3 Hz, 1H), 7.00–7.10 (m, 2H), 7.17–7.22 (m, 1H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 328.17; found 328.42.</div><div class="NLM_p last"><b>33</b>: <i>R</i><sub><i>f</i></sub> = 0.14 (petroleum ether/Et<sub>2</sub>O = 10/1, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.36 (dt, <i>J</i> = 12.3, 4.2 Hz, 1H), 1.39 (dt, <i>J</i> = 12.3, 4.2 Hz, 1H), 1.46 (s, 9H), 1.70–1.77 (m, 2H), 2.23–2.33 (m, 1H), 2.76 (t, <i>J</i> = 11.0 Hz, 2H), 4.12 (bs, 2H), 6.20 (dd, <i>J</i> = 16.1, 7.0 Hz, 1H), 6.53 (d, <i>J</i> = 16.1 Hz, 1H), 6.99 (ddd, <i>J</i> = 10.8, 8.1, 1.2 Hz, 1H), 7.05 (dt, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.12–7.18 (m, 1H), 7.41 (dt, <i>J</i> = 7.7, 1.8 Hz, 1H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 328.17; found 328.42.</div></div><div id="sec4_2_7_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>tert</i>-Butyl 4-(2-Chloro-4-fluorostyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>34</b> and (<i>E</i>)-<b>35</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (1.50 g, 7.03 mmol, 1.0 equiv), <b>27c</b> (3.76 g, 7.74 mmol, 1.1 equiv) and NaHMDS (2 N in THF, 4.22 mL, 8.44 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 10/1 (v/v). Overall yield of reaction: 52% (mass of both <i>Z</i> and <i>E</i> isomers, 1.24 g); isolated pure <i>Z</i> isomer, 114 mg; isolated pure <i>E</i> isomer, 285 mg; mixture of <i>E</i>/<i>Z</i> isomers, 0.841 g.</div><div class="NLM_p"><b>34</b>: <i>R</i><sub><i>f</i></sub> = 0.73 (EtOAc/n-hex = 1/2, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.27 (dt, <i>J</i> = 12.9, 4.4 Hz, 1H), 1.30 (dt, <i>J</i> = 12.3, 4.0 Hz, 1H), 1.39 (s, 9H), 1.50–1.58 (m, 2H), 2.60–2.40 (m, 1H), 2.60 (t, <i>J</i> = 11.4 Hz, 2H), 4.01 (bs, 2H), 5.51 (dd, <i>J</i> = 11.4, 10.2 Hz, 1H), 6.29 (d, <i>J</i> = 11.5 Hz, 1H), 6.89 (dt, <i>J</i> = 8.5, 3.0 Hz, 1H), 7.06 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 7.13 (dd, <i>J</i> = 8.6, 6.2 Hz, 1H). MS (ESI+): <i>m</i>/<i>z</i> [M + K]<sup>+</sup> 378.10; found 378.66.</div><div class="NLM_p last"><b>35</b>: <i>R</i><sub><i>f</i></sub> = 0.68 (EtOAc/n-hex = 1/2, v/v); white crystals, mp 90–92 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.36 (dt, <i>J</i> = 12.4, 4.1 Hz, 1H), 1.39 (dt, <i>J</i> = 12.3, 4.2 Hz, 1H), 1.46 (s, 9H), 1.72–1.79 (m, 2H), 2.27–2.36 (m, 1H), 2.77 (t, <i>J</i> = 11.4 Hz, 2H), 4.13 (bs, 2H), 6.04 (dd, <i>J</i> = 15.9, 6.9 Hz, 1H), 6.67 (d, <i>J</i> = 15.9 Hz, 1H), 6.92 (dt, <i>J</i> = 8.4, 2.6 Hz, 1H), 7.07 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 7.44 (dd, <i>J</i> = 8.8, 6.1 Hz, 1H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 362.13; found 362.40.</div></div><div id="sec4_2_7_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>tert</i>-Butyl 4-(4-Methylstyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>36</b> and (<i>E</i>)-<b>37</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (1.49 g, 7.00 mmol, 1.0 equiv), <b>27d</b> (3.13 g, 7.00 mmol, 1.0 equiv), and KHMDS (0.5 M in toluene, 15.40 mL, 7.70 mmol, 1.1 equiv) via general procedure B. Column chromatography, EtOAc/n-hex = 1/5 (v/v). Overall yield of reaction: 45% (mass of both <i>Z</i> and <i>E</i> isomers, 0.94 g); isolated pure <i>Z</i> isomer, 159 mg; isolated pure <i>E</i> isomer, 155 mg; mixture of <i>E</i>/<i>Z</i> isomers, 0.626 g.</div><div class="NLM_p"><b>36</b>: <i>R</i><sub><i>f</i></sub> = 0.75 (EtOAc/n-hex = 1/5, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.29–1.41 (m, 2H), 1.46 (s, 9H), 1.64–1.70 (m, 2H), 2.35 (s, 3H), 2.66–2.77 (m, 3H), 4.08 (bs, 2H), 5.41 (dd, <i>J</i> = 11.6, 10.0 Hz, 1H), 6.36 (d, <i>J</i> = 11.5 Hz, 1H), 7.12–7.17 (m, 4H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 324.19; found 324.63.</div><div class="NLM_p last"><b>37</b>: <i>R</i><sub><i>f</i></sub> = 0.72 (EtOAc/n-hex = 1/5, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.36 (dt, <i>J</i> = 12.2, 4.2 Hz, 1H), 1.39 (dt, <i>J</i> = 12.4, 4.3 Hz, 1H), 1.47 (s, 9H), 1.71–1.78 (m, 2H), 2.22–2.31 (m, 1H), 2.32 (s, 3H), 2.77 (t, <i>J</i> = 12,6 Hz, 2H), 4.12 (bs, 2H), 6.09 (dd, <i>J</i> = 16.0, 6.9 Hz, 1H), 6.35 (d, <i>J</i> = 15.8 Hz, 1H), 7.09–7.12 (m, 2H), 7.22–7.25 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 302.21; found 302.60.</div></div><div id="sec4_2_7_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>tert</i>-Butyl 4-(4-Isopropylstyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>38</b> and (<i>E</i>)-<b>39</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (1.30 g, 6.10 mmol, 1.0 equiv), <b>27e</b> (3.19 g, 6.71 mmol, 1.1 equiv), and NaHMDS (2 N in THF, 3.66 mL, 7.32 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 9/1 (v/v). Overall yield of reaction: 65% (mass of both <i>Z</i> and <i>E</i> isomers, 1.78 g); isolated pure <i>Z</i> isomer, 194 mg; isolated pure <i>E</i> isomer, 235 mg; mixture of <i>E</i>/<i>Z</i> isomers, 1.351 g.</div><div class="NLM_p"><b>38</b>: <i>R</i><sub><i>f</i></sub> = 0.31 (petroleum ether/Et<sub>2</sub>O = 10/1, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.28 (d, <i>J</i> = 7.0 Hz, 6H), 1.36 (dd, <i>J</i> = 11.9, 3.3 Hz, 1H), 1.39 (dd, <i>J</i> = 11.8, 3.0 Hz, 1H), 1.49 (s, 9H), 1.68–1.75 (m, 2H), 2.72–2.81 (m, 3H), 2.92 (sept, <i>J</i> = 6.9 Hz, 1H), 4.11 (bs, 2H), 5.42 (dd, <i>J</i> = 11.7, 10.0 Hz, 1H), 6.36 (d, <i>J</i> = 11.7 Hz, 1H), 7.18–7.23 (m, 4H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 352.22; found 352.00.</div><div class="NLM_p last"><b>39</b>: <i>R</i><sub><i>f</i></sub> = 0.24 (petroleum ether/Et<sub>2</sub>O = 10/1, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.25 (d, <i>J</i> = 7.0 Hz, 6H), 1.37 (dd, <i>J</i> = 12.8, 4.1 Hz, 1H), 1.40 (dd, <i>J</i> = 12.1, 3.9 Hz, 1H), 1.49 (s, 9H), 1.71–1.79 (m, 2H), 2.22–2.30 (m, 1H), 2.78 (t, <i>J</i> = 11.4 Hz, 2H), 2.89 (sept, <i>J</i> = 7.0 Hz, 1H), 4.14 (bs, 2H), 6.11 (dd, <i>J</i> = 16.0, 6.9 Hz, 1H), 6.38 (d, <i>J</i> = 15.9 Hz, 1H), 7.16–7.18 (m, 2H), 7.28–7.30 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 352.22; found 352.01.</div></div><div id="sec4_2_7_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>tert</i>-Butyl 4-(4-Chlorostyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>40</b> and (<i>E</i>)-<b>41</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (2.00 g, 9.38 mmol, 1.0 equiv), <b>27f</b> (4.37 g, 10.32 mmol, 1.1 equiv), and NaHMDS (2 N in THF, 5.63 mL, 11.26 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 10/1 (v/v). Overall yield of reaction: 63% (mass of both <i>Z</i> and <i>E</i> isomers, 1.78 g); isolated pure <i>Z</i> isomer, 202 mg; isolated pure <i>E</i> isomer, 221 mg; mixture of <i>E</i>/<i>Z</i> isomers, 1.357 g.</div><div class="NLM_p"><b>40</b>: <i>R</i><sub><i>f</i></sub> = 0.15 (petroleum ether/Et<sub>2</sub>O = 10/1, v/v); white crystals, mp 69–70 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.38 (ddd, <i>J</i> = 17.4, 13.3, 4.7 Hz, 2H), 1.46 (s, 9H), 1.61–1.67 (m, 2H), 2.58–2.76 (m, 3H), 4.08 (bs, 2H), 5.47 (dd, <i>J</i> = 11.6, 10.1 Hz, 1H), 6.36 (d, <i>J</i> = 11.7 Hz, 1H), 7.14–7.17 (m, 2H), 7.28–7.32 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 344.14; found 344.54.</div><div class="NLM_p last"><b>41</b>: <i>R</i><sub><i>f</i></sub> = 0.10 (petroleum ether/Et<sub>2</sub>O = 10/1, v/v); white crystals, mp 60–62 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.35 (dd, <i>J</i> = 12.4, 4.1 Hz, 1H), 1.38 (dd, <i>J</i> = 12.2, 4.1 Hz, 1H), 1.46 (s, 9H), 1.71–1.77 (m, 2H), 2.22–2.31 (m, 1H), 2.77 (t, <i>J</i> = 11.5 Hz, 2H), 4.14 (bs, 2H), 6.11 (dd, <i>J</i> = 16.0, 6.9 Hz, 1H), 6.32 (dd, <i>J</i> = 16.0, 1.2 Hz, 1H), 7.52 (s, 4H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 344.14; found 344.48.</div></div><div id="sec4_2_7_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>tert</i>-Butyl 4-(4-Bromostyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>42</b> and (<i>E</i>)-<b>43</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (2.00 g, 9.38 mmol, 1.0 equiv), <b>27g</b> (5.28 g, 10.31 mmol, 1.1 equiv), and NaHMDS (2 N in THF, 5.63 mL, 11.26 mmol, 1.2 equiv) via general procedure B. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Overall yield of reaction: 48% (mass of both <i>Z</i> and <i>E</i> isomers, 1.66 g); pure <i>Z</i> isomer was not isolated; isolated pure <i>E</i> isomer, 325 mg; mixture of <i>E</i>/<i>Z</i> isomers, 1.335 g.</div><div class="NLM_p last"><b>43</b>: <i>R</i><sub><i>f</i></sub> = 0.40 (EtOAc/n-hex = 1/2, v/v); white crystals, mp 65–67 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.36 (dt, <i>J</i> = 12.4, 4.2 Hz, 1H), 1.39 (dt, <i>J</i> = 12.4, 4.5 Hz, 1H), 1.47 (s, 9H), 1.71–1.78 (m, 2H), 2.22–2.32 (m, 1H), 2.74–2.81 (m, 2H), 4.12 (bs, 2H), 6.13 (dd, <i>J</i> = 16.0, 6.8 Hz, 1H), 6.32 (d, <i>J</i> = 16.0 Hz, 1H), 7.19–7.22 (m, 2H), 7.39–7.43 (m, 2H).</div></div><div id="sec4_2_7_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>tert</i>-Butyl 4-(4-Methoxystyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>44</b> and (<i>E</i>)-<b>45</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (1.87 g, 8.77 mmol, 1.0 equiv), <b>27h</b> (4.04 g, 9.65 mmol, 1.1 equiv), and NaHMDS (2 N in THF, 5.26 mL, 10.52 mmol, 1.2 equiv) via general procedure B. Column chromatography, EtOAc/n-hex = 1/9 (v/v) yielding a mixture of <i>cis/trans</i> isomers (ratio 20/80, estimated from <sup>1</sup>H NMR). Overall yield of reaction: 40% (mass of both <i>Z</i> and <i>E</i> isomers, 1.12 g); pure <i>Z</i> and <i>E</i> isomers were not isolated.</div><div class="NLM_p last"><b>44</b> and <b>45</b> (mixture of both isomers): <i>R</i><sub><i>f</i></sub> = 0.13 (EtOAc/n-hex = 1/9, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.31–1.41 (m, 2.6H), 1.46–1.47 (m, 11.5H), 1.63–1.75 (m, 2.6H), 2.20–2.29 (m, 1H), 2.69–2.82 (m, 2.6H), 3.78 (s, 3H), 3.78 (s, 0.7H), 4.12 (bs, 2.6H), 5.36 (dd, <i>J</i> = 11.6, 10.0 Hz, 0.2H), 5.99 (dd, <i>J</i> = 16.0, 6.9 Hz, 1H), 6.30–6.34 (m, 1.2H), 6.81–6.85 (m, 2H), 6.85–6.89 (m, 0.5H), 7.16–7.19 (m, 0.5H), 7.24–7.29 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 340.19; found 340.04.</div></div><div id="sec4_2_7_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> <i>tert</i>-Butyl 4-(4-(Trifluoromethyl)styryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>46</b> and (<i>E</i>)-<b>47</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (2.00 g, 9.38 mmol, 1.0 equiv), <b>27i</b> (5.56 g, 10.32 mmol, 1.1 equiv), and NaHMDS (2 N in THF, 5.63 mL, 11.26 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 9/1 (v/v). Overall yield of reaction: 66% (mass of both <i>Z</i> and <i>E</i> isomers, 2.18 g); isolated pure <i>Z</i> isomer, 85 mg; isolated pure <i>E</i> isomer, 780 mg; mixture of <i>E</i>/<i>Z</i> isomers, 1.305 g.</div><div class="NLM_p"><b>46</b>: <i>R</i><sub><i>f</i></sub> = 0.23 (petroleum ether/Et<sub>2</sub>O = 9/1, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.32–1.42 (m, 2H), 1.45 (s, 9H), 1.62–1.67 (m, 2H), 2.59–2.68 (m, 1H), 2.71 (t, <i>J</i> = 12.8 Hz, 2H), 4.09 (bs, 2H), 5.56 (dd, <i>J</i> = 11.7, 10.2 Hz, 1H), 6.36 (d, <i>J</i> = 11.7 Hz, 1H), 7.32 (d, <i>J</i> = 8.5 Hz, 2H), 7.58 (d, <i>J</i> = 8.1 Hz, 2H).</div><div class="NLM_p last"><b>47</b>: <i>R</i><sub><i>f</i></sub> = 0.18 (petroleum ether/Et<sub>2</sub>O = 9/1, v/v); white crystals, mp 46–48 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.35 (dd, <i>J</i> = 12.2, 4.1 Hz, 1H), 1.39 (dd, <i>J</i> = 12.5, 4.1 Hz, 1H), 1.46 (s, 9H), 1.71–1.77 (m, 2H), 2.24–2.33 (m, 1H), 2.76 (t, <i>J</i> = 11.4 Hz, 2H), 4.14 (bs, 2H), 6.22 (dd, <i>J</i> = 16.0, 6.8 Hz, 1H), 6.38 (d, <i>J</i> = 16.1 Hz, 1H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 7.51 (d, <i>J</i> = 8.2 Hz, 2H).</div></div><div id="sec4_2_7_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>tert</i>-Butyl 4-(3-(Trifluoromethyl)styryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>48</b> and (<i>E</i>)-<b>49</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (1.49 g, 7.00 mmol, 1.0 equiv), <b>27j</b> (3.51 g, 7.00 mmol, 1.0 equiv), and KHMDS (0.5 M in toluene, 15.40 mL, 7.70 mmol, 1.1 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 8/1, (v/v). Overall yield of reaction: 62% (mass of both <i>Z</i> and <i>E</i> isomers, 1.53 g); isolated pure <i>Z</i> isomer, 51 mg; isolated pure <i>E</i> isomer, 404 mg; mixture of <i>E</i>/<i>Z</i> isomers, 1.075 g.</div><div class="NLM_p"><b>48</b>: <i>R</i><sub><i>f</i></sub> = 0.20 (petroleum ether/Et<sub>2</sub>O = 8/1, v/v), colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ: 1.35 (dt, <i>J</i> = 12.6, 4.0 Hz, 1H), 1.36–1.43 (m, 1H), 1.45 (s, 9H), 1.61–1.68 (m, 2H), 2.56–2.66 (m, 1H), 2.71 (t, <i>J</i> = 11.2 Hz, 2H), 4.08 (bs, 2H), 5.55 (dd, <i>J</i> = 11.6, 10.2 Hz, 1H), 6.40 (d, <i>J</i> = 11.6 Hz, 1H), 7.38–7.50 (m, 4H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 378.17; found 378.76.</div><div class="NLM_p last"><b>49</b><i>: R</i><sub>f</sub> = 0.15 (petroleum ether/Et<sub>2</sub>O = 8/1, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.37 (dt, <i>J</i> = 12.4, 4.3 Hz, 1H), 1.40 (dt, <i>J</i> = 12.2, 4.1 Hz, 1H), 1.47 (s, 9H), 1.73–1.80 (m, 2H), 2.26–2.36 (m, 1H), 2.78 (t, <i>J</i> = 12.0 Hz, 2H), 4.14 (bs, 2H), 6.22 (dd, <i>J</i> = 16.0, 6.9 Hz, 1H), 6.41 (d, <i>J</i> = 16.0 Hz, 1H), 7.38–7.46 (m, 2H), 7.48–7.51 (m, 1H), 7.57–7.59 (m, 1H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 378.17; found 378.69.</div></div><div id="sec4_2_7_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>tert</i>-Butyl 4-(4-Cyanostyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>50</b> and (<i>E</i>)-<b>51</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (2.35 g, 11.02 mmol, 1.0 equiv), <b>27k</b> (5.56 g, 12.12 mmol, 1.1 equiv), and NaHMDS (2 N in THF, 6.61 mL, 13.22 mmol, 1.2 equiv) via general procedure B. Column chromatography, petroleum ether/Et<sub>2</sub>O = 3/1 (v/v). Overall yield of reaction: 39% (mass of both <i>Z</i> and <i>E</i> isomers, 1.35 g); isolated pure <i>Z</i> isomer, 370 mg; isolated pure <i>E</i> isomer, 320 mg; mixture of <i>E</i>/<i>Z</i> isomers, 0.66 g.</div><div class="NLM_p"><b>50</b>: <i>R</i><sub><i>f</i></sub> = 0.20 (petroleum ether/Et<sub>2</sub>O = 3/1, v/v); white crystals, mp 65–68 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.31–1.40 (m, 2H), 1.43 (s, 9H), 1.57–1.64 (m, 2H), 2.54–2.64 (m, 1H), 2.70 (t, <i>J</i> = 11.7 Hz, 2H), 4.05 (bs, 2H), 5.58 (dd, <i>J</i> = 11.7, 10.2 Hz, 1H), 6.36 (d, <i>J</i> = 11.8 Hz, 1H), 7.28–7.31 (m, 2H), 7.58–7.61 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 335.17; found 335.31.</div><div class="NLM_p last"><b>51</b>: <i>R</i><sub><i>f</i></sub> = 0.14 (petroleum ether/Et<sub>2</sub>O = 3/1, v/v); white crystals, mp 88–90 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.30–1.40 (m, 2H), 1.43 (s, 9H), 1.70–1.75 (m, 2H), 2.25–2.34 (m, 1H), 2.75 (t, <i>J</i> = 10.7 Hz, 2H), 4.11 (bs, 2H), 6.26 (dd, <i>J</i> = 16.0, 6.6 Hz, 1H), 6.36 (d, <i>J</i> = 16.0 Hz, 1H), 7.37–7.39 (m, 2H), 7.52–7.55 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M – H]<sup>−</sup> 311.17; found 311.37.</div></div><div id="sec4_2_7_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>tert</i>-Butyl 4-(4-(Methylsulfonyl)styryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>52</b> and (<i>E</i>)-<b>53</b>]</h3><div class="NLM_p">Synthesized from aldehyde <b>3</b> (0.94 g, 4.10 mmol, 1.0 equiv), <b>27l</b> (1.94 g, 4.50 mmol, 1.1 equiv), and NaHMDS (2 N in THF, 2.45 mL, 4.90 mmol, 1.2 equiv) via general procedure B. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Overall yield of reaction: 30% (mass of both <i>Z</i> and <i>E</i> isomers, 0.46 g); isolated pure <i>Z</i> isomer, 180 mg; isolated pure <i>E</i> isomer, 260 mg; mixture of <i>E</i>/<i>Z</i> isomers, 0.02 g.</div><div class="NLM_p"><b>52</b>: <i>R</i><sub><i>f</i></sub> = 0.27 (EtOAc/n-hex = 1/2, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.34–1.45 (m, 2H), 1.47 (s, 9H), 1.62–1.69 (m, 2H), 2.58–2.68 (m, 1H), 2.72 (t, <i>J</i> = 12.0 Hz, 2H), 3.08 (s, 3H), 4.11 (bs, 2H), 5.62 (dd, <i>J</i> = 11.6, 10.4 Hz, 1H), 6.44 (d, <i>J</i> = 11.6 Hz, 1H), 7.40–7.43 (m, 2H), 7.90–7.93 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 388.16; found 387.91.</div><div class="NLM_p last"><b>53</b>: <i>R</i><sub><i>f</i></sub> = 0.22 (EtOAc/n-hex = 1/2, v/v); white crystals, mp 93–97 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.38 (dt, <i>J</i> = 12.4, 4.1 Hz, 1H), 1.41 (dd, <i>J</i> = 12.4, 4.0 Hz, 1H), 1.47 (s, 9H), 1.75–1.83 (m, 2H), 2.30–2.39 (m, 1H), 2.79 (t, <i>J</i> = 10.7 Hz, 2H), 3.05 (s, 3H), 4.15 (bs, 2H), 6.33 (dd, <i>J</i> = 16.0, 6.7 Hz, 1H), 6.45 (d, <i>J</i> = 16.0 Hz, 1H), 7.50–7.53 (m, 2H), 7.85–7.88 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 388.16; found 387.91.</div></div><div id="sec4_2_7_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> <i>tert</i>-Butyl 4-(4-Cyclopropylstyryl)piperidine-1-carboxylate [Isomers (<i>Z</i>)-<b>54</b> and (<i>E</i>)-<b>55</b>]</h3><div class="NLM_p">To the solution of <b>42</b> and <b>43</b> (0.733 g, 2.0 mmol, 1.0 equiv), cyclopropylboronic acid (0.224 g, 2.60 mmol, 1.3 equiv), K<sub>3</sub>PO<sub>4</sub> (1.48 g, 7.00 mmol, 3.5 equiv) and tricyclohexylphosphine (20% solution in toluene, 0.316 mL, 0.20 mmol, 0.1 equiv) in toluene (10 mL) and water (0.4 mL), Pd(OAc)<sub>2</sub> (23 mg, 0.1 mmol, 0.05 equiv) was added under an argon atmosphere. The reaction mixture was stirred at 100 °C for 3 h and then allowed to cool down to room temperature. Water (20 mL) was added to the mixture, which was then transferred into a separating funnel, and extracted with EtOAc (2 × 50 mL). Combined organic layers were washed with saturated brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. Column chromatography, petroleum ether/Et<sub>2</sub>O = 10/1 (v/v). Overall yield of reaction: 78% (mass of both <i>Z</i> and <i>E</i> isomers, 0.511 g); isolated pure <i>Z</i> isomer, 85 mg; isolated pure <i>E</i> isomer, 210 mg; mixture of <i>E</i>/<i>Z</i> isomers, 0.216 g.</div><div class="NLM_p"><b>54</b>: <i>R</i><sub><i>f</i></sub> = 0.29 (petroleum ether/Et<sub>2</sub>O = 10/1, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.68–0.73 (m, 2H), 0.94–1.00 (m, 2H), 1.30–1.41 (m, 2H), 1.47 (s, 9H), 1.63–1.70 (m, 2H), 1.86–1.93 (m, 1H), 2.67–2.79 (m, 3H), 4.09 (bs, 2H), 5.40 (dd, <i>J</i> = 11.6, 10.0 Hz, 1H), 6.35 (d, <i>J</i> = 11.6 Hz, 1H), 7.03–7.06 (m, 2H), 7.12–7.16 (m, 2H).</div><div class="NLM_p last"><b>55</b>: <i>R</i><sub><i>f</i></sub> = 0.22 (petroleum ether/Et<sub>2</sub>O = 10/1, v/v); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.66–0.70 (m, 2H), 0.92–0.97 (m, 2H), 1.36 (dt, <i>J</i> = 12.7, 4.4 Hz, 1H), 1.39 (dt, <i>J</i> = 12.3, 4.1 Hz, 1H), 1.48 (s, 9H), 1.70–1.78 (m, 2H), 1.83–1.90 (m, 1H), 2.21–2.31 (m, 1H), 2.78 (t, <i>J</i> = 11.6 Hz, 2H), 4.13 (bs, 2H), 6.08 (dd, <i>J</i> = 16.0, 6.9 Hz, 1H), 6.34 (d, <i>J</i> = 16.0 Hz, 1H), 6.98–7.02 (m, 2H), 7.22–7.25 (m, 2H).</div></div><div id="sec4_2_7_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>tert</i>-Butyl 4-Phenethylpiperidine-1-carboxylate (<b>56</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>28</b> and <b>29</b> (1.139 g, 4.84 mmol, 1.0 equiv) via general procedure C. Yield: quantitative (1.39 g); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.21 (ddd, <i>J</i> = 16.5, 12.5, 4.3 Hz, 2H), 1.35–1.43 (m, 1H), 1.45 (s, 9H), 1.53–1.59 (m, 2H), 1.68–1.71 (m, 2H), 2.60–2.69 (m, 4H), 4.07 (bs, 2H), 7.15–7.19 (m, 3H), 7.24–7.29 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 312.19; found 311.91.</div></div><div id="sec4_2_7_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>tert</i>-Butyl 4-(3-Fluorophenethyl)piperidine-1-carboxylate (<b>57</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>30</b> and <b>31</b> (0.452 g, 1.48 mmol, 1.0 equiv) via general procedure C. Yield: 95% (0.432 g); pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.11 (dt, <i>J</i> = 12.3, 4.1 Hz, 1H), 1.14 (dt, <i>J</i> = 12.5, 4.2 Hz, 1H), 1.35–1.44 (m, 1H), 1.45 (s, 9H), 1.50–1.59 (m, 2H), 1.65–1.72 (m, 2H), 2.59–2.72 (m, 4H), 4.08 (bs, 2H), 6.84–6.89 (m, 2H), 6.91–6.95 (m, 1H), 7.22 (ddd, <i>J</i> = 8.9, 7.6, 6.1 Hz, 1H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 330.18; found 330.42.</div></div><div id="sec4_2_7_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>tert</i>-Butyl 4-(2-Fluorophenethyl)piperidine-1-carboxylate (<b>58</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>32</b> and <b>33</b> (0.252 g, 0.83 mmol, 1.0 equiv) via general procedure C. Yield: 95% (0.242 g); pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.12 (dt, <i>J</i> = 12.4, 4.1 Hz, 1H), 1.15 (dt, <i>J</i> = 12.4, 4.2 Hz, 1H), 1.37–1.44 (m, 1H), 1.46 (s, 9H), 1.52–1.59 (m, 2H), 1.69–1.76 (m, 2H), 2.58–2.72 (m, 4H), 4.08 (bs, 2H), 6.97–7.02 (m, 1H), 7.03–7.04 (m, 1H), 7.13–7.19 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 330.18; found 330.41.</div></div><div id="sec4_2_7_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> <i>tert</i>-Butyl 4-(4-Methylphenethyl)piperidine-1-carboxylate (<b>59</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>36</b> and <b>37</b> (0.28 g, 0.93 mmol, 1.0 equiv) via general procedure C. Yield: quantitative; yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.11 (dt, <i>J</i> = 12.3, 4.1 Hz, 1H), 1.14 (dt, <i>J</i> = 12.4, 4.1 Hz, 1H), 1.36–1.44 (m, 1H), 1.45 (s, 9H), 1.51–1.57 (m, 2H), 1.65–1.73 (m, 2H), 2.32 (s, 3H), 2.56–2.61 (m, 2H), 2.63–2.70 (m, 2H), 4.07 (bs, 2H), 7.04–7.10 (m, 4H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 326.21; found 326.73.</div></div><div id="sec4_2_7_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>tert</i>-Butyl 4-(4-Isopropylphenethyl)piperidine-1-carboxylate (<b>60</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>38</b> and <b>39</b> (0.870 g, 2.64 mmol, 1.0 equiv) via general procedure C. Yield: 83% (0.727 g); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.16 (ddd, <i>J</i> = 16.9, 12.9, 5.5 Hz, 2H), 1.27 (d, <i>J</i> = 7.0 Hz, 6H), 1.40–1.47 (m, 1H), 1.49 (s, 9H), 1.54–1.61 (m, 2H), 1.70–1.76 (m, 2H), 2.61–2.64 (m, 2H), 2.70 (t, <i>J</i> = 11.5 Hz, 2H), 2.91 (sept. <i>J</i> = 6.9 Hz, 1H), 4.10 (bs, 2H), 7.11–7.13 (m, 2H), 7.16–7.18 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 354.24; found 354.05.</div></div><div id="sec4_2_7_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>tert</i>-Butyl 4-(4-Chlorophenethyl)piperidine-1-carboxylate (<b>61</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>40</b> and <b>41</b> (0.850 g, 2.64 mmol, 1.0 equiv) via general procedure C. Column chromatography, petroleum ether/Et<sub>2</sub>O = 3/1 (v/v). Yield: 86% (0.736 g); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.08 (dd, <i>J</i> = 12.3, 4.2 Hz, 1H), 1.11 (dd, <i>J</i> = 12.8, 3.9 Hz, 1H), 1.33–1.40 (m, 1H), 1.44 (s, 9H), 1.48–1.53 (m, 2H), 1.63–1.68 (m, 2H), 2.55–2.59 (m, 2H), 2.64 (t, <i>J</i> = 11.6 Hz, 2H), 4.07 (bs, 2H), 7.05–7.08 (m, 2H), 7.18–7.22 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 346.15; found 346.55.</div></div><div id="sec4_2_7_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> <i>tert</i>-Butyl 4-(4-Methoxyphenethyl)piperidine-1-carboxylate (<b>62</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>44</b> and <b>45</b> (0.250 g, 0.79 mmol, 1.0 equiv) via general procedure C. Yield: 86% (0.245 g); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.12 (ddd, <i>J</i> = 16.3, 12.5, 4.3 Hz, 2H), 1.35–1.43 (m, 1H), 1.45 (s, 9H), 1.50–1.56 (m, 2H), 1.64–1.71 (m, 2H), 2.55–2.59 (m, 2H), 2.66 (t, <i>J</i> = 11.8 Hz, 2H), 3.79 (s, 3H), 4.07 (bs, 2H), 6.81–6.84 (m, 2H), 7.07–7.10 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 342.20; found 342.59.</div></div><div id="sec4_2_7_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> <i>tert</i>-Butyl 4-(4-(Trifluoromethyl)phenethyl)piperidine-1-carboxylate (<b>63</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>46</b> and <b>47</b> (0.24 g, 0.68 mmol, 1.0 equiv) via general procedure C. Yield: quantitative; yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.12 (dt, <i>J</i> = 12.4, 4.2 Hz, 1H), 1.15 (dt, <i>J</i> = 12.3, 4.3 Hz, 1H), 1.36–1.44 (m, 1H), 1.45 (s, 9H), 1.53–1.61 (m, 2H), 1.65–1.73 (m, 2H), 2.60–2.70 (m, 4H), 4.08 (bs, 2H), 7.25–7.28 (m, 2H), 7.50–7.53 (m, 2H).</div></div><div id="sec4_2_7_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> <i>tert</i>-Butyl 4-(3-(Trifluoromethyl)phenethyl)piperidine-1-carboxylate (<b>64</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>48</b> and <b>49</b> (0.27 g, 0.76 mmol, 1.0 equiv) via general procedure C. Yield: quantitative; colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.13 (dt, <i>J</i> = 12.2, 4.2 Hz, 1H), 1.16 (dt, <i>J</i> = 12.4, 4.2 Hz, 1H), 1.37–1.45 (m, 1H), 1.46 (s, 9H), 1.55–1.61 (m, 2H), 1.67–1.74 (m, 2H), 2.63–2.72 (m, 4H), 4.09 (bs, 2H), 7.34–7.45 (m, 4H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 380.18; found 380.77.</div></div><div id="sec4_2_7_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> <i>tert</i>-Butyl 4-(4-Cyanophenethyl)piperidine-1-carboxylate (<b>65</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>50</b> and <b>51</b> (0.658 g, 2.11 mmol, 1.0 equiv) via general procedure C. Column chromatography, petroleum ether/Et<sub>2</sub>O = 3/1 (v/v). Yield: 95% (0.632 g); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.09 (dd, <i>J</i> = 12.4, 4.2 Hz, 1H), 1.12 (dd, <i>J</i> = 12.5, 4.3 Hz, 1H), 1.34–1.40 (m, 1H), 1.42 (s, 9H), 1.51–1.58 (m, 2H), 1.63–1.68 (m, 2H), 2.61–2.68 (m, 4H), 4.06 (bs, 2H), 7.23–7.25 (m, 2H), 7.51–7.54 (m, 2H). MS (ESI+): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> 337.19; found 337.07.</div></div><div id="sec4_2_7_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> <i>tert</i>-Butyl 4-(4-Propylphenethyl)piperidine-1-carboxylate (<b>66</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>54</b> and <b>55</b> (0.216 g, 0.660 mmol, 1.0 equiv) via general procedure C. The reaction conditions applied resulted in cyclopropyl ring opening to yield the titled compound. Yield: 92% (0.200 g); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.95 (t, <i>J</i> = 7.3 Hz, 3H), 1.07–1.17 (m, 2H), 1.37–1.45 (m, 1H), 1.45 (s, 9H), 1.52–1.67 (m, 6H), 2.53–2.61 (m, 4H), 2.67 (t, <i>J</i> = 13.0 Hz, 2H), 4.07 (bs, 2H), 7.06–7.11 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 13.89, 24.63, 28.47, 32.11, 32.48, 35.53, 37.64, 38.41, 43.98, 79.17, 128.10, 128.40, 139.65, 140.03, 154.89. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>33</sub>O<sub>2</sub>NNa [M + Na]<sup>+</sup> 354.2404; found 354.2401.</div></div><div id="sec4_2_7_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (<i>Z</i>)-1-(Prop-2-yn-1-yl)-4-styrylpiperidine (<b>67</b>)</h3><div class="NLM_p last">Synthesized from <b>28</b> (0.100 g, 0.348 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 82% (64 mg); white crystals, mp 42–43 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.50–1.60 (m, 2H), 1.74 (bd, <i>J</i> = 16.0 Hz, 2H), 2.19–2.26 (m, 3H), 2.52–2.62 (m, 1H), 2.86–2.90 (m, 2H), 3.29 (d, <i>J</i> = 2.4 Hz, 2H), 5.49 (dd, <i>J</i> = 11.4, 10.3 Hz, 1H), 6.38 (d, <i>J</i> = 11.7 Hz, 1H), 7.21–7.25 (m, 3H), 7.31–7.35 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.29, 34.38, 47.23, 51.87, 72.93, 79.03, 126.55, 128.03, 128.18, 128.45, 137.19, 137.57. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>20</sub>N [M + H]<sup>+</sup> 226.1596; found 226.1598. IR (ATR): 3210, 2988, 2945, 2917, 2800, 1498, 1446, 1425, 1330, 1311, 1127, 1103, 1073, 969, 904, 799, 775, 727, 696, 670, 560 cm<sup>–1</sup>. HPLC purity, 99.9% (<i>t</i><sub>R</sub> = 8.86 min).</div></div><div id="sec4_2_7_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (<i>E</i>)-1-(Prop-2-yn-1-yl)-4-styrylpiperidine (<b>68</b>)</h3><div class="NLM_p last">Synthesized from <b>29</b> (0.196 g, 0.682 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 89% (137 mg); white crystals, mp 44–46 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.56 (dd, <i>J</i> = 11.9, 3.9 Hz, 1H), 1.59 (dd, <i>J</i> = 11.9, 3.9 Hz, 1H), 1.79–1.84 (m, 2H), 2.09–2.19 (m, 1H), 2.25–2.31 (m, 3H), 2.94 (td, <i>J</i> = 11.1, 2.4 Hz, 2H), 3.33 (d, <i>J</i> = 2.5 Hz, 2H), 6.18 (dd, <i>J</i> = 16.0, 7.0 Hz, 1H), 6.39 (d, <i>J</i> = 16.5 Hz, 1H), 7.18–7.22 (m, 1H), 7.26–7.32 (m, 2H), 7.34–7.37 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.91, 38.71, 47.13, 52.13, 72.91, 78.98, 125.87, 126.85, 128.10, 128.35, 134.76, 137.47. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>20</sub>N [M + H]<sup>+</sup> 226.1596; found 226.1594. IR (ATR): 3264, 2929, 2909, 2805, 1446, 1429, 1315, 1223, 1135, 1106, 976, 962, 897, 744, 686, 670, 619, 519 cm<sup>–1</sup>. HPLC purity, 99.2% (<i>t</i><sub>R</sub> = 8.90 min).</div></div><div id="sec4_2_7_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (<i>Z</i>)-4-(3-Fluorostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>69</b>)</h3><div class="NLM_p last">Synthesized from <b>30</b> (110 mg, 0.360 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 12% (11 mg); yellow crystals, mp 51–53 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.49–1.60 (m, 2H), 1.69–1.76 (m, 2H), 2.23 (dt, <i>J</i> = 11.7, 2.5 Hz, 2H), 2.24 (t, <i>J</i> = 2.4 Hz, 1H), 2.48–2.58 (m, 1H), 2.86–2.91 (m, 2H), 3.30 (d, <i>J</i> = 2.4 Hz, 2H), 5.53 (dd, <i>J</i> = 11.6, 10.2 Hz, 1H), 6.33 (d, <i>J</i> = 11.7 Hz, 1H), 6.90–6.95 (m, 2H), 6.99–7.01 (m, 1H), 7.26–7.31 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.16, 34.45, 47.23, 51.81, 73.02, 78.96, 113.44 (d, <i>J</i><sub>C,F</sub> = 21.2 Hz), 115.17 (d, <i>J</i><sub>C,F</sub> = 21.3 Hz), 124.22 (d, <i>J</i><sub>C,F</sub> = 2.8 Hz), 127.01 (d, <i>J</i><sub>C,F</sub> = 2.1 Hz), 129.62 (d, <i>J</i><sub>C,F</sub> = 8.6 Hz), 138.29, 139.76 (d, <i>J</i><sub>C,F</sub> = 7.9 Hz), 162.66 (d, <i>J</i><sub>C,F</sub> = 245.2 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>FN [M + H]<sup>+</sup> 244.1502; found 244.1504. IR (ATR): 3304, 2924, 2851, 2805, 2755, 1611, 1580, 1513, 1487, 1465, 1444, 1386, 1364, 1335, 1311, 1272, 1247, 1231, 1138, 1124, 1105, 1073, 1018, 973, 937, 923, 878, 792, 764, 752, 694, 667, 634 cm<sup>–1</sup>. HPLC purity, 97.9% (<i>t</i><sub>R</sub> = 9.10 min).</div></div><div id="sec4_2_7_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> (<i>E</i>)-4-(3-Fluorostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>70</b>)</h3><div class="NLM_p last">Synthesized from <b>31</b> (0.300 g, 0.982 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 38% (91 mg); pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.57 (dt, <i>J</i> = 12.0, 3.9 Hz, 1H), 1.60 (dt, <i>J</i> = 11.9, 3.9 Hz, 1H), 1.78–1.84 (m, 2H), 2.10–2.19 (m, 1H), 2.27 (t, <i>J</i> = 2.5 Hz, 1H), 2.31 (dt, <i>J</i> = 11.7, 2.5 Hz, 2H), 2.93–2.98 (m, 2H), 3.35 (d, <i>J</i> = 2.5 Hz, 2H), 6.17 (dd, <i>J</i> = 16.0, 6.9 Hz, 1H), 6.34 (d, <i>J</i> = 16.0 Hz, 1H), 6.88 (ddt, <i>J</i> = 8.4, 2.6, 0.9 Hz, 1H), 7.02–7.06 (m, 1H), 7.07–7.11 (m, 1H), 7.21–7.27 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.71, 38.64, 47.15, 52.10, 73.32, 78.62, 112.39 (d, <i>J</i><sub>C,F</sub> = 22.0 Hz), 113.73 (d, <i>J</i><sub>C,F</sub> = 21.3 Hz), 121.87 (d, <i>J</i><sub>C,F</sub> = 2.9 Hz), 127.33 (d, <i>J</i><sub>C,F</sub> = 2.9 Hz), 129.84 (d, <i>J</i><sub>C,F</sub> = 8.7 Hz), 136.10, 139.94 (d, <i>J</i><sub>C,F</sub> = 7.3 Hz), 163.06 (d, <i>J</i><sub>C,F</sub> = 244.9 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>FN [M + H]<sup>+</sup> 244.1502; found 244.1504. IR (ATR): 3303, 2931, 2808, 2751, 1651, 1611, 1583, 491, 1466, 1445, 1385, 1364, 1336, 1312, 1267, 1245, 1140, 1106, 1074, 962, 939, 897, 873, 829, 809, 777, 684, 631, 590 cm<sup>–1</sup>. HPLC purity, 99.6% (<i>t</i><sub>R</sub> = 9.15 min).</div></div><div id="sec4_2_7_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> (<i>Z</i>)-4-(2-Fluorostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>71</b>)</h3><div class="NLM_p last">Synthesized <b>32</b> (225 mg, 0.737 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 5% (9 mg); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.49–1.59 (m, 2H), 1.68–1.75 (m, 2H), 2.16–2.23 (m, 2H), 2.23 (t, <i>J</i> = 2.4 Hz, 1H), 2.33–2.43 (m, 1H), 2.85–2.90 (m, 2H), 3.30 (d, <i>J</i> = 2.4 Hz, 2H), 5.62 (dd, <i>J</i> = 11.6, 10.2 Hz, 1H), 6.37 (d, <i>J</i> = 11.4 Hz, 1H), 7.03–7.08 (m, 1H), 7.09–7.13 (m, 1H), 7.21–7.26 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.11, 34.98, 47.28, 51.89, 72.94, 79.08, 115.43 (d, <i>J</i><sub>C,F</sub> = 22.3 Hz), 120.66 (d, <i>J</i><sub>C,F</sub> = 3.0 Hz), 123.66 (d, <i>J</i><sub>C,F</sub> = 3.6 Hz), 125.22 (d, <i>J</i><sub>C,F</sub> = 15.0 Hz), 128.45 (d, <i>J</i><sub>C,F</sub> = 8.2 Hz), 130.28 (d, <i>J</i><sub>C,F</sub> = 3.7 Hz), 139.25, 160.03 (d, <i>J</i><sub>C,F</sub> = 246.6 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>FN [M + H]<sup>+</sup> 244.1502; found 244.1505. IR (ATR): 3300, 2918, 2802, 2754, 1485, 1451, 1334, 1310, 1272, 1232, 1134, 1095, 972, 835, 780, 758, 634 cm<sup>–1</sup>. HPLC purity, 97.1% (<i>t</i><sub>R</sub> = 9.04 min).</div></div><div id="sec4_2_7_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> (<i>E</i>)-4-(2-Fluorostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>72</b>)</h3><div class="NLM_p last">Synthesized from <b>33</b> (0.180 g, 0.589 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 58% (83 mg); pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.56 (dt, <i>J</i> = 12.0, 3.9 Hz, 1H), 1.59 (dt, <i>J</i> = 12.0, 3.9 Hz, 1H), 1.79–1.85 (m, 2H), 2.12–2.20 (m, 1H), 2.25 (t, <i>J</i> = 2.4 Hz, 1H), 2.28 (dt, <i>J</i> = 11.7, 2.5 Hz, 2H), 2.91–2.96 (m, 2H), 3.33 (d, <i>J</i> = 2.4 Hz, 2H), 6.23 (dd, <i>J</i> = 16.1, 7.1 Hz, 1H), 6.55 (d, <i>J</i> = 16.1 Hz, 1H), 7.00 (ddd, <i>J</i> = 10.8, 8.1, 1.2 Hz, 1H), 7.07 (dt, <i>J</i> = 7.4, 1.0 Hz, 1H), 7.14–7.19 (m, 1H), 7.44 (dt, <i>J</i> = 7.7, 1.7 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.93, 39.22, 47.24, 52.21, 72.97, 79.06, 115.58 (d, <i>J</i><sub>C,F</sub> = 22.3 Hz), 120.59 (d, <i>J</i><sub>C,F</sub> = 3.8 Hz), 123.95 (d, <i>J</i><sub>C,F</sub> = 3.6 Hz), 125.32 (d, <i>J</i><sub>C,F</sub> = 12.3 Hz), 126.88 (d, <i>J</i><sub>C,F</sub> = 12.3 Hz), 128.14 (d, <i>J</i><sub>C,F</sub> = 8.5 Hz), 137.41 (d, <i>J</i><sub>C,F</sub> = 4.2 Hz), 159.94 (d, <i>J</i><sub>C,F</sub> = 248.4 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>FN [M + H]<sup>+</sup> 244.1502; found 244.1500. IR (ATR): 3183, 2947, 2921, 2802, 2756, 1576, 1485, 1455, 1445, 1389, 1371, 1360, 1331, 1301, 1277, 1263, 1230, 1213, 1194, 1183, 1141, 1108, 1091, 1031, 1020, 983, 968, 946, 842, 811, 777, 754, 713 cm<sup>–1</sup>. HPLC purity, 99.5% (<i>t</i><sub>R</sub> = 9.09 min).</div></div><div id="sec4_2_7_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (<i>Z</i>)-4-(2-Chloro-4-fluorostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>73</b>)</h3><div class="NLM_p last">Synthesized from <b>34</b> (110 mg, 0.324 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 6% (5 mg); white-yellow crystals, mp 51–53 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.48–1.58 (m, 2H), 1.64–1.69 (m, 2H), 2.13–2.30 (m, 3H), 2.23 (t, <i>J</i> = 2.4 Hz, 1H), 2.83–2.88 (m, 2H), 3.28 (d, <i>J</i> = 2.4 Hz, 2H), 5.61 (dd, <i>J</i> = 10.8, 10.4 Hz, 1H), 6.35 (d, <i>J</i> = 11.5 Hz, 1H), 6.96 (dt, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.14 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.19 (dd, <i>J</i> = 8.2, 6.4 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.09, 34.57, 47.23, 51.78, 72.99, 78.97, 113.64 (d, <i>J</i><sub>C,F</sub> = 20.7 Hz), 116.70 (d, <i>J</i><sub>C,F</sub> = 24.8 Hz), 124.51, 130.93 (d, <i>J</i><sub>C,F</sub> = 8.3 Hz), 132.06 (d, <i>J</i><sub>C,F</sub> = 3.7 Hz), 134.16 (d, <i>J</i><sub>C,F</sub> = 10.2 Hz), 138.65, 161.35 (d, <i>J</i><sub>C,F</sub> = 248.6 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>18</sub>FClN [M + H]<sup>+</sup> 278.1112; found 244.1105. IR (ATR): 3166, 3010, 2932, 2789, 2758, 1601, 1574, 1485, 1467, 1445, 1403, 1390, 1367, 1331, 1307, 1295, 1271, 1257, 1230, 1221, 1210, 1169, 1142, 1121, 1109, 1064, 1041, 1016, 1006, 973, 951, 901, 875, 863, 821, 790, 768, 747, 704, 687, 643, 615, 583, 547 cm<sup>–1</sup>. HPLC purity, 99.7% (<i>t</i><sub>R</sub> = 9.85 min).</div></div><div id="sec4_2_7_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> (<i>E</i>)-4-(2-Chloro-4-fluorostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>74</b>)</h3><div class="NLM_p last">Synthesized from <b>35</b> (0.263 g, 0.774 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 58% (125 mg); pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.56 (dt, <i>J</i> = 12.0, 3.9 Hz, 1H), 1.59 (dt, <i>J</i> = 11.9, 3.9 Hz, 1H), 1.77–1.85 (m, 2H), 2.12–2.23 (m, 1H), 2.25 (t, <i>J</i> = 2.4 Hz, 1H), 2.28 (dt, <i>J</i> = 11.7, 2.5 Hz, 2H), 2.91–2.96 (m, 2H), 3.32 (d, <i>J</i> = 2.4 Hz, 2H), 6.07 (dd, <i>J</i> = 15.9, 7.1 Hz, 1H), 6.68 (d, <i>J</i> = 15.9 Hz, 1H), 6.90–6.95 (m, 1H), 7.08 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 7.47 (dt, <i>J</i> = 8.8, 6.1 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.88, 38.93, 47.18, 52.10, 72.95, 78.98, 114.11 (d, <i>J</i><sub>C,F</sub> = 21.3 Hz), 116.56 (d, <i>J</i><sub>C,F</sub> = 24.7 Hz), 123.61 (d, <i>J</i><sub>C,F</sub> = 1.1 Hz), 127.48 (d, <i>J</i><sub>C,F</sub> = 8.8 Hz), 131.97 (d, <i>J</i><sub>C,F</sub> = 3.7 Hz), 133.00 (d, <i>J</i><sub>C,F</sub> = 10.2 Hz), 137.51 (d, <i>J</i><sub>C,F</sub> = 1.7 Hz), 161.32 (d, <i>J</i><sub>C,F</sub> = 249.4 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>18</sub>FClN [M + H]<sup>+</sup> 278.1112; found 278.1120. IR (ATR): 3303, 2933, 2803, 2753, 1650, 1600, 1574, 1466, 1445, 1396, 1364, 1336, 1312, 1269, 1258, 1237, 1183, 1137, 1122, 1040, 966, 904, 858, 805, 776, 760, 686, 627, 579 cm<sup>–1</sup>. HPLC purity, 100% (<i>t</i><sub>R</sub> = 9.86 min).</div></div><div id="sec4_2_7_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> (<i>Z</i>)-4-(4-Methylstyryl)-1-(prop-2-yn-1-yl)piperidine (<b>75</b>)</h3><div class="NLM_p last">Synthesized from <b>36</b> (0.07 g, 0.23 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 49% (27 mg); yellow crystals, mp 85–86 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.49–1.57 (m, 2H), 1.72–1.76 (m, 2H), 2.20–2.26 (m, 3H), 2.35 (s, 3H), 2.52–2.62 (m, 1H), 2.86–2.91 (m, 2H), 3.30 (d, <i>J</i> = 2.4 Hz, 2H), 5.45 (dd, <i>J</i> = 11.6, 10.0 Hz, 1H), 6.35 (d, <i>J</i> = 11.6 Hz, 1H), 7.15 (s, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 21.16, 32.36, 34.45, 47.29, 51.96, 72.94, 79.10, 127.94, 128.43, 128.94, 134.74, 136.33, 136.62. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>22</sub>N [M + H]<sup>+</sup> 240.1752; found 240.1756. IR (ATR): 3210, 2934, 2858, 2798, 2756, 1466, 1450, 1432, 1335, 1272, 1143, 1109, 1067, 972, 946, 836, 824, 810, 785, 738, 687, 560 cm<sup>–1</sup>. HPLC purity, 100% (<i>t</i><sub>R</sub> = 9.62 min).</div></div><div id="sec4_2_7_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> (<i>E</i>)-4-(4-Methylstyryl)-1-(prop-2-yn-1-yl)piperidine (<b>76</b>)</h3><div class="NLM_p last">Synthesized from <b>37</b> (0.42 g, 1.39 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/3 (v/v). Yield: 36% (121 mg); orange crystals, mp 65–67 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.62–1.72 (m, 2H), 1.89–1.95 (m, 2H), 2.18–2.28 (m, 1H), 2.34–2.41 (m, 3H), 2.43 (s, 3H), 3.01–3.06 (m, 2H), 3.43 (d, <i>J</i> = 2.5 Hz, 2H), 6.22 (dd, <i>J</i> = 16.0, 7.0 Hz, 1H), 6.46 (d, <i>J</i> = 15.9 Hz, 1H), 7.21 (d, <i>J</i> = 7.9 Hz, 2H), 7.36 (d, <i>J</i> = 8.3 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 21.09, 32.04, 38.77, 47.21, 52.25, 72.92, 79.07, 125.83, 127.98, 129.13, 133.84, 134.78, 136.62. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>22</sub>N [M + H]<sup>+</sup> 240.1752; found 240.1756. IR (ATR): 3209, 2933, 2858, 2800, 2756, 1513, 1450, 1427, 1335, 1311, 1271, 1134, 1109, 1067, 1019, 972, 910, 824, 795, 785, 739, 685, 642, 561, 518 cm<sup>–1</sup>. HPLC purity, 97.7% (<i>t</i><sub>R</sub> = 9.65 min).</div></div><div id="sec4_2_7_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> (<i>Z</i>)-4-(4-Isopropylstyryl)-1-(prop-2-yn-1-yl)piperidine (<b>77</b>)</h3><div class="NLM_p last">Synthesized from <b>38</b> (0.180 g, 0.546 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 79% (115 mg); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.27 (d, <i>J</i> = 6.9 Hz, 6H), 1.50–1.60 (m, 2H), 1.74–1.78 (m, 2H), 2.21–2.28 (m, 2H), 2.24 (t, <i>J</i> = 2.4 Hz, 1H), 2.56–2.66 (m, 1H), 2.87–2.95 (m, 3H), 3.31 (d, <i>J</i> = 2.5 Hz, 2H), 5.45 (dd, <i>J</i> = 11.7, 10.0 Hz, 1H), 6.35 (d, <i>J</i> = 11.7 Hz, 1H), 7.17–7.23 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 23.95, 32.36, 33.77, 34.44, 47.28, 51.95, 72.93, 79.10, 126.29, 127.90, 128.49, 135.09, 136.56, 147.27. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>26</sub>N [M + H]<sup>+</sup> 268.2065; found 268.2061. IR (ATR): 3295, 2958, 2937, 2801, 1508, 1335, 1311, 1136, 973, 849, 676 cm<sup>–1</sup>. HPLC purity, 99.1% (<i>t</i><sub>R</sub> = 10.83 min).</div></div><div id="sec4_2_7_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> (<i>E</i>)-4-(4-Isopropylstyryl)-1-(prop-2-yn-1-yl)piperidine (<b>78</b>)</h3><div class="NLM_p last">Synthesized from <b>39</b> (0.207 g, 0.628 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 45% (76 mg); pale yellow crystals, mp 60–64 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.24 (d, <i>J</i> = 6.9 Hz, 6H), 1.52–1.61 (m, 2H), 1.78–1.83 (m, 2H), 2.05–2.20 (m, 1H), 2.24–2.31 (m, 2H), 2.26 (t, <i>J</i> = 2.5 Hz, 1H), 2.83–2.95 (m, 3H), 3.32 (d, <i>J</i> = 2.5 Hz, 2H), 6.13 (dd, <i>J</i> = 16.0, 7.0 Hz, 1H), 6.37 (d, <i>J</i> = 16.6 Hz, 1H), 7.15–7.17 (m, 2H), 7.28–7.30 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 23.93, 32.05, 33.76, 38.76, 47.23, 52.25, 72.90, 79.08, 125.89, 126.549, 127.96, 134.01, 135.21, 147.73. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>26</sub>N [M + H]<sup>+</sup> 268.2065; found 268.2062. IR (ATR): 3299, 2959, 2936, 2908, 2802, 1514, 1457, 1425, 1384, 1310, 1131, 1103, 1053, 977, 899, 855, 812, 762, 685, 654, 639, 553 cm<sup>–1</sup>. HPLC purity, 98.5% (<i>t</i><sub>R</sub> = 10.89 min).</div></div><div id="sec4_2_7_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> (<i>Z</i>)-4-(4-Chlorostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>79</b>)</h3><div class="NLM_p last">Synthesized from <b>40</b> (0.150 g, 0.466 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 67% (81 mg); white crystals, mp 97–99 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.49–1.59 (m, 2H), 1.68–1.74 (m, 2H), 2.18–2.25 (m, 2H), 2.23 (t, <i>J</i> = 2.5 Hz, 1H), 2.44–2.54 (m, 1H), 2.85–2.90 (m, 2H), 3.30 (d, <i>J</i> = 2.5 Hz, 2H), 5.51 (dd, <i>J</i> = 11.6, 10.1 Hz, 1H), 6.32 (d, <i>J</i> = 11.7 Hz, 1H), 7.14–7.17 (m, 2H), 7.28–7.31 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.20, 34.45, 47.24, 51.83, 73.01, 78.97, 126.92, 128.37, 129.74, 132.30, 135.99, 137.88. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>ClN [M + H]<sup>+</sup> 260.1206; found 260.1201. IR (ATR): 3198, 2936, 2800, 2757, 1487, 1452, 1335, 1272, 1144, 1120, 1090, 1068, 971, 836, 797, 756, 716, 695, 586, 557 cm<sup>–1</sup>. HPLC purity, 98.6% (<i>t</i><sub>R</sub> = 9.78 min).</div></div><div id="sec4_2_7_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> (<i>E</i>)-4-(4-Chlorostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>80</b>)</h3><div class="NLM_p last">Synthesized from <b>41</b> (0.165 g, 0.513 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 45% (87 mg); white crystals, mp 83–85 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.49–1.59 (m, 2H), 1.76–1.82 (m, 2H), 2.06–2.16 (m, 1H), 2.23–2.29 (m, 2H), 2.25 (t, <i>J</i> = 2.4 Hz, 1H), 2.92 (td, <i>J</i> = 11.1, 2.4 Hz, 2H), 3.31 (d, <i>J</i> = 2.5 Hz, 2H), 6.13 (dd, <i>J</i> = 16.0, 7.0 Hz, 1H), 6.31 (dd, <i>J</i> = 16.0, 1.1 Hz, 1H), 7.22–7.27 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.89, 38.77, 47.18, 52.15, 72.95, 79.00, 127.00, 127.13, 128.51, 132.39, 135.55, 136.04. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>ClN [M + H]<sup>+</sup> 260.1206; found 260.1207. IR (ATR): 3154, 2931, 2916, 2797, 1489, 1441, 1422, 1329, 1313, 1135, 1089, 1010, 971, 907, 850, 801, 722, 594, 519 cm<sup>–1</sup>. HPLC purity, 99.6% (<i>t</i><sub>R</sub> = 9.81 min).</div></div><div id="sec4_2_7_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> (<i>E</i>)-4-(4-Bromostyryl)-1-(prop-2-yn-1-yl)piperidine (<b>81</b>)</h3><div class="NLM_p last">Synthesized from <b>43</b> (0.36 g, 0.98 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 34% (102 mg); white crystals, mp 103–106 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.50–1.60 (m, 2H), 1.77–1.83 (m, 2H), 2.08–2.17 (m, 1H), 2.24–2.30 (m, 3H), 2.91–2.95 (m, 2H), 3.32 (d, <i>J</i> = 2.2 Hz, 2H), 6.15 (dd, <i>J</i> = 16.0, 6.9 Hz, 1H), 6.31 (d, <i>J</i> = 16.2 Hz, 1H), 7.19–7.22 (m, 2H), 7.39–7.42 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.93, 38.85, 47.25, 52.22, 72.96, 79.06, 120.59, 127.15, 127.56, 131.53, 135.78, 136.59. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>NBr [M + H]<sup>+</sup> 304.0701; found 304.0706. IR (ATR): 3150, 2929, 2850, 2798, 2745, 1485, 1466, 1423, 1328, 1310, 1135, 1117, 1098, 1069, 1007, 970, 906, 848, 822, 798, 754, 715, 579, 516 cm<sup>–1</sup>. HPLC purity, 100% (<i>t</i><sub>R</sub> = 10.00 min).</div></div><div id="sec4_2_7_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> (<i>E</i>)-4-(4-Methoxystyryl)-1-(prop-2-yn-1-yl)piperidine (<b>82</b>)</h3><div class="NLM_p last">Synthesized from a mixture of <b>44</b> and <b>45</b> (0.810 g, 2.552 mmol, 1.0 equiv) via general procedures D and E. Column chromatography EtOAc/n-hex = 1/1 (v/v), yielding only <i>trans</i> isomer <b>82</b>. Yield: 32% (192 mg); white crystals, mp 59–61 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.50–1.60 (m, 2H), 1.76–1.82 (m, 2H), 2.06–2.15 (m, 1H), 2.23–2.30 (m, 2H), 2.25 (t, <i>J</i> = 2.4 Hz, 1H), 2.90–2.95 (m, 2H), 3.32 (d, <i>J</i> = 2.4 Hz, 2H), 3.79 (s, 3H), 6.02 (dd, <i>J</i> = 15.9, 7.0 Hz, 1H), 6.32 (d, <i>J</i> = 15.9 Hz, 1H), 6.81–6.85 (m, 2H), 7.26–7.30 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.13, 38.77, 47.23, 52.28, 55.23, 72.90, 79.11, 113.85, 127.02, 127.49, 130.39, 132.77, 158.69. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>22</sub>NO [M + H]<sup>+</sup> 256.1701; found 256.1706. IR (ATR): 3270, 2940, 2907, 2825, 1604, 1509, 1467, 1313, 1241, 1176, 1128, 1029, 968, 959, 906, 854, 831, 801, 769, 719, 645, 622, 529 cm<sup>–1</sup>. HPLC purity, 97.7% (<i>t</i><sub>R</sub> = 8.92 min).</div></div><div id="sec4_2_7_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> (<i>Z</i>)-1-(Prop-2-yn-1-yl)-4-(4-(trifluoromethyl)styryl)piperidine (<b>83</b>)</h3><div class="NLM_p last">Synthesized from <b>46</b> (0.075 g, 0.211 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 2/1 (v/v). Yield: 81% (45 mg); pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.51–1.61 (m, 2H), 1.70–1.74 (m, 2H), 2.19–2.25 (m, 2H), 2.24 (t, <i>J</i> = 2.5 Hz, 1H), 2.45–2.55 (m, 1H), 2.87–2.91 (m, 2H), 3.30 (d, <i>J</i> = 2.5 Hz, 2H), 5.60 (dd, <i>J</i> = 11.7, 10.2 Hz, 1H), 6.39 (d, <i>J</i> = 11.7 Hz, 1H), 7.33 (d, <i>J</i> = 8.6 Hz, 2H), 7.59 (d, <i>J</i> = 8.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.18, 34.55, 47.24, 51.78, 73.05, 78.92, 124.19 (q, <i>J</i><sub>C,F</sub> = 271.8 Hz), 125.17 (q, <i>J</i><sub>C,F</sub> = 3.9 Hz), 126.89, 128.58 (t, <i>J</i><sub>C,F</sub> = 32.3 Hz), 128.67, 139.22, 141.18 (q, <i>J</i><sub>C,F</sub> = 1.4 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>19</sub>F<sub>3</sub>N [M + H]<sup>+</sup> 294.1470; found 294.1469. IR (ATR): 3305, 2933, 2805, 1615, 1331, 1167, 1129, 1068, 1017, 973, 851, 634, 603 cm<sup>–1</sup>. HPLC purity, 100% (<i>t</i><sub>R</sub> = 10.21 min).</div></div><div id="sec4_2_7_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> (<i>E</i>)-1-(Prop-2-yn-1-yl)-4-(4-(trifluoromethyl)styryl)piperidine (<b>84</b>)</h3><div class="NLM_p last">Synthesized from <b>47</b> (0.580 g, 1.632 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 2/1 (v/v). Yield: 85% (376 mg); white crystals, mp 72–74 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.52–1.62 (m, 2H), 1.80–1.85 (m, 2H), 2.12–2.20 (m, 1H), 2.26 (t, <i>J</i> = 2.4 Hz, 1H), 2.25–2.32 (m, 2H), 2.92–2.96 (m, 2H), 3.33 (d, <i>J</i> = 2.5 Hz, 2H), 6.27 (dd, <i>J</i> = 16.0, 6.9 Hz, 1H), 6.41 (d, <i>J</i> = 16.0 Hz, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.54 (d, <i>J</i> = 8.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.78, 38.84, 47.17, 52.11, 72.97, 78.95, 124.20 (q, <i>J</i><sub>C,F</sub> = 271.8 Hz), 125.34 (q, <i>J</i><sub>C,F</sub> = 3.9 Hz), 126.07, 127.02, 128.69 (q, <i>J</i><sub>C,F</sub> = 32.4 Hz), 137.62, 141.07 (q, <i>J</i><sub>C,F</sub> = 1.4 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>19</sub>F<sub>3</sub>N [M + H]<sup>+</sup> 294.1470; found 294.1464. IR (ATR): 3157, 2933, 2917, 2806, 1613, 1312, 1160, 1109, 1066, 1055, 972, 866, 831, 736, 600, 579, 517 cm<sup>–1</sup>. HPLC purity, 99.9% (<i>t</i><sub>R</sub> = 10.19 min).</div></div><div id="sec4_2_7_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> (<i>Z</i>)-1-(Prop-2-yn-1-yl)-4-(3-(trifluoromethyl)styryl)piperidine (<b>85</b>)</h3><div class="NLM_p last">Synthesized from <b>48</b> (0.05 g, 0.14 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/3 (v/v). Yield: 27% (11 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.59–1.77 (m, 2H), 1.75 (dd, <i>J</i> = 12.8, 2.2 Hz, 2H), 2.26–2.32 (m, 3H), 2.44–2.54 (m, 1H), 2.92–2.98 (m, 2H), 3.35 (d, <i>J</i> = 2.4 Hz, 2H), 5.60 (dd, <i>J</i> = 11.6, 10.2 Hz, 1H), 5.41 (d, <i>J</i> = 11.7 Hz, 1H), 7.39–7.51 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.83, 34.35, 47.10, 51.69, 73.79, 78.08, 123.37 (q, <i>J</i><sub>C,F</sub> = 3.8 Hz), 124.10 (q, <i>J</i><sub>C,F</sub> = 272.3 Hz), 125.21 (q, <i>J</i><sub>C,F</sub> = 3.7 Hz), 127.08, 128.72, 130.64 (q, <i>J</i><sub>C,F</sub> = 32.2 Hz), 131.60, 138.20, 138.45. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>19</sub>NF<sub>3</sub> [M + H]<sup>+</sup> 294.1470; found 294.1466. IR (ATR): 3306, 2933, 2850, 2804, 2757, 1688, 1444, 1327, 1162, 1122, 1092, 1072, 972, 905, 807, 703, 696, 656, 628 cm<sup>–1</sup>. HPLC purity, 95.9% (<i>t</i><sub>R</sub> = 10.13 min).</div></div><div id="sec4_2_7_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> (<i>E</i>)-1-(Prop-2-yn-1-yl)-4-(3-(trifluoromethyl)styryl)piperidine (<b>86</b>)</h3><div class="NLM_p last">Synthesized from <b>49</b> (0.19 g, 0.53 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/3 (v/v). Yield: 70% (109 mg); green oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.52–1.62 (m, 2H), 1.78–1.84 (m, 2H), 2.11–2.20 (m, 1H), 2.26 (t, <i>J</i> = 2.4 Hz, 1H), 2.29 (dt, <i>J</i> = 11.8, 2.3 Hz, 2H), 2.91–2.97 (m, 2H), 3.33 (d, <i>J</i> = 2.4 Hz, 2H), 6.24 (dd, <i>J</i> = 16.0, 6.9 Hz, 1H), 6.41 (d, <i>J</i> = 16.0 Hz, 1H), 7.38–7.45 (m, 2H), 7.51 (d, <i>J</i> = 7.5 Hz, 1H), 7.58 (s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.87, 38.86, 47.24, 52.18, 73.01, 79.02, 122.64 (q, <i>J</i><sub>C,F</sub> = 3.9 Hz), 123.50 (q, <i>J</i><sub>C,F</sub> = 3.9 Hz), 124.16 (q, <i>J</i><sub>C,F</sub> = 272.3 Hz), 127.03, 128.88, 129.18, 130.85 (q, <i>J</i><sub>C,F</sub> = 32.1 Hz), 136.91, 138.39. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>19</sub>NF<sub>3</sub> [M + H]<sup>+</sup> 294.1470; found 294.1465. IR (ATR): 3306, 2934, 2849, 2804, 2755, 1444, 1329, 1201, 1162, 1120, 1094, 1071, 965, 900, 792, 696, 662, 628 cm<sup>–1</sup>. HPLC purity, 99.8% (<i>t</i><sub>R</sub> = 10.16 min).</div></div><div id="sec4_2_7_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> (<i>Z</i>)-4-(2-(1-(Prop-2-yn-1-yl)piperidin-4-yl)vinyl)benzonitrile (<b>87</b>)</h3><div class="NLM_p last">Synthesized from <b>50</b> (0.350 g, 1.120 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/CH<sub>2</sub>Cl<sub>2</sub> = 3/7 (v/v). Yield: 50% (125 mg); white crystals, mp 118–121 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.51–1.61 (m, 2H), 1.68–1.74 (m, 2H), 2.19–2.25 (m, 2H), 2.24 (t, <i>J</i> = 2.4 Hz, 1H), 2.42–2.50 (m, 1H), 2.86–2.91 (m, 2H), 3.30 (d, <i>J</i> = 2.5 Hz, 2H), 5.64 (dd, <i>J</i> = 11.7, 10.2 Hz, 1H), 6.37 (d, <i>J</i> = 11.8 Hz, 1H), 7.30–7.33 (m, 2H), 7.61–7.63 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.01, 34.61, 47.15, 51.64, 73.05, 78.81, 110.05, 118.88, 126.58, 129.00, 132.02, 140.13, 142.21. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>19</sub>N<sub>2</sub> [M + H]<sup>+</sup> 251.1548; found 251.1550. IR (ATR): 3199, 2930, 2812, 2793, 2771, 2225, 1602, 1500, 1451, 1396, 1337, 1274, 1226, 1143, 1110, 970, 850,729, 697, 569, 528 cm<sup>–1</sup>. HPLC purity, 98.3% (<i>t</i><sub>R</sub> = 8.39 min).</div></div><div id="sec4_2_7_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> (<i>E</i>)-4-(2-(1-(Prop-2-yn-1-yl)piperidin-4-yl)vinyl)benzonitrile (<b>88</b>)</h3><div class="NLM_p last">Synthesized from (<b>51</b> (0.300 g, 0.960 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 50/1 (v/v). Yield: 54% (130 mg); white crystals, mp 59–62 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.47–1.58 (m, 2H), 1.74–1.80 (m, 2H), 2.09–2.18 (m, 1H), 2.21–2.27 (m, 2H), 2.23 (t, <i>J</i> = 2.4 Hz, 1H), 2.87–2.92 (m, 2H), 3.28 (d, <i>J</i> = 2.5 Hz, 2H), 6.27 (dd, <i>J</i> = 16.0, 6.5 Hz, 1H), 6.35 (d, <i>J</i> = 16.1 Hz, 1H), 7.36–7.39 (m, 2H), 7.51–7.54 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.58, 38.79, 47.06, 51.95, 72.96, 78.83, 109.93, 118.93, 126.35, 126.77, 132.16, 138.94, 141.99. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>19</sub>N<sub>2</sub> [M + H]<sup>+</sup> 251.1548; found 251.1549. IR (ATR): 3284, 2941, 2916, 2802, 2224, 1646, 1602, 1503, 1423, 1382, 1338, 1315, 1223, 1138, 1104, 984, 970, 900, 855, 831, 762, 692, 630, 551 cm<sup>–1</sup>. HPLC purity, 99.3% (<i>t</i><sub>R</sub> = 8.34 min).</div></div><div id="sec4_2_7_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> (<i>Z</i>)-4-(4-(Methylsulfonyl)styryl)-1-(prop-2-yn-1-yl)piperidine (<b>89</b>)</h3><div class="NLM_p last">Synthesized from <b>52</b> (0.126 g, 0.346 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 2/1 (v/v). Yield: 76% (80 mg); white crystals, mp 71–74 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.49–1.60 (m, 2H), 1.67–1.73 (m, 2H), 2.20 (dt, <i>J</i> = 11.7, 2.5 Hz, 2H), 2.23 (t, <i>J</i> = 2.4 Hz, 1H), 2.41–2.51 (m, 1H), 2.86 (td, <i>J</i> = 8.9, 2.7 Hz, 2H), 3.05 (s, 3H), 3.28 (d, <i>J</i> = 2.5 Hz, 2H), 5.64 (dd, <i>J</i> = 11.7, 10.3 Hz, 1H), 6.39 (d, <i>J</i> = 11.7 Hz, 1H), 7.37–7.40 (m, 2H), 7.86–7.90 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.03, 34.60, 44.46, 47.16, 51.64, 73.08, 78.82, 126.42, 127.32, 129.17, 138.28, 140.29, 143.22. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>22</sub>NO<sub>2</sub>S [M + H]<sup>+</sup> 304.1371; found 304.1370. IR (ATR): 3273, 2937, 2799, 2757, 1640, 1593, 1463, 1415, 1296, 1141, 1078, 955, 848, 774, 723, 679, 615, 593, 525 cm<sup>–1</sup>. HPLC purity, 98.3% (<i>t</i><sub>R</sub> = 4.60 min).</div></div><div id="sec4_2_7_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> (<i>E</i>)-4-(4-(Methylsulfonyl)styryl)-1-(prop-2-yn-1-yl)piperidine (<b>90</b>)</h3><div class="NLM_p last">Synthesized from <b>53</b> (0.205 g, 0.56 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 2/1 (v/v). Yield: 85% (145 mg); white crystals, mp 101–105 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.52–1.62 (m, 2H), 1.80–1.85 (m, 2H), 2.14–2.23 (m, 1H), 2.25–2.32 (m, 3H), 2.92–2.97 (m, 2H), 3.04 (s, 3H), 3.33 (d, <i>J</i> = 2.2 Hz, 2H), 6.34 (dd, <i>J</i> = 16.0, 6.6 Hz, 1H), 6.43 (d, <i>J</i> = 16.1 Hz, 1H), 7.51 (d, <i>J</i> = 8.1 Hz, 2H), 7.85 (d, <i>J</i> = 8.0 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.73, 38.98, 44.60, 47.22, 52.11, 73.05, 78.94, 126.66, 126.74, 127.68, 138.37, 139.35, 143.16. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>22</sub>NO<sub>2</sub>S [M + H]<sup>+</sup> 304.1371; found 304.1372. IR (ATR): 3282, 2927, 2797, 2750, 1647, 1595, 1466, 1404, 1303, 1146, 1091, 960, 858, 767, 705, 684, 649, 595, 544, 526 cm<sup>–1</sup>. HPLC purity, 95.1% (<i>t</i><sub>R</sub> = 5.06 min).</div></div><div id="sec4_2_7_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> (<i>Z</i>)-4-(4-Cyclopropylstyryl)-1-(prop-2-yn-1-yl)piperidine (<b>91</b>)</h3><div class="NLM_p last">Synthesized from <b>54</b> (0.080 g, 0.244 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 20% (16 mg); colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.68–0.72 (m, 2H), 0.94–0.99 (m, 2H), 1.49–1.59 (m, 2H), 1.71–1.77 (m, 2H), 1.86–1.92 (m, 1H), 2.20–2.26 (m, 3H), 2.52–2.62 (m, 1H), 2.86–2.91 (m, 2H), 3.30 (d, <i>J</i> = 2.5 Hz, 2H), 5.43 (dd, <i>J</i> = 11.6, 10.0 Hz, 1H), 6.33 (d, <i>J</i> = 11.6 Hz, 1H), 7.02–7.06 (m, 2H), 7.12–7.16 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 9.31, 15.16, 32.35, 34.45, 47.28, 51.95, 72.96, 79.08, 125.44, 127.88, 128.47, 134.75, 136.53, 142.48. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>24</sub>N [M + H]<sup>+</sup> 266.1909; found 266.1905. IR (ATR): 3355, 2973, 2916, 2849, 1739, 1654, 1468, 1373, 1239, 1086, 1045, 879, 719 cm<sup>–1</sup>. HPLC purity, 95.9% (<i>t</i><sub>R</sub> = 10.27 min).</div></div><div id="sec4_2_7_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> (<i>E</i>)-4-(4-Cyclopropylstyryl)-1-(prop-2-yn-1-yl)piperidine (<b>92</b>)</h3><div class="NLM_p last">Synthesized from <b>55</b> (0.200 g, 0.611 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 40% (65 mg); pale yellow crystals, mp 66–68 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.66–0.70 (m, 2H), 0.92–0.97 (m, 2H), 1.50–1.61 (dt, 2H), 1.77–1.83 (m, 2H), 1.85–1.90 (m, 1H), 2.07–2.17 (m, 1H), 2.26 (t, <i>J</i> = 2.4 Hz, 1H), 2.27 (dt, <i>J</i> = 11.7, 2.5 Hz, 2H), 2.90–2.95 (m, 2H), 3.32 (d, <i>J</i> = 2.4 Hz, 2H), 6.10 (dd, <i>J</i> = 15.9, 7.0 Hz, 1H), 6.34 (d, <i>J</i> = 15.9 Hz, 1H), 6.98–7.01 (m, 2H), 7.23–7.26 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 9.17, 15.12, 32.04, 38.75, 47.20, 52.23, 72.91, 79.06, 125.66, 125.84, 127.90, 133.77, 134.82, 142.79. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>24</sub>N [M + H]<sup>+</sup> 266.1909; found 266.1908. IR (ATR): 3007, 2932, 2919, 2854, 2805, 2748, 1607, 1514, 1424, 1385, 1312, 1135, 1103, 1041, 1022, 972, 891, 851, 804, 684, 665, 644, 630, 546 cm<sup>–1</sup>. HPLC purity, 98.1% (<i>t</i><sub>R</sub> = 10.27 min).</div></div><div id="sec4_2_7_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> 4-Phenethyl-1-(prop-2-yn-1-yl)piperidine (<b>93</b>)</h3><div class="NLM_p last">Synthesized from <b>56</b> (1.040 g, 3.593 mmol, 1.0 equiv) via general procedures D and E. Column chromatographym EtOAc/n-hex = 1/2 (v/v). Yield: 56% (202 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.24–1.39 (m, 3H), 1.56–1.62 (m, 2H), 1.75–1.81 (m, 2H), 2.15–2.22 (m, 2H), 2.24 (t, <i>J</i> = 2.5 Hz, 1H), 2.62–2.66 (m, 2H), 2.87–2.92 (m, 2H), 3.30 (d, <i>J</i> = 2.5 Hz, 2H), 7.16–7.21 (m, 3H), 7.26–7.31 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.05, 32.89, 34.58, 38.15, 47.03, 52.34, 72.74, 79.02, 125.44, 128.10 (4 × C), 142.43. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>22</sub>N [M + H]<sup>+</sup> 228.1752; found 228.1755. IR (ATR): 3297, 2935, 2908, 2801, 1496, 1337, 1313, 750, 700, 641 cm<sup>–1</sup>. HPLC purity, 99.9% (<i>t</i><sub>R</sub> = 8.86 min).</div></div><div id="sec4_2_7_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> 4-(3-Fluorophenethyl)-1-(prop-2-yn-1-yl)piperidine (<b>94</b>)</h3><div class="NLM_p last">Synthesized from <b>57</b> (0.320 g, 1.04 mmol, 1.0 equiv) via general procedures D and E. Column chromatography EtOAc/n-hex = 1/2 (v/v). Yield: 18% (46 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.21–1.37 (m, 3H), 1.52–1.58 (m, 2H), 1.73–1.78 (m, 2H), 2.14–2.20 (m, 2H), 2.23 (t, <i>J</i> = 2.4 Hz, 1H), 2.59–2.63 (m, 2H), 2.86–2.91 (m, 2H), 3.29 (d, <i>J</i> = 2.4 Hz, 2H), 6.83–6.89 (m, 2H), 6.92–6.95 (m, 1H), 7.18–7.24 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.10, 32.76, 32.78 34.64, 37.90, 47.14, 52.45, 72.93, 79.04, 112.46 (d, <i>J</i><sub>C,F</sub> = 21.9 Hz), 115.04 (d, <i>J</i><sub>C,F</sub> = 20.5 Hz), 123.90 (d, <i>J</i><sub>C,F</sub> = 2.2 Hz), 129.60 (d, <i>J</i><sub>C,F</sub> = 8.7 Hz), 145.18 (d, <i>J</i><sub>C,F</sub> = 7.2 Hz), 162.83 (d, <i>J</i><sub>C,F</sub> = 245.0 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>21</sub>FN [M + H]<sup>+</sup> 246.1658; found 246.1659. IR (ATR): 3305, 2919, 2849, 2803, 2755, 1616, 1588, 1488, 1466, 1446, 1387, 1367, 1337, 1312, 1251, 1183, 1139, 1125, 1105, 1085, 1021, 995, 976, 959, 934, 888, 866, 782, 741, 719, 691, 629 cm<sup>–1</sup>. HPLC purity, 97.6% (<i>t</i><sub>R</sub> = 9.26 min).</div></div><div id="sec4_2_7_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> 4-(2-Fluorophenethyl)-1-(prop-2-yn-1-yl)piperidine (<b>95</b>)</h3><div class="NLM_p last">Synthesized from <b>58</b> (0.220 g, 0.716 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 8% (14 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.25–1.37 (m, 3H), 1.53–1.58 (m, 2H), 1.77–1.80 (m, 2H), 2.15–2.20 (m, 2H), 2.23 (t, <i>J</i> = 2.4 Hz, 1H), 2.63–2.67 (m, 2H), 2.87–2.90 (m, 2H), 3.30 (d, <i>J</i> = 2.4 Hz, 2H), 6.97–7.02 (m, 1H), 7.03–7.07 (m, 1H), 7.13–7.20 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 26.17, 32.12, 34.85, 36.88, 47.20, 52.53, 72.89, 79.15, 115.15 (d, <i>J</i><sub>C,F</sub> = 22.5 Hz), 123.88 (d, <i>J</i><sub>C,F</sub> = 3.4 Hz), 127.32 (d, <i>J</i><sub>C,F</sub> = 8.0 Hz), 129.41 (d, <i>J</i><sub>C,F</sub> = 16.1 Hz), 130.41 (d, <i>J</i><sub>C,F</sub> = 5.3 Hz), 161.08 (d, <i>J</i><sub>C,F</sub> = 244.5 Hz). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>21</sub>FN [M + H]<sup>+</sup> 246.1658; found 246.1657. IR (ATR): 3383, 2975, 2931, 1691, 1638, 1492, 1453, 1423, 1366, 1324, 1277, 1228, 1161, 1127, 1086, 1033, 966, 863, 804, 757 cm<sup>–1</sup>. HPLC purity, 95.1% (<i>t</i><sub>R</sub> = 9.20 min).</div></div><div id="sec4_2_7_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> 4-(4-Methylphenethyl)-1-(prop-2-yn-1-yl)piperidine (<b>96</b>)</h3><div class="NLM_p last">Synthesized from <b>59</b> (0.28 g, 0.92 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/3 (v/v). Yield: 36% (79 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.21–1.36 (m, 3H), 1.52–1.57 (m, 2H), 1.75–1.78 (m, 2H), 2.14–2.20 (m, 2H), 2.23 (t, <i>J</i> = 2.4 Hz, 1H), 2.31 (s, 3H), 2.56–2.60 (m, 2H), 2.86–2.89 (m, 2H), 3.29 (d, <i>J</i> = 2.4 Hz, 2H), 7.05–7.10 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 20.97, 32.21, 32.57, 34.68, 38.43, 47.21, 52.55, 72.83, 79.05, 128.17, 128.97, 135.05, 139.58. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>24</sub>N [M + H]<sup>+</sup> 242.1909; found 242.1904. IR (ATR): 3183, 2932, 2917, 2847, 2798, 2752, 1515, 1451, 1333, 1293, 1270, 1144, 1103, 1080, 974, 850, 800, 784, 739, 559, 506 cm<sup>–1</sup>. HPLC purity, 97.4% (<i>t</i><sub>R</sub> = 9.75 min).</div></div><div id="sec4_2_7_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> 4-(4-Isopropylphenethyl)-1-(prop-2-yn-1-yl)piperidine (<b>97</b>)</h3><div class="NLM_p last">Synthesized from <b>60</b> (0.290 g, 0.875 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 55% (112 mg); yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.28 (d, <i>J</i> = 7.0 Hz, 6H), 1.32–1.39 (m, 3H), 1.58–1.63 (m, 2H), 1.79–1.84 (m, 2H), 2.19–2.25 (m, 2H), 2.26 (t, <i>J</i> = 2.4 Hz, 1H), 2.62–2.66 (m, 2H), 2.88–2.95 (m, 3H), 3.33 (d, <i>J</i> = 2.5 Hz, 2H), 7.13–7.16 (m, 2H), 7.17–7.20 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 24.02, 32.18, 32.56, 33.59, 34.76, 38.34, 47.16, 52.50, 72.78, 79.17, 126.24, 128.10, 139.90, 146.03. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>28</sub>N [M + H]<sup>+</sup> 270.2222; found 270.2226. IR (ATR): 3282, 2958, 2933, 2908, 2801, 2753, 1512, 1128, 1105, 976, 817, 677, 654, 641 cm<sup>–1</sup>. HPLC purity, 99.8% (<i>t</i><sub>R</sub> = 10.99 min).</div></div><div id="sec4_2_7_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> 4-(4-Chlorophenethyl)-1-(prop-2-yn-1-yl)piperidine (<b>98</b>)</h3><div class="NLM_p last">Synthesized from <b>61</b> (0.195 g, 0.602 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 62% (85 mg); white crystals, mp 37–39 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.18–1.34 (m, 3H), 1.49–1.55 (m, 2H), 1.70–1.76 (m, 2H), 2.12–2.18 (m, 2H), 2.22 (t, <i>J</i> = 2.5 Hz, 1H), 2.55–2.59 (m, 2H), 2.84–2.89 (m, 2H), 3.27 (d, <i>J</i> = 2.5 Hz, 2H), 7.06–7.10 (m, 2H), 7.20–7.24 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.11, 32.32, 34.60, 38.09, 47.13, 52.42, 72.82, 79.10, 128.28, 129.55, 131.21, 140.97. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>21</sub>ClN [M + H]<sup>+</sup> 262.1363; found 262.1362. IR (ATR): 3219, 2931, 2919, 2863, 2801, 2758, 1492, 1451, 1407, 1335, 1282, 1261, 1138, 1121, 1109, 1084, 1015, 992, 974, 826, 797, 729, 688, 631, 539 cm<sup>–1</sup>. HPLC purity, 100% (<i>t</i><sub>R</sub> = 9.90 min).</div></div><div id="sec4_2_7_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> 4-(4-Methoxyphenethyl)-1-(prop-2-yn-1-yl)piperidine (<b>99</b>)</h3><div class="NLM_p last">Synthesized from <b>62</b> (0.230 g, 0.720 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 57% (103 mg); white crystals, mp 31–32 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.22–1.36 (m, 3H), 1.50–1.56 (m, 2H), 1.73–1.77 (m, 2H), 2.13–2.19 (m, 2H), 2.23 (t, <i>J</i> = 2.5 Hz, 1H), 2.54–2.58 (m, 2H), 2.85–2.90 (m, 2H), 3.28 (d, <i>J</i> = 2.5 Hz, 2H), 3.77 (s, 3H), 6.80–6.84 (m, 2H), 7.07–7.10 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.01, 32.14, 34.57, 38.46, 47.13, 52.46, 55.10, 72.77, 79.15, 113.60, 129.04, 134.60, 157.51. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>24</sub>NO [M + H]<sup>+</sup> 258.1858; found 258.1857. IR (ATR): 3273, 2926, 2908, 2850, 2806, 1609, 1510, 1314, 1250, 1238, 1175, 1101, 1031, 975, 898, 832, 812, 702, 640, 577, 523 cm<sup>–1</sup>. HPLC purity, 100% (<i>t</i><sub>R</sub> = 8.95 min).</div></div><div id="sec4_2_7_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> 1-(Prop-2-yn-1-yl)-4-(4-(trifluoromethyl)phenethyl)piperidine (<b>100</b>)</h3><div class="NLM_p last">Synthesized from <b>63</b> (0.23 g, 0.64 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 7% (14 mg); brown crystals, mp 31–33 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.23–1.37 (m, 3H), 1.54–1.60 (m, 2H), 1.74–1.78 (m, 2H), 2.14–2.20 (m, 2H), 2.23 (t, <i>J</i> = 2.4 Hz, 1H), 2.65–2.70 (m, 2H), 2.86–2.90 (m, 2H), 3.29 (d, <i>J</i> = 2.4 Hz, 2H), 7.26–7.28 (m, 2H), 7.51–7.53 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.14, 32.91, 34.71, 37.97, 47.17, 52.45, 72.89, 79.11, 124.34 (q, <i>J</i><sub>C,F</sub> = 270.0 Hz), 125.20 (q, <i>J</i><sub>C,F</sub> = 7.9 Hz), 128.02 (q, <i>J</i><sub>C,F</sub> = 32.3 Hz) 128.57, 146.77. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>21</sub>F<sub>3</sub>N [M + H]<sup>+</sup> 296.1626; found 296.1625. IR (ATR): 3153, 2932, 2852, 2798, 1615, 1429, 1318, 1157, 1116, 1093, 1065, 1017, 978, 910, 854, 831, 735, 682, 637, 598, 552, 511 cm<sup>–1</sup>. HPLC purity, 100% (<i>t</i><sub>R</sub> = 10.29 min).</div></div><div id="sec4_2_7_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> 1-(Prop-2-yn-1-yl)-4-(3-(trifluoromethyl)phenethyl)piperidine (<b>101</b>)</h3><div class="NLM_p last">Synthesized from <b>64</b> (0.27 g, 0.76 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/3 (v/v). Yield: 29% (65 mg); yellow-orange oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.22–1.37 (m, 3H), 1.54–1.59 (m, 2H), 1.72–1.78 (m, 2H), 2.14–2.19 (m, 2H), 2.22 (t, <i>J</i> = 2.4 Hz, 1H), 2.64–2.69 (m, 2H), 2.86–2.90 (m, 2H), 3.28 (d, <i>J</i> = 2.46 Hz, 2H), 7.32–7.43 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.10, 32.88, 34.82, 38.03, 47.13, 52.43, 72.86, 79.07, 122.51 (q, <i>J</i><sub>C,F</sub> = 3.8 Hz), 124.21 (q, <i>J</i><sub>C,F</sub> = 272.2 Hz), 124.88 (q, <i>J</i><sub>C,F</sub> = 3.7 Hz), 128.63, 130.51 (q, <i>J</i><sub>C,F</sub> = 31.8 Hz), 131.64, 143.48. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>21</sub>NF<sub>3</sub> [M + H]<sup>+</sup> 296.1626; found 296.1629. IR (ATR): 3308, 2923, 2849, 2804, 2757, 1449, 1329, 1199, 1161, 1121, 1072, 976, 900, 879, 800, 735, 702, 660, 631 cm<sup>–1</sup>. HPLC purity, 98.7% (<i>t</i><sub>R</sub> = 10.25 min).</div></div><div id="sec4_2_7_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> 4-(2-(1-(Prop-2-yn-1-yl)piperidin-4-yl)ethyl)benzonitrile (<b>102</b>)</h3><div class="NLM_p last">Synthesized from <b>65</b> (0.075 g, 0.239 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/1 (v/v). Yield: 59% (106 mg); white crystals, mp 40–42 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.20–1.36 (m, 3H), 1.53–1.58 (m, 2H), 1.72–1.77 (m, 2H), 2.13–2.19 (m, 2H), 2.22 (t, <i>J</i> = 2.4 Hz, 1H), 2.65–2.69 (m, 2H), 2.85–2.90 (m, 2H), 3.28 (d, <i>J</i> = 2.5 Hz, 2H), 7.25–7.28 (m, 2H), 7.54–7.57 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.99, 33.13, 34.62, 37.60, 47.03, 52.28, 72.82, 78.97, 109.39, 118.96, 128.96, 132.01, 148.23. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>21</sub>N<sub>2</sub> [M + H]<sup>+</sup> 253.1705; found 253.1706. IR (ATR): 3270, 2925, 2795, 2224, 1606, 1424, 1326, 1310, 1180, 1137, 1105, 977, 901, 852, 836, 821, 766, 682, 573, 545 cm<sup>–1</sup>. HPLC purity, 96.0% (<i>t</i><sub>R</sub> = 8.42 min).</div></div><div id="sec4_2_7_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> 1-(Prop-2-yn-1-yl)-4-(4-propylphenethyl)piperidine (<b>103</b>)</h3><div class="NLM_p last">Synthesized from <b>66</b> (0.185 g, 0.561 mmol, 1.0 equiv) via general procedures D and E. Column chromatography, EtOAc/n-hex = 1/2 (v/v). Yield: 45% (68 mg); pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.95 (t, <i>J</i> = 7.4 Hz, 3H), 1.25–1.37 (m, 3H), 1.53–1.59 (m, 2H), 1.60–1.68 (m, 2H), 1.76–1.80 (m, 2H), 2.15–2.21 (m, 2H), 2.23 (t, <i>J</i> = 2.4 Hz, 1H), 2.53–2.62 (m, 4H), 2.87–2.91 (m, 2H), 3.30 (d, <i>J</i> = 2.4 Hz, 2H), 7.07–7.11 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 13.86, 24.60, 32.20, 32.60, 34.75, 37.61, 38.37, 47.19, 52.53, 72.80, 79.20, 128.07, 128.32, 139.80 139.88. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>28</sub>N [M + H]<sup>+</sup> 270.2216; found 270.2215. IR (ATR): 3008, 2925, 2852, 2801, 2753, 1513, 1454, 1337, 1312, 1117, 1106, 1021, 976, 897, 806, 787, 679, 645, 623, 503 cm<sup>–1</sup>. HPLC purity, 97.1% (<i>t</i><sub>R</sub> = 11.12 min).</div></div><div id="sec4_2_7_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> (<i>Z</i>)-4-(2-(1-(Prop-2-yn-1-yl)piperidin-4-yl)vinyl)benzamide (<b>104</b>)</h3><div class="NLM_p last">Synthesized from <b>87</b> (0.065 g, 0.260 mmol, 1.0 equiv) via general procedure F. Column chromatography, CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 20/1 (v/v). Yield: 46% (32 mg); white crystals, mp 127–130 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.49–1.59 (m, 2H), 1.68–1.74 (m, 2H), 2.20 (td, <i>J</i> = 11.7, 2.6 Hz, 2H), 2.23 (t, <i>J</i> = 2.4 Hz, 1H), 2.46–2.57 (m, 1H), 2.87 (dt, <i>J</i> = 11.0, 2.4 Hz, 2H), 3.28 (d, <i>J</i> = 2.5 Hz, 2H), 5.57 (dd, <i>J</i> = 11.7, 10.1 Hz, 1H), 6.27 (bs, 2H), 6.39 (d, <i>J</i> = 11.7 Hz, 1H), 7.27–7.30 (m, 2H), 7.77–7.80 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 32.12, 34.58, 47.19, 51.77, 73.07, 78.89, 127.17, 127.34, 128.61, 131.35, 139.00, 141.40, 169.32. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>21</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 269.1654; found 269.1652. IR (ATR): 3331, 3307, 3285, 3204, 2928, 2806, 1658, 1604, 1550, 1418, 1386, 1309, 1259, 1131, 1122, 1104, 969, 856, 794, 765, 736, 659, 636, 509 cm<sup>–1</sup>. HPLC purity, 98.2% (<i>t</i><sub>R</sub> = 6.34 min).</div></div><div id="sec4_2_7_87" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> (<i>E</i>)-4-(2-(1-(Prop-2-yn-1-yl)piperidin-4-yl)vinyl)benzamide (<b>105</b>)</h3><div class="NLM_p last">Synthesized from <b>88</b> (0.080 g, 0.320 mmol, 1.0 equiv) via general procedure F. Column chromatography, CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 20/1 (v/v). Yield: 63% (54 mg); white crystals, mp 181–184 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.42 (dq, <i>J</i> = 12.7, 3.9 Hz, 2H), 1.72–1.75 (m, 2H), 2.06–2.12 (m, 1H), 2.17 (td, <i>J</i> = 11.5, 2.2 Hz, 2H), 2.79–2.83 (m, 2H), 3.14 (t, <i>J</i> = 2.4 Hz, 1H), 3.26 (d, <i>J</i> = 2.4 Hz, 2H), 6.36–6.46 (m, 2H), 7.30 (bs, 1H), 7.45–7.47 (m, 2H), 7.80–7.82 (m, 2H), 7.93 (bs, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 31.34, 38.32, 46.38, 51.42, 75.53, 79.53, 125.53, 126.96, 127.75, 132.40, 137.04, 139.99, 167.43. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>21</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 269.1654; found 269.1656. IR (ATR): 3401, 3281, 3147, 2937, 2913, 2805, 1645, 1614, 1564, 1442, 1415, 1393, 1313, 1289, 1221, 1136, 1101, 976, 870, 829, 800, 767, 682, 647, 635, 599, 544 cm<sup>–1</sup>. HPLC purity, 99.4% (<i>t</i><sub>R</sub> = 6.20 min).</div></div><div id="sec4_2_7_88" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> 4-(2-(1-(Prop-2-yn-1-yl)piperidin-4-yl)ethyl)benzamide (<b>106</b>)</h3><div class="NLM_p last">Synthesized from <b>102</b> (0.075 g, 0.297 mmol, 1.0 equiv) via general procedure F. Column chromatography, CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 9/1 (v/v). Yield: 42% (34 mg); white crystals, mp 155–158 °C. <sup>1</sup>H NMR (400 MHz, MeOD): δ 1.28–1.36 (m, 3H), 1.58–1.63 (m, 2H), 1.80–1.83 (m, 2H), 2.21 (t, <i>J</i> = 11.3 Hz, 2H), 2.69 (t, <i>J</i> = 2.5 Hz, 1H), 2.70–2.74 (m, 2H), 2.94–2.99 (m, 2H), 3.29 (d, <i>J</i> = 2.5 Hz, 2H), 7.30–7.32 (m, 2H), 7.79–7.82 (m, 2H), resonances for N<u class="uu">H</u><sub>2</sub> missing (exchange with MeOD). <sup>13</sup>C NMR (100 MHz, MeOD): δ 32.74, 33.88, 35.92, 39.11, 47.65, 53.55, 75.10, 79.19, 128.82, 129.50, 132.39, 148.40, 172.38. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>23</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 269.1810; found 269.1816. IR (ATR): 3178, 2932, 2919, 2847, 2798, 2752, 2543, 2373, 1610, 1563, 1421, 1404, 1333, 1270, 1186, 1144, 1103, 1019, 973, 915, 859, 767, 755, 709, 594 cm<sup>–1</sup>. HPLC purity, 99.6% (<i>t</i><sub>R</sub> = 6.29 min).</div></div><div id="sec4_2_7_89" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> 4-(2-(1-(Prop-2-yn-1-yl)piperidin-4-yl)ethyl)phenol (<b>107</b>)</h3><div class="NLM_p last">The methoxy substituted compound <b>99</b> (50 mg, 0.194 mmol, 1.0 equiv) was dissolved in anhydrous toluene (6 mL) under argon and cooled to −20 °C. BBr<sub>3</sub> (1 M in CH<sub>2</sub>Cl<sub>2</sub>, 582 μL, 0.582 mmol, 3.0 equiv) was added dropwise and the reaction mixture was stirred for another hour at −20 °C. The mixture was allowed to warm up to room temperature (1 h). Saturated aqueous NaHCO<sub>3</sub> (10 mL) was added, and the resulting emulsion was stirred vigorously for 15 min before EtOAc (30 mL) was added. The phases were separated, and the organic layer was washed with saturated brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. Column chromatography, CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 20/1 (v/v). Yield: 57% (27 mg); white crystals, mp 104–106 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.23–1.39 (m, 3H), 1.48–1.54 (m, 2H), 1.73–1.79 (m, 2H), 2.21–2.27 (m, 2H), 2.25 (t, <i>J</i> = 2.4 Hz, 1H), 2.51–2.55 (m, 2H), 2.90–2.94 (m, 2H), 3.32 (d, <i>J</i> = 2.5 Hz, 2H), 6.71–6.73 (m, 2H), 6.99–7.02 (m, 2H), resonance for O<u class="uu">H</u> missing (exchange with water in solvent). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 31.89, 32.09, 34.56, 38.41, 47.07, 52.42, 73.33, 78.68, 115.28, 129.27, 134.34, 153.91. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>22</sub>NO [M + H]<sup>+</sup> 244.1701; found 244.1697. IR (ATR): 3278, 2909, 2853, 2815, 2598, 1614, 1593, 1515, 1464, 1392, 1337, 1269, 1249, 1170, 1116, 974, 819, 785, 692, 636, 563, 516, 501 cm<sup>–1</sup>. HPLC purity, 96.1% (<i>t</i><sub>R</sub> = 7.17 min).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Preparation of Hydrochloride Salts</h3><div class="NLM_p last">Compounds <b>1</b>, <b>6</b>, <b>67</b>, <b>69</b>, <b>84</b>, <b>97</b>, and <b>100</b> were transformed into corresponding hydrochloride salts following the described procedure. Compound in the form of a free base (0.2–2.5 g, 1.0 equiv) was dissolved in MeOH (5–20 mL). Then a 2 M solution of HCl in Et<sub>2</sub>O (2.0 equiv) was added at room temperature under vigorous stirring with magnetic stirrer. The precipitate formed was filtered off, washed with Et<sub>2</sub>O (50–100 mL), and dried at reduced pressure to obtain hydrochloride salts. These salts were used for the crystallization, permeability, <i>ex vivo</i> and <i>in vivo</i> experiments.</div></div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Biology. Protein Production, Enzymatic Assays, and X-ray Crystallography</h3><div class="NLM_p last">All of the reagents were purchased from Sigma-Aldrich unless specified otherwise. The effects of the compounds on hMAO-A and hMAO-B were first investigated by determining the IC<sub>50</sub> values using a previously described fluorimetric assay.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The inhibitory activities of the compounds were determined according to their effects on the generation of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) as a side-product of hMAO activity. For details on protein production, enzymatic assays, and X-ray crystallography, see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> Cell Culture and Treatments</h3><div class="NLM_p last">The human neuroblastoma SH-SY5Y cell line was purchased from American Type Culture Collection (CRL-2266; VA, USA). These cells were cultured in Advanced Dulbecco’s modified Eagle’s medium (Gibco, Thermo Fisher Scientific, MA, USA) supplemented with 10% fetal bovine serum (Gibco), 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 50 U/mL penicillin, and 50 μg/mL streptomycin (Sigma, MO, USA) in a humidified atmosphere of 95% air and 5% CO<sub>2</sub> at 37 °C and grown to 80% confluence. Prior to cell treatments, the complete medium was replaced with serum-depleted medium. Compounds were prepared as stock solutions of 20 mM in DMSO and were used at concentrations of 5–50 μM. For the cytotoxic stimuli, the 10 mM 6-OHDA (Sigma, MO, USA) stock was prepared in phosphate buffered saline, pH 7.4, with 0.01% ascorbic acid. For the detailed experimental procedures see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> Animals</h3><div class="NLM_p last">Adult male Swiss mice (weight, 25–30 g) and adult male Wistar rats (weight, 200–300 g) were obtained from the Central Animal House of the School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina. For behavioral assays, the mice were housed in groups of five in a controlled environment (20–23 °C), with free access to food and water, and maintained on a 12 h/12 h day/night cycle, with light on at 07:00 h. The housing, handling, and experimental procedures for both the mice and rats complied with the recommendations set out by the National Institutes of Health Guide for Care and Use of Laboratory Animals (NIH Publication No. 8023, revised 1996) and the Institutional Committees for the Care and Use of Laboratory Animals of the Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Argentina (Code 31682/2014). All efforts were taken to minimize animal suffering. The number of animals used was the minimum number consistent with obtaining significant data. The mice were randomly assigned to the treatment groups and were used only once. The pharmacological tests were evaluated by experimenters who were not aware of the treatments administered and were performed between 10:00 h and 14:00 h.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> Administrations and Procedures</h3><div class="NLM_p">The test compounds (used as their hydrochloride salts) were dissolved in 0.9% saline. Haloperidol, diazepam, and imipramine were diluted by sequential additions of DMSO, an aqueous solution of 0.25% Tween 80, and 0.9% saline to their final concentrations of 5%, 20%, and 75%, respectively. In each session, a control group of mice received only vehicle, in parallel with the mice that received the drug treatments. The volumes of the ip injections and oral gavage (po) administrations were 0.10–0.20 mL/30 g body weight and 0.30 mL/30 g body weight, respectively. The protein concentrations in the mouse brain homogenates were determined using the method of Bradford, with bovine serum albumin as the standard.</div><div class="NLM_p last">For the acute behavioral assays, all of the compounds were tested 30 min after ip administrations. For the chronical treatments, the mice were injected ip with 0.3 mg/kg <b>69</b>, <b>100</b> or 0.9% saline (control group) once a day between 09:00 and 10:00 h over 10 consecutive days. On days 1, 3, 5, 7, and 9, these mice were weighted. On day 8, at 30 min after the relevant ip treatment, the mice were submitted to the plus maze (for <b>69</b>) or the hole–board tests (for <b>100</b>), and their locomotor activity was recorded immediately afterward. On day 10, at 30 min after the relevant ip treatment, the mice were submitted to the tail suspension test (for <b>69</b>) or the haloperidol-induced catalepsy assay (for <b>100</b>) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Figures S10 and S11</a>). For all of these behavioral assays, the arena/apparatus was cleaned with 60% ethanol between each trial with each mouse. Behavioral assays are described in detail in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> Mouse Brain Homogenate Preparation</h3><div class="NLM_p last">The mice were killed humanely by decapitation at 30 min after drug or 0.9% saline treatment (for acute ip injections), at 60 min after drug or 0.9% saline treatment (for acute oral gavage), or on day 10 at 90 min after the last drug or 0.9% saline ip treatment after the tail suspension test (for the mice chronically treated with <b>69</b>) or after haloperidol-induced catalepsy test (for the mice chronically treated with <b>100</b>). Also, three mice that were chronically treated with <b>100</b> or 0.9% saline ip but without the haloperidol injection were also tested to determine any haloperidol effects in the <i>ex vivo</i> MAO-B activity assay (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Figures S10 and S11</a>). After removal of the olfactory bulb, the whole mouse brains were washed several times in ice-cold 50 mM potassium phosphate buffer (pH 7.4, 0.05% [v/v] Triton X-114). Then, each brain was independently homogenized using a blender homogenizer (PRO Scientific Inc., CT, USA) at 30 000 rpm for 1 min, in 1.5 mL of 100 mM potassium phosphate buffer (pH 7.4, 0.1% [v/v] Triton X-114) at 4 °C (in ice). The homogenate was then centrifuged at 3000<i>g</i> for 20 min at 4 °C. The supernatant was stored at −20 °C until the following day for the MAO inhibition assays.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> <i>Ex Vivo</i> MAO Inhibition Assay</h3><div class="NLM_p last">The <i>ex vivo</i> effects of <b>69</b> on MAO-A and <b>100</b> on MAO-B enzymatic activities (ip or oral administration, 30 min before decapitation) in the mouse brain homogenates were investigated using a previously described fluorimetric assay, with minor modifications.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> For details see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i122"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01886" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70172" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70172" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01886?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01886</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Supplementary figures, supplementary tables, supplementary results and discussion, supplementary methods, HPLC traces for representative final compounds, and <sup>1</sup>H and <sup>13</sup>C NMR spectra for final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Movie for undocking experiment, MAO-A (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_002.mp4" class="ext-link">MP4</a>)</p></li><li><p class="inline">Movie for undocking experiment, MAO-B (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_003.mp4" class="ext-link">MP4</a>)</p></li><li><p class="inline">Molecular formula strings and activity data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_004.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Model of undocking in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Model of undocking in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Model of undocking in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_007.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Model of undocking in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_008.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf">jm9b01886_si_001.pdf (9.39 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_002.mp4">jm9b01886_si_002.mp4 (214.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_003.mp4">jm9b01886_si_003.mp4 (381.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_004.csv">jm9b01886_si_004.csv (3.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_005.pdb">jm9b01886_si_005.pdb (342.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_006.pdb">jm9b01886_si_006.pdb (342.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_007.pdb">jm9b01886_si_007.pdb (333.29 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_008.pdb">jm9b01886_si_008.pdb (333.29 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates and structure factors have been deposited in the PDB under accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKB">6RKB</a> (compound <b>1</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKP">6RKP</a> (compound <b>84</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RLE">6RLE</a> (compound <b>97</b>). Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01886" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77554" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77554" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudia Binda</span> - <span class="hlFld-Affiliation affiliation">Department
of Biology and Biotechnology, University
of Pavia, Via Ferrata 1, 27100 Pavia, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2038-9845" title="Orcid link">http://orcid.org/0000-0003-2038-9845</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5437383521303d357a363d3a303514213a3d24227a3d20"><span class="__cf_email__" data-cfemail="a6c5cac7d3c2cfc788c4cfc8c2c7e6d3c8cfd6d088cfd2">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mariel Marder</span> - <span class="hlFld-Affiliation affiliation">Universidad
de Buenos Aires, Consejo Nacional de Investigaciones Científicas
y Técnicas, and Instituto de Química y Fisicoquímica
Biológicas, Facultad de Farmacia y Bioquímica, Universidad
de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#412c2c20332524330130236f272738236f3423206f2033"><span class="__cf_email__" data-cfemail="563b3b37243233241627347830302f3478233437783724">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stanislav Gobec</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9678-3083" title="Orcid link">http://orcid.org/0000-0002-9678-3083</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#443730252a2d372825326a232b262127042222256a312a2d69282e6a372d"><span class="__cf_email__" data-cfemail="0c7f786d62657f606d7a226b636e696f4c6a6a6d22796265216066227f65">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Damijan Knez</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natalia Colettis</span> - <span class="hlFld-Affiliation affiliation">Universidad
de Buenos Aires, Consejo Nacional de Investigaciones Científicas
y Técnicas, and Instituto de Química y Fisicoquímica
Biológicas, Facultad de Farmacia y Bioquímica, Universidad
de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luca G. Iacovino</span> - <span class="hlFld-Affiliation affiliation">Department
of Biology and Biotechnology, University
of Pavia, Via Ferrata 1, 27100 Pavia, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matej Sova</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anja Pišlar</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janez Konc</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Chemistry, Hajdrihova 19, 1000 Ljubljana, Slovenia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samo Lešnik</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Chemistry, Hajdrihova 19, 1000 Ljubljana, Slovenia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josefina Higgs</span> - <span class="hlFld-Affiliation affiliation">Universidad
de Buenos Aires, Consejo Nacional de Investigaciones Científicas
y Técnicas, and Instituto de Química y Fisicoquímica
Biológicas, Facultad de Farmacia y Bioquímica, Universidad
de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabiola Kamecki</span> - <span class="hlFld-Affiliation affiliation">Universidad
de Buenos Aires, Consejo Nacional de Investigaciones Científicas
y Técnicas, and Instituto de Química y Fisicoquímica
Biológicas, Facultad de Farmacia y Bioquímica, Universidad
de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Irene Mangialavori</span> - <span class="hlFld-Affiliation affiliation">Universidad
de Buenos Aires, Consejo Nacional de Investigaciones Científicas
y Técnicas, and Instituto de Química y Fisicoquímica
Biológicas, Facultad de Farmacia y Bioquímica, Universidad
de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ana Dolšak</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Žakelj</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jurij Trontelj</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janko Kos</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>D.K., N.C., and L.G.I. contributed equally to this work. D.K. designed the inhibitors, performed the chemistry and in vitro MAO inhibition, participated in the inhibition kinetic studies, crystallographic studies, and ex vivo and in vivo evaluations, and oversaw the full study. N.C. performed the ex vivo and in vivo assays and contributed to the statistical analysis of the data. L.G.I. performed the inhibition kinetic studies and UV–vis measurements and refined and analyzed the crystallographic data. M.S. performed the chemistry. A.P. performed the cytotoxicity and neuroprotection assays with the SH-SY5Y cells. J.K. and S.L. performed the molecular modeling. J.H. performed the in vitro binding experiments and participated in the in vivo assays. F.K. performed the ex vivo assays and participated in the in vitro binding experiments. I.M. participated in the ex vivo assays and contributed to the statistical analysis of the data. A.D. performed the chemistry. S.Ž. performed the in vitro permeability assays and contributed to the LC–MS analysis. J.T. performed the LC–MS analysis. J.K. oversaw the cytotoxicity and neuroprotection assays with the SH-SY5Y cells. C.B. supervised the inhibition kinetic studies, UV–vis measurements, and crystallography analysis. M.M. designed and performed the in vivo experiments. S.G. designed and oversaw the project and contributed to the editing of the manuscript. All of the authors contributed to the design, analysis, and discussion of the research and the writing of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i125">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42136" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42136" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by ARRS (Grants P1-0208, L1-8157, BI-AR/15-17-003, P4-0127, L7-8269), Fondazione Cariplo (Grant 2014-0672), MIUR “Dipartimenti di Eccellenza” Programme (2018–2022), and European Community Seventh Framework Programme (FP7/2007–2013) under BioStruct-X (Grants 7551 and 10205) and CALIPSOplus (Horizon 2020 EC access program). Financial support is acknowledged from CONICET (PIP No. 112 201501 00410), UBA (UBACyT No. 20020100100415 and 20020150100012BA), ANPCyT (PICT No. 2011-0328), and MINCYT. We thank ESRF (Grenoble) and SLS (Villigen) for use of synchrotrons. We also thank Chris Berrie for critical reading of the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">FAD</td><td class="NLM_def"><p class="first last">flavin adenine dinucleotide</p></td></tr><tr><td class="NLM_term">hMAO-A/B</td><td class="NLM_def"><p class="first last">human monoamine oxidases A and B</p></td></tr><tr><td class="NLM_term">KHMDS</td><td class="NLM_def"><p class="first last">potassium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">NaHMDS</td><td class="NLM_def"><p class="first last">sodium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">n-hex</td><td class="NLM_def"><p class="first last"><i>n</i>-hexane</p></td></tr><tr><td class="NLM_term">LDH</td><td class="NLM_def"><p class="first last">lactate dehydrogenase</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last">2-(1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i127">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43226" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43226" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Persch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumele, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span> <span> </span><span class="NLM_article-title">Molecular Recognition in Chemical and Biological Systems</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3290</span>– <span class="NLM_lpage">3327</span>, <span class="refDoi"> DOI: 10.1002/anie.201408487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1002%2Fanie.201408487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslCitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=3290-3327&issue=11&author=E.+Perschauthor=O.+Dumeleauthor=F.+Diederich&title=Molecular+Recognition+in+Chemical+and+Biological+Systems&doi=10.1002%2Fanie.201408487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition in Chemical and Biological Systems</span></div><div class="casAuthors">Persch, Elke; Dumele, Oliver; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3290-3327</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Structure-based ligand design in medicinal chem. and crop protection relies on the identification and quantification of weak noncovalent interactions and understanding the role of water.  Small-mol. and protein structural database searches are important tools to retrieve existing knowledge.  Thermodn. profiling, combined with x-ray structural and computational studies, is the key to elucidate the energetics of the replacement of water by ligands.  Biol. receptor sites vary greatly in shape, conformational dynamics, and polarity, and require different ligand-design strategies, as shown for various case studies.  Interactions between dipoles have become a central theme of mol. recognition.  Orthogonal interactions, halogen bonding, and amide···π stacking provide new tools for innovative lead optimization.  The combination of synthetic models and biol. complexation studies is required to gather reliable information on weak noncovalent interactions and the role of water.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCPoHWAmEzr7Vg90H21EOLACvtfcHk0li-ZCofeRs0uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslCitbY%253D&md5=6cc7102842c1e16e4a64352214f038b7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fanie.201408487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201408487%26sid%3Dliteratum%253Aachs%26aulast%3DPersch%26aufirst%3DE.%26aulast%3DDumele%26aufirst%3DO.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DMolecular%2520Recognition%2520in%2520Chemical%2520and%2520Biological%2520Systems%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26issue%3D11%26spage%3D3290%26epage%3D3327%26doi%3D10.1002%2Fanie.201408487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasprzyk-Hordern, B.</span></span> <span> </span><span class="NLM_article-title">Pharmacologically Active Compounds in the Environment and Their Chirality</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4466</span>– <span class="NLM_lpage">4503</span>, <span class="refDoi"> DOI: 10.1039/c000408c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1039%2Fc000408c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=20852776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlShtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=4466-4503&issue=11&author=B.+Kasprzyk-Hordern&title=Pharmacologically+Active+Compounds+in+the+Environment+and+Their+Chirality&doi=10.1039%2Fc000408c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologically active compounds in the environment and their chirality</span></div><div class="casAuthors">Kasprzyk-Hordern, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4466-4503</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Pharmacol. active compds. including both legally used pharmaceuticals and illicit drugs are potent environmental contaminants.  Extensive research has been undertaken over the recent years to understand their environmental fate and toxicity.  The one very important phenomenon that has been overlooked by environmental researchers studying the fate of pharmacol. active compds. in the environment is their chirality.  Chiral drugs can exist in the form of enantiomers, which have similar physicochem. properties but differ in their biol. properties such as distribution, metab. and excretion, as these processes (due to stereospecific interactions of enantiomers with biol. systems) usually favor one enantiomer over the other.  Addnl., due to different pharmacol. activity, enantiomers of chiral drugs can differ in toxicity.  Furthermore, degrdn. of chiral drugs during wastewater treatment and in the environment can be stereoselective and can lead to chiral products of varied toxicity.  The distribution of different enantiomers of the same chiral drug in the aquatic environment and biota can also be stereoselective.  Biol. processes can lead to stereoselective enrichment or depletion of the enantiomeric compn. of chiral drugs.  As a result the very same drug might reveal different activity and toxicity and this will depend on its origin and exposure to several factors governing its fate in the environment.  In this crit. review a discussion of the importance of chirality of pharmacol. active compds. in the environmental context is undertaken and suggestions for directions in further research are made.  Several groups of chiral drugs of major environmental relevance are discussed and their pharmacol. action and disposition in the body is also outlined as it is a key factor in developing a full understanding of their environmental occurrence, fate and toxicity.  This review will be of interest to environmental scientists, esp. those interested in issues assocd. with environmental contamination with pharmacol. active compds. and chiral pollutants.  As the review will outline current state of knowledge on chiral drugs, it will be of value to anyone interested in the phenomenon of chirality, chiral drugs, their stereoselective disposition in the body and environmental fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFRoN4-pwcmLVg90H21EOLACvtfcHk0lgsfBUTqqBO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlShtb3J&md5=8fe00731e6fc2763aec5869cd12f3b3c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1039%2Fc000408c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc000408c%26sid%3Dliteratum%253Aachs%26aulast%3DKasprzyk-Hordern%26aufirst%3DB.%26atitle%3DPharmacologically%2520Active%2520Compounds%2520in%2520the%2520Environment%2520and%2520Their%2520Chirality%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2010%26volume%3D39%26issue%3D11%26spage%3D4466%26epage%3D4503%26doi%3D10.1039%2Fc000408c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, K. G.</span></span> <span> </span><span class="NLM_article-title">The Significance of Chirality in Drug Design and Development</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.2174/156802611795165098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.2174%2F156802611795165098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=21291399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=760-770&issue=7&author=W.+H.+Brooksauthor=W.+C.+Guidaauthor=K.+G.+Daniel&title=The+Significance+of+Chirality+in+Drug+Design+and+Development&doi=10.2174%2F156802611795165098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The significance of chirality in drug design and development</span></div><div class="casAuthors">Brooks, W. H.; Guida, W. C.; Daniel, K. G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">760-770</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteins are often enantioselective towards their binding partners.  When designing small mols. to interact with these targets, one should consider stereoselectivity.  As considerations for exploring structure space evolve, chirality is increasingly important.  Binding affinity for a chiral drug can differ for diastereomers and between enantiomers.  For the virtual screening and computational design stage of drug development, this problem can be compounded by incomplete stereochem. information in structure libraries leading to a "coin toss" as to whether or not the "ideal" chiral structure is present.  Creating every stereoisomer for each chiral compd. in a structure library leads to an exponential increase in the no. of structures resulting in potentially unmanageable file sizes and screening times.  Therefore, only key chiral structures, enantiomeric pairs based on relative stereochem. need be included, and lead to a compromise between exploration of chem. space and maintaining manageable libraries.  In clin. environments, enantiomers of chiral drugs can have reduced, no, or even deleterious effects.  This underscores the need to avoid mixts. of compds. and focus on chiral synthesis.  Governmental regulations emphasizing the need to monitor chirality in drug development have increased.  The United States Food and Drug Administration issued guidelines and policies in 1992 concerning the development of chiral compds.  These guidelines require that abs. stereochem. be known for compds. with chiral centers and that this information should be established early in drug development in order that the anal. can be considered valid.  From exploration of structure space to governmental regulations it is clear that the question of chirality in drug design is of vital importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4TgZ0W1QUdrVg90H21EOLACvtfcHk0lgsfBUTqqBO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D&md5=eb78aca17518a7fd04d8cfc3c5d0ec78</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F156802611795165098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795165098%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DW.%2BH.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DDaniel%26aufirst%3DK.%2BG.%26atitle%3DThe%2520Significance%2520of%2520Chirality%2520in%2520Drug%2520Design%2520and%2520Development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26issue%3D7%26spage%3D760%26epage%3D770%26doi%3D10.2174%2F156802611795165098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nafisi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norouzi, Z.</span></span> <span> </span><span class="NLM_article-title">A Comparative Study on the Interaction of <i>Cis</i>- and <i>Trans</i>-Platin with DNA and RNA</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1089/dna.2009.0894</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1089%2Fdna.2009.0894" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=19558218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVCgu7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=469-477&issue=9&author=S.+Nafisiauthor=Z.+Norouzi&title=A+Comparative+Study+on+the+Interaction+of+Cis-+and+Trans-Platin+with+DNA+and+RNA&doi=10.1089%2Fdna.2009.0894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Comparative Study on the Interaction of Cis- and Trans-Platin with DNA and RNA</span></div><div class="casAuthors">Nafisi, Shohreh; Norouzi, Zeinab</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">469-477</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Cis-diamminedichloroplatinum(II) is a frequently used and very effective chemotherapeutic drug for treatment of various malignancies; however, the trans isomer is clin. ineffective.  Cis-platin exerts its antitumor activity by binding to DNA via intrastrand cross-links to d(GpG) (dG = deoxyguanosine) and to d(ApG) (dA = deoxyadenosine), interfering with DNA replication and transcription and causing cell death.  The trans-diamminedichloroplatinum(II) isomer also binds DNA, but is clin. ineffective.  This study was designed to examine the interactions of cis- and trans-platin with calf thymus DNA and yeast RNA in aq. soln. at physiol. conditions, using a const. DNA and RNA concn. (6.25 mM) and various platin salts/polynucleotide (phosphate) ratios of 1/100, 1/50, 1/25, and 1/12.5.  Fourier transform IR, UV-visible spectroscopic methods were used to det. the drug binding modes, the binding consts., and the stability of cis- and trans-platin-DNA and -RNA complexes in aq. soln.  Spectroscopic evidence showed that cis- and trans-platin bind to the major and minor grooves of DNA (via G, A, T, and C bases), while RNA binding is through G, U, A, and C bases with some degree of the pt-phosphate (PO2) interaction for both isomers and overall binding consts. of K(cis-platin-DNA) = 5.51 × 104 M-1, K(trans-platin-DNA) = 2.26 × 104 M-1, K(cis-platin-RNA) = 1.9 × 104 M-1, and K(trans-platin-RNA) = 1.75 × 104 M-1.  DNA and RNA aggregations occurred at high platin concns.  No biopolymer conformational changes were obsd. upon cis- and trans-platin interactions, while DNA remains in the B-family, and RNA retains its A-family structure.  The order of platin compd.-polymer stability was cis-platin-DNA > trans-platin-DNA > cis-platin-RNA > trans-platin-RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGNCiLGNn_0rVg90H21EOLACvtfcHk0lgsfBUTqqBO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVCgu7fJ&md5=2b70fd7fb46601328c7e206e0f31f599</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1089%2Fdna.2009.0894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2009.0894%26sid%3Dliteratum%253Aachs%26aulast%3DNafisi%26aufirst%3DS.%26aulast%3DNorouzi%26aufirst%3DZ.%26atitle%3DA%2520Comparative%2520Study%2520on%2520the%2520Interaction%2520of%2520Cis-%2520and%2520Trans-Platin%2520with%2520DNA%2520and%2520RNA%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2009%26volume%3D28%26issue%3D9%26spage%3D469%26epage%3D477%26doi%3D10.1089%2Fdna.2009.0894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorke, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen Antiestrogens. A Comparison of the Activity, Pharmacokinetics, and Metabolic Activation of the <i>Cis</i> and <i>Trans</i> Isomers of Tamoxifen</span>. <i>J. Steroid Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/0022-4731(82)90137-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2F0022-4731%2882%2990137-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=7062732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADyaL38XktFOgur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1982&pages=1-13&issue=1&author=D.+W.+Robertsonauthor=J.+A.+Katzenellenbogenauthor=D.+J.+Longauthor=E.+A.+Rorkeauthor=B.+S.+Katzenellenbogen&title=Tamoxifen+Antiestrogens.+A+Comparison+of+the+Activity%2C+Pharmacokinetics%2C+and+Metabolic+Activation+of+the+Cis+and+Trans+Isomers+of+Tamoxifen&doi=10.1016%2F0022-4731%2882%2990137-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen antiestrogens.  A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen</span></div><div class="casAuthors">Robertson, David W.; Katzenellenbogen, John A.; Long, Deborah J.; Rorke, Ellen A.; Katzenellenbogen, Benita S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JSTBBK</span>;
        ISSN:<span class="NLM_cas:issn">0022-4731</span>.
    </div><div class="casAbstract">In immature rats 3H-labeled trans-tamoxifen (trans-I)  [10540-29-1] was a partial agonist-partial antagonist of estrogen in terms of uterine wt. stimulation, whereas cis-I  [13002-65-8] was a pure agonist.  Both isomers gave little stimulation of uterine peroxidase  [9003-99-0], and only trans-I was able to inhibit peroxidase stimulation by estradiol.  After administration of trans-I-3H to rats in vivo, trans-hydroxytamoxifen  [68047-06-3] and a yet more polar metabolite accumulated in the uterine nuclear fraction.  With cis-I-3H, there was no accumulation of these metabolites in the uterus; in the nuclear and cytosolic fractions, there were slightly less and more polar metabolites, resp.  There was no evidence of isomerization of I or hydroxytamoxifen.  In in vitro incubations with rat liver microsomes, both trans- and cis-I-3H underwent hydroxylation and to a lesser extent demethylation.  Thus, the selective accumulation of trans-hydroxytamoxifen in the uterus apparently results from its greater affinity for the estrogen receptor (285% vs. estradiol = 100%) relative to that of cis-hydroxytamoxifen [174592-47-3] (5%).  The different metabolites that accumulate in the uterus following treatment with trans- or cis-I may account for their different agonist-antagonist character.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7buf-wRj6ibVg90H21EOLACvtfcHk0lhp48-lnVdCog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XktFOgur0%253D&md5=b88af914fc2822bb745eb337f75dcde9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0022-4731%2882%2990137-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-4731%252882%252990137-6%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DD.%2BW.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DLong%26aufirst%3DD.%2BJ.%26aulast%3DRorke%26aufirst%3DE.%2BA.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26atitle%3DTamoxifen%2520Antiestrogens.%2520A%2520Comparison%2520of%2520the%2520Activity%252C%2520Pharmacokinetics%252C%2520and%2520Metabolic%2520Activation%2520of%2520the%2520Cis%2520and%2520Trans%2520Isomers%2520of%2520Tamoxifen%26jtitle%3DJ.%2520Steroid%2520Biochem.%26date%3D1982%26volume%3D16%26issue%3D1%26spage%3D1%26epage%3D13%26doi%3D10.1016%2F0022-4731%2882%2990137-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of <i>Cis</i>- and <i>Trans</i>-Combretastatin Binding to Tubulin</span>. <i>Chem-US</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1016/j.chempr.2016.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.chempr.2016.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ojsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=102-113&issue=1&author=R.+Gaspariauthor=A.+E.+Protaauthor=K.+Bargstenauthor=A.+Cavalliauthor=M.+O.+Steinmetz&title=Structural+Basis+of+Cis-+and+Trans-Combretastatin+Binding+to+Tubulin&doi=10.1016%2Fj.chempr.2016.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of cis- and trans-Combretastatin Binding to Tubulin</span></div><div class="casAuthors">Gaspari, Roberto; Prota, Andrea E.; Bargsten, Katja; Cavalli, Andrea; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Chem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-113</span>CODEN:
                <span class="NLM_cas:coden">CHEMVE</span>;
        ISSN:<span class="NLM_cas:issn">2451-9294</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Combretastatin A4 (CA-4) derivs. are microtubule-destabilizing agents, some of which are in advanced clin. trials for cancer therapy.  The active cis conformation of CA-4 can readily isomerize into a thermodynamically more stable but significantly less active trans form.  Here, we solved the high-resoln. crystal structure of cis-CA-4 in complex with tubulin.  The compd. binds to the colchicine site of tubulin and displays both common and distinct interaction points with colchicine.  Using metadynamics simulations, we generated the trans form of the ligand within its binding site and computed the relative binding free energy of the cis-CA-4 and trans-CA-4 isomers via a thermodn. cycle.  The calcns. suggest structural distortions of the bound trans-CA-4 mol. as the likely cause of its reduced activity in comparison with that of its cis isomer.  Our findings could open up unique possibilities for structure-guided drug engineering with the aim of discovering combretastatin variants with improved chem. properties and pharmacol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTIALJ_hR7a7Vg90H21EOLACvtfcHk0lhp48-lnVdCog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ojsb8%253D&md5=0225f4aa6700d7f99923d0e2b7997dc1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.chempr.2016.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chempr.2016.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DGaspari%26aufirst%3DR.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DStructural%2520Basis%2520of%2520Cis-%2520and%2520Trans-Combretastatin%2520Binding%2520to%2520Tubulin%26jtitle%3DChem-US%26date%3D2017%26volume%3D2%26issue%3D1%26spage%3D102%26epage%3D113%26doi%3D10.1016%2Fj.chempr.2016.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bembenek, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeburg, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J. C.</span></span> <span> </span><span class="NLM_article-title">Cdna Cloning of Human Liver Monoamine Oxidase A and B: Molecular Basis of Differences in Enzymatic Properties</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4934</span>– <span class="NLM_lpage">4938</span>, <span class="refDoi"> DOI: 10.1073/pnas.85.13.4934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1073%2Fpnas.85.13.4934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=3387449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADyaL1MXhtV2hs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1988&pages=4934-4938&issue=13&author=A.+W.+Bachauthor=N.+C.+Lanauthor=D.+L.+Johnsonauthor=C.+W.+Abellauthor=M.+E.+Bembenekauthor=S.+W.+Kwanauthor=P.+H.+Seeburgauthor=J.+C.+Shih&title=Cdna+Cloning+of+Human+Liver+Monoamine+Oxidase+A+and+B%3A+Molecular+Basis+of+Differences+in+Enzymatic+Properties&doi=10.1073%2Fpnas.85.13.4934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">cDNA cloning of human liver monoamine oxidase A and B:  molecular basis of differences in enzymic properties</span></div><div class="casAuthors">Bach, Alfred W. J.; Lan, Nancy C.; Johnson, Deborah L.; Abell, Creed W.; Bembenek, Michael E.; Kwan, Sau Wah; Seeburg, Peter H.; Shih, Jean C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4934-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The monoamine oxidases play a vital role in the metab. of biogenic amines in the central nervous system and in peripheral tissues.  Oligonucleotide probes derived from three sequenced peptide fragments were used to isolate cDNA clones that encode the A and B forms of monoamine oxidase.  The nucleotide sequences of these cDNAs were detd.  Comparison of the deduced amino acid sequences shows that the A and B forms have subunit mol. wts. of 59,700 and 58,800, resp., and have 70% sequence identity.  Both sequences contain the pentapeptide Ser-Gly-Gly-Cys-Tyr, in which the obligatory cofactor FAD is covalently bound to cysteine.  Based on differences in primary amino acid sequences and RNA gel blot anal. of mRNAs, the A and B forms of monoamine oxidase appear to be derived from sep. genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UdSC3-Af4rVg90H21EOLACvtfcHk0lhp48-lnVdCog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhtV2hs7Y%253D&md5=2b699f8c1d71214ee769d8b7bfb33501</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.85.13.4934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.85.13.4934%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DA.%2BW.%26aulast%3DLan%26aufirst%3DN.%2BC.%26aulast%3DJohnson%26aufirst%3DD.%2BL.%26aulast%3DAbell%26aufirst%3DC.%2BW.%26aulast%3DBembenek%26aufirst%3DM.%2BE.%26aulast%3DKwan%26aufirst%3DS.%2BW.%26aulast%3DSeeburg%26aufirst%3DP.%2BH.%26aulast%3DShih%26aufirst%3DJ.%2BC.%26atitle%3DCdna%2520Cloning%2520of%2520Human%2520Liver%2520Monoamine%2520Oxidase%2520A%2520and%2520B%253A%2520Molecular%2520Basis%2520of%2520Differences%2520in%2520Enzymatic%2520Properties%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1988%26volume%3D85%26issue%3D13%26spage%3D4934%26epage%3D4938%26doi%3D10.1073%2Fpnas.85.13.4934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Colibus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span> <span> </span><span class="NLM_article-title">Three-Dimensional Structure of Human Monoamine Oxidase A (Mao A): Relation to the Structures of Rat MAO A and Human MAO B</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">12684</span>– <span class="NLM_lpage">12689</span>, <span class="refDoi"> DOI: 10.1073/pnas.0505975102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1073%2Fpnas.0505975102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=16129825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWktLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=12684-12689&issue=36&author=L.+De%0AColibusauthor=M.+Liauthor=C.+Bindaauthor=A.+Lustigauthor=D.+E.+Edmondsonauthor=A.+Mattevi&title=Three-Dimensional+Structure+of+Human+Monoamine+Oxidase+A+%28Mao+A%29%3A+Relation+to+the+Structures+of+Rat+MAO+A+and+Human+MAO+B&doi=10.1073%2Fpnas.0505975102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B</span></div><div class="casAuthors">De Colibus, Luigi; Li, Min; Binda, Claudia; Lustig, Ariel; Edmondson, Dale E.; Mattevi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">12684-12689</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The 3-dimensional x-ray crystal structure of recombinant human monoamine oxidase A (hMAO A) as its clorgyline-inhibited adduct is described.  Although the chain-fold of hMAO A was similar to that of rat MAO A and human MAO B (hMAO B), hMAO A was unique in that it crystd. as a monomer and exhibited the soln. hydrodynamic behavior of a monomeric form rather than the dimeric form of hMAO B and rat MAO A.  The hMAO A active site consisted of a single hydrophobic cavity of ∼550 Å3, which was smaller than that detd. from the structure of deprenyl-inhibited hMAO B (∼700 Å3) but larger than that of rat MAO A (∼450 Å3).  An important component of the active site structure of hMAO A was the loop conformation of residues 210-216, which differred from that of hMAO B and rat MAO A.  The origin of this structural alteration was suggested to have resulted from long-range interactions in the monomeric form of the enzyme.  In addn. to serving as a basis for the development of hMAO A-specific inhibitors, these data supported the proposal that hMAO A involves a change from the dimeric to the monomeric form through a E151K mutation that is specific to hMAO A.  These considerations place into question the use of MAO A from non-human sources in drug development for use in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPY_EaAsj_1rVg90H21EOLACvtfcHk0lhfZU__MU36GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWktLnJ&md5=5db5a50007df0a15df8cbfbc72670de9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0505975102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0505975102%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BColibus%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DLustig%26aufirst%3DA.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26aulast%3DMattevi%26aufirst%3DA.%26atitle%3DThree-Dimensional%2520Structure%2520of%2520Human%2520Monoamine%2520Oxidase%2520A%2520%2528Mao%2520A%2529%253A%2520Relation%2520to%2520the%2520Structures%2520of%2520Rat%2520MAO%2520A%2520and%2520Human%2520MAO%2520B%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26issue%3D36%26spage%3D12684%26epage%3D12689%26doi%3D10.1073%2Fpnas.0505975102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milczek, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D. E.</span></span> <span> </span><span class="NLM_article-title">The ’Gating’ Residues Ile199 and Tyr326 in Human Monoamine Oxidase B Function in Substrate and Inhibitor Recognition</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">4860</span>– <span class="NLM_lpage">4869</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2011.08386.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1111%2Fj.1742-4658.2011.08386.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=21978362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1antrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=4860-4869&issue=24&author=E.+M.+Milczekauthor=C.+Bindaauthor=S.+Rovidaauthor=A.+Matteviauthor=D.+E.+Edmondson&title=The+%E2%80%99Gating%E2%80%99+Residues+Ile199+and+Tyr326+in+Human+Monoamine+Oxidase+B+Function+in+Substrate+and+Inhibitor+Recognition&doi=10.1111%2Fj.1742-4658.2011.08386.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The gating residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition</span></div><div class="casAuthors">Milczek, Erika M.; Binda, Claudia; Rovida, Stefano; Mattevi, Andrea; Edmondson, Dale E.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4860-4869</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The major structural difference between human monoamine oxidases A (MAO A) and B (MAO B) is that MAO A has a monopartite substrate cavity of ∼550 Å3 vol. and MAO B contains a dipartite cavity structure with vols. of ∼290 Å3 (entrance cavity) and ∼400 Å3 (substrate cavity).  The Ile-199 and Tyr-326 side-chains sep. these 2 cavities in MAO B.  To probe the function of these gating residues, I199A and I199A/Y326A mutant forms of MAO B were investigated.  Structural data on the I199A MAO B mutant showed no alterations in active site geometries compared with the wild-type enzyme while the I199A/Y326A MAO B mutant exhibited alterations in residues 100-103 which were part of the loop gating the entrance to the active site.  Both mutant enzymes exhibited catalytic properties with increased amine Km but unaltered kcat values.  The altered Km values on mutation were attributed to the influence of the cavity structure in the binding and subsequent deprotonation of the amine substrate.  Both mutant enzymes exhibited weaker binding affinities relative to the wild-type enzyme for small reversible inhibitors.  I199A MAO B exhibited an increase in binding affinity for reversible MAO B-specific inhibitors which bridged both cavities.  The I199A/Y326A double mutant exhibited inhibitor binding properties more similar to those of MAO A than to MAO B.  These results demonstrated that the bipartite cavity structure in MAO B plays an important role in substrate and inhibitor recognition to distinguish its specificities from those of MAO A and provides insights into specific reversible inhibitor design for these membrane-bound enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeXi4q0VP7f7Vg90H21EOLACvtfcHk0lhfZU__MU36GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1antrbL&md5=66e480131b37dc3f025167d0d70d9959</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2011.08386.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2011.08386.x%26sid%3Dliteratum%253Aachs%26aulast%3DMilczek%26aufirst%3DE.%2BM.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DRovida%26aufirst%3DS.%26aulast%3DMattevi%26aufirst%3DA.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26atitle%3DThe%2520%25E2%2580%2599Gating%25E2%2580%2599%2520Residues%2520Ile199%2520and%2520Tyr326%2520in%2520Human%2520Monoamine%2520Oxidase%2520B%2520Function%2520in%2520Substrate%2520and%2520Inhibitor%2520Recognition%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26issue%3D24%26spage%3D4860%26epage%3D4869%26doi%3D10.1111%2Fj.1742-4658.2011.08386.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span> <span> </span><span class="NLM_article-title">Molecular Aspects of Monoamine Oxidase B</span>. <i>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.pnpbp.2016.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.pnpbp.2016.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=26891670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlKhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=81-89&author=R.+R.+Ramsay&title=Molecular+Aspects+of+Monoamine+Oxidase+B&doi=10.1016%2Fj.pnpbp.2016.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular aspects of monoamine oxidase B</span></div><div class="casAuthors">Ramsay, Rona R.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">81-89</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Monoamine oxidases (MAO) influence the monoamine levels in brain by virtue of their role in neurotransmitter breakdown.  MAO B is the predominant form in glial cells and in platelets.  MAO B structure, function and kinetics are described as a background for the effect of alterations in its activity on behavior.  The need to inhibit MAO B to combat decreased brain amines continues to drive the search for new drugs.  Reversible and irreversible inhibitors are now designed using data-mining, computational screening, docking and mol. dynamics.  Multi-target ligands designed to combat the elevated activity of MAO B in Alzheimer's and Parkinson's Diseases incorporate MAO inhibition (usually irreversible) as well as iron chelation, antioxidant or neuroprotective properties.  The main focus of drug design is the catalytic activity of MAO, but the imidazoline I2 site in the entrance cavity of MAO B is also a pharmacol. target.  Endogenous regulation of MAO B expression is discussed briefly in light of new studies measuring mRNA, protein, or activity in healthy and degenerative samples, including the effect of DNA methylation on the expression.  Overall, this review focuses on examples of recent research on the mol. aspects of the expression, activity, and inhibition of MAO B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWqBth0WA0EbVg90H21EOLACvtfcHk0lhfZU__MU36GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlKhurw%253D&md5=53857d746ee164dcc74469832516a0cd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2016.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2016.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26atitle%3DMolecular%2520Aspects%2520of%2520Monoamine%2520Oxidase%2520B%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2016%26volume%3D69%26spage%3D81%26epage%3D89%26doi%3D10.1016%2Fj.pnpbp.2016.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albreht, A.</span></span> <span> </span><span class="NLM_article-title">Kinetics, Mechanism, and Inhibition of Monoamine Oxidase</span>. <i>J. Neural Transm. (Vienna)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1659</span>– <span class="NLM_lpage">1683</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1861-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1007%2Fs00702-018-1861-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=29516165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BC1MrovVegsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1659-1683&issue=11&author=R.+R.+Ramsayauthor=A.+Albreht&title=Kinetics%2C+Mechanism%2C+and+Inhibition+of+Monoamine+Oxidase&doi=10.1007%2Fs00702-018-1861-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics, mechanism, and inhibition of monoamine oxidase</span></div><div class="casAuthors">Ramsay Rona R; Albreht Alen; Albreht Alen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission (Vienna, Austria : 1996)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1659-1683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Monoamine oxidases (MAOs) catalyse the oxidation of neurotransmitter amines and a wide variety of primary, secondary and tertiary amine xenobiotics, including therapeutic drugs.  While inhibition of MAO activity in the periphery removes protection from biogenic amines and so is undesirable, inhibition in the brain gives vital antidepressant and behavioural advantages that make MAO a major pharmaceutical target for inhibitor design.  In neurodegenerative diseases, MAO inhibitors can help to maintain neurotransmitter levels, making it a common feature in novel multi-target combinations designed to combat Alzheimer's disease, albeit not yet proven clinically.  Vital information for inhibitor design comes from an understanding of the structure, mechanism, and kinetics of the catalyst.  This review will summarize the kinetic behaviour of MAO A and B and the kinetic evaluation of reversible inhibitors that transiently decrease catalysis.  Kinetic parameters and crystal structures have enabled computational approaches to ligand discovery and validation of hits by docking.  Kinetics and a wide variety of substrates and inhibitors along with theoretical modelling have also contributed to proposed schemes for the still debated chemical mechanism of amine oxidation.  However, most of the marketed MAO drugs are long-lasting irreversible inactivators.  The mechanism of irreversible inhibition by hydrazine, cyclopropylamine, and propargylamine drugs will be discussed.  The article finishes with some examples of the propargylamine moiety in multi-target ligand design to combat neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDjJ7nVDp8seLt9HypzAgQfW6udTcc2ebuEwxdxi9yBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrovVegsQ%253D%253D&md5=6562f2d88d8febadcfe0fe83bb687805</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1861-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1861-9%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DAlbreht%26aufirst%3DA.%26atitle%3DKinetics%252C%2520Mechanism%252C%2520and%2520Inhibition%2520of%2520Monoamine%2520Oxidase%26jtitle%3DJ.%2520Neural%2520Transm.%2520%2528Vienna%2529%26date%3D2018%26volume%3D125%26issue%3D11%26spage%3D1659%26epage%3D1683%26doi%3D10.1007%2Fs00702-018-1861-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sailor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook-Jung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. H.</span></span> <span> </span><span class="NLM_article-title">Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer’s Disease in Mice, Observed by in Vivo Two-Photon Imaging</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">975</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.6b00309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.6b00309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2lsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=967-975&issue=12&author=D.+Kimauthor=S.+H.+Baikauthor=S.+Kangauthor=S.+W.+Choauthor=J.+Baeauthor=M.+Y.+Chaauthor=M.+J.+Sailorauthor=I.+Mook-Jungauthor=K.+H.+Ahn&title=Close+Correlation+of+Monoamine+Oxidase+Activity+with+Progress+of+Alzheimer%E2%80%99s+Disease+in+Mice%2C+Observed+by+in+Vivo+Two-Photon+Imaging&doi=10.1021%2Facscentsci.6b00309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer's Disease in Mice, Observed by in Vivo Two-Photon Imaging</span></div><div class="casAuthors">Kim, Dokyoung; Baik, Sung Hoon; Kang, Seokjo; Cho, Seo Won; Bae, Juryang; Cha, Moon-Yong; Sailor, Michael J.; Mook-Jung, Inhee; Ahn, Kyo Han</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">967-975</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoamine oxidases (MAOs) play an important role in Alzheimer's disease (AD) pathol.  We report in vivo comonitoring of MAO activity and amyloid-β (Aβ) plaques dependent on the aging of live mice with AD, using a two-photon fluorescence probe.  The probe under the catalytic action of MAO produces a dipolar fluorophore that senses Aβ plaques, a general AD biomarker, enabling us to comonitor the enzyme activity and the progress of AD indicated by Aβ plaques.  The results show that the progress of AD has a close correlation with MAO activity, which can be categorized into three stages: slow initiation stage up to three months, an aggressive stage, and a satn. stage from nine months.  Histol. anal. also reveals elevation of MAO activity around Aβ plaques in aged mice.  The close correlation between the MAO activity and AD progress obsd. by in vivo monitoring for the first time prompts us to investigate the enzyme as a potential biomarker of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV85cVN9zcP7Vg90H21EOLACvtfcHk0lhHFK70YGrbvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2lsLbM&md5=290052c37b8836d7811e6041b62822b4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.6b00309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.6b00309%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DBaik%26aufirst%3DS.%2BH.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DS.%2BW.%26aulast%3DBae%26aufirst%3DJ.%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DSailor%26aufirst%3DM.%2BJ.%26aulast%3DMook-Jung%26aufirst%3DI.%26aulast%3DAhn%26aufirst%3DK.%2BH.%26atitle%3DClose%2520Correlation%2520of%2520Monoamine%2520Oxidase%2520Activity%2520with%2520Progress%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%2520in%2520Mice%252C%2520Observed%2520by%2520in%2520Vivo%2520Two-Photon%2520Imaging%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2016%26volume%3D2%26issue%3D12%26spage%3D967%26epage%3D975%26doi%3D10.1021%2Facscentsci.6b00309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schedin-Weiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hromadkova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teranishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiehager, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winblad, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandebring-Matton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frykman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjernberg, L. O.</span></span> <span> </span><span class="NLM_article-title">Monoamine Oxidase B is Elevated in Alzheimer Disease Neurons, is Associated with γ-Secretase and Regulates Neuronal Amyloid β-Peptide Levels</span>. <i>Alzheimer’s Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s13195-017-0279-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1186%2Fs13195-017-0279-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVOmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=57&issue=1&author=S.+Schedin-Weissauthor=M.+Inoueauthor=L.+Hromadkovaauthor=Y.+Teranishiauthor=N.+G.+Yamamotoauthor=B.+Wiehagerauthor=N.+Bogdanovicauthor=B.+Winbladauthor=A.+Sandebring-Mattonauthor=S.+Frykmanauthor=L.+O.+Tjernberg&title=Monoamine+Oxidase+B+is+Elevated+in+Alzheimer+Disease+Neurons%2C+is+Associated+with+%CE%B3-Secretase+and+Regulates+Neuronal+Amyloid+%CE%B2-Peptide+Levels&doi=10.1186%2Fs13195-017-0279-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels</span></div><div class="casAuthors">Schedin-Weiss, Sophia; Inoue, Mitsuhiro; Hromadkova, Lenka; Teranishi, Yasuhiro; Yamamoto, Natsuko Goto; Wiehager, Birgitta; Bogdanovic, Nenad; Winblad, Bengt; Sandebring-Matton, Anna; Frykman, Susanne; Tjernberg, Lars O.</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's Research & Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57/1-57/19</span>CODEN:
                <span class="NLM_cas:coden">ARTLCD</span>;
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Increased levels of the pathogenic amyloid β-peptide (Aβ), released from its precursor by the transmembrane protease γ-secretase, are found in Alzheimer disease (AD) brains.  Interestingly, monoamine oxidase B (MAO-B) activity is also increased in AD brain, but its role in AD pathogenesis is not known.  Recent neuroimaging studies have shown that the increased MAO-B expression in AD brain starts several years before the onset of the disease.  Here, we show a potential connection between MAO-B, γ-secretase and Aβ in neurons.  Methods: MAO-B immunohistochem. was performed on postmortem human brain.  Affinity purifn. of γ-secretase followed by mass spectrometry was used for unbiased identification of γ-secretase-assocd. proteins.  The assocn. of MAO-B with γ-secretase was studied by coimmunopptn. from brain homogenate, and by in-situ proximity ligation assay (PLA) in neurons as well as mouse and human brain sections.  The effect of MAO-B on Aβ prodn. and Notch processing in cell cultures was analyzed by siRNA silencing or overexpression expts. followed by ELISA, western blot or FRET anal.  Methodol. for measuring relative intraneuronal MAO-B and Aβ42 levels in single cells was developed by combining immunocytochem. and confocal microscopy with quant. image anal.  Results: Immunohistochem. revealed MAO-B staining in neurons in the frontal cortex, hippocampus CA1 and entorhinal cortex in postmortem human brain.  Interestingly, the neuronal staining intensity was higher in AD brain than in control brain in these regions.  Mass spectrometric data from affinity purified γ-secretase suggested that MAO-B is a γ-secretase-assocd. protein, which was confirmed by immunopptn. and PLA, and a neuronal location of the interaction was shown.  Strikingly, intraneuronal Aβ42 levels correlated with MAO-B levels, and siRNA silencing of MAO-B resulted in significantly reduced levels of intraneuronal Aβ42.  Furthermore, overexpression of MAO-B enhanced Aβ prodn.  Conclusions: This study shows that MAO-B levels are increased not only in astrocytes but also in pyramidal neurons in AD brain.  The study also suggests that MAO-B regulates Aβ prodn. in neurons via γ-secretase and thereby provides a key to understanding the relationship between MAO-B and AD pathogenesis.  Potentially, the γ-secretase/MAO-B assocn. may be a target for reducing Aβ levels using protein-protein interaction breakers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOuXrvzc_LEbVg90H21EOLACvtfcHk0ljPc9VynB3qaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVOmsbo%253D&md5=2e23a8fa1fa44e0d75501e8683028f3d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs13195-017-0279-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-017-0279-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchedin-Weiss%26aufirst%3DS.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DHromadkova%26aufirst%3DL.%26aulast%3DTeranishi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DN.%2BG.%26aulast%3DWiehager%26aufirst%3DB.%26aulast%3DBogdanovic%26aufirst%3DN.%26aulast%3DWinblad%26aufirst%3DB.%26aulast%3DSandebring-Matton%26aufirst%3DA.%26aulast%3DFrykman%26aufirst%3DS.%26aulast%3DTjernberg%26aufirst%3DL.%2BO.%26atitle%3DMonoamine%2520Oxidase%2520B%2520is%2520Elevated%2520in%2520Alzheimer%2520Disease%2520Neurons%252C%2520is%2520Associated%2520with%2520%25CE%25B3-Secretase%2520and%2520Regulates%2520Neuronal%2520Amyloid%2520%25CE%25B2-Peptide%2520Levels%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2017%26volume%3D9%26issue%3D1%26spage%3D57%26doi%3D10.1186%2Fs13195-017-0279-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiuccariello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkowska, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitan, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolla, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J. H.</span></span> <span> </span><span class="NLM_article-title">Elevated Monoamine Oxidase A Binding During Major Depressive Episodes is Associated with Greater Severity and Reversed Neurovegetative Symptoms</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1038%2Fnpp.2013.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=24154665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyrtL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=973-980&issue=4&author=L.+Chiuccarielloauthor=S.+Houleauthor=L.+Milerauthor=R.+G.+Cookeauthor=P.+M.+Rusjanauthor=G.+Rajkowskaauthor=R.+D.+Levitanauthor=S.+J.+Kishauthor=N.+J.+Kollaauthor=X.+Ouauthor=A.+A.+Wilsonauthor=J.+H.+Meyer&title=Elevated+Monoamine+Oxidase+A+Binding+During+Major+Depressive+Episodes+is+Associated+with+Greater+Severity+and+Reversed+Neurovegetative+Symptoms&doi=10.1038%2Fnpp.2013.297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated Monoamine Oxidase A Binding During Major Depressive Episodes Is Associated with Greater Severity and Reversed Neurovegetative Symptoms</span></div><div class="casAuthors">Chiuccariello, Lina; Houle, Sylvain; Miler, Laura; Cooke, Robert G.; Rusjan, Pablo M.; Rajkowska, Grazyna; Levitan, Robert D.; Kish, Stephen J.; Kolla, Nathan J.; Ou, Xiaoming; Wilson, Alan A.; Meyer, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">973-980</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inadequate treatment response occurs in approx. 40% of major depressive episodes (MDEs), and one approach to solve this is careful matching of treatment to the specific pathologies of MDE.  One such biol. abnormality is elevated monoamine oxidase A (MAO-A) levels, which occurs in the prefrontal and anterior cingulate cortex (PFC and ACC) during MDE; however, the subtypes for which this abnormality is most prominent are unknown.  We hypothesized that MAO-A levels in the PFC and ACC are most elevated in MDE with greater severity and reversed neurovegetative symptoms (hypersomnia and either hyperphagia or wt. gain).  MAO-A VT (an index of MAO-A d.) was measured using [11C]harmine positron emission tomog. (PET) in 42 subjects with MDEs secondary to major depressive disorder and 37 healthy controls.  The effect of severity and reversed neurovegetative symptoms on MAO-A VT in the PFC and ACC was analyzed using a multivariate anal. of variance (MANOVA).  Greater severity and reversed neurovegetative symptoms were assocd. with elevated MAO-A VT in the PFC and ACC (MANOVA, severity: F(2,38)=5.44, p=0.008; reversed neurovegetative symptoms: F(2,38)=5.13, p=0.01).  Increased MAO-A level, when greater severity and reversed neurovegetative symptoms are present, may explain the assocn. of these clin. features with a preferential response to MAO inhibitors, which is esp. well-evidenced for reversed neurovegetative symptoms in MDE.  As MAO-A creates oxidative stress, facilitates apoptosis, and metabolizes monoamines, therapeutics opposing these processes are predicted to best treat MDE with greater severity and reversed neurovegetative symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq42LaYJ_gP6bVg90H21EOLACvtfcHk0ljPc9VynB3qaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyrtL7K&md5=f1e12253de5946c1406b4b3e5e65ca44</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.297%26sid%3Dliteratum%253Aachs%26aulast%3DChiuccariello%26aufirst%3DL.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DMiler%26aufirst%3DL.%26aulast%3DCooke%26aufirst%3DR.%2BG.%26aulast%3DRusjan%26aufirst%3DP.%2BM.%26aulast%3DRajkowska%26aufirst%3DG.%26aulast%3DLevitan%26aufirst%3DR.%2BD.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DKolla%26aufirst%3DN.%2BJ.%26aulast%3DOu%26aufirst%3DX.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DMeyer%26aufirst%3DJ.%2BH.%26atitle%3DElevated%2520Monoamine%2520Oxidase%2520A%2520Binding%2520During%2520Major%2520Depressive%2520Episodes%2520is%2520Associated%2520with%2520Greater%2520Severity%2520and%2520Reversed%2520Neurovegetative%2520Symptoms%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26issue%3D4%26spage%3D973%26epage%3D980%26doi%3D10.1038%2Fnpp.2013.297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Sante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Lisa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaludercic, N.</span></span> <span> </span><span class="NLM_article-title">Emerging Role of Monoamine Oxidase as a Therapeutic Target for Cardiovascular Disease</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.coph.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=28528298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFekt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=64-69&author=S.+Deshwalauthor=M.+Di+Santeauthor=F.+Di+Lisaauthor=N.+Kaludercic&title=Emerging+Role+of+Monoamine+Oxidase+as+a+Therapeutic+Target+for+Cardiovascular+Disease&doi=10.1016%2Fj.coph.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease</span></div><div class="casAuthors">Deshwal, Soni; Di Sante, Moises; Di Lisa, Fabio; Kaludercic, Nina</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">64-69</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the past decade, accumulating evidence highlighted the role of monoamine oxidases (MAOs) in cardiovascular disease (CVD).  MAOs are flavoenzymes located in the outer mitochondrial membrane, responsible for the degrdn. of neurotransmitters and biogenic amines.  During this process they generate hydrogen peroxide, aldehydes and ammonia, species that can target mitochondria and induce mitochondrial dysfunction and cardiomyocyte death.  Indeed, MAO inhibition affords cardioprotection in several models of CVD, such as ischemia/reperfusion, heart failure and diabetes.  Importantly, a few studies provided encouraging results suggesting that MAO inhibition might be beneficial also in patients with CVD.  Thus, selective and reversible MAO inhibitors, currently used as therapy for depression and neurodegenerative disorders, might be considered as candidate drugs for the treatment of CVD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgFZrpZbH4ALVg90H21EOLACvtfcHk0ljPc9VynB3qaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFekt7w%253D&md5=47b04c6835ab1638be9885164030c7ae</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DDeshwal%26aufirst%3DS.%26aulast%3DDi%2BSante%26aufirst%3DM.%26aulast%3DDi%2BLisa%26aufirst%3DF.%26aulast%3DKaludercic%26aufirst%3DN.%26atitle%3DEmerging%2520Role%2520of%2520Monoamine%2520Oxidase%2520as%2520a%2520Therapeutic%2520Target%2520for%2520Cardiovascular%2520Disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2017%26volume%3D33%26spage%3D64%26epage%3D69%26doi%3D10.1016%2Fj.coph.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J. C.</span></span> <span> </span><span class="NLM_article-title">Monoamine Oxidase Isoenzymes: Genes, Functions and Targets for Behavior and Cancer Therapy</span>. <i>J. Neural Transm. (Vienna)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1553</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1927-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1007%2Fs00702-018-1927-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=30259128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BB3czjtFKnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1553-1566&issue=11&author=J.+C.+Shih&title=Monoamine+Oxidase+Isoenzymes%3A+Genes%2C+Functions+and+Targets+for+Behavior+and+Cancer+Therapy&doi=10.1007%2Fs00702-018-1927-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy</span></div><div class="casAuthors">Shih Jean C; Shih Jean C; Shih Jean C; Shih Jean C; Shih Jean C</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission (Vienna, Austria : 1996)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1553-1566</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Monoamine oxidase (MAO) catalyzes the oxidative deamination of monoamine neurotransmitters and dietary amines.  Two pharmacological types with different substrate and inhibitor specificities were reported.  Molecular cloning revealed that the two types of MAO were different genes expressed as different proteins with different functions.  MAO A and B have identical intron-exon organization derived by duplication of a common ancestral gene thus they are termed isoenzymes.  MAO A knockout mice exhibited aggression, the first clear evidence linking genes to behavior.  MAO A KO mice exhibited autistic-like behaviors which could be prevented by reducing serotonin levels at an early developmental age (P1-P7) providing potential therapy.  MAO B KO mice were non-aggressive and resistant to Parkinsongenic neurotoxin.  More recently it was found that MAO A is overexpressed in prostate cancer and correlates with degree of malignancy.  The oncogenic mechanism involves a ROS-activated AKT/FOXO1/TWIST1 signaling pathway.  Deletion of MAO A reduced prostate cancer stem cells and suppressed invasive adenocarcinoma.  MAO A was also overexpressed in classical Hodgkin lymphoma and glioma brain tumors.  MAO B was overexpressed in glioma and non-small cell lung cancer.  MAO A inhibitors reduce the growth of prostate cancer, drug sensitive and resistant gliomas and classical Hodgkin lymphoma, and enhance standard chemotherapy.  Currently, we are developing NIR dye-conjugated clorgyline (MAO A inhibitor) as a novel dual therapeutic/diagnostic agent for cancer.  A phase II clinical trial of MAO inhibitor for biochemical recurrent prostate cancer is ongoing.  The role of MAO A and B in several cancer types opens new avenues for cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7YIgiqqt3BgaK-_ZudimnfW6udTcc2eYN-ujvJ-xZFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czjtFKnuw%253D%253D&md5=8f145b7766496b62856a9fb4e9401ab9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1927-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1927-8%26sid%3Dliteratum%253Aachs%26aulast%3DShih%26aufirst%3DJ.%2BC.%26atitle%3DMonoamine%2520Oxidase%2520Isoenzymes%253A%2520Genes%252C%2520Functions%2520and%2520Targets%2520for%2520Behavior%2520and%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Neural%2520Transm.%2520%2528Vienna%2529%26date%3D2018%26volume%3D125%26issue%3D11%26spage%3D1553%26epage%3D1566%26doi%3D10.1007%2Fs00702-018-1927-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span> <span> </span><span class="NLM_article-title">The Role of Monoamine Oxidase Inhibitors in Depression Treatment Guidelines</span>. <i>J. Clin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">Suppl. 1</span>),  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.4088/JCP.11096su1c.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.4088%2FJCP.11096su1c.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=22951237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGrt7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2012&pages=10-16&issue=Suppl.+1&author=M.+E.+Thase&title=The+Role+of+Monoamine+Oxidase+Inhibitors+in+Depression+Treatment+Guidelines&doi=10.4088%2FJCP.11096su1c.02"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The role of monoamine oxidase inhibitors in depression treatment guidelines</span></div><div class="casAuthors">Thase, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry (Memphis, TN, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">10-16</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">A review.  Monoamine oxidase inhibitors (MAOIs) have proven efficacy for treating depression and for decades have been a preferred treatment for patients with atypical depression, high levels of anxiety, anergic bipolar depression, and treatment-resistant depression.  However, MAOIs are infrequently used due to safety and tolerability concerns and the need for dietary restrictions.  Current guidelines, which are reviewed here, recommend MAOIs as third-, fourth-, or fifth-line treatments due to these concerns.  However, a transdermal formulation of selegiline limits the need for dietary restrictions and has fewer side effects than many more widely used antidepressants.  The availability of a safer and more tolerable formulation gives clinicians another option in their armamentarium for treating depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSi6yLVJ2cXrVg90H21EOLACvtfcHk0lj15bhInX3HKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGrt7nM&md5=32ae705ff860c62310a8742b39ffb8f2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4088%2FJCP.11096su1c.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.11096su1c.02%26sid%3Dliteratum%253Aachs%26aulast%3DThase%26aufirst%3DM.%2BE.%26atitle%3DThe%2520Role%2520of%2520Monoamine%2520Oxidase%2520Inhibitors%2520in%2520Depression%2520Treatment%2520Guidelines%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2012%26volume%3D73%26issue%3DSuppl.%25201%26spage%3D10%26epage%3D16%26doi%3D10.4088%2FJCP.11096su1c.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dezsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vecsei, L.</span></span> <span> </span><span class="NLM_article-title">Monoamine Oxidase B Inhibitors in Parkinson’s Disease</span>. <i>CNS Neurol. Disord.: Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.2174/1871527316666170124165222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.2174%2F1871527316666170124165222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=28124620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1SmtLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=425-439&issue=4&author=L.+Dezsiauthor=L.+Vecsei&title=Monoamine+Oxidase+B+Inhibitors+in+Parkinson%E2%80%99s+Disease&doi=10.2174%2F1871527316666170124165222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine Oxidase B Inhibitors in Parkinson's Disease</span></div><div class="casAuthors">Dezsi, Livia; Vecsei, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">CNS & Neurological Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-439</span>CODEN:
                <span class="NLM_cas:coden">CNDDA3</span>;
        ISSN:<span class="NLM_cas:issn">1871-5273</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a neurodegenerative disorder with a prevalence increasing with age.  Oxidative stress and glutamate toxicity are involved in its pathomechanism.  There are still many unmet needs of PD patients, including the alleviation of motor fluctuations and dyskinesias, and the development of therapies with neuroprotective potential.  To give an overview of the pharmacol. properties, the efficacy and safety of the monoamine oxidase B (MAO-B) inhibitors in the treatment of PD, with special focus on the results of randomized clin. trials.  A literature search was conducted in PubMed for 'PD treatment', 'MAO-B inhibitors', 'selegiline', 'rasagiline', 'safinamide' and 'clin. trials' with 'MAO-B inhibitors' in 'Parkinson' disease'.  Results: MAO-B inhibitors have a favorable pharmacokinetic profile, improve the dopamine deficient state and may have neuroprotective properties.  Safinamide exhibits an anti-glutamatergic effect as well.  When applied as monotherapy, MAO-B inhibitors provide a modest, but significant improvement of motor function and delay the need for levodopa.  Rasagiline and safinamide were proven safe and effective when added to a dopamine agonist in early PD.  As add-on to levodopa, MAO-B inhibitors significantly reduced off-time and were comparable in efficacy to COMT inhibitors.  Improvements were achieved as regards certain non-motor symptoms as well.  Due to the efficacy shown in clin. trials and their favorable side-effect profile, MAO-B inhibitors are valuable drugs in the treatment of PD.  They are recommended as monotherapy in the early stages of the disease and as add-on therapy to levodopa in advanced PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMA_sgCUd0GrVg90H21EOLACvtfcHk0lj15bhInX3HKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1SmtLbE&md5=0d7e67bbd9daf48131efbd6494c620ad</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F1871527316666170124165222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871527316666170124165222%26sid%3Dliteratum%253Aachs%26aulast%3DDezsi%26aufirst%3DL.%26aulast%3DVecsei%26aufirst%3DL.%26atitle%3DMonoamine%2520Oxidase%2520B%2520Inhibitors%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DCNS%2520Neurol.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2017%26volume%3D16%26issue%3D4%26spage%3D425%26epage%3D439%26doi%3D10.2174%2F1871527316666170124165222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B. H.</span></span> <span> </span><span class="NLM_article-title">Monoamine Oxidase Inhibitors, and Iron Chelators in Depressive Illness and Neurodegenerative Diseases</span>. <i>J. Neural. Transm. (Vienna)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1733</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1942-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1007%2Fs00702-018-1942-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=30341696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BB3cvhtlyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1719-1733&issue=11&author=M.+B.+H.+Youdim&title=Monoamine+Oxidase+Inhibitors%2C+and+Iron+Chelators+in+Depressive+Illness+and+Neurodegenerative+Diseases&doi=10.1007%2Fs00702-018-1942-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases</span></div><div class="casAuthors">Youdim Moussa B H; Youdim Moussa B H</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission (Vienna, Austria : 1996)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1719-1733</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In early 1920s, tyramine oxidase was discovered that metabolized tyramine and in 1933 Blaschko demonstrated that this enzyme also metabolized adrenaline, noradrenaline and dopamine.  Zeller gave it the name monoamine oxidase (MAO) to distinguish it from the enzyme that oxidatively deaminated diamines.  MAO was recognized as an enzyme of crucial interest to pharmacologists because it catalyzed the major inactivation pathway for the catecholamines (and, later, 5-hydroxytryptamine, as well).  Within the few decade, the inhibitors of MAO were discovered and introduced for the treatment of depressive illness which was established clinically.  However, the first clinical use exposed serious side effects, pharmacological interest in, and investigation of, MAO continued, resulting in the characterization of two forms, distinct forms, MAO-A and -B, and selective inhibitors for them.  Selective inhibitors of MAO-B (selegiline, rasagiline and safinamide) have found a therapeutic role in the treatment of Parkinson's disease and reversible inhibitors of MAO-A offered antidepressant activity without the serious side effects of the earlier nonselective MAO inhibitors.  Subsequent molecular pharmacological have also generated the concept of neuroprotection, reflecting the possibility of slowing, halting and maybe reversing, neurodegeneration in Parkinson's or Alzheimer's diseases.  Increased levels of oxidative stress through the accumulation of iron in the Parkinsonian and Alzheimer brains has been suggested to be critical for the initiation and progress of neurodegeneration.  Selective inhibition of brain MAO could contribute importantly to lowering such stress, preventing the formation of hydrogen peroxide.  Interaction of Iron with hydrogen peroxide and lead to Fenton reaction and production of the most reactive radical, namely hydroxyl radical.  There are complex interactions between free iron levels in brain and MAO, and cascade of neurotoxic events may have practical outcomes for depressive disorders and neurodegenerative diseases.  As consequence recent novel therapeutic drugs for neurodegenerative diseases has led to the development of multi target drugs, that possess selective brain MAO A and B inhibitory moiety, iron chelating and antioxidant activities and the ability to increase brain levels of endogenous neurotrophins, such as BDNF, GDNF VEGF and erythropoietin and induce mitochondrial biogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSojcxi5hdr-WgRQsDqrjW_fW6udTcc2eYN-ujvJ-xZFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvhtlyhsw%253D%253D&md5=71184ea386596ea4a0ecf24d95fab7cf</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1942-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1942-9%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26atitle%3DMonoamine%2520Oxidase%2520Inhibitors%252C%2520and%2520Iron%2520Chelators%2520in%2520Depressive%2520Illness%2520and%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Neural.%2520Transm.%2520%2528Vienna%2529%26date%3D2018%26volume%3D125%26issue%3D11%26spage%3D1719%26epage%3D1733%26doi%3D10.1007%2Fs00702-018-1942-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span> <span> </span><span class="NLM_article-title">The Therapeutic Potential of Monoamine Oxidase Inhibitors</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1038/nrn1883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1038%2Fnrn1883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=16552415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1Gksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=295-309&issue=4&author=M.+B.+Youdimauthor=D.+Edmondsonauthor=K.+F.+Tipton&title=The+Therapeutic+Potential+of+Monoamine+Oxidase+Inhibitors&doi=10.1038%2Fnrn1883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The therapeutic potential of monoamine oxidase inhibitors</span></div><div class="casAuthors">Youdim, Moussa B. H.; Edmondson, Dale; Tipton, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-309</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Monoamine oxidase inhibitors were among the first antidepressants to be discovered and have long been used as such.  It now seems that many of these agents might have therapeutic value in several common neurodegenerative conditions, independently of their inhibition of monoamine oxidase activity.  However, many claims and some counter-claims have been made about the physiol. importance of these enzymes and the potential of their inhibitors.  We evaluate these arguments in the light of what we know, and still have to learn, of the structure, function and genetics of the monoamine oxidases and the disparate actions of their inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3A0wRL6nnL7Vg90H21EOLACvtfcHk0ljNcgsg9xFwqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1Gksrs%253D&md5=b35546920d95fa031ff2f884949372a7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrn1883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1883%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DEdmondson%26aufirst%3DD.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26atitle%3DThe%2520Therapeutic%2520Potential%2520of%2520Monoamine%2520Oxidase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2006%26volume%3D7%26issue%3D4%26spage%3D295%26epage%3D309%26doi%3D10.1038%2Fnrn1883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otyepka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosinova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damborsky, J.</span></span> <span> </span><span class="NLM_article-title">Caver: A New Tool to Explore Routes from Protein Clefts, Pockets and Cavities</span>. <i>BMC Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">316</span>, <span class="refDoi"> DOI: 10.1186/1471-2105-7-316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1186%2F1471-2105-7-316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=16792811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BD28vnsleltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=316&author=M.+Petrekauthor=M.+Otyepkaauthor=P.+Banasauthor=P.+Kosinovaauthor=J.+Kocaauthor=J.+Damborsky&title=Caver%3A+A+New+Tool+to+Explore+Routes+from+Protein+Clefts%2C+Pockets+and+Cavities&doi=10.1186%2F1471-2105-7-316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">CAVER: a new tool to explore routes from protein clefts, pockets and cavities</span></div><div class="casAuthors">Petrek Martin; Otyepka Michal; Banas Pavel; Kosinova Pavlina; Koca Jaroslav; Damborsky Jiri</div><div class="citationInfo"><span class="NLM_cas:title">BMC bioinformatics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">316</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The main aim of this study was to develop and implement an algorithm for the rapid, accurate and automated identification of paths leading from buried protein clefts, pockets and cavities in dynamic and static protein structures to the outside solvent.  RESULTS:  The algorithm to perform a skeleton search was based on a reciprocal distance function grid that was developed and implemented for the CAVER program.  The program identifies and visualizes routes from the interior of the protein to the bulk solvent.  CAVER was primarily developed for proteins, but the algorithm is sufficiently robust to allow the analysis of any molecular system, including nucleic acids or inorganic material.  Calculations can be performed using discrete structures from crystallographic analysis and NMR experiments as well as with trajectories from molecular dynamics simulations.  The fully functional program is available as a stand-alone version and as plug-in for the molecular modeling program PyMol.  Additionally, selected functions are accessible in an online version.  CONCLUSION:  The algorithm developed automatically finds the path from a starting point located within the interior of a protein.  The algorithm is sufficiently rapid and robust to enable routine analysis of molecular dynamics trajectories containing thousands of snapshots.  The algorithm is based on reciprocal metrics and provides an easy method to find a centerline, i.e. the spine, of complicated objects such as a protein tunnel.  It can also be applied to many other molecules.  CAVER is freely available from the web site http://loschmidt.chemi.muni.cz/caver/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYFNI2kCdJVkQ0lWbKiCflfW6udTcc2ebfQ5yeNlNXDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vnsleltw%253D%253D&md5=e3bd3da0db628ec71e802092708017f3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2F1471-2105-7-316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2105-7-316%26sid%3Dliteratum%253Aachs%26aulast%3DPetrek%26aufirst%3DM.%26aulast%3DOtyepka%26aufirst%3DM.%26aulast%3DBanas%26aufirst%3DP.%26aulast%3DKosinova%26aufirst%3DP.%26aulast%3DKoca%26aufirst%3DJ.%26aulast%3DDamborsky%26aufirst%3DJ.%26atitle%3DCaver%253A%2520A%2520New%2520Tool%2520to%2520Explore%2520Routes%2520from%2520Protein%2520Clefts%252C%2520Pockets%2520and%2520Cavities%26jtitle%3DBMC%2520Bioinf.%26date%3D2006%26volume%3D7%26spage%3D316%26doi%3D10.1186%2F1471-2105-7-316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filipovič, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vávra, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plhák, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednář, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brezovský, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matyska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damborský, J.</span></span> <span> </span><span class="NLM_article-title">CaverDock: A Novel Method for the Fast Analysis of Ligand Transport</span>. <i>arXiv</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">1809.03453</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=1809.03453&author=J.+Filipovi%C4%8Dauthor=O.+V%C3%A1vraauthor=J.+Plh%C3%A1kauthor=D.+Bedn%C3%A1%C5%99author=S.+M.+Marquesauthor=J.+Brezovsk%C3%BDauthor=L.+Matyskaauthor=J.+Damborsk%C3%BD&title=CaverDock%3A+A+Novel+Method+for+the+Fast+Analysis+of+Ligand+Transport"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFilipovi%25C4%258D%26aufirst%3DJ.%26aulast%3DV%25C3%25A1vra%26aufirst%3DO.%26aulast%3DPlh%25C3%25A1k%26aufirst%3DJ.%26aulast%3DBedn%25C3%25A1%25C5%2599%26aufirst%3DD.%26aulast%3DMarques%26aufirst%3DS.%2BM.%26aulast%3DBrezovsk%25C3%25BD%26aufirst%3DJ.%26aulast%3DMatyska%26aufirst%3DL.%26aulast%3DDamborsk%25C3%25BD%26aufirst%3DJ.%26atitle%3DCaverDock%253A%2520A%2520Novel%2520Method%2520for%2520the%2520Fast%2520Analysis%2520of%2520Ligand%2520Transport%26jtitle%3DarXiv%26date%3D2018%26spage%3D1809.03453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldeck, D. H.</span></span> <span> </span><span class="NLM_article-title">Photoisomerization Dynamics of Stilbenes</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1021/cr00003a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00003a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADyaK3MXitVKitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1991&pages=415-436&issue=3&author=D.+H.+Waldeck&title=Photoisomerization+Dynamics+of+Stilbenes&doi=10.1021%2Fcr00003a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Photoisomerization dynamics of stilbenes</span></div><div class="casAuthors">Waldeck, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">415-36</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with >175 refs. including spectral studies, mechanism, theor. models, and rate studies in dense gases and liqs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpS-7aP8XWkrVg90H21EOLACvtfcHk0ljTP1HsKvLLPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXitVKitbk%253D&md5=624f87a3475c51eb0091ea45fa90d731</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fcr00003a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00003a007%26sid%3Dliteratum%253Aachs%26aulast%3DWaldeck%26aufirst%3DD.%2BH.%26atitle%3DPhotoisomerization%2520Dynamics%2520of%2520Stilbenes%26jtitle%3DChem.%2520Rev.%26date%3D1991%26volume%3D91%26issue%3D3%26spage%3D415%26epage%3D436%26doi%3D10.1021%2Fcr00003a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albreht, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vovk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span> <span> </span><span class="NLM_article-title">Evidence for a Cyanine Link between Propargylamine Drugs and Monoamine Oxidase Clarifies the Inactivation Mechanism</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">169</span>, <span class="refDoi"> DOI: 10.3389/fchem.2018.00169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.3389%2Ffchem.2018.00169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=29892597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2rtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=169&author=A.+Albrehtauthor=I.+Vovkauthor=J.+Mavriauthor=J.+Marco-Contellesauthor=R.+R.+Ramsay&title=Evidence+for+a+Cyanine+Link+between+Propargylamine+Drugs+and+Monoamine+Oxidase+Clarifies+the+Inactivation+Mechanism&doi=10.3389%2Ffchem.2018.00169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a cyanine link between propargylamine drugs and monoamine oxidase clarifies the inactivation mechanism</span></div><div class="casAuthors">Albreht, Alen; Vovk, Irena; Mavri, Janez; Marco-Contelles, Jose; Ramsay, Rona R.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">169/1-169/11</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Successful propargylamine drugs such as deprenyl inactivate monoamine oxidase (MAO), a target in multi-faceted approaches to prevent neurodegeneration in the aging population, but the chem. structure and mechanism of the irreversible inhibition are still debated.  We characterized the covalent cyanine structure linking the multi-target propargylamine inhibitor ASS234 and the FAD in MAO-A using a combination of ultra-high performance liq. chromatog., spectroscopy, mass spectrometry, and computational methods.  The partial double bond character of the cyanine chain gives rise to 4 interconverting geometric isomers of the adduct which were chromatog. sepd. at low temps.  The configuration of the cyanine linker governs adduct stability with segments of much higher flexibility and rigidity than previously hypothesized.  The findings indicate the importance of intramol. electrostatic interactions in the MAO binding site and provide key information relevant to incorporation of the propargyl moiety into novel multi-target drugs.  Based on the structure, we propose a mechanism of MAO inactivation applicable to all propargylamine inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5rqCMiMig07Vg90H21EOLACvtfcHk0ljTP1HsKvLLPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2rtLzI&md5=761e1d3e0bae22bce03bf2eba88d7bb1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00169%26sid%3Dliteratum%253Aachs%26aulast%3DAlbreht%26aufirst%3DA.%26aulast%3DVovk%26aufirst%3DI.%26aulast%3DMavri%26aufirst%3DJ.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26atitle%3DEvidence%2520for%2520a%2520Cyanine%2520Link%2520between%2520Propargylamine%2520Drugs%2520and%2520Monoamine%2520Oxidase%2520Clarifies%2520the%2520Inactivation%2520Mechanism%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D169%26doi%3D10.3389%2Ffchem.2018.00169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span> <span> </span><span class="NLM_article-title">Kinetic and Structural Analysis of the Irreversible Inhibition of Human Monoamine Oxidases by ASS234, a Multi-Target Compound Designed for Use in Alzheimer’s Disease</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1844</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1104</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2014.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.bbapap.2014.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=24642166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntVeqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1844&publication_year=2014&pages=1104-1110&issue=6&author=G.+Estebanauthor=J.+Allanauthor=A.+Samadiauthor=A.+Matteviauthor=M.+Unzetaauthor=J.+Marco-Contellesauthor=C.+Bindaauthor=R.+R.+Ramsay&title=Kinetic+and+Structural+Analysis+of+the+Irreversible+Inhibition+of+Human+Monoamine+Oxidases+by+ASS234%2C+a+Multi-Target+Compound+Designed+for+Use+in+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.bbapap.2014.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease</span></div><div class="casAuthors">Esteban, Gerard; Allan, Jennifer; Samadi, Abdelouahid; Mattevi, Andrea; Unzeta, Mercedes; Marco-Contelles, Jose; Binda, Claudia; Ramsay, Rona R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1844</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1104-1110</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Monoamine oxidases (MAO) and cholinesterases are validated targets in the design of drugs for the treatment of Alzheimer's disease.  The multi-target compd. N-((5-(3-(1-benzylpiperidin-4-yl)propoxy)-1-methyl-1H-indol-2-yl)methyl)-N-methylprop-2-yn-1-amine (ASS234), bearing the MAO-inhibiting propargyl group attached to a donepezil moiety that inhibits cholinesterases, retained activity against human acetyl- and butyryl-cholinesterases.  The inhibition of MAO A and MAO B by ASS234 was characterized and compared to other known MAO inhibitors.  ASS234 was almost as effective as clorgyline (kinact/KI = 3 × 106 min- 1 M- 1) and was shown by structural studies to form the same N5 covalent adduct with the FAD cofactor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqdbntEH0c5rVg90H21EOLACvtfcHk0ljTP1HsKvLLPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntVeqtLg%253D&md5=6bb57337217cbf2813593c9cb36eea0f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2014.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2014.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DAllan%26aufirst%3DJ.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DMattevi%26aufirst%3DA.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26atitle%3DKinetic%2520and%2520Structural%2520Analysis%2520of%2520the%2520Irreversible%2520Inhibition%2520of%2520Human%2520Monoamine%2520Oxidases%2520by%2520ASS234%252C%2520a%2520Multi-Target%2520Compound%2520Designed%2520for%2520Use%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2014%26volume%3D1844%26issue%3D6%26spage%3D1104%26epage%3D1110%26doi%3D10.1016%2Fj.bbapap.2014.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of Monoamine Oxidase B in Complex with Four Inhibitors of the <i>N</i>-Propargylaminoindan Class</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1774</span>, <span class="refDoi"> DOI: 10.1021/jm031087c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031087c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1767-1774&issue=7&author=C.+Bindaauthor=F.+Hubalekauthor=M.+Liauthor=Y.+Herzigauthor=J.+Sterlingauthor=D.+E.+Edmondsonauthor=A.+Mattevi&title=Crystal+Structures+of+Monoamine+Oxidase+B+in+Complex+with+Four+Inhibitors+of+the+N-Propargylaminoindan+Class&doi=10.1021%2Fjm031087c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Monoamine Oxidase B in Complex with Four Inhibitors of the N-Propargylaminoindan Class</span></div><div class="casAuthors">Binda, Claudia; Hubalek, Frantisek; Li, Min; Herzig, Yaacov; Sterling, Jeffrey; Edmondson, Dale E.; Mattevi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1767-1774</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoamine oxidase B (MAO B) is an outer mitochondrial membrane enzyme that catalyzes the oxidn. of arylalkylamine neurotransmitters.  The crystal structures of MAO B in complex with four of the N-propargylaminoindan class of MAO covalent inhibitors (rasagiline, N-propargyl-1(S)-aminoindan, 6-hydroxy-N-propargyl-1(R)-aminoindan, and N-methyl-N-propargyl-1(R)-aminoindan) have been detd. at a resoln. of better than 2.1 Å.  Rasagiline, 6-hydroxy-N-propargyl-1(R)-aminoindan, and N-methyl-N-propargyl-1(R)-aminoindan adopt essentially the same conformation with the extended propargyl chain covalently bound to the flavin and the indan ring located in the rear of the substrate cavity.  N-Propargyl-1(S)-aminoindan binds with the indan ring in a flipped conformation with respect to the other inhibitors, which causes a slight movement of the Tyr326 side chain.  Four ordered water mols. are an integral part of the active site and establish H-bond interactions to the inhibitor atoms.  These structural studies may guide future drug design to improve selectivity and efficacy by introducing appropriate substituents on the rasagiline mol. scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkiXn0OI5eubVg90H21EOLACvtfcHk0ljTP1HsKvLLPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit70%253D&md5=7b3df3c611e3f0dd59342a59096402dd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm031087c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031087c%26sid%3Dliteratum%253Aachs%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DHubalek%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHerzig%26aufirst%3DY.%26aulast%3DSterling%26aufirst%3DJ.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26aulast%3DMattevi%26aufirst%3DA.%26atitle%3DCrystal%2520Structures%2520of%2520Monoamine%2520Oxidase%2520B%2520in%2520Complex%2520with%2520Four%2520Inhibitors%2520of%2520the%2520N-Propargylaminoindan%2520Class%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D7%26spage%3D1767%26epage%3D1774%26doi%3D10.1021%2Fjm031087c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagide, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mialet-Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span> <span> </span><span class="NLM_article-title">Tight-Binding Inhibition of Human Monoamine Oxidase B by Chromone Analogs: A Kinetic, Crystallographic, and Biological Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4203</span>– <span class="NLM_lpage">4212</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFSnsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4203-4212&issue=9&author=J.+Reisauthor=N.+Manzellaauthor=F.+Cagideauthor=J.+Mialet-Perezauthor=E.+Uriarteauthor=A.+Pariniauthor=F.+Borgesauthor=C.+Binda&title=Tight-Binding+Inhibition+of+Human+Monoamine+Oxidase+B+by+Chromone+Analogs%3A+A+Kinetic%2C+Crystallographic%2C+and+Biological+Analysis&doi=10.1021%2Facs.jmedchem.8b00357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Tight-Binding Inhibition of Human Monoamine Oxidase B by Chromone Analogs: A Kinetic, Crystallographic, and Biological Analysis</span></div><div class="casAuthors">Reis, Joana; Manzella, Nicola; Cagide, Fernando; Mialet-Perez, Jeanne; Uriarte, Eugenio; Parini, Angelo; Borges, Fernanda; Binda, Claudia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4203-4212</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoamine oxidase B (MAO-B) is a validated drug target for Parkinson's disease.  Chromone derivs. were identified as novel potent and reversible MAO-B inhibitors, and herewith we report on a crystallog. and biochem. anal. to investigate their inhibition mechanism.  The crystal structures of human MAO-B in complex with three chromone analogs bearing different substituents on the exocyclic arom. ring (detd. at 1.6-1.8 Å resoln.) showed that they all bind in the active site cavity of the protein with the chromone moiety located in front of the FAD cofactor.  These inhibitors form two hydrogen bonds with Tyr435 and Cys172 and perfectly fit the hydrophobic flat active site of human MAO-B.  This is reflected in their tight-binding mechanism of inhibition with Ki values of 55, 17, and 31 nM for N-(3',4'-dimethylphenyl)-4-oxo-4H-chromene-3-carboxamide (1), N-(3'-chlorophenyl)-4-oxo-4H-chromene-3-carboxamide (2), and N-(3'-fluorophenyl)-4-oxo-4H-chromene-3-carboxamide (3), resp.  These compds. were also 1000-fold more effective than L-deprenyl in reducing the cellular levels of reactive oxygen species (ROS).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI4_ZAaYfpTbVg90H21EOLACvtfcHk0lhIi81aNLQvpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFSnsrw%253D&md5=129e0b5bbd744bc3ef74a75bda97a550</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00357%26sid%3Dliteratum%253Aachs%26aulast%3DReis%26aufirst%3DJ.%26aulast%3DManzella%26aufirst%3DN.%26aulast%3DCagide%26aufirst%3DF.%26aulast%3DMialet-Perez%26aufirst%3DJ.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DParini%26aufirst%3DA.%26aulast%3DBorges%26aufirst%3DF.%26aulast%3DBinda%26aufirst%3DC.%26atitle%3DTight-Binding%2520Inhibition%2520of%2520Human%2520Monoamine%2520Oxidase%2520B%2520by%2520Chromone%2520Analogs%253A%2520A%2520Kinetic%252C%2520Crystallographic%252C%2520and%2520Biological%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D9%26spage%3D4203%26epage%3D4212%26doi%3D10.1021%2Facs.jmedchem.8b00357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Frota Junior, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotto-Filho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurer, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpo, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapczinski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, J. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da
Cruz Fernandes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klamt, F.</span></span> <span> </span><span class="NLM_article-title">Comparison between Proliferative and Neuron-Like SS-SY5Y Cells as an in Vitro Model for Parkinson Disease Studies</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1337</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2010.03.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.brainres.2010.03.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=20380819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslWis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1337&publication_year=2010&pages=85-94&author=F.+M.+Lopesauthor=R.+Schroderauthor=M.+L.+da+Frota+Juniorauthor=A.+Zanotto-Filhoauthor=C.+B.+Mullerauthor=A.+S.+Piresauthor=R.+T.+Meurerauthor=G.+D.+Colpoauthor=D.+P.+Gelainauthor=F.+Kapczinskiauthor=J.+C.+F.+Moreiraauthor=M.+da%0ACruz+Fernandesauthor=F.+Klamt&title=Comparison+between+Proliferative+and+Neuron-Like+SS-SY5Y+Cells+as+an+in+Vitro+Model+for+Parkinson+Disease+Studies&doi=10.1016%2Fj.brainres.2010.03.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies</span></div><div class="casAuthors">Lopes, Fernanda Martins; Schroeder, Rafael; Conte da Frota, Mario Luiz, Jr.; Zanotto-Filho, Alfeu; Mueller, Carolina Beatriz; Pires, Andre Simoes; Meurer, Rosalva Thereza; Colpo, Gabriela Delevati; Gelain, Daniel Pens; Kapczinski, Flavio; Moreira, Jose Claudio Fonseca; Fernandes, Marilda da Cruz; Klamt, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1337</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mol. mechanisms underlying the cellular lost found in the nigrostriatal pathway during the progression of Parkinson's disease (PD) are not completely understood.  Human neuroblastoma cell line SH-SY5Y challenged with 6-hydroxydopamine (6-OHDA) has been widely used as an in vitro model for PD.  Although this cell line differentiates to dopaminergic neuron-like cells in response to low serum and retinoic acid (RA) treatment, there are few studies investigating the differences between proliferative and RA-differentiated SH-SY5Y cells.  Here we evaluate morphol. and biochem. changes which occurs during the differentiation of SH-SY5Y cells, and their responsiveness to 6-OHDA toxicity.  Exponentially growing SH-SY5Y cells were maintained with DMEM/F12 medium plus 10% of fetal bovine serum (FBS).  Differentiation was triggered by the combination of 10 μM RA plus 1% of FBS during 4, 7 and 10 days in culture.  We found that SH-SY5Y cells differentiated for 7 days show an increase immunocontent of several relevant neuronal markers with the concomitant decrease in non-differentiated cell marker.  Moreover, cells became two-fold more sensitive to 6-OHDA toxicity during the differentiation process.  Time course expts. showed loss of mitochondrial membrane potential triggered by 6-OHDA (mitochondrial dysfunction parameter), which firstly occurs in proliferative than neuron-like differentiated cells.  This finding could be related to the increase in the immunocontent of the neuroprotective protein DJ-1 during differentiation.  Our data suggest that SH-SY5Y cells differentiated by 7 days with the protocol described here represent a more suitable exptl. model for studying the mol. and cellular mechanisms underlying the pathophysiol. of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp106_9hpIIu7Vg90H21EOLACvtfcHk0lhIi81aNLQvpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslWis7s%253D&md5=83c035ab4a0e891f927d0ba073f34a20</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2010.03.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2010.03.102%26sid%3Dliteratum%253Aachs%26aulast%3DLopes%26aufirst%3DF.%2BM.%26aulast%3DSchroder%26aufirst%3DR.%26aulast%3Dda%2BFrota%2BJunior%26aufirst%3DM.%2BL.%26aulast%3DZanotto-Filho%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DC.%2BB.%26aulast%3DPires%26aufirst%3DA.%2BS.%26aulast%3DMeurer%26aufirst%3DR.%2BT.%26aulast%3DColpo%26aufirst%3DG.%2BD.%26aulast%3DGelain%26aufirst%3DD.%2BP.%26aulast%3DKapczinski%26aufirst%3DF.%26aulast%3DMoreira%26aufirst%3DJ.%2BC.%2BF.%26aulast%3Dda%2BCruz%2BFernandes%26aufirst%3DM.%26aulast%3DKlamt%26aufirst%3DF.%26atitle%3DComparison%2520between%2520Proliferative%2520and%2520Neuron-Like%2520SS-SY5Y%2520Cells%2520as%2520an%2520in%2520Vitro%2520Model%2520for%2520Parkinson%2520Disease%2520Studies%26jtitle%3DBrain%2520Res.%26date%3D2010%26volume%3D1337%26spage%3D85%26epage%3D94%26doi%3D10.1016%2Fj.brainres.2010.03.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finberg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabey, J. M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">340</span>, <span class="refDoi"> DOI: 10.3389/fphar.2016.00340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.3389%2Ffphar.2016.00340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=27803666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=340&author=J.+P.+Finbergauthor=J.+M.+Rabey&title=Inhibitors+of+MAO-A+and+MAO-B+in+Psychiatry+and+Neurology&doi=10.3389%2Ffphar.2016.00340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of MAO-A and MAO-B in psychiatry and neurology</span></div><div class="casAuthors">Finberg, John P. M.; Rabey, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">340-354</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Inhibitors of MAO-A and MAO-B are in clin. use for the treatment of psychiatric and neurol. disorders resp.  Elucidation of the mol. structure of the active sites of the enzymes has enabled a precise detn. of the way in which substrates and inhibitor mols. are metabolized, or inhibit metab. of substrates, resp.  Despite the knowledge of the strong antidepressant efficacy of irreversible MAO inhibitors, their clin. use has been limited by their side effect of potentiation of the cardiovascular effects of dietary amines ("cheese effect").  A no. of reversible MAO-A inhibitors which are devoid of cheese effect have been described in the literature, but only one, moclobemide, is currently in clin. use.  The irreversible inhibitors of MAO-B, selegiline and rasagiline, are used clin. in treatment of Parkinson's disease, and a recently introduced reversible MAO-B inhibitor, safinamide, has also been found efficacious.  Modification of the pharmacokinetic characteristics of selegiline by transdermal administration has led to the development of a new drug form for treatment of depression.  The clin. potential of MAO inhibitors together with detailed knowledge of the enzyme's binding site structure should lead to future developments with these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUpMUqQ2oLP7Vg90H21EOLACvtfcHk0ljyAU3ezm99fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWnu7k%253D&md5=7d7cf400373f86aa87e1147ce52b6d16</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2016.00340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2016.00340%26sid%3Dliteratum%253Aachs%26aulast%3DFinberg%26aufirst%3DJ.%2BP.%26aulast%3DRabey%26aufirst%3DJ.%2BM.%26atitle%3DInhibitors%2520of%2520MAO-A%2520and%2520MAO-B%2520in%2520Psychiatry%2520and%2520Neurology%26jtitle%3DFront.%2520Pharmacol.%26date%3D2016%26volume%3D7%26spage%3D340%26doi%3D10.3389%2Ffphar.2016.00340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shulman, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. E.</span></span> <span> </span><span class="NLM_article-title">Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1007/s40263-013-0097-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1007%2Fs40263-013-0097-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=23934742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSms73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=789-797&issue=10&author=K.+I.+Shulmanauthor=N.+Herrmannauthor=S.+E.+Walker&title=Current+Place+of+Monoamine+Oxidase+Inhibitors+in+the+Treatment+of+Depression&doi=10.1007%2Fs40263-013-0097-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression</span></div><div class="casAuthors">Shulman, Kenneth I.; Herrmann, Nathan; Walker, Scott E.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">789-797</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  This paper reviews the discovery and history of the use of irreversible monoamine oxidase (MAO) inhibitors (MAOIs) such as phenelzine, tranylcypromine and isocarboxazid, as well as the second generation selective and reversible MAOIs such as the MAO-A inhibitor, moclobemide and the MAO-B inhibitor, selegiline.  Data for review were identified from a literature search of OvidSP Medline and PsycInfo performed in July 2012, using the subject terms and keywords of 'monoamine oxidase inhibitors', 'major depression', 'depressive disorder' and 'depression (emotion)'.  The search was limited to papers published in the English language and from 2007 onward only.  Irreversible MAOIs have the potential to treat the most challenging mood disorder patients including those with treatment-resistant depression, atypical depression and bipolar depression.  Unfortunately, the use of irreversible MAOIs has been declining sharply due to lack of marketing and the excessive fears of clinicians.  Moreover, few clinicians now have any experience, let alone comfort, in prescribing this class of antidepressants.  The newer MAOIs are available as another option for the treatment of major depression but have not replaced the irreversible MAOIs for the specific sub-types of depression for which they are now recommended in most consensus guidelines and treatment algorithms.  The pharmacol., drug interactions and dietary recommendations assocd. with the use of MAOIs are reviewed.  With the appropriate dietary restrictions and attention to potential drug interactions with serotonin and noradrenaline agents this class of drugs can be used effectively and safely.  The MAOIs still represent an important element in our therapeutic armamentarium.  Despite recommendations by opinion leaders and consensus guidelines for the use of MAOIs in specific sub-types of depression, the prescription rate of MAOIs is far less than expected and is decreasing.  The "bad reputation" and the lack of industry support for this class of agents (esp. the irreversible MAOIs) must be overcome in order to continue to provide a potentially useful treatment for a very vulnerable yet substantial sub-population of mood disorder patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9oHuy14vFo7Vg90H21EOLACvtfcHk0ljyAU3ezm99fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSms73J&md5=f297225f058268df2a6b096e49904715</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs40263-013-0097-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-013-0097-3%26sid%3Dliteratum%253Aachs%26aulast%3DShulman%26aufirst%3DK.%2BI.%26aulast%3DHerrmann%26aufirst%3DN.%26aulast%3DWalker%26aufirst%3DS.%2BE.%26atitle%3DCurrent%2520Place%2520of%2520Monoamine%2520Oxidase%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Depression%26jtitle%3DCNS%2520Drugs%26date%3D2013%26volume%3D27%26issue%3D10%26spage%3D789%26epage%3D797%26doi%3D10.1007%2Fs40263-013-0097-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kircanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeMoult, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotlib, I. H.</span></span> <span> </span><span class="NLM_article-title">Investigating the Nature of Co-Occurring Depression and Anxiety: Comparing Diagnostic and Dimensional Research Approaches</span>. <i>J. Affective Disord.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.jad.2016.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.jad.2016.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=27554605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BC2szjsFygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2017&pages=123-135&author=K.+Kircanskiauthor=J.+LeMoultauthor=S.+Ordazauthor=I.+H.+Gotlib&title=Investigating+the+Nature+of+Co-Occurring+Depression+and+Anxiety%3A+Comparing+Diagnostic+and+Dimensional+Research+Approaches&doi=10.1016%2Fj.jad.2016.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating the nature of co-occurring depression and anxiety: Comparing diagnostic and dimensional research approaches</span></div><div class="casAuthors">Kircanski Katharina; LeMoult Joelle; Gotlib Ian H; Ordaz Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of affective disorders</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-135</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Although approximately half of adults diagnosed with a depressive or anxiety disorder exhibit their simultaneous co-occurrence, traditional research has centered on single-target diagnoses, overlooking comorbidities within samples.  In this article, we review and extend the literature that directly investigates co-occurring depression and anxiety, with the goal of shifting the focus from co-occurring diagnoses to symptom dimensions.  METHODS:  First, we review studies that have directly compared psychobiological features (neural, neuroendocrine, autonomic) across depression, anxiety, and their co-occurrence, defined either categorically or dimensionally.  Second, we analyze adults' diurnal cortisol secretion to examine the independent and interactive relations of continuously-assessed depressive and anxiety symptoms to neuroendocrine function.  RESULTS:  Previous findings on the psychobiology of diagnostic co-occurrence are mixed.  While nascent, evidence from dimensionally focused studies suggests that co-occurring levels of depressive and anxiety symptoms can interact with one another, as reflected in a distinct psychobiological profile for individuals with high levels of both symptom dimensions.  Results of our analyses support this formulation: we found that depressive and anxiety symptom dimensions interacted consistently in their relation to the measures of diurnal cortisol.  LIMITATIONS:  The illustrative sample was relatively small and included only women; future research should examine generalizability of these findings.  CONCLUSIONS:  A dimensional approach to investigating the psychobiology of co-occurring depression and anxiety affords both conceptual and practical advantages.  Simultaneously assessing depressive and anxiety symptom dimensions can efficiently capture their unique, shared, and interactive features, thereby identifying targets for intervention across a wide range of symptom presentations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUoeyc0x-yUxwLZxei1HN8fW6udTcc2eb-eVksImjCHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szjsFygtw%253D%253D&md5=2964f6072d83bf3d098b784d6befec58</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2016.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2016.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DKircanski%26aufirst%3DK.%26aulast%3DLeMoult%26aufirst%3DJ.%26aulast%3DOrdaz%26aufirst%3DS.%26aulast%3DGotlib%26aufirst%3DI.%2BH.%26atitle%3DInvestigating%2520the%2520Nature%2520of%2520Co-Occurring%2520Depression%2520and%2520Anxiety%253A%2520Comparing%2520Diagnostic%2520and%2520Dimensional%2520Research%2520Approaches%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2017%26volume%3D216%26spage%3D123%26epage%3D135%26doi%3D10.1016%2Fj.jad.2016.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akimova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanzenberger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, S.</span></span> <span> </span><span class="NLM_article-title">The Serotonin-1A Receptor in Anxiety Disorders</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2009.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.biopsych.2009.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=19423077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWqtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=627-635&issue=7&author=E.+Akimovaauthor=R.+Lanzenbergerauthor=S.+Kasper&title=The+Serotonin-1A+Receptor+in+Anxiety+Disorders&doi=10.1016%2Fj.biopsych.2009.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The Serotonin-1A Receptor in Anxiety Disorders</span></div><div class="casAuthors">Akimova, Elena; Lanzenberger, Rupert; Kasper, Siegfried</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">627-635</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The serotonin system plays an important role in the neural processing of anxiety.  The involvement of the main inhibitory serotonergic receptor, the serotonin-1A (5-HT1A) subtype, in dysfunctional forms of anxiety has been supported by findings from a wide range of preclin. research and clin. trials, including treatment studies, genetic research, and neuroimaging data.  The following article summarizes preclin. results with a focus on 5-HT1A receptor knockout and transgenic mice as genetic models of anxiety.  Behavioral, autonomic, and endocrinol. changes in these mice are reported.  This article also presents genetic polymorphisms in humans assocd. with increased anxiety scores and pharmacol. data focused on 5-HT1A receptor agonists and antagonists.  Furthermore, mol. neuroimaging results are presented.  Recent positron emission tomog. (PET) studies have reported reduced 5-HT1A receptor binding in patients with panic disorder and social anxiety disorder, but not in posttraumatic stress disorder.  In healthy subjects, increased anxiety scores might be assocd. with lower 5-HT1A receptor binding.  This overview of preclin. and clin. data provides strong evidence for the key role of the 5-HT1A receptor in the serotonergic dysregulation of anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6rff9u48uMbVg90H21EOLACvtfcHk0ljyAU3ezm99fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWqtLbI&md5=2ea0a9d4c1223825478e4263e5062991</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2009.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2009.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DAkimova%26aufirst%3DE.%26aulast%3DLanzenberger%26aufirst%3DR.%26aulast%3DKasper%26aufirst%3DS.%26atitle%3DThe%2520Serotonin-1A%2520Receptor%2520in%2520Anxiety%2520Disorders%26jtitle%3DBiol.%2520Psychiatry%26date%3D2009%26volume%3D66%26issue%3D7%26spage%3D627%26epage%3D635%26doi%3D10.1016%2Fj.biopsych.2009.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasowski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loscalzo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granger, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladini, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marder, M.</span></span> <span> </span><span class="NLM_article-title">Central Nervous System Depressant Action of Flavonoid Glycosides</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>539</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2006.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.ejphar.2006.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=16698011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XltFOqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=539&publication_year=2006&pages=168-176&issue=3&author=S.+P.+Fernandezauthor=C.+Wasowskiauthor=L.+M.+Loscalzoauthor=R.+E.+Grangerauthor=G.+A.+Johnstonauthor=A.+C.+Paladiniauthor=M.+Marder&title=Central+Nervous+System+Depressant+Action+of+Flavonoid+Glycosides&doi=10.1016%2Fj.ejphar.2006.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Central nervous system depressant action of flavonoid glycosides</span></div><div class="casAuthors">Fernandez, Sebastian P.; Wasowski, Cristina; Loscalzo, Leonardo M.; Granger, Renee E.; Johnston, Graham A. R.; Paladini, Alejandro C.; Marder, Mariel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">539</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">168-176</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The pharmacol. effects on the central nervous system (CNS) of a range of available flavonoid glycosides were explored and compared to those of the glycosides 2S-hesperidin and linarin, recently isolated from valeriana.  The glycosides 2S-neohesperidin, 2S-naringin, diosmin, gossypin and rutin exerted a depressant action on the CNS of mice following i.p. injection, similar to that found with 2S-hesperidin and linarin.  We demonstrate in this work that these behavioral actions, as measured in the hole board, thiopental induced sleeping time and locomotor activity tests, are unlikely to involve a direct action on γ-aminobutyric acid type A (GABAA) receptors.  The corresponding aglycons were inactive, pointing to the importance of the sugar moieties in the glycosides in their CNS depressant action following systemic administration.  The pharmacol. properties of the flavonoid glycosides studied here, in addn. to our previous results with hesperidin and linarin, opens a promising new avenue of research in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPw80KbqQYi7Vg90H21EOLACvtfcHk0ljNOgZt2drp7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltFOqsbs%253D&md5=9c50ee2bcdbecb7b08d1d2bf3b05a128</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez%26aufirst%3DS.%2BP.%26aulast%3DWasowski%26aufirst%3DC.%26aulast%3DLoscalzo%26aufirst%3DL.%2BM.%26aulast%3DGranger%26aufirst%3DR.%2BE.%26aulast%3DJohnston%26aufirst%3DG.%2BA.%26aulast%3DPaladini%26aufirst%3DA.%2BC.%26aulast%3DMarder%26aufirst%3DM.%26atitle%3DCentral%2520Nervous%2520System%2520Depressant%2520Action%2520of%2520Flavonoid%2520Glycosides%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D539%26issue%3D3%26spage%3D168%26epage%3D176%26doi%3D10.1016%2Fj.ejphar.2006.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaggi, A. S.</span></span> <span> </span><span class="NLM_article-title">Preclinical Experimental Stress Studies: Protocols, Assessment and Comparison</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>746</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.ejphar.2014.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=25446911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWisbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=746&publication_year=2015&pages=282-292&author=A.+Baliauthor=A.+S.+Jaggi&title=Preclinical+Experimental+Stress+Studies%3A+Protocols%2C+Assessment+and+Comparison&doi=10.1016%2Fj.ejphar.2014.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical experimental stress studies: Protocols, assessment and comparison</span></div><div class="casAuthors">Bali, Anjana; Jaggi, Amteshwar Singh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">746</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">282-292</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Stress is a state of threatened homeostasis during which a variety of adaptive processes are activated to produce physiol. and behavioral changes.  Preclin. models are pivotal for understanding these physiol. or pathophysiol. changes in the body in response to stress.  Furthermore, these models are also important for the development of novel pharmacol. agents for stress management.  The well described preclin. stress models include immobilization, restraint, elec. foot shock and social isolation stress.  Stress assessment in animals is done at the behavioral level using open field, social interaction, hole board test; at the biochem. level by measuring plasma corticosterone and ACTH; at the physiol. level by measuring food intake, body wt., adrenal gland wt. and gastric ulceration.  Furthermore the comparison between different stressors including elec. foot shock, immobilization and cold stressor is described in terms of intensity, hormonal release, protein changes in brain, adaptation and sleep pattern.  This present review describes these preclin. stress protocols, and stress assessment at different levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx22IsqEcKbbVg90H21EOLACvtfcHk0ljNOgZt2drp7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWisbfN&md5=7d884e624f69c790bf586cff543aff64</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DBali%26aufirst%3DA.%26aulast%3DJaggi%26aufirst%3DA.%2BS.%26atitle%3DPreclinical%2520Experimental%2520Stress%2520Studies%253A%2520Protocols%252C%2520Assessment%2520and%2520Comparison%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D746%26spage%3D282%26epage%3D292%26doi%3D10.1016%2Fj.ejphar.2014.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraf, S. K.</span></span> <span> </span><span class="NLM_article-title">Privileged Scaffolds as MAO Inhibitors: Retrospect and Prospects</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.ejmech.2018.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=29335210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVens7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2018&pages=445-497&author=A.+C.+Tripathiauthor=S.+Upadhyayauthor=S.+Paliwalauthor=S.+K.+Saraf&title=Privileged+Scaffolds+as+MAO+Inhibitors%3A+Retrospect+and+Prospects&doi=10.1016%2Fj.ejmech.2018.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged scaffolds as MAO inhibitors: Retrospect and prospects</span></div><div class="casAuthors">Tripathi, Avinash C.; Upadhyay, Savita; Paliwal, Sarvesh; Saraf, Shailendra K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">445-497</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This review aims to be a comprehensive, authoritative, crit., and readable review of general interest to the medicinal chem. community because it focuses on the pharmacol., chem., structural and computational aspects of diverse chem. categories as monoamine oxidase inhibitors (MAOIs).  Monoamine oxidases (MAOs), namely MAO-A and MAO-B represent an enormously valuable class of neuronal enzymes embodying neurobiol. origin and functions, serving as potential therapeutic target in neuronal pharmacotherapy, and hence we have coined the term "Neurozymes" which is being introduced for the first time ever.  Nowadays, therapeutic attention on MAOIs engrosses two imperative categories; MAO-A inhibitors, in certain mental disorders such as depression and anxiety, and MAO-B inhibitors, in neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD).  The use of MAOIs declined due to some potential side effects, food and drug interactions, and introduction of other classes of drugs.  However, curiosity in MAOIs is reviving and the recent developments of new generation of highly selective and reversible MAOIs, have renewed the therapeutic prospective of these compds.  The initial section of the review emphasizes on the detailed classification, structural and binding characteristics, therapeutic potential, current status and future challenges of the privileged pharmacophores.  However, the chem. prospective of privileged scaffolds such as; aliph. and arom. amines, amides, hydrazines, azoles, diazoles, tetrazoles, indoles, azines, diazines, xanthenes, tricyclics, benzopyrones, and more interestingly natural products, along with their conclusive SARs have been discussed in the later segment of review.  The last segment of the article encompasses some patents granted in the field of MAOIs, in a simplistic way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqYob-n4zgsLVg90H21EOLACvtfcHk0ljNOgZt2drp7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVens7k%253D&md5=4fa0cc226ee27522671188d0cfe62ab2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DTripathi%26aufirst%3DA.%2BC.%26aulast%3DUpadhyay%26aufirst%3DS.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DSaraf%26aufirst%3DS.%2BK.%26atitle%3DPrivileged%2520Scaffolds%2520as%2520MAO%2520Inhibitors%253A%2520Retrospect%2520and%2520Prospects%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D145%26spage%3D445%26epage%3D497%26doi%3D10.1016%2Fj.ejmech.2018.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holt, A.</span></span> <span> </span><span class="NLM_article-title">On the Practical Aspects of Characterising Monoamine Oxidase Inhibition in Vitro</span>. <i>J. Neural. Transm. (Vienna)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1685</span>– <span class="NLM_lpage">1705</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1943-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1007%2Fs00702-018-1943-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=30374594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BB3cvks1Glug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1685-1705&issue=11&author=A.+Holt&title=On+the+Practical+Aspects+of+Characterising+Monoamine+Oxidase+Inhibition+in+Vitro&doi=10.1007%2Fs00702-018-1943-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">On the practical aspects of characterising monoamine oxidase inhibition in vitro</span></div><div class="casAuthors">Holt Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission (Vienna, Austria : 1996)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1685-1705</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The development of novel inhibitors of human monoamine oxidase enzymes with improved pharmacodynamic and pharmacokinetic profiles has, in the past, been hampered by limited access to enzyme, by assay protocols offering limited throughput, and by inappropriate analyses of kinetic data.  More recently, high-level expression of human enzymes in yeast has facilitated thorough examinations of steady-state enzyme behaviour that have led to improvements in our understanding of the mathematical underpinnings of kinetic analyses of monoamine oxidases.  However, with these improvements have come a realisation that to be useful, more data points across wider concentration ranges are required.  In turn, many discontinuous assay approaches, such as those involving radiolabelled substrates or chromatographic separation of product from substrate, have been rendered somewhat obsolete.  Justification for the use of a platereader-based approach to assess the effects of novel inhibitors on monamine oxidases is provided, along with details of experimental design optimised to address the unexpectedly complex kinetics followed by these enzymes.  Potential sources of error are discussed, and comments provided on techniques that may enhance the quality of experimental data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLQ9Tr45XEAp0d-O_J5C0AfW6udTcc2eblEe91h9KnC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvks1Glug%253D%253D&md5=6c716e83045d9735c4c07ddc1d6c65f9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1943-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1943-8%26sid%3Dliteratum%253Aachs%26aulast%3DHolt%26aufirst%3DA.%26atitle%3DOn%2520the%2520Practical%2520Aspects%2520of%2520Characterising%2520Monoamine%2520Oxidase%2520Inhibition%2520in%2520Vitro%26jtitle%3DJ.%2520Neural.%2520Transm.%2520%2528Vienna%2529%26date%3D2018%26volume%3D125%26issue%3D11%26spage%3D1685%26epage%3D1705%26doi%3D10.1007%2Fs00702-018-1943-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonesson, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of a Set of Para-Substituted 4-Phenylpiperidines and 4-Phenylpiperazines as Monoamine Oxidase (MAO) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3242</span>– <span class="NLM_lpage">3249</span>, <span class="refDoi"> DOI: 10.1021/jm201692d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201692d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Srtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3242-3249&issue=7&author=F.+Petterssonauthor=P.+Svenssonauthor=S.+Watersauthor=N.+Watersauthor=C.+Sonesson&title=Synthesis+and+Evaluation+of+a+Set+of+Para-Substituted+4-Phenylpiperidines+and+4-Phenylpiperazines+as+Monoamine+Oxidase+%28MAO%29+Inhibitors&doi=10.1021%2Fjm201692d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of a Set of Para-Substituted 4-Phenylpiperidines and 4-Phenylpiperazines as Monoamine Oxidase (MAO) Inhibitors</span></div><div class="casAuthors">Pettersson, Fredrik; Svensson, Peder; Waters, Susanna; Waters, Nicholas; Sonesson, Clas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3242-3249</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of para-substituted 4-phenylpiperidines/piperazines have been synthesized and their affinity to recombinant rat cerebral cortex monoamine oxidases A (MAO A) and B (MAO B) detd.  Para-substituents with low dipole moment increased the affinity to MAO A, whereas groups with high dipole moment yielded compds. with no or weak affinity.  In contrast, the properties affecting MAO B affinity were the polarity and bulk of the para-substituent, with large hydrophobic substituents producing compds. with high MAO B affinity.  In addn., these compds. were tested in freely moving rats and the effect on the post-mortem neurochem. was measured.  A linear correlation was demonstrated between the affinity for MAO A, but not MAO B, and the levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-methoxytyramine (3-MT) in the striatum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrugvUaJuL0LLVg90H21EOLACvtfcHk0lj3DUKgCw9_9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Srtbc%253D&md5=99d694bfa2bb530cbb72c7e7cc7da3e9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm201692d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201692d%26sid%3Dliteratum%253Aachs%26aulast%3DPettersson%26aufirst%3DF.%26aulast%3DSvensson%26aufirst%3DP.%26aulast%3DWaters%26aufirst%3DS.%26aulast%3DWaters%26aufirst%3DN.%26aulast%3DSonesson%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520a%2520Set%2520of%2520Para-Substituted%25204-Phenylpiperidines%2520and%25204-Phenylpiperazines%2520as%2520Monoamine%2520Oxidase%2520%2528MAO%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D7%26spage%3D3242%26epage%3D3249%26doi%3D10.1021%2Fjm201692d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heuson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charmantray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gefflaut, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span> <span> </span><span class="NLM_article-title">Profiling Substrate Specificity of Two Series of Phenethylamine Analogs at Monoamine Oxidase A and B</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">8689</span>– <span class="NLM_lpage">8695</span>, <span class="refDoi"> DOI: 10.1039/C4OB01377H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1039%2FC4OB01377H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=25253656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WitLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=8689-8695&issue=43&author=E.+Heusonauthor=M.+Storgaardauthor=T.+H.+Huynhauthor=F.+Charmantrayauthor=T.+Gefflautauthor=L.+Bunch&title=Profiling+Substrate+Specificity+of+Two+Series+of+Phenethylamine+Analogs+at+Monoamine+Oxidase+A+and+B&doi=10.1039%2FC4OB01377H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling substrate specificity of two series of phenethylamine analogs at monoamine oxidase A and B</span></div><div class="casAuthors">Heuson, Egon; Storgaard, Morten; Huynh, Tri H. V.; Charmantray, Franck; Gefflaut, Thierry; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">8689-8695</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The membrane bound enzyme monoamine oxidase exist in two splice variants designated A and B (MAO-A and MAO-B) and are key players in the oxidative metab. of monoamines in mammalians.  Despite their importance and being a prevalent target for the development of inhibitors as drugs, no systematic study of substrate specificity has been reported.  In this study we present a systematic study of the MAO-A and MAO-B substrate specificity profile by probing two series of phenethylamine analogs.  Km and kcat values were detd. for four N-alkyl analogs 2-5 and four aryl halide analogs 6-9 at MAO-A and MAO-B.  A following in silico study disclosed a new adjacent compartment to the MAO-B substrate pocket defined by amino acids Tyr188, Tyr435, Tyr398, Thr399, Cys172 and Gly434.  This new insight is important for the understanding of the substrate specificity of the MAO-B enzyme and will be relevant for future drug design within the field of monoamines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4EgaQ2sgNq7Vg90H21EOLACvtfcHk0lj3DUKgCw9_9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WitLnN&md5=8c909937cc8c54362c3f8ec01be703e0</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1039%2FC4OB01377H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4OB01377H%26sid%3Dliteratum%253Aachs%26aulast%3DHeuson%26aufirst%3DE.%26aulast%3DStorgaard%26aufirst%3DM.%26aulast%3DHuynh%26aufirst%3DT.%2BH.%26aulast%3DCharmantray%26aufirst%3DF.%26aulast%3DGefflaut%26aufirst%3DT.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DProfiling%2520Substrate%2520Specificity%2520of%2520Two%2520Series%2520of%2520Phenethylamine%2520Analogs%2520at%2520Monoamine%2520Oxidase%2520A%2520and%2520B%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2014%26volume%3D12%26issue%3D43%26spage%3D8689%26epage%3D8695%26doi%3D10.1039%2FC4OB01377H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baboota, S.</span></span> <span> </span><span class="NLM_article-title">Design Expert(®) Supported Optimization and Predictive Analysis of Selegiline Nanoemulsion <i>Via</i> the Olfactory Region with Enhanced Behavioural Performance in Parkinson’s Disease</span>. <i>Nanotechnology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">435101</span>, <span class="refDoi"> DOI: 10.1088/0957-4484/27/43/435101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1088%2F0957-4484%2F27%2F43%2F435101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=27655136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOlt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=435101&issue=43&author=S.+Kumarauthor=J.+Aliauthor=S.+Baboota&title=Design+Expert%28%C2%AE%29+Supported+Optimization+and+Predictive+Analysis+of+Selegiline+Nanoemulsion+Via+the+Olfactory+Region+with+Enhanced+Behavioural+Performance+in+Parkinson%E2%80%99s+Disease&doi=10.1088%2F0957-4484%2F27%2F43%2F435101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Design Expert supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson's disease</span></div><div class="casAuthors">Kumar, Shobhit; Ali, Javed; Baboota, Sanjula</div><div class="citationInfo"><span class="NLM_cas:title">Nanotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">435101/1-435101/24</span>CODEN:
                <span class="NLM_cas:coden">NNOTER</span>;
        ISSN:<span class="NLM_cas:issn">1361-6528</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">Selegiline is a monoamine oxidase B (MAO-B) inhibitor and is used in the treatment of Parkinson's disease.  The main problem assocd. with its oral administration is its low oral bioavailability (10%) due to its poor aq. soly. and extensive first pass metab.  The aim of the present research work was to develop a nanoemulsion loaded with selegiline for direct nose-to-brain delivery for the better management of Parkinson's disease.  A quality by design (QbD) approach was used in a statistical multivariate method for the prepn. and optimization of nanoemulsion.  In this study, four independent variables were chosen, in which two were compns. and two were process variables, while droplet size, transmittance, zeta potential and drug release were selected as response variables.  The optimized formulation was assessed for efficacy in Parkinson's disease using behavioral studies, namely forced swimming, locomotor, catalepsy, muscle coordination, akinesia and bradykinesia or pole test in Wistar rats.  The obsd. droplet size, polydispersity index (PDI), refractive index, transmittance, zeta potential and viscosity of selegiline nanoemulsion were found to be 61.43 ± 4.10 nm, 0.203 ± 0.005, 1.30 ± 0.01, 99.80 ± 0.04%, -34 mV and 31.85 ± 0.24 mPas resp.  Surface characterization studies demonstrated a spherical shape of nanoemulsion which showed 3.7 times enhancement in drug permeation as compared to drug suspension.  The results of behavior studies showed that treatment of haloperidol induced Parkinson's disease in rats with selegiline nanoemulsion (administered intranasally) showed significant improvement in behavioral activities in comparison to orally administered drug.  These findings demonstrate that nanoemulsion could be a promising new drug delivery carrier for intranasal delivery of selegiline in the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY8fTm-JjnlrVg90H21EOLACvtfcHk0ljLsXloQTknAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOlt7vE&md5=598c99317c3d81659246509da6cb2e63</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1088%2F0957-4484%2F27%2F43%2F435101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F0957-4484%252F27%252F43%252F435101%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DAli%26aufirst%3DJ.%26aulast%3DBaboota%26aufirst%3DS.%26atitle%3DDesign%2520Expert%2528%25C2%25AE%2529%2520Supported%2520Optimization%2520and%2520Predictive%2520Analysis%2520of%2520Selegiline%2520Nanoemulsion%2520Via%2520the%2520Olfactory%2520Region%2520with%2520Enhanced%2520Behavioural%2520Performance%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DNanotechnology%26date%3D2016%26volume%3D27%26issue%3D43%26spage%3D435101%26doi%3D10.1088%2F0957-4484%2F27%2F43%2F435101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">42717</span>, <span class="refDoi"> DOI: 10.1038/srep42717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1038%2Fsrep42717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=28256516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42717&author=A.+Dainaauthor=O.+Michielinauthor=V.+Zoete&title=SwissADME%3A+A+Free+Web+Tool+to+Evaluate+Pharmacokinetics%2C+Drug-Likeness+and+Medicinal+Chemistry+Friendliness+of+Small+Molecules&doi=10.1038%2Fsrep42717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span></div><div class="casAuthors">Daina Antoine; Michielin Olivier; Zoete Vincent; Michielin Olivier; Michielin Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42717</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.  Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited.  In that context, computer models constitute valid alternatives to experiments.  Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar.  Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch.  Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl_Uk5dOMKs6qcneEtCi92fW6udTcc2ebo0dVEbLCCRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D&md5=9715b8cb8a34b17c4c73ff69a5a8cc50</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fsrep42717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42717%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DSwissADME%253A%2520A%2520Free%2520Web%2520Tool%2520to%2520Evaluate%2520Pharmacokinetics%252C%2520Drug-Likeness%2520and%2520Medicinal%2520Chemistry%2520Friendliness%2520of%2520Small%2520Molecules%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42717%26doi%3D10.1038%2Fsrep42717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&issue=7&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0ljLsXloQTknAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchuk-Voloshina, N.</span></span> <span> </span><span class="NLM_article-title">A One-Step Fluorometric Method for the Continuous Measurement of Monoamine Oxidase Activity</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>253</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1006/abio.1997.2392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1006%2Fabio.1997.2392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=9367499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADyaK2sXnsFahsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1997&pages=169-174&issue=2&author=M.+Zhouauthor=N.+Panchuk-Voloshina&title=A+One-Step+Fluorometric+Method+for+the+Continuous+Measurement+of+Monoamine+Oxidase+Activity&doi=10.1006%2Fabio.1997.2392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A one-step fluorometric method for the continuous measurement of monoamine oxidase activity</span></div><div class="casAuthors">Zhou, Mingjie; Panchuk-Voloshina, Nataliya</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-174</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A 1-step fluorometric method was developed for the measurement of monoamine oxidase (MAO) activity in 96-well microplates with a sensitivity 10-fold higher than the conventional spectrophotometric assay method.  This assay was based on the detection of H2O2 in a horseradish peroxidase-coupled reaction using N-acetyl-3,7-dihydroxyphenoxazine (Amplex Red), a highly sensitive and stable probe for H2O2.  With a single sampling, this assay was useful for performing both end-point and continuous measurements of MAO activity.  Using a com. available enzyme, the assay allowed the detection of MAO B activity as low as 1.2 × 10-5 U/mL.  When applied to crude tissue homogenates, it was possible to selectively detect both MAO A and MAO B from bovine brain tissue with a protein content as low as 200 μg per sample.  The potential applications of this assay include the measurement of MAO activity in normal and diseased tissues, blood samples and other biol. fluids, and the screening of drugs for the treatment of MAO-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql6SqApG0lS7Vg90H21EOLACvtfcHk0lg15rT72qgW5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsFahsr8%253D&md5=b828a3cc40db9fd5b251fd138268b1d7</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1006%2Fabio.1997.2392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1997.2392%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DPanchuk-Voloshina%26aufirst%3DN.%26atitle%3DA%2520One-Step%2520Fluorometric%2520Method%2520for%2520the%2520Continuous%2520Measurement%2520of%2520Monoamine%2520Oxidase%2520Activity%26jtitle%3DAnal.%2520Biochem.%26date%3D1997%26volume%3D253%26issue%3D2%26spage%3D169%26epage%3D174%26doi%3D10.1006%2Fabio.1997.2392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 11 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wei-Guo Jia, Xue-Ting Zhi, Xiao-Dong Li, Jun-Peng Zhou, Rui Zhong, Haibo Yu, <span class="NLM_string-name hlFld-ContribAuthor">Richmond Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Postsynthetic Modification of Half-Sandwich Ruthenium Complexes by Mechanochemical Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2021,</strong> <em>60 </em>
                                    (7)
                                     , 4313-4321. <a href="https://doi.org/10.1021/acs.inorgchem.1c00059" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.1c00059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.1c00059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.1c00059%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DPostsynthetic%252BModification%252Bof%252BHalf-Sandwich%252BRuthenium%252BComplexes%252Bby%252BMechanochemical%252BSynthesis%26aulast%3DJia%26aufirst%3DWei-Guo%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08012021%26date%3D24032021%26volume%3D60%26issue%3D7%26spage%3D4313%26epage%3D4321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chuan-Fei Jin, Zhi-Zheng Wang, Kang-Zhi Chen, Teng-Fei Xu, <span class="NLM_string-name hlFld-ContribAuthor">Ge-Fei Hao</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 15021-15036. <a href="https://doi.org/10.1021/acs.jmedchem.0c01663" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01663</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01663%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComputational%252BFragment-Based%252BDesign%252BFacilitates%252BDiscovery%252Bof%252BPotent%252Band%252BSelective%252BMonoamine%252BOxidase-B%252B%252528MAO-B%252529%252BInhibitor%26aulast%3DJin%26aufirst%3DChuan-Fei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D23092020%26date%3D19112020%26volume%3D63%26issue%3D23%26spage%3D15021%26epage%3D15036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changjun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yangjing  Lv</span>, <span class="hlFld-ContribAuthor ">Renren  Bai</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Structural exploration of multifunctional monoamine oxidase B inhibitors as potential drug candidates against Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105070. <a href="https://doi.org/10.1016/j.bioorg.2021.105070" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105070%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DStructural%252Bexploration%252Bof%252Bmultifunctional%252Bmonoamine%252Boxidase%252BB%252Binhibitors%252Bas%252Bpotential%252Bdrug%252Bcandidates%252Bagainst%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DZhang%26aufirst%3DChangjun%26date%3D2021%26volume%3D114%26spage%3D105070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tjaša  Mazej</span>, <span class="hlFld-ContribAuthor ">Damijan  Knez</span>, <span class="hlFld-ContribAuthor ">Anže  Meden</span>, <span class="hlFld-ContribAuthor ">Stanislav  Gobec</span>, <span class="hlFld-ContribAuthor ">Matej  Sova</span>. </span><span class="cited-content_cbyCitation_article-title">4-Phenethyl-1-Propargylpiperidine-Derived Dual Inhibitors of Butyrylcholinesterase and Monoamine Oxidase B. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4118. <a href="https://doi.org/10.3390/molecules26144118" title="DOI URL">https://doi.org/10.3390/molecules26144118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144118%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3D4-Phenethyl-1-Propargylpiperidine-Derived%252BDual%252BInhibitors%252Bof%252BButyrylcholinesterase%252Band%252BMonoamine%252BOxidase%252BB%26aulast%3DMazej%26aufirst%3DTja%25C5%25A1a%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Narayan D.  Chaurasiya</span>, <span class="hlFld-ContribAuthor ">Haining  Liu</span>, <span class="hlFld-ContribAuthor ">Robert J.  Doerksen</span>, <span class="hlFld-ContribAuthor ">N. P. Dhammika  Nanayakkara</span>, <span class="hlFld-ContribAuthor ">Larry A.  Walker</span>, <span class="hlFld-ContribAuthor ">Babu L.  Tekwani</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Interactions of Anti-Infective 8-Aminoquinoline Therapeutics with Human Monoamine Oxidases A and B. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (5)
                                     , 398. <a href="https://doi.org/10.3390/ph14050398" title="DOI URL">https://doi.org/10.3390/ph14050398</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14050398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14050398%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DEnantioselective%252BInteractions%252Bof%252BAnti-Infective%252B8-Aminoquinoline%252BTherapeutics%252Bwith%252BHuman%252BMonoamine%252BOxidases%252BA%252Band%252BB%26aulast%3DChaurasiya%26aufirst%3DNarayan%2BD.%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D5%26spage%3D398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Badr  Jismy</span>, <span class="hlFld-ContribAuthor ">Abdelkarim  El Qami</span>, <span class="hlFld-ContribAuthor ">Anja  Pišlar</span>, <span class="hlFld-ContribAuthor ">Rok  Frlan</span>, <span class="hlFld-ContribAuthor ">Janko  Kos</span>, <span class="hlFld-ContribAuthor ">Stanislav  Gobec</span>, <span class="hlFld-ContribAuthor ">Damijan  Knez</span>, <span class="hlFld-ContribAuthor ">Mohamed  Abarbri</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112911. <a href="https://doi.org/10.1016/j.ejmech.2020.112911" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112911</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112911%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimido%25255B1%25252C2-b%25255Dindazole%252Bderivatives%25253A%252BSelective%252Binhibitors%252Bof%252Bhuman%252Bmonoamine%252Boxidase%252BB%252Bwith%252Bneuroprotective%252Bactivity%26aulast%3DJismy%26aufirst%3DBadr%26date%3D2021%26volume%3D209%26spage%3D112911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Derya  OSMANİYE</span>, <span class="hlFld-ContribAuthor ">Yusuf  ÖZKAY</span>. </span><span class="cited-content_cbyCitation_article-title">Potansiyel MAO-B İnhibitörü Olarak Propargil Yan Zinciri İçeren Yeni Bileşiklerin Sentezi ve Karakterizasyonu. </span><span class="cited-content_cbyCitation_journal-name">Bilecik Şeyh Edebali Üniversitesi Fen Bilimleri Dergisi</span><span> <strong>2020,</strong> <em> </em><a href="https://doi.org/10.35193/bseufbd.681580" title="DOI URL">https://doi.org/10.35193/bseufbd.681580</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.35193/bseufbd.681580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.35193%2Fbseufbd.681580%26sid%3Dliteratum%253Aachs%26jtitle%3DBilecik%2520%25C5%259Eeyh%2520Edebali%2520%25C3%259Cniversitesi%2520Fen%2520Bilimleri%2520Dergisi%26atitle%3DPotansiyel%252BMAO-B%252B%2525C4%2525B0nhibit%2525C3%2525B6r%2525C3%2525BC%252BOlarak%252BPropargil%252BYan%252BZinciri%252B%2525C4%2525B0%2525C3%2525A7eren%252BYeni%252BBile%2525C5%25259Fiklerin%252BSentezi%252Bve%252BKarakterizasyonu%26aulast%3DOSMAN%25C4%25B0YE%26aufirst%3DDerya%26date%3D2020%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sai-Sai  Xie</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Chunli  Tang</span>, <span class="hlFld-ContribAuthor ">Chengyun  Pang</span>, <span class="hlFld-ContribAuthor ">Qing  Li</span>, <span class="hlFld-ContribAuthor ">Yuelian  Qin</span>, <span class="hlFld-ContribAuthor ">Xiaojie  Nong</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Jie  Guo</span>, <span class="hlFld-ContribAuthor ">Maojun  Cheng</span>, <span class="hlFld-ContribAuthor ">Weizhong  Tang</span>, <span class="hlFld-ContribAuthor ">Ningsheng  Liang</span>, <span class="hlFld-ContribAuthor ">Neng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>202 </em>, 112475. <a href="https://doi.org/10.1016/j.ejmech.2020.112475" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112475</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112475%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Brasagiline-clorgyline%252Bhybrids%252Bas%252Bnovel%252Bdual%252Binhibitors%252Bof%252Bmonoamine%252Boxidase-B%252Band%252Bamyloid-%2525CE%2525B2%252Baggregation%252Bagainst%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DXie%26aufirst%3DSai-Sai%26date%3D2020%26volume%3D202%26spage%3D112475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca G.  Iacovino</span>, <span class="hlFld-ContribAuthor ">Joana  Reis</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>, <span class="hlFld-ContribAuthor ">Claudia  Binda</span>, <span class="hlFld-ContribAuthor ">Andrea  Mattevi</span>. </span><span class="cited-content_cbyCitation_article-title">Diphenylene Iodonium Is a Noncovalent MAO Inhibitor: A Biochemical and Structural Analysis. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (15)
                                     , 1394-1397. <a href="https://doi.org/10.1002/cmdc.202000264" title="DOI URL">https://doi.org/10.1002/cmdc.202000264</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000264%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDiphenylene%252BIodonium%252BIs%252Ba%252BNoncovalent%252BMAO%252BInhibitor%25253A%252BA%252BBiochemical%252Band%252BStructural%252BAnalysis%26aulast%3DIacovino%26aufirst%3DLuca%2BG.%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D15%26spage%3D1394%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">Jean Jacques  Vanden Eynde</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">CongBao  Kang</span>, <span class="hlFld-ContribAuthor ">Arduino A.  Mangoni</span>, <span class="hlFld-ContribAuthor ">Paola  Fossa</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>, <span class="hlFld-ContribAuthor ">Andrea  Trabocchi</span>, <span class="hlFld-ContribAuthor ">Peter J. H.  Scott</span>, <span class="hlFld-ContribAuthor ">Jóhannes  Reynisson</span>, <span class="hlFld-ContribAuthor ">Simona  Rapposelli</span>, <span class="hlFld-ContribAuthor ">Stefania  Galdiero</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Winum</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Katalin  Prokai-Tatrai</span>, <span class="hlFld-ContribAuthor ">Arun K.  Sharma</span>, <span class="hlFld-ContribAuthor ">Matthieu  Schapira</span>, <span class="hlFld-ContribAuthor ">Yasu-Taka  Azuma</span>, <span class="hlFld-ContribAuthor ">Laura  Cerchia</span>, <span class="hlFld-ContribAuthor ">Mariana  Spetea</span>, <span class="hlFld-ContribAuthor ">Giangiacomo  Torri</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>, <span class="hlFld-ContribAuthor ">Athina  Geronikaki</span>, <span class="hlFld-ContribAuthor ">Alfonso T.  García-Sosa</span>, <span class="hlFld-ContribAuthor ">M. Helena  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">Maria Emília  Sousa</span>, <span class="hlFld-ContribAuthor ">Ivan  Kosalec</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Iola F.  Duarte</span>, <span class="hlFld-ContribAuthor ">Jorge A. R.  Salvador</span>, <span class="hlFld-ContribAuthor ">Massimo  Bertinaria</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>, <span class="hlFld-ContribAuthor ">Jussara  Amato</span>, <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>, <span class="hlFld-ContribAuthor ">Paula A. C.  Gomes</span>, <span class="hlFld-ContribAuthor ">Rita C.  Guedes</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Sabatier</span>, <span class="hlFld-ContribAuthor ">Ana  Estévez-Braun</span>, <span class="hlFld-ContribAuthor ">Bruno  Pagano</span>, <span class="hlFld-ContribAuthor ">Stefano  Mangani</span>, <span class="hlFld-ContribAuthor ">Rino  Ragno</span>, <span class="hlFld-ContribAuthor ">George  Kokotos</span>, <span class="hlFld-ContribAuthor ">Margherita  Brindisi</span>, <span class="hlFld-ContribAuthor ">Florenci V.  González</span>, <span class="hlFld-ContribAuthor ">Fernanda  Borges</span>, <span class="hlFld-ContribAuthor ">Mariarosaria  Miloso</span>, <span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Diego  Muñoz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–7. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (13)
                                     , 2968. <a href="https://doi.org/10.3390/molecules25132968" title="DOI URL">https://doi.org/10.3390/molecules25132968</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25132968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25132968%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBreakthroughs%252Bin%252BMedicinal%252BChemistry%25253A%252BNew%252BTargets%252Band%252BMechanisms%25252C%252BNew%252BDrugs%25252C%252BNew%252BHopes%2525E2%252580%2525937%26aulast%3DG%25C3%25BCtschow%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D13%26spage%3D2968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Damijan  Knez</span>, <span class="hlFld-ContribAuthor ">Izidor  Sosič</span>, <span class="hlFld-ContribAuthor ">Ana  Mitrović</span>, <span class="hlFld-ContribAuthor ">Anja  Pišlar</span>, <span class="hlFld-ContribAuthor ">Janko  Kos</span>, <span class="hlFld-ContribAuthor ">Stanislav  Gobec</span>. </span><span class="cited-content_cbyCitation_article-title">8-Hydroxyquinoline-based anti-Alzheimer multimodal agents. </span><span class="cited-content_cbyCitation_journal-name">Monatshefte für Chemie - Chemical Monthly</span><span> <strong>2020,</strong> <em>151 </em>
                                    (7)
                                     , 1111-1120. <a href="https://doi.org/10.1007/s00706-020-02651-0" title="DOI URL">https://doi.org/10.1007/s00706-020-02651-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00706-020-02651-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00706-020-02651-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMonatshefte%2520f%25C3%25BCr%2520Chemie%2520-%2520Chemical%2520Monthly%26atitle%3D8-Hydroxyquinoline-based%252Banti-Alzheimer%252Bmultimodal%252Bagents%26aulast%3DKnez%26aufirst%3DDamijan%26date%3D2020%26date%3D2020%26volume%3D151%26issue%3D7%26spage%3D1111%26epage%3D1120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Stilbene derivatives and MAO inhibitory potencies. Chemical structures of <i>cis</i>/<i>trans</i>-combretastatin A4 (CA-4) (A) and hit inhibitor <b>1</b> (B) and <i>cis</i> isomer <b>6</b> (B). The stilbene core is blue, and the stilbene-like moiety of inhibitor <b>1</b> is red. (C) <sup>a</sup>IC<sub>50</sub> values are mean ± SEM values (<i>n</i> = 2, 3). <sup>b</sup>Selectivity ratio is defined as IC<sub>50</sub>(hMAO-A)/IC<sub>50</sub>(hMAO-B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Resynthesis of Hit Inhibitor <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 1) Boc<sub>2</sub>O, 1.0 M NaOH, 1,4-dioxane, 0 °C, rt, 1 h (91%); 2) <i>N</i>,<i>O</i>-dimethyhydroxylamine hydrochloride, Et<sub>3</sub>N, TBTU, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, overnight (76%); (ii) LiAlH<sub>4</sub>, anh THF, 0 °C, 1 h (crude product, 83%); (iii) (4-fluorobenzyl)triphenylphosphonium bromide, sodium bis(trimethylsilyl)amide (NaHMDS, 2 N in THF), anh THF, Ar(g), rt, overnight (52%); (iv) (1) 4.0 M HCl in 1,4-dioxane, 80 °C, 2 h (100%); (2) propargyl bromide (80% solution in toluene), Cs<sub>2</sub>CO<sub>3</sub>, DMF, Ar(g), 0 °C, rt, overnight (yield, <b>1</b>, 26%; <b>6</b>, 72%).</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Active sites of hMAO-A (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z5X">2Z5X</a>) and hMAO-B (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FVZ">6FVZ</a>). (A) MAO-A; FAD cofactor (green sticks); active site (red surface) spans from FAD to the entrance; bottleneck residues Leu97, Gly110, and Val210 at the entrance (salmon sticks). (B) MAO-B; FAD cofactor (green sticks); active site (violet surface) spans from FAD to the entrance; bottleneck residues Glu84, Pro102, and Ser200 at the entrance (purple sticks).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Undocking of <i>trans</i> (<b>1</b>) and <i>cis</i> (<b>6</b>) isomers in hMAO-A and hMAO-B. (A) Docked <b>6</b> in hMAO-A: <i>cis</i> isomer (yellow sticks) with propargyl group facing the FAD cofactor (green sticks), with binding energy of −8.3 kcal/mol; bottleneck residues at the active site entrance at the back (salmon sticks). (B) Energy profile for undocking of <b>6</b> from active site of hMAO-A in the correct conformation (propargyl facing FAD). (C) Docked <b>1</b> in hMAO-A: <i>trans</i> isomer (violet sticks) with propargyl group facing the FAD cofactor (green sticks), with binding energy of −6.2 kcal/mol; bottleneck residues at active site entrance at the back (salmon sticks). (D) Energy profile for undocking of <b>1</b> from active site of hMAO-A. (E) Docked <b>6</b> in hMAO-B: <i>cis</i> isomer (gray sticks) with propargyl group facing FAD cofactor (green sticks), with binding energy of −6.5 kcal/mol; bottleneck residues at entrance at the back (violet sticks). (F) Energy profile for undocking of <b>6</b> from active site of hMAO-B. (G) Docked <b>1</b> in hMAO-B: <i>trans</i> isomer (purple sticks) with propargyl group facing FAD cofactor (green sticks), with binding energy of −7.4 kcal/mol; bottleneck residues at entrance at the back (violet sticks). (H) Energy profile for undocking of <b>1</b> from active site of hMAO-B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Inhibitors <b>19</b>–<b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 1) Boc<sub>2</sub>O, 1.0 M NaOH, 1,4-dioxane, 0 °C, rt, 1–3 h (86–91%); (2) <i>N</i>,<i>O</i>-dimethyhydroxylamine hydrochloride, Et<sub>3</sub>N, TBTU, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, overnight (76–82%); (ii) LiAlH<sub>4</sub>, anh THF, 0 °C, 1–2 h (crude products, 79–83%); (iii) corresponding Wittig salts ((4-fluorobenzyl)triphenylphosphonium bromide or (2,4,5-trifluorobenzyl)triphenylphosphonium bromide), NaHMDS (2 N in THF), anh THF, Ar(g), rt, overnight (overall yield for both isomers combined, 47–56%); (iv) corresponding mixture of <i>cis</i> and <i>trans</i> isomer (<b>9</b>–<b>14</b>), H<sub>2</sub>(g), Pd/C, EtOH, rt, overnight (97–100%); (v) (1) 4.0 M HCl in 1,4-dioxane, 80 °C, 2 h (100%); (2) propargyl bromide (80% solution in toluene), Cs<sub>2</sub>CO<sub>3</sub>, DMF, Ar(g), 0 °C, rt, overnight (26–85%).</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Inhibitors <b>67</b>–<b>107</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) benzyl halide, PPh<sub>3</sub>, MeCN, 85 °C, overnight (80–97%); (ii) corresponding Wittig salts (<b>27a</b>–<b>l</b>), NaHMDS (2 N in THF)/KHMDS (0.5 M in toluene), anh THF, Ar(g), rt, overnight (overall yield, 30–66%); (iii) mixture of <i>cis</i> and <i>trans</i> isomers (<b>28</b>–<b>55</b>), H<sub>2</sub>(g), Pd/C, EtOH, rt, overnight (83–100%); (iv) (1) 4.0 M HCl in 1,4-dioxane (or HCl in EtOH), 80 °C, 2 h (100%); (2) propargyl bromide (80% in toluene), K<sub>2</sub>CO<sub>3</sub>, MeCN, Ar(g), 0 °C, rt, overnight (6–89%); (v) cyclopropylboronic acid, K<sub>3</sub>PO<sub>4</sub>, tricyclohexylphosphine (20% in toluene), Pd(OAc)<sub>2</sub>, toluene, water, Ar(g), 100 °C, 3 h (78%); (vi) KOH, <i>t</i>BuOH, 90 °C, 12–24 h (42–63%); (vii) BBr<sub>3</sub> (1 M in CH<sub>2</sub>Cl<sub>2</sub>), toluene, Ar(g), – 20 °C, 1 h, rt, 1 h (57%).</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crucial observations regarding SARs of the stilbene-like MAO inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. UV–vis absorption spectra of the hMAO enzymes after FAD cofactor modification by irreversible covalent inhibitors. The oxidized enzyme (10 μM) before inhibitor addition (100 μM) is shown as the continuous black line, whereas the gray profile indicates the final spectrum (i.e., no further changes were observed), which was reached at different times depending on the inhibitor. The intermediate spectra are shown as either dotted or dashed lines. (A) hMAO-A and <b>69</b>; (B) hMAO-B and <b>84</b>; (C) hMAO-B and <b>1</b>; (D) hMAO-B and <b>97</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Crystal structures of the active site of hMAO-B-inhibitor complexes. The hMAO-B active site cavity is shown as a gray semitransparent surface, which is lined by the protein residues (represented in cyan). Water molecules are red spheres, and hydrogen bonds are dashed lines. The FAD cofactor is in yellow stick representation. The inhibitor molecule bound in the hMAO-B active site cavity is shown as sticks, with carbon, nitrogen, and fluorine in magenta, blue, and black, respectively. The refined 2<i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> electron density map contoured at 1.2σ is shown in blue for the inhibitor and the FAD molecules. (A) Active site of hMAO-B in complex with <b>1</b> (2.3 Å resolution; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKB">6RKB</a>). (B) Active site of hMAO-B in complex with <b>84</b> (1.7 Å resolution; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKP">6RKP</a>). (C) Active site of hMAO-B in complex with <b>97</b> (2.3 Å resolution; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RLE">6RLE</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structural superposition to highlight differences and common features in the binding modes of the hMAO-B inhibitors. The protein, inhibitor, and cofactor atoms are represented as sticks (color code as in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> except for the carbon atoms of protein and inhibitor molecules, which are depicted accordingly to distinguish the different structures). For clarity, only Cys172 and Tyr188 of the protein active site residues are shown, which undergo some conformational changes. (A) Superposition of structures in complex with <b>84</b> (green), safinamide (gray) and <span class="smallcaps smallerCapital">l</span>-deprenyl (pink). (B) Superposition of structures in complex with <b>84</b> (green) and <b>97</b> (light gray).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of inhibitors on 6-OHDA-induced cell death in SH-SY5Y cells. (A, B) SH-SY5Y cells were pretreated with the compounds (5 μM) for 30 min (as indicated) and then treated with 6-OHDA (100 μM). After 24 h, LDH assays (A) and PI staining (B) were performed. Data are mean values ± standard deviation (<i>n</i> ≥ 2; each in duplicate): ∗, <i>p</i> < 0.05 (one-way ANOVA, with Bonferroni correction, followed by <i>t</i>-tests).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/medium/jm9b01886_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <i>In vivo</i> evaluation in mice of antidepressant-like activity of the selective MAO-A inhibitors <b>6</b>, <b>67</b>, and <b>69</b>. (A) Effects of acute ip treatment with <b>6</b> (3, 10 mg/kg, <i>n</i> = 13, 9), <b>67</b> (3, 10 mg/kg, <i>n</i> = 6, 10), and <b>69</b> (1, 3, 10, 30 mg/kg, <i>n</i> = 8, 7, 8, 6) and imipramine (30 mg/kg, <i>n</i> = 8) in the tail suspension test. Data are mean values ± SEM of immobility time in comparison to control mice (SAL, <i>n</i> = 23): ∗, <i>p</i> < 0.05; ∗∗∗, <i>p</i> < 0.001 (one-way ANOVA, followed by Dunnett’s tests). (B) Effects of acute ip treatment with <b>6</b> (3, 10 mg/kg, <i>n</i> = 8, 8), <b>67</b> (1, 3, 6 mg/kg; <i>n</i> = 5, 5, 5), and <b>69</b> (1, 3, 6 mg/kg, <i>n</i> = 10, 5, 5) on locomotor activity of the mice. Data are mean values ± SEM of spontaneous locomotor activity counts recorded in 5 min sessions: ∗∗∗, <i>p</i> < 0.001 (one-way ANOVA, followed by Dunnett’s tests). (C) Effects of 10-day chronic ip treatment with <b>69</b> (0.3 mg/kg, daily; <i>n</i> = 10) in the tail suspension test. Data are mean values ± SEM of the immobility time, compared to control mice (<i>n</i> = 8): ∗∗, <i>p</i> < 0.01 (unpaired <i>t</i>-test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-3/acs.jmedchem.9b01886/20200207/images/large/jm9b01886_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01886&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i127">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43011" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43011" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Persch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumele, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span> <span> </span><span class="NLM_article-title">Molecular Recognition in Chemical and Biological Systems</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3290</span>– <span class="NLM_lpage">3327</span>, <span class="refDoi"> DOI: 10.1002/anie.201408487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1002%2Fanie.201408487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslCitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=3290-3327&issue=11&author=E.+Perschauthor=O.+Dumeleauthor=F.+Diederich&title=Molecular+Recognition+in+Chemical+and+Biological+Systems&doi=10.1002%2Fanie.201408487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition in Chemical and Biological Systems</span></div><div class="casAuthors">Persch, Elke; Dumele, Oliver; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3290-3327</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Structure-based ligand design in medicinal chem. and crop protection relies on the identification and quantification of weak noncovalent interactions and understanding the role of water.  Small-mol. and protein structural database searches are important tools to retrieve existing knowledge.  Thermodn. profiling, combined with x-ray structural and computational studies, is the key to elucidate the energetics of the replacement of water by ligands.  Biol. receptor sites vary greatly in shape, conformational dynamics, and polarity, and require different ligand-design strategies, as shown for various case studies.  Interactions between dipoles have become a central theme of mol. recognition.  Orthogonal interactions, halogen bonding, and amide···π stacking provide new tools for innovative lead optimization.  The combination of synthetic models and biol. complexation studies is required to gather reliable information on weak noncovalent interactions and the role of water.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCPoHWAmEzr7Vg90H21EOLACvtfcHk0lgEYjIsdJnNfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslCitbY%253D&md5=6cc7102842c1e16e4a64352214f038b7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fanie.201408487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201408487%26sid%3Dliteratum%253Aachs%26aulast%3DPersch%26aufirst%3DE.%26aulast%3DDumele%26aufirst%3DO.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DMolecular%2520Recognition%2520in%2520Chemical%2520and%2520Biological%2520Systems%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26issue%3D11%26spage%3D3290%26epage%3D3327%26doi%3D10.1002%2Fanie.201408487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasprzyk-Hordern, B.</span></span> <span> </span><span class="NLM_article-title">Pharmacologically Active Compounds in the Environment and Their Chirality</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4466</span>– <span class="NLM_lpage">4503</span>, <span class="refDoi"> DOI: 10.1039/c000408c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1039%2Fc000408c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=20852776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlShtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=4466-4503&issue=11&author=B.+Kasprzyk-Hordern&title=Pharmacologically+Active+Compounds+in+the+Environment+and+Their+Chirality&doi=10.1039%2Fc000408c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologically active compounds in the environment and their chirality</span></div><div class="casAuthors">Kasprzyk-Hordern, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4466-4503</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Pharmacol. active compds. including both legally used pharmaceuticals and illicit drugs are potent environmental contaminants.  Extensive research has been undertaken over the recent years to understand their environmental fate and toxicity.  The one very important phenomenon that has been overlooked by environmental researchers studying the fate of pharmacol. active compds. in the environment is their chirality.  Chiral drugs can exist in the form of enantiomers, which have similar physicochem. properties but differ in their biol. properties such as distribution, metab. and excretion, as these processes (due to stereospecific interactions of enantiomers with biol. systems) usually favor one enantiomer over the other.  Addnl., due to different pharmacol. activity, enantiomers of chiral drugs can differ in toxicity.  Furthermore, degrdn. of chiral drugs during wastewater treatment and in the environment can be stereoselective and can lead to chiral products of varied toxicity.  The distribution of different enantiomers of the same chiral drug in the aquatic environment and biota can also be stereoselective.  Biol. processes can lead to stereoselective enrichment or depletion of the enantiomeric compn. of chiral drugs.  As a result the very same drug might reveal different activity and toxicity and this will depend on its origin and exposure to several factors governing its fate in the environment.  In this crit. review a discussion of the importance of chirality of pharmacol. active compds. in the environmental context is undertaken and suggestions for directions in further research are made.  Several groups of chiral drugs of major environmental relevance are discussed and their pharmacol. action and disposition in the body is also outlined as it is a key factor in developing a full understanding of their environmental occurrence, fate and toxicity.  This review will be of interest to environmental scientists, esp. those interested in issues assocd. with environmental contamination with pharmacol. active compds. and chiral pollutants.  As the review will outline current state of knowledge on chiral drugs, it will be of value to anyone interested in the phenomenon of chirality, chiral drugs, their stereoselective disposition in the body and environmental fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFRoN4-pwcmLVg90H21EOLACvtfcHk0lgEYjIsdJnNfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlShtb3J&md5=8fe00731e6fc2763aec5869cd12f3b3c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1039%2Fc000408c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc000408c%26sid%3Dliteratum%253Aachs%26aulast%3DKasprzyk-Hordern%26aufirst%3DB.%26atitle%3DPharmacologically%2520Active%2520Compounds%2520in%2520the%2520Environment%2520and%2520Their%2520Chirality%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2010%26volume%3D39%26issue%3D11%26spage%3D4466%26epage%3D4503%26doi%3D10.1039%2Fc000408c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, K. G.</span></span> <span> </span><span class="NLM_article-title">The Significance of Chirality in Drug Design and Development</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.2174/156802611795165098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.2174%2F156802611795165098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=21291399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=760-770&issue=7&author=W.+H.+Brooksauthor=W.+C.+Guidaauthor=K.+G.+Daniel&title=The+Significance+of+Chirality+in+Drug+Design+and+Development&doi=10.2174%2F156802611795165098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The significance of chirality in drug design and development</span></div><div class="casAuthors">Brooks, W. H.; Guida, W. C.; Daniel, K. G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">760-770</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteins are often enantioselective towards their binding partners.  When designing small mols. to interact with these targets, one should consider stereoselectivity.  As considerations for exploring structure space evolve, chirality is increasingly important.  Binding affinity for a chiral drug can differ for diastereomers and between enantiomers.  For the virtual screening and computational design stage of drug development, this problem can be compounded by incomplete stereochem. information in structure libraries leading to a "coin toss" as to whether or not the "ideal" chiral structure is present.  Creating every stereoisomer for each chiral compd. in a structure library leads to an exponential increase in the no. of structures resulting in potentially unmanageable file sizes and screening times.  Therefore, only key chiral structures, enantiomeric pairs based on relative stereochem. need be included, and lead to a compromise between exploration of chem. space and maintaining manageable libraries.  In clin. environments, enantiomers of chiral drugs can have reduced, no, or even deleterious effects.  This underscores the need to avoid mixts. of compds. and focus on chiral synthesis.  Governmental regulations emphasizing the need to monitor chirality in drug development have increased.  The United States Food and Drug Administration issued guidelines and policies in 1992 concerning the development of chiral compds.  These guidelines require that abs. stereochem. be known for compds. with chiral centers and that this information should be established early in drug development in order that the anal. can be considered valid.  From exploration of structure space to governmental regulations it is clear that the question of chirality in drug design is of vital importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4TgZ0W1QUdrVg90H21EOLACvtfcHk0lgEYjIsdJnNfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D&md5=eb78aca17518a7fd04d8cfc3c5d0ec78</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F156802611795165098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795165098%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DW.%2BH.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DDaniel%26aufirst%3DK.%2BG.%26atitle%3DThe%2520Significance%2520of%2520Chirality%2520in%2520Drug%2520Design%2520and%2520Development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26issue%3D7%26spage%3D760%26epage%3D770%26doi%3D10.2174%2F156802611795165098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nafisi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norouzi, Z.</span></span> <span> </span><span class="NLM_article-title">A Comparative Study on the Interaction of <i>Cis</i>- and <i>Trans</i>-Platin with DNA and RNA</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1089/dna.2009.0894</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1089%2Fdna.2009.0894" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=19558218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVCgu7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=469-477&issue=9&author=S.+Nafisiauthor=Z.+Norouzi&title=A+Comparative+Study+on+the+Interaction+of+Cis-+and+Trans-Platin+with+DNA+and+RNA&doi=10.1089%2Fdna.2009.0894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Comparative Study on the Interaction of Cis- and Trans-Platin with DNA and RNA</span></div><div class="casAuthors">Nafisi, Shohreh; Norouzi, Zeinab</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">469-477</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Cis-diamminedichloroplatinum(II) is a frequently used and very effective chemotherapeutic drug for treatment of various malignancies; however, the trans isomer is clin. ineffective.  Cis-platin exerts its antitumor activity by binding to DNA via intrastrand cross-links to d(GpG) (dG = deoxyguanosine) and to d(ApG) (dA = deoxyadenosine), interfering with DNA replication and transcription and causing cell death.  The trans-diamminedichloroplatinum(II) isomer also binds DNA, but is clin. ineffective.  This study was designed to examine the interactions of cis- and trans-platin with calf thymus DNA and yeast RNA in aq. soln. at physiol. conditions, using a const. DNA and RNA concn. (6.25 mM) and various platin salts/polynucleotide (phosphate) ratios of 1/100, 1/50, 1/25, and 1/12.5.  Fourier transform IR, UV-visible spectroscopic methods were used to det. the drug binding modes, the binding consts., and the stability of cis- and trans-platin-DNA and -RNA complexes in aq. soln.  Spectroscopic evidence showed that cis- and trans-platin bind to the major and minor grooves of DNA (via G, A, T, and C bases), while RNA binding is through G, U, A, and C bases with some degree of the pt-phosphate (PO2) interaction for both isomers and overall binding consts. of K(cis-platin-DNA) = 5.51 × 104 M-1, K(trans-platin-DNA) = 2.26 × 104 M-1, K(cis-platin-RNA) = 1.9 × 104 M-1, and K(trans-platin-RNA) = 1.75 × 104 M-1.  DNA and RNA aggregations occurred at high platin concns.  No biopolymer conformational changes were obsd. upon cis- and trans-platin interactions, while DNA remains in the B-family, and RNA retains its A-family structure.  The order of platin compd.-polymer stability was cis-platin-DNA > trans-platin-DNA > cis-platin-RNA > trans-platin-RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGNCiLGNn_0rVg90H21EOLACvtfcHk0ljSRJ5_6a2aEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVCgu7fJ&md5=2b70fd7fb46601328c7e206e0f31f599</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1089%2Fdna.2009.0894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2009.0894%26sid%3Dliteratum%253Aachs%26aulast%3DNafisi%26aufirst%3DS.%26aulast%3DNorouzi%26aufirst%3DZ.%26atitle%3DA%2520Comparative%2520Study%2520on%2520the%2520Interaction%2520of%2520Cis-%2520and%2520Trans-Platin%2520with%2520DNA%2520and%2520RNA%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2009%26volume%3D28%26issue%3D9%26spage%3D469%26epage%3D477%26doi%3D10.1089%2Fdna.2009.0894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorke, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen Antiestrogens. A Comparison of the Activity, Pharmacokinetics, and Metabolic Activation of the <i>Cis</i> and <i>Trans</i> Isomers of Tamoxifen</span>. <i>J. Steroid Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/0022-4731(82)90137-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2F0022-4731%2882%2990137-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=7062732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADyaL38XktFOgur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1982&pages=1-13&issue=1&author=D.+W.+Robertsonauthor=J.+A.+Katzenellenbogenauthor=D.+J.+Longauthor=E.+A.+Rorkeauthor=B.+S.+Katzenellenbogen&title=Tamoxifen+Antiestrogens.+A+Comparison+of+the+Activity%2C+Pharmacokinetics%2C+and+Metabolic+Activation+of+the+Cis+and+Trans+Isomers+of+Tamoxifen&doi=10.1016%2F0022-4731%2882%2990137-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen antiestrogens.  A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen</span></div><div class="casAuthors">Robertson, David W.; Katzenellenbogen, John A.; Long, Deborah J.; Rorke, Ellen A.; Katzenellenbogen, Benita S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JSTBBK</span>;
        ISSN:<span class="NLM_cas:issn">0022-4731</span>.
    </div><div class="casAbstract">In immature rats 3H-labeled trans-tamoxifen (trans-I)  [10540-29-1] was a partial agonist-partial antagonist of estrogen in terms of uterine wt. stimulation, whereas cis-I  [13002-65-8] was a pure agonist.  Both isomers gave little stimulation of uterine peroxidase  [9003-99-0], and only trans-I was able to inhibit peroxidase stimulation by estradiol.  After administration of trans-I-3H to rats in vivo, trans-hydroxytamoxifen  [68047-06-3] and a yet more polar metabolite accumulated in the uterine nuclear fraction.  With cis-I-3H, there was no accumulation of these metabolites in the uterus; in the nuclear and cytosolic fractions, there were slightly less and more polar metabolites, resp.  There was no evidence of isomerization of I or hydroxytamoxifen.  In in vitro incubations with rat liver microsomes, both trans- and cis-I-3H underwent hydroxylation and to a lesser extent demethylation.  Thus, the selective accumulation of trans-hydroxytamoxifen in the uterus apparently results from its greater affinity for the estrogen receptor (285% vs. estradiol = 100%) relative to that of cis-hydroxytamoxifen [174592-47-3] (5%).  The different metabolites that accumulate in the uterus following treatment with trans- or cis-I may account for their different agonist-antagonist character.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7buf-wRj6ibVg90H21EOLACvtfcHk0ljSRJ5_6a2aEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XktFOgur0%253D&md5=b88af914fc2822bb745eb337f75dcde9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0022-4731%2882%2990137-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-4731%252882%252990137-6%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DD.%2BW.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DLong%26aufirst%3DD.%2BJ.%26aulast%3DRorke%26aufirst%3DE.%2BA.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26atitle%3DTamoxifen%2520Antiestrogens.%2520A%2520Comparison%2520of%2520the%2520Activity%252C%2520Pharmacokinetics%252C%2520and%2520Metabolic%2520Activation%2520of%2520the%2520Cis%2520and%2520Trans%2520Isomers%2520of%2520Tamoxifen%26jtitle%3DJ.%2520Steroid%2520Biochem.%26date%3D1982%26volume%3D16%26issue%3D1%26spage%3D1%26epage%3D13%26doi%3D10.1016%2F0022-4731%2882%2990137-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of <i>Cis</i>- and <i>Trans</i>-Combretastatin Binding to Tubulin</span>. <i>Chem-US</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1016/j.chempr.2016.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.chempr.2016.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ojsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=102-113&issue=1&author=R.+Gaspariauthor=A.+E.+Protaauthor=K.+Bargstenauthor=A.+Cavalliauthor=M.+O.+Steinmetz&title=Structural+Basis+of+Cis-+and+Trans-Combretastatin+Binding+to+Tubulin&doi=10.1016%2Fj.chempr.2016.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of cis- and trans-Combretastatin Binding to Tubulin</span></div><div class="casAuthors">Gaspari, Roberto; Prota, Andrea E.; Bargsten, Katja; Cavalli, Andrea; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Chem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-113</span>CODEN:
                <span class="NLM_cas:coden">CHEMVE</span>;
        ISSN:<span class="NLM_cas:issn">2451-9294</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Combretastatin A4 (CA-4) derivs. are microtubule-destabilizing agents, some of which are in advanced clin. trials for cancer therapy.  The active cis conformation of CA-4 can readily isomerize into a thermodynamically more stable but significantly less active trans form.  Here, we solved the high-resoln. crystal structure of cis-CA-4 in complex with tubulin.  The compd. binds to the colchicine site of tubulin and displays both common and distinct interaction points with colchicine.  Using metadynamics simulations, we generated the trans form of the ligand within its binding site and computed the relative binding free energy of the cis-CA-4 and trans-CA-4 isomers via a thermodn. cycle.  The calcns. suggest structural distortions of the bound trans-CA-4 mol. as the likely cause of its reduced activity in comparison with that of its cis isomer.  Our findings could open up unique possibilities for structure-guided drug engineering with the aim of discovering combretastatin variants with improved chem. properties and pharmacol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTIALJ_hR7a7Vg90H21EOLACvtfcHk0lgEokb4SpLh3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ojsb8%253D&md5=0225f4aa6700d7f99923d0e2b7997dc1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.chempr.2016.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chempr.2016.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DGaspari%26aufirst%3DR.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DStructural%2520Basis%2520of%2520Cis-%2520and%2520Trans-Combretastatin%2520Binding%2520to%2520Tubulin%26jtitle%3DChem-US%26date%3D2017%26volume%3D2%26issue%3D1%26spage%3D102%26epage%3D113%26doi%3D10.1016%2Fj.chempr.2016.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bembenek, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeburg, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J. C.</span></span> <span> </span><span class="NLM_article-title">Cdna Cloning of Human Liver Monoamine Oxidase A and B: Molecular Basis of Differences in Enzymatic Properties</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4934</span>– <span class="NLM_lpage">4938</span>, <span class="refDoi"> DOI: 10.1073/pnas.85.13.4934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1073%2Fpnas.85.13.4934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=3387449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADyaL1MXhtV2hs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1988&pages=4934-4938&issue=13&author=A.+W.+Bachauthor=N.+C.+Lanauthor=D.+L.+Johnsonauthor=C.+W.+Abellauthor=M.+E.+Bembenekauthor=S.+W.+Kwanauthor=P.+H.+Seeburgauthor=J.+C.+Shih&title=Cdna+Cloning+of+Human+Liver+Monoamine+Oxidase+A+and+B%3A+Molecular+Basis+of+Differences+in+Enzymatic+Properties&doi=10.1073%2Fpnas.85.13.4934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">cDNA cloning of human liver monoamine oxidase A and B:  molecular basis of differences in enzymic properties</span></div><div class="casAuthors">Bach, Alfred W. J.; Lan, Nancy C.; Johnson, Deborah L.; Abell, Creed W.; Bembenek, Michael E.; Kwan, Sau Wah; Seeburg, Peter H.; Shih, Jean C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4934-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The monoamine oxidases play a vital role in the metab. of biogenic amines in the central nervous system and in peripheral tissues.  Oligonucleotide probes derived from three sequenced peptide fragments were used to isolate cDNA clones that encode the A and B forms of monoamine oxidase.  The nucleotide sequences of these cDNAs were detd.  Comparison of the deduced amino acid sequences shows that the A and B forms have subunit mol. wts. of 59,700 and 58,800, resp., and have 70% sequence identity.  Both sequences contain the pentapeptide Ser-Gly-Gly-Cys-Tyr, in which the obligatory cofactor FAD is covalently bound to cysteine.  Based on differences in primary amino acid sequences and RNA gel blot anal. of mRNAs, the A and B forms of monoamine oxidase appear to be derived from sep. genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UdSC3-Af4rVg90H21EOLACvtfcHk0lgEokb4SpLh3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhtV2hs7Y%253D&md5=2b699f8c1d71214ee769d8b7bfb33501</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.85.13.4934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.85.13.4934%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DA.%2BW.%26aulast%3DLan%26aufirst%3DN.%2BC.%26aulast%3DJohnson%26aufirst%3DD.%2BL.%26aulast%3DAbell%26aufirst%3DC.%2BW.%26aulast%3DBembenek%26aufirst%3DM.%2BE.%26aulast%3DKwan%26aufirst%3DS.%2BW.%26aulast%3DSeeburg%26aufirst%3DP.%2BH.%26aulast%3DShih%26aufirst%3DJ.%2BC.%26atitle%3DCdna%2520Cloning%2520of%2520Human%2520Liver%2520Monoamine%2520Oxidase%2520A%2520and%2520B%253A%2520Molecular%2520Basis%2520of%2520Differences%2520in%2520Enzymatic%2520Properties%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1988%26volume%3D85%26issue%3D13%26spage%3D4934%26epage%3D4938%26doi%3D10.1073%2Fpnas.85.13.4934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Colibus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span> <span> </span><span class="NLM_article-title">Three-Dimensional Structure of Human Monoamine Oxidase A (Mao A): Relation to the Structures of Rat MAO A and Human MAO B</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">12684</span>– <span class="NLM_lpage">12689</span>, <span class="refDoi"> DOI: 10.1073/pnas.0505975102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1073%2Fpnas.0505975102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=16129825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWktLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=12684-12689&issue=36&author=L.+De%0AColibusauthor=M.+Liauthor=C.+Bindaauthor=A.+Lustigauthor=D.+E.+Edmondsonauthor=A.+Mattevi&title=Three-Dimensional+Structure+of+Human+Monoamine+Oxidase+A+%28Mao+A%29%3A+Relation+to+the+Structures+of+Rat+MAO+A+and+Human+MAO+B&doi=10.1073%2Fpnas.0505975102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B</span></div><div class="casAuthors">De Colibus, Luigi; Li, Min; Binda, Claudia; Lustig, Ariel; Edmondson, Dale E.; Mattevi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">12684-12689</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The 3-dimensional x-ray crystal structure of recombinant human monoamine oxidase A (hMAO A) as its clorgyline-inhibited adduct is described.  Although the chain-fold of hMAO A was similar to that of rat MAO A and human MAO B (hMAO B), hMAO A was unique in that it crystd. as a monomer and exhibited the soln. hydrodynamic behavior of a monomeric form rather than the dimeric form of hMAO B and rat MAO A.  The hMAO A active site consisted of a single hydrophobic cavity of ∼550 Å3, which was smaller than that detd. from the structure of deprenyl-inhibited hMAO B (∼700 Å3) but larger than that of rat MAO A (∼450 Å3).  An important component of the active site structure of hMAO A was the loop conformation of residues 210-216, which differred from that of hMAO B and rat MAO A.  The origin of this structural alteration was suggested to have resulted from long-range interactions in the monomeric form of the enzyme.  In addn. to serving as a basis for the development of hMAO A-specific inhibitors, these data supported the proposal that hMAO A involves a change from the dimeric to the monomeric form through a E151K mutation that is specific to hMAO A.  These considerations place into question the use of MAO A from non-human sources in drug development for use in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPY_EaAsj_1rVg90H21EOLACvtfcHk0lgWPWGEdEnyIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWktLnJ&md5=5db5a50007df0a15df8cbfbc72670de9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0505975102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0505975102%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BColibus%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DLustig%26aufirst%3DA.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26aulast%3DMattevi%26aufirst%3DA.%26atitle%3DThree-Dimensional%2520Structure%2520of%2520Human%2520Monoamine%2520Oxidase%2520A%2520%2528Mao%2520A%2529%253A%2520Relation%2520to%2520the%2520Structures%2520of%2520Rat%2520MAO%2520A%2520and%2520Human%2520MAO%2520B%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26issue%3D36%26spage%3D12684%26epage%3D12689%26doi%3D10.1073%2Fpnas.0505975102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milczek, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D. E.</span></span> <span> </span><span class="NLM_article-title">The ’Gating’ Residues Ile199 and Tyr326 in Human Monoamine Oxidase B Function in Substrate and Inhibitor Recognition</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">4860</span>– <span class="NLM_lpage">4869</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2011.08386.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1111%2Fj.1742-4658.2011.08386.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=21978362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1antrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=4860-4869&issue=24&author=E.+M.+Milczekauthor=C.+Bindaauthor=S.+Rovidaauthor=A.+Matteviauthor=D.+E.+Edmondson&title=The+%E2%80%99Gating%E2%80%99+Residues+Ile199+and+Tyr326+in+Human+Monoamine+Oxidase+B+Function+in+Substrate+and+Inhibitor+Recognition&doi=10.1111%2Fj.1742-4658.2011.08386.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The gating residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition</span></div><div class="casAuthors">Milczek, Erika M.; Binda, Claudia; Rovida, Stefano; Mattevi, Andrea; Edmondson, Dale E.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4860-4869</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The major structural difference between human monoamine oxidases A (MAO A) and B (MAO B) is that MAO A has a monopartite substrate cavity of ∼550 Å3 vol. and MAO B contains a dipartite cavity structure with vols. of ∼290 Å3 (entrance cavity) and ∼400 Å3 (substrate cavity).  The Ile-199 and Tyr-326 side-chains sep. these 2 cavities in MAO B.  To probe the function of these gating residues, I199A and I199A/Y326A mutant forms of MAO B were investigated.  Structural data on the I199A MAO B mutant showed no alterations in active site geometries compared with the wild-type enzyme while the I199A/Y326A MAO B mutant exhibited alterations in residues 100-103 which were part of the loop gating the entrance to the active site.  Both mutant enzymes exhibited catalytic properties with increased amine Km but unaltered kcat values.  The altered Km values on mutation were attributed to the influence of the cavity structure in the binding and subsequent deprotonation of the amine substrate.  Both mutant enzymes exhibited weaker binding affinities relative to the wild-type enzyme for small reversible inhibitors.  I199A MAO B exhibited an increase in binding affinity for reversible MAO B-specific inhibitors which bridged both cavities.  The I199A/Y326A double mutant exhibited inhibitor binding properties more similar to those of MAO A than to MAO B.  These results demonstrated that the bipartite cavity structure in MAO B plays an important role in substrate and inhibitor recognition to distinguish its specificities from those of MAO A and provides insights into specific reversible inhibitor design for these membrane-bound enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeXi4q0VP7f7Vg90H21EOLACvtfcHk0lgWPWGEdEnyIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1antrbL&md5=66e480131b37dc3f025167d0d70d9959</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2011.08386.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2011.08386.x%26sid%3Dliteratum%253Aachs%26aulast%3DMilczek%26aufirst%3DE.%2BM.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DRovida%26aufirst%3DS.%26aulast%3DMattevi%26aufirst%3DA.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26atitle%3DThe%2520%25E2%2580%2599Gating%25E2%2580%2599%2520Residues%2520Ile199%2520and%2520Tyr326%2520in%2520Human%2520Monoamine%2520Oxidase%2520B%2520Function%2520in%2520Substrate%2520and%2520Inhibitor%2520Recognition%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26issue%3D24%26spage%3D4860%26epage%3D4869%26doi%3D10.1111%2Fj.1742-4658.2011.08386.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span> <span> </span><span class="NLM_article-title">Molecular Aspects of Monoamine Oxidase B</span>. <i>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.pnpbp.2016.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.pnpbp.2016.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=26891670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlKhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2016&pages=81-89&author=R.+R.+Ramsay&title=Molecular+Aspects+of+Monoamine+Oxidase+B&doi=10.1016%2Fj.pnpbp.2016.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular aspects of monoamine oxidase B</span></div><div class="casAuthors">Ramsay, Rona R.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">81-89</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Monoamine oxidases (MAO) influence the monoamine levels in brain by virtue of their role in neurotransmitter breakdown.  MAO B is the predominant form in glial cells and in platelets.  MAO B structure, function and kinetics are described as a background for the effect of alterations in its activity on behavior.  The need to inhibit MAO B to combat decreased brain amines continues to drive the search for new drugs.  Reversible and irreversible inhibitors are now designed using data-mining, computational screening, docking and mol. dynamics.  Multi-target ligands designed to combat the elevated activity of MAO B in Alzheimer's and Parkinson's Diseases incorporate MAO inhibition (usually irreversible) as well as iron chelation, antioxidant or neuroprotective properties.  The main focus of drug design is the catalytic activity of MAO, but the imidazoline I2 site in the entrance cavity of MAO B is also a pharmacol. target.  Endogenous regulation of MAO B expression is discussed briefly in light of new studies measuring mRNA, protein, or activity in healthy and degenerative samples, including the effect of DNA methylation on the expression.  Overall, this review focuses on examples of recent research on the mol. aspects of the expression, activity, and inhibition of MAO B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWqBth0WA0EbVg90H21EOLACvtfcHk0lgWPWGEdEnyIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlKhurw%253D&md5=53857d746ee164dcc74469832516a0cd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2016.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2016.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26atitle%3DMolecular%2520Aspects%2520of%2520Monoamine%2520Oxidase%2520B%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2016%26volume%3D69%26spage%3D81%26epage%3D89%26doi%3D10.1016%2Fj.pnpbp.2016.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albreht, A.</span></span> <span> </span><span class="NLM_article-title">Kinetics, Mechanism, and Inhibition of Monoamine Oxidase</span>. <i>J. Neural Transm. (Vienna)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1659</span>– <span class="NLM_lpage">1683</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1861-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1007%2Fs00702-018-1861-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=29516165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BC1MrovVegsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1659-1683&issue=11&author=R.+R.+Ramsayauthor=A.+Albreht&title=Kinetics%2C+Mechanism%2C+and+Inhibition+of+Monoamine+Oxidase&doi=10.1007%2Fs00702-018-1861-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics, mechanism, and inhibition of monoamine oxidase</span></div><div class="casAuthors">Ramsay Rona R; Albreht Alen; Albreht Alen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission (Vienna, Austria : 1996)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1659-1683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Monoamine oxidases (MAOs) catalyse the oxidation of neurotransmitter amines and a wide variety of primary, secondary and tertiary amine xenobiotics, including therapeutic drugs.  While inhibition of MAO activity in the periphery removes protection from biogenic amines and so is undesirable, inhibition in the brain gives vital antidepressant and behavioural advantages that make MAO a major pharmaceutical target for inhibitor design.  In neurodegenerative diseases, MAO inhibitors can help to maintain neurotransmitter levels, making it a common feature in novel multi-target combinations designed to combat Alzheimer's disease, albeit not yet proven clinically.  Vital information for inhibitor design comes from an understanding of the structure, mechanism, and kinetics of the catalyst.  This review will summarize the kinetic behaviour of MAO A and B and the kinetic evaluation of reversible inhibitors that transiently decrease catalysis.  Kinetic parameters and crystal structures have enabled computational approaches to ligand discovery and validation of hits by docking.  Kinetics and a wide variety of substrates and inhibitors along with theoretical modelling have also contributed to proposed schemes for the still debated chemical mechanism of amine oxidation.  However, most of the marketed MAO drugs are long-lasting irreversible inactivators.  The mechanism of irreversible inhibition by hydrazine, cyclopropylamine, and propargylamine drugs will be discussed.  The article finishes with some examples of the propargylamine moiety in multi-target ligand design to combat neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDjJ7nVDp8seLt9HypzAgQfW6udTcc2eafD9wFdAfioLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrovVegsQ%253D%253D&md5=6562f2d88d8febadcfe0fe83bb687805</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1861-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1861-9%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DAlbreht%26aufirst%3DA.%26atitle%3DKinetics%252C%2520Mechanism%252C%2520and%2520Inhibition%2520of%2520Monoamine%2520Oxidase%26jtitle%3DJ.%2520Neural%2520Transm.%2520%2528Vienna%2529%26date%3D2018%26volume%3D125%26issue%3D11%26spage%3D1659%26epage%3D1683%26doi%3D10.1007%2Fs00702-018-1861-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baik, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sailor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook-Jung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. H.</span></span> <span> </span><span class="NLM_article-title">Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer’s Disease in Mice, Observed by in Vivo Two-Photon Imaging</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">975</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.6b00309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.6b00309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2lsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=967-975&issue=12&author=D.+Kimauthor=S.+H.+Baikauthor=S.+Kangauthor=S.+W.+Choauthor=J.+Baeauthor=M.+Y.+Chaauthor=M.+J.+Sailorauthor=I.+Mook-Jungauthor=K.+H.+Ahn&title=Close+Correlation+of+Monoamine+Oxidase+Activity+with+Progress+of+Alzheimer%E2%80%99s+Disease+in+Mice%2C+Observed+by+in+Vivo+Two-Photon+Imaging&doi=10.1021%2Facscentsci.6b00309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer's Disease in Mice, Observed by in Vivo Two-Photon Imaging</span></div><div class="casAuthors">Kim, Dokyoung; Baik, Sung Hoon; Kang, Seokjo; Cho, Seo Won; Bae, Juryang; Cha, Moon-Yong; Sailor, Michael J.; Mook-Jung, Inhee; Ahn, Kyo Han</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">967-975</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoamine oxidases (MAOs) play an important role in Alzheimer's disease (AD) pathol.  We report in vivo comonitoring of MAO activity and amyloid-β (Aβ) plaques dependent on the aging of live mice with AD, using a two-photon fluorescence probe.  The probe under the catalytic action of MAO produces a dipolar fluorophore that senses Aβ plaques, a general AD biomarker, enabling us to comonitor the enzyme activity and the progress of AD indicated by Aβ plaques.  The results show that the progress of AD has a close correlation with MAO activity, which can be categorized into three stages: slow initiation stage up to three months, an aggressive stage, and a satn. stage from nine months.  Histol. anal. also reveals elevation of MAO activity around Aβ plaques in aged mice.  The close correlation between the MAO activity and AD progress obsd. by in vivo monitoring for the first time prompts us to investigate the enzyme as a potential biomarker of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV85cVN9zcP7Vg90H21EOLACvtfcHk0lj4UzHZH2jmOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2lsLbM&md5=290052c37b8836d7811e6041b62822b4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.6b00309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.6b00309%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DBaik%26aufirst%3DS.%2BH.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DS.%2BW.%26aulast%3DBae%26aufirst%3DJ.%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DSailor%26aufirst%3DM.%2BJ.%26aulast%3DMook-Jung%26aufirst%3DI.%26aulast%3DAhn%26aufirst%3DK.%2BH.%26atitle%3DClose%2520Correlation%2520of%2520Monoamine%2520Oxidase%2520Activity%2520with%2520Progress%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%2520in%2520Mice%252C%2520Observed%2520by%2520in%2520Vivo%2520Two-Photon%2520Imaging%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2016%26volume%3D2%26issue%3D12%26spage%3D967%26epage%3D975%26doi%3D10.1021%2Facscentsci.6b00309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schedin-Weiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hromadkova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teranishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiehager, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winblad, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandebring-Matton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frykman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjernberg, L. O.</span></span> <span> </span><span class="NLM_article-title">Monoamine Oxidase B is Elevated in Alzheimer Disease Neurons, is Associated with γ-Secretase and Regulates Neuronal Amyloid β-Peptide Levels</span>. <i>Alzheimer’s Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s13195-017-0279-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1186%2Fs13195-017-0279-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVOmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=57&issue=1&author=S.+Schedin-Weissauthor=M.+Inoueauthor=L.+Hromadkovaauthor=Y.+Teranishiauthor=N.+G.+Yamamotoauthor=B.+Wiehagerauthor=N.+Bogdanovicauthor=B.+Winbladauthor=A.+Sandebring-Mattonauthor=S.+Frykmanauthor=L.+O.+Tjernberg&title=Monoamine+Oxidase+B+is+Elevated+in+Alzheimer+Disease+Neurons%2C+is+Associated+with+%CE%B3-Secretase+and+Regulates+Neuronal+Amyloid+%CE%B2-Peptide+Levels&doi=10.1186%2Fs13195-017-0279-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels</span></div><div class="casAuthors">Schedin-Weiss, Sophia; Inoue, Mitsuhiro; Hromadkova, Lenka; Teranishi, Yasuhiro; Yamamoto, Natsuko Goto; Wiehager, Birgitta; Bogdanovic, Nenad; Winblad, Bengt; Sandebring-Matton, Anna; Frykman, Susanne; Tjernberg, Lars O.</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's Research & Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57/1-57/19</span>CODEN:
                <span class="NLM_cas:coden">ARTLCD</span>;
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Increased levels of the pathogenic amyloid β-peptide (Aβ), released from its precursor by the transmembrane protease γ-secretase, are found in Alzheimer disease (AD) brains.  Interestingly, monoamine oxidase B (MAO-B) activity is also increased in AD brain, but its role in AD pathogenesis is not known.  Recent neuroimaging studies have shown that the increased MAO-B expression in AD brain starts several years before the onset of the disease.  Here, we show a potential connection between MAO-B, γ-secretase and Aβ in neurons.  Methods: MAO-B immunohistochem. was performed on postmortem human brain.  Affinity purifn. of γ-secretase followed by mass spectrometry was used for unbiased identification of γ-secretase-assocd. proteins.  The assocn. of MAO-B with γ-secretase was studied by coimmunopptn. from brain homogenate, and by in-situ proximity ligation assay (PLA) in neurons as well as mouse and human brain sections.  The effect of MAO-B on Aβ prodn. and Notch processing in cell cultures was analyzed by siRNA silencing or overexpression expts. followed by ELISA, western blot or FRET anal.  Methodol. for measuring relative intraneuronal MAO-B and Aβ42 levels in single cells was developed by combining immunocytochem. and confocal microscopy with quant. image anal.  Results: Immunohistochem. revealed MAO-B staining in neurons in the frontal cortex, hippocampus CA1 and entorhinal cortex in postmortem human brain.  Interestingly, the neuronal staining intensity was higher in AD brain than in control brain in these regions.  Mass spectrometric data from affinity purified γ-secretase suggested that MAO-B is a γ-secretase-assocd. protein, which was confirmed by immunopptn. and PLA, and a neuronal location of the interaction was shown.  Strikingly, intraneuronal Aβ42 levels correlated with MAO-B levels, and siRNA silencing of MAO-B resulted in significantly reduced levels of intraneuronal Aβ42.  Furthermore, overexpression of MAO-B enhanced Aβ prodn.  Conclusions: This study shows that MAO-B levels are increased not only in astrocytes but also in pyramidal neurons in AD brain.  The study also suggests that MAO-B regulates Aβ prodn. in neurons via γ-secretase and thereby provides a key to understanding the relationship between MAO-B and AD pathogenesis.  Potentially, the γ-secretase/MAO-B assocn. may be a target for reducing Aβ levels using protein-protein interaction breakers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOuXrvzc_LEbVg90H21EOLACvtfcHk0lgGH9FcXS2D7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVOmsbo%253D&md5=2e23a8fa1fa44e0d75501e8683028f3d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs13195-017-0279-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-017-0279-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchedin-Weiss%26aufirst%3DS.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DHromadkova%26aufirst%3DL.%26aulast%3DTeranishi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DN.%2BG.%26aulast%3DWiehager%26aufirst%3DB.%26aulast%3DBogdanovic%26aufirst%3DN.%26aulast%3DWinblad%26aufirst%3DB.%26aulast%3DSandebring-Matton%26aufirst%3DA.%26aulast%3DFrykman%26aufirst%3DS.%26aulast%3DTjernberg%26aufirst%3DL.%2BO.%26atitle%3DMonoamine%2520Oxidase%2520B%2520is%2520Elevated%2520in%2520Alzheimer%2520Disease%2520Neurons%252C%2520is%2520Associated%2520with%2520%25CE%25B3-Secretase%2520and%2520Regulates%2520Neuronal%2520Amyloid%2520%25CE%25B2-Peptide%2520Levels%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2017%26volume%3D9%26issue%3D1%26spage%3D57%26doi%3D10.1186%2Fs13195-017-0279-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiuccariello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusjan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkowska, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitan, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolla, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J. H.</span></span> <span> </span><span class="NLM_article-title">Elevated Monoamine Oxidase A Binding During Major Depressive Episodes is Associated with Greater Severity and Reversed Neurovegetative Symptoms</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">980</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1038%2Fnpp.2013.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=24154665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyrtL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=973-980&issue=4&author=L.+Chiuccarielloauthor=S.+Houleauthor=L.+Milerauthor=R.+G.+Cookeauthor=P.+M.+Rusjanauthor=G.+Rajkowskaauthor=R.+D.+Levitanauthor=S.+J.+Kishauthor=N.+J.+Kollaauthor=X.+Ouauthor=A.+A.+Wilsonauthor=J.+H.+Meyer&title=Elevated+Monoamine+Oxidase+A+Binding+During+Major+Depressive+Episodes+is+Associated+with+Greater+Severity+and+Reversed+Neurovegetative+Symptoms&doi=10.1038%2Fnpp.2013.297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated Monoamine Oxidase A Binding During Major Depressive Episodes Is Associated with Greater Severity and Reversed Neurovegetative Symptoms</span></div><div class="casAuthors">Chiuccariello, Lina; Houle, Sylvain; Miler, Laura; Cooke, Robert G.; Rusjan, Pablo M.; Rajkowska, Grazyna; Levitan, Robert D.; Kish, Stephen J.; Kolla, Nathan J.; Ou, Xiaoming; Wilson, Alan A.; Meyer, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">973-980</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inadequate treatment response occurs in approx. 40% of major depressive episodes (MDEs), and one approach to solve this is careful matching of treatment to the specific pathologies of MDE.  One such biol. abnormality is elevated monoamine oxidase A (MAO-A) levels, which occurs in the prefrontal and anterior cingulate cortex (PFC and ACC) during MDE; however, the subtypes for which this abnormality is most prominent are unknown.  We hypothesized that MAO-A levels in the PFC and ACC are most elevated in MDE with greater severity and reversed neurovegetative symptoms (hypersomnia and either hyperphagia or wt. gain).  MAO-A VT (an index of MAO-A d.) was measured using [11C]harmine positron emission tomog. (PET) in 42 subjects with MDEs secondary to major depressive disorder and 37 healthy controls.  The effect of severity and reversed neurovegetative symptoms on MAO-A VT in the PFC and ACC was analyzed using a multivariate anal. of variance (MANOVA).  Greater severity and reversed neurovegetative symptoms were assocd. with elevated MAO-A VT in the PFC and ACC (MANOVA, severity: F(2,38)=5.44, p=0.008; reversed neurovegetative symptoms: F(2,38)=5.13, p=0.01).  Increased MAO-A level, when greater severity and reversed neurovegetative symptoms are present, may explain the assocn. of these clin. features with a preferential response to MAO inhibitors, which is esp. well-evidenced for reversed neurovegetative symptoms in MDE.  As MAO-A creates oxidative stress, facilitates apoptosis, and metabolizes monoamines, therapeutics opposing these processes are predicted to best treat MDE with greater severity and reversed neurovegetative symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq42LaYJ_gP6bVg90H21EOLACvtfcHk0lgGH9FcXS2D7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyrtL7K&md5=f1e12253de5946c1406b4b3e5e65ca44</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.297%26sid%3Dliteratum%253Aachs%26aulast%3DChiuccariello%26aufirst%3DL.%26aulast%3DHoule%26aufirst%3DS.%26aulast%3DMiler%26aufirst%3DL.%26aulast%3DCooke%26aufirst%3DR.%2BG.%26aulast%3DRusjan%26aufirst%3DP.%2BM.%26aulast%3DRajkowska%26aufirst%3DG.%26aulast%3DLevitan%26aufirst%3DR.%2BD.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DKolla%26aufirst%3DN.%2BJ.%26aulast%3DOu%26aufirst%3DX.%26aulast%3DWilson%26aufirst%3DA.%2BA.%26aulast%3DMeyer%26aufirst%3DJ.%2BH.%26atitle%3DElevated%2520Monoamine%2520Oxidase%2520A%2520Binding%2520During%2520Major%2520Depressive%2520Episodes%2520is%2520Associated%2520with%2520Greater%2520Severity%2520and%2520Reversed%2520Neurovegetative%2520Symptoms%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26issue%3D4%26spage%3D973%26epage%3D980%26doi%3D10.1038%2Fnpp.2013.297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Sante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Lisa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaludercic, N.</span></span> <span> </span><span class="NLM_article-title">Emerging Role of Monoamine Oxidase as a Therapeutic Target for Cardiovascular Disease</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.coph.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=28528298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFekt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=64-69&author=S.+Deshwalauthor=M.+Di+Santeauthor=F.+Di+Lisaauthor=N.+Kaludercic&title=Emerging+Role+of+Monoamine+Oxidase+as+a+Therapeutic+Target+for+Cardiovascular+Disease&doi=10.1016%2Fj.coph.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease</span></div><div class="casAuthors">Deshwal, Soni; Di Sante, Moises; Di Lisa, Fabio; Kaludercic, Nina</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">64-69</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the past decade, accumulating evidence highlighted the role of monoamine oxidases (MAOs) in cardiovascular disease (CVD).  MAOs are flavoenzymes located in the outer mitochondrial membrane, responsible for the degrdn. of neurotransmitters and biogenic amines.  During this process they generate hydrogen peroxide, aldehydes and ammonia, species that can target mitochondria and induce mitochondrial dysfunction and cardiomyocyte death.  Indeed, MAO inhibition affords cardioprotection in several models of CVD, such as ischemia/reperfusion, heart failure and diabetes.  Importantly, a few studies provided encouraging results suggesting that MAO inhibition might be beneficial also in patients with CVD.  Thus, selective and reversible MAO inhibitors, currently used as therapy for depression and neurodegenerative disorders, might be considered as candidate drugs for the treatment of CVD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgFZrpZbH4ALVg90H21EOLACvtfcHk0ljUivzsOVHxJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFekt7w%253D&md5=47b04c6835ab1638be9885164030c7ae</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DDeshwal%26aufirst%3DS.%26aulast%3DDi%2BSante%26aufirst%3DM.%26aulast%3DDi%2BLisa%26aufirst%3DF.%26aulast%3DKaludercic%26aufirst%3DN.%26atitle%3DEmerging%2520Role%2520of%2520Monoamine%2520Oxidase%2520as%2520a%2520Therapeutic%2520Target%2520for%2520Cardiovascular%2520Disease%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2017%26volume%3D33%26spage%3D64%26epage%3D69%26doi%3D10.1016%2Fj.coph.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J. C.</span></span> <span> </span><span class="NLM_article-title">Monoamine Oxidase Isoenzymes: Genes, Functions and Targets for Behavior and Cancer Therapy</span>. <i>J. Neural Transm. (Vienna)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1553</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1927-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1007%2Fs00702-018-1927-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=30259128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BB3czjtFKnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1553-1566&issue=11&author=J.+C.+Shih&title=Monoamine+Oxidase+Isoenzymes%3A+Genes%2C+Functions+and+Targets+for+Behavior+and+Cancer+Therapy&doi=10.1007%2Fs00702-018-1927-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy</span></div><div class="casAuthors">Shih Jean C; Shih Jean C; Shih Jean C; Shih Jean C; Shih Jean C</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission (Vienna, Austria : 1996)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1553-1566</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Monoamine oxidase (MAO) catalyzes the oxidative deamination of monoamine neurotransmitters and dietary amines.  Two pharmacological types with different substrate and inhibitor specificities were reported.  Molecular cloning revealed that the two types of MAO were different genes expressed as different proteins with different functions.  MAO A and B have identical intron-exon organization derived by duplication of a common ancestral gene thus they are termed isoenzymes.  MAO A knockout mice exhibited aggression, the first clear evidence linking genes to behavior.  MAO A KO mice exhibited autistic-like behaviors which could be prevented by reducing serotonin levels at an early developmental age (P1-P7) providing potential therapy.  MAO B KO mice were non-aggressive and resistant to Parkinsongenic neurotoxin.  More recently it was found that MAO A is overexpressed in prostate cancer and correlates with degree of malignancy.  The oncogenic mechanism involves a ROS-activated AKT/FOXO1/TWIST1 signaling pathway.  Deletion of MAO A reduced prostate cancer stem cells and suppressed invasive adenocarcinoma.  MAO A was also overexpressed in classical Hodgkin lymphoma and glioma brain tumors.  MAO B was overexpressed in glioma and non-small cell lung cancer.  MAO A inhibitors reduce the growth of prostate cancer, drug sensitive and resistant gliomas and classical Hodgkin lymphoma, and enhance standard chemotherapy.  Currently, we are developing NIR dye-conjugated clorgyline (MAO A inhibitor) as a novel dual therapeutic/diagnostic agent for cancer.  A phase II clinical trial of MAO inhibitor for biochemical recurrent prostate cancer is ongoing.  The role of MAO A and B in several cancer types opens new avenues for cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7YIgiqqt3BgaK-_ZudimnfW6udTcc2eaPEMtZ81F3ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czjtFKnuw%253D%253D&md5=8f145b7766496b62856a9fb4e9401ab9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1927-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1927-8%26sid%3Dliteratum%253Aachs%26aulast%3DShih%26aufirst%3DJ.%2BC.%26atitle%3DMonoamine%2520Oxidase%2520Isoenzymes%253A%2520Genes%252C%2520Functions%2520and%2520Targets%2520for%2520Behavior%2520and%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Neural%2520Transm.%2520%2528Vienna%2529%26date%3D2018%26volume%3D125%26issue%3D11%26spage%3D1553%26epage%3D1566%26doi%3D10.1007%2Fs00702-018-1927-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span> <span> </span><span class="NLM_article-title">The Role of Monoamine Oxidase Inhibitors in Depression Treatment Guidelines</span>. <i>J. Clin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">Suppl. 1</span>),  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.4088/JCP.11096su1c.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.4088%2FJCP.11096su1c.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=22951237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGrt7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2012&pages=10-16&issue=Suppl.+1&author=M.+E.+Thase&title=The+Role+of+Monoamine+Oxidase+Inhibitors+in+Depression+Treatment+Guidelines&doi=10.4088%2FJCP.11096su1c.02"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The role of monoamine oxidase inhibitors in depression treatment guidelines</span></div><div class="casAuthors">Thase, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry (Memphis, TN, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">10-16</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">A review.  Monoamine oxidase inhibitors (MAOIs) have proven efficacy for treating depression and for decades have been a preferred treatment for patients with atypical depression, high levels of anxiety, anergic bipolar depression, and treatment-resistant depression.  However, MAOIs are infrequently used due to safety and tolerability concerns and the need for dietary restrictions.  Current guidelines, which are reviewed here, recommend MAOIs as third-, fourth-, or fifth-line treatments due to these concerns.  However, a transdermal formulation of selegiline limits the need for dietary restrictions and has fewer side effects than many more widely used antidepressants.  The availability of a safer and more tolerable formulation gives clinicians another option in their armamentarium for treating depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSi6yLVJ2cXrVg90H21EOLACvtfcHk0lh6vJH-V4zodQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGrt7nM&md5=32ae705ff860c62310a8742b39ffb8f2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4088%2FJCP.11096su1c.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.11096su1c.02%26sid%3Dliteratum%253Aachs%26aulast%3DThase%26aufirst%3DM.%2BE.%26atitle%3DThe%2520Role%2520of%2520Monoamine%2520Oxidase%2520Inhibitors%2520in%2520Depression%2520Treatment%2520Guidelines%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2012%26volume%3D73%26issue%3DSuppl.%25201%26spage%3D10%26epage%3D16%26doi%3D10.4088%2FJCP.11096su1c.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dezsi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vecsei, L.</span></span> <span> </span><span class="NLM_article-title">Monoamine Oxidase B Inhibitors in Parkinson’s Disease</span>. <i>CNS Neurol. Disord.: Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.2174/1871527316666170124165222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.2174%2F1871527316666170124165222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=28124620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1SmtLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=425-439&issue=4&author=L.+Dezsiauthor=L.+Vecsei&title=Monoamine+Oxidase+B+Inhibitors+in+Parkinson%E2%80%99s+Disease&doi=10.2174%2F1871527316666170124165222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine Oxidase B Inhibitors in Parkinson's Disease</span></div><div class="casAuthors">Dezsi, Livia; Vecsei, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">CNS & Neurological Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-439</span>CODEN:
                <span class="NLM_cas:coden">CNDDA3</span>;
        ISSN:<span class="NLM_cas:issn">1871-5273</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a neurodegenerative disorder with a prevalence increasing with age.  Oxidative stress and glutamate toxicity are involved in its pathomechanism.  There are still many unmet needs of PD patients, including the alleviation of motor fluctuations and dyskinesias, and the development of therapies with neuroprotective potential.  To give an overview of the pharmacol. properties, the efficacy and safety of the monoamine oxidase B (MAO-B) inhibitors in the treatment of PD, with special focus on the results of randomized clin. trials.  A literature search was conducted in PubMed for 'PD treatment', 'MAO-B inhibitors', 'selegiline', 'rasagiline', 'safinamide' and 'clin. trials' with 'MAO-B inhibitors' in 'Parkinson' disease'.  Results: MAO-B inhibitors have a favorable pharmacokinetic profile, improve the dopamine deficient state and may have neuroprotective properties.  Safinamide exhibits an anti-glutamatergic effect as well.  When applied as monotherapy, MAO-B inhibitors provide a modest, but significant improvement of motor function and delay the need for levodopa.  Rasagiline and safinamide were proven safe and effective when added to a dopamine agonist in early PD.  As add-on to levodopa, MAO-B inhibitors significantly reduced off-time and were comparable in efficacy to COMT inhibitors.  Improvements were achieved as regards certain non-motor symptoms as well.  Due to the efficacy shown in clin. trials and their favorable side-effect profile, MAO-B inhibitors are valuable drugs in the treatment of PD.  They are recommended as monotherapy in the early stages of the disease and as add-on therapy to levodopa in advanced PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMA_sgCUd0GrVg90H21EOLACvtfcHk0lh6vJH-V4zodQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1SmtLbE&md5=0d7e67bbd9daf48131efbd6494c620ad</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F1871527316666170124165222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871527316666170124165222%26sid%3Dliteratum%253Aachs%26aulast%3DDezsi%26aufirst%3DL.%26aulast%3DVecsei%26aufirst%3DL.%26atitle%3DMonoamine%2520Oxidase%2520B%2520Inhibitors%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DCNS%2520Neurol.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2017%26volume%3D16%26issue%3D4%26spage%3D425%26epage%3D439%26doi%3D10.2174%2F1871527316666170124165222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B. H.</span></span> <span> </span><span class="NLM_article-title">Monoamine Oxidase Inhibitors, and Iron Chelators in Depressive Illness and Neurodegenerative Diseases</span>. <i>J. Neural. Transm. (Vienna)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1733</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1942-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1007%2Fs00702-018-1942-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=30341696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BB3cvhtlyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1719-1733&issue=11&author=M.+B.+H.+Youdim&title=Monoamine+Oxidase+Inhibitors%2C+and+Iron+Chelators+in+Depressive+Illness+and+Neurodegenerative+Diseases&doi=10.1007%2Fs00702-018-1942-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases</span></div><div class="casAuthors">Youdim Moussa B H; Youdim Moussa B H</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission (Vienna, Austria : 1996)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1719-1733</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In early 1920s, tyramine oxidase was discovered that metabolized tyramine and in 1933 Blaschko demonstrated that this enzyme also metabolized adrenaline, noradrenaline and dopamine.  Zeller gave it the name monoamine oxidase (MAO) to distinguish it from the enzyme that oxidatively deaminated diamines.  MAO was recognized as an enzyme of crucial interest to pharmacologists because it catalyzed the major inactivation pathway for the catecholamines (and, later, 5-hydroxytryptamine, as well).  Within the few decade, the inhibitors of MAO were discovered and introduced for the treatment of depressive illness which was established clinically.  However, the first clinical use exposed serious side effects, pharmacological interest in, and investigation of, MAO continued, resulting in the characterization of two forms, distinct forms, MAO-A and -B, and selective inhibitors for them.  Selective inhibitors of MAO-B (selegiline, rasagiline and safinamide) have found a therapeutic role in the treatment of Parkinson's disease and reversible inhibitors of MAO-A offered antidepressant activity without the serious side effects of the earlier nonselective MAO inhibitors.  Subsequent molecular pharmacological have also generated the concept of neuroprotection, reflecting the possibility of slowing, halting and maybe reversing, neurodegeneration in Parkinson's or Alzheimer's diseases.  Increased levels of oxidative stress through the accumulation of iron in the Parkinsonian and Alzheimer brains has been suggested to be critical for the initiation and progress of neurodegeneration.  Selective inhibition of brain MAO could contribute importantly to lowering such stress, preventing the formation of hydrogen peroxide.  Interaction of Iron with hydrogen peroxide and lead to Fenton reaction and production of the most reactive radical, namely hydroxyl radical.  There are complex interactions between free iron levels in brain and MAO, and cascade of neurotoxic events may have practical outcomes for depressive disorders and neurodegenerative diseases.  As consequence recent novel therapeutic drugs for neurodegenerative diseases has led to the development of multi target drugs, that possess selective brain MAO A and B inhibitory moiety, iron chelating and antioxidant activities and the ability to increase brain levels of endogenous neurotrophins, such as BDNF, GDNF VEGF and erythropoietin and induce mitochondrial biogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSojcxi5hdr-WgRQsDqrjW_fW6udTcc2eYvED1YAJFnTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvhtlyhsw%253D%253D&md5=71184ea386596ea4a0ecf24d95fab7cf</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1942-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1942-9%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%2BH.%26atitle%3DMonoamine%2520Oxidase%2520Inhibitors%252C%2520and%2520Iron%2520Chelators%2520in%2520Depressive%2520Illness%2520and%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Neural.%2520Transm.%2520%2528Vienna%2529%26date%3D2018%26volume%3D125%26issue%3D11%26spage%3D1719%26epage%3D1733%26doi%3D10.1007%2Fs00702-018-1942-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span> <span> </span><span class="NLM_article-title">The Therapeutic Potential of Monoamine Oxidase Inhibitors</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1038/nrn1883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1038%2Fnrn1883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=16552415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1Gksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=295-309&issue=4&author=M.+B.+Youdimauthor=D.+Edmondsonauthor=K.+F.+Tipton&title=The+Therapeutic+Potential+of+Monoamine+Oxidase+Inhibitors&doi=10.1038%2Fnrn1883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The therapeutic potential of monoamine oxidase inhibitors</span></div><div class="casAuthors">Youdim, Moussa B. H.; Edmondson, Dale; Tipton, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-309</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Monoamine oxidase inhibitors were among the first antidepressants to be discovered and have long been used as such.  It now seems that many of these agents might have therapeutic value in several common neurodegenerative conditions, independently of their inhibition of monoamine oxidase activity.  However, many claims and some counter-claims have been made about the physiol. importance of these enzymes and the potential of their inhibitors.  We evaluate these arguments in the light of what we know, and still have to learn, of the structure, function and genetics of the monoamine oxidases and the disparate actions of their inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3A0wRL6nnL7Vg90H21EOLACvtfcHk0lgY-EVcgyC8gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1Gksrs%253D&md5=b35546920d95fa031ff2f884949372a7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrn1883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1883%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DEdmondson%26aufirst%3DD.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26atitle%3DThe%2520Therapeutic%2520Potential%2520of%2520Monoamine%2520Oxidase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2006%26volume%3D7%26issue%3D4%26spage%3D295%26epage%3D309%26doi%3D10.1038%2Fnrn1883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otyepka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosinova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damborsky, J.</span></span> <span> </span><span class="NLM_article-title">Caver: A New Tool to Explore Routes from Protein Clefts, Pockets and Cavities</span>. <i>BMC Bioinf.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">316</span>, <span class="refDoi"> DOI: 10.1186/1471-2105-7-316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1186%2F1471-2105-7-316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=16792811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BD28vnsleltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=316&author=M.+Petrekauthor=M.+Otyepkaauthor=P.+Banasauthor=P.+Kosinovaauthor=J.+Kocaauthor=J.+Damborsky&title=Caver%3A+A+New+Tool+to+Explore+Routes+from+Protein+Clefts%2C+Pockets+and+Cavities&doi=10.1186%2F1471-2105-7-316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">CAVER: a new tool to explore routes from protein clefts, pockets and cavities</span></div><div class="casAuthors">Petrek Martin; Otyepka Michal; Banas Pavel; Kosinova Pavlina; Koca Jaroslav; Damborsky Jiri</div><div class="citationInfo"><span class="NLM_cas:title">BMC bioinformatics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">316</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The main aim of this study was to develop and implement an algorithm for the rapid, accurate and automated identification of paths leading from buried protein clefts, pockets and cavities in dynamic and static protein structures to the outside solvent.  RESULTS:  The algorithm to perform a skeleton search was based on a reciprocal distance function grid that was developed and implemented for the CAVER program.  The program identifies and visualizes routes from the interior of the protein to the bulk solvent.  CAVER was primarily developed for proteins, but the algorithm is sufficiently robust to allow the analysis of any molecular system, including nucleic acids or inorganic material.  Calculations can be performed using discrete structures from crystallographic analysis and NMR experiments as well as with trajectories from molecular dynamics simulations.  The fully functional program is available as a stand-alone version and as plug-in for the molecular modeling program PyMol.  Additionally, selected functions are accessible in an online version.  CONCLUSION:  The algorithm developed automatically finds the path from a starting point located within the interior of a protein.  The algorithm is sufficiently rapid and robust to enable routine analysis of molecular dynamics trajectories containing thousands of snapshots.  The algorithm is based on reciprocal metrics and provides an easy method to find a centerline, i.e. the spine, of complicated objects such as a protein tunnel.  It can also be applied to many other molecules.  CAVER is freely available from the web site http://loschmidt.chemi.muni.cz/caver/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYFNI2kCdJVkQ0lWbKiCflfW6udTcc2eYAgKetJmtjbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vnsleltw%253D%253D&md5=e3bd3da0db628ec71e802092708017f3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2F1471-2105-7-316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2105-7-316%26sid%3Dliteratum%253Aachs%26aulast%3DPetrek%26aufirst%3DM.%26aulast%3DOtyepka%26aufirst%3DM.%26aulast%3DBanas%26aufirst%3DP.%26aulast%3DKosinova%26aufirst%3DP.%26aulast%3DKoca%26aufirst%3DJ.%26aulast%3DDamborsky%26aufirst%3DJ.%26atitle%3DCaver%253A%2520A%2520New%2520Tool%2520to%2520Explore%2520Routes%2520from%2520Protein%2520Clefts%252C%2520Pockets%2520and%2520Cavities%26jtitle%3DBMC%2520Bioinf.%26date%3D2006%26volume%3D7%26spage%3D316%26doi%3D10.1186%2F1471-2105-7-316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filipovič, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vávra, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plhák, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednář, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brezovský, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matyska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damborský, J.</span></span> <span> </span><span class="NLM_article-title">CaverDock: A Novel Method for the Fast Analysis of Ligand Transport</span>. <i>arXiv</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_fpage">1809.03453</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=1809.03453&author=J.+Filipovi%C4%8Dauthor=O.+V%C3%A1vraauthor=J.+Plh%C3%A1kauthor=D.+Bedn%C3%A1%C5%99author=S.+M.+Marquesauthor=J.+Brezovsk%C3%BDauthor=L.+Matyskaauthor=J.+Damborsk%C3%BD&title=CaverDock%3A+A+Novel+Method+for+the+Fast+Analysis+of+Ligand+Transport"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFilipovi%25C4%258D%26aufirst%3DJ.%26aulast%3DV%25C3%25A1vra%26aufirst%3DO.%26aulast%3DPlh%25C3%25A1k%26aufirst%3DJ.%26aulast%3DBedn%25C3%25A1%25C5%2599%26aufirst%3DD.%26aulast%3DMarques%26aufirst%3DS.%2BM.%26aulast%3DBrezovsk%25C3%25BD%26aufirst%3DJ.%26aulast%3DMatyska%26aufirst%3DL.%26aulast%3DDamborsk%25C3%25BD%26aufirst%3DJ.%26atitle%3DCaverDock%253A%2520A%2520Novel%2520Method%2520for%2520the%2520Fast%2520Analysis%2520of%2520Ligand%2520Transport%26jtitle%3DarXiv%26date%3D2018%26spage%3D1809.03453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldeck, D. H.</span></span> <span> </span><span class="NLM_article-title">Photoisomerization Dynamics of Stilbenes</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1021/cr00003a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00003a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADyaK3MXitVKitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1991&pages=415-436&issue=3&author=D.+H.+Waldeck&title=Photoisomerization+Dynamics+of+Stilbenes&doi=10.1021%2Fcr00003a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Photoisomerization dynamics of stilbenes</span></div><div class="casAuthors">Waldeck, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">415-36</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with >175 refs. including spectral studies, mechanism, theor. models, and rate studies in dense gases and liqs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpS-7aP8XWkrVg90H21EOLACvtfcHk0lj-iF5KG13PFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXitVKitbk%253D&md5=624f87a3475c51eb0091ea45fa90d731</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fcr00003a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00003a007%26sid%3Dliteratum%253Aachs%26aulast%3DWaldeck%26aufirst%3DD.%2BH.%26atitle%3DPhotoisomerization%2520Dynamics%2520of%2520Stilbenes%26jtitle%3DChem.%2520Rev.%26date%3D1991%26volume%3D91%26issue%3D3%26spage%3D415%26epage%3D436%26doi%3D10.1021%2Fcr00003a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albreht, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vovk, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span> <span> </span><span class="NLM_article-title">Evidence for a Cyanine Link between Propargylamine Drugs and Monoamine Oxidase Clarifies the Inactivation Mechanism</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">169</span>, <span class="refDoi"> DOI: 10.3389/fchem.2018.00169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.3389%2Ffchem.2018.00169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=29892597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2rtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=169&author=A.+Albrehtauthor=I.+Vovkauthor=J.+Mavriauthor=J.+Marco-Contellesauthor=R.+R.+Ramsay&title=Evidence+for+a+Cyanine+Link+between+Propargylamine+Drugs+and+Monoamine+Oxidase+Clarifies+the+Inactivation+Mechanism&doi=10.3389%2Ffchem.2018.00169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a cyanine link between propargylamine drugs and monoamine oxidase clarifies the inactivation mechanism</span></div><div class="casAuthors">Albreht, Alen; Vovk, Irena; Mavri, Janez; Marco-Contelles, Jose; Ramsay, Rona R.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">169/1-169/11</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Successful propargylamine drugs such as deprenyl inactivate monoamine oxidase (MAO), a target in multi-faceted approaches to prevent neurodegeneration in the aging population, but the chem. structure and mechanism of the irreversible inhibition are still debated.  We characterized the covalent cyanine structure linking the multi-target propargylamine inhibitor ASS234 and the FAD in MAO-A using a combination of ultra-high performance liq. chromatog., spectroscopy, mass spectrometry, and computational methods.  The partial double bond character of the cyanine chain gives rise to 4 interconverting geometric isomers of the adduct which were chromatog. sepd. at low temps.  The configuration of the cyanine linker governs adduct stability with segments of much higher flexibility and rigidity than previously hypothesized.  The findings indicate the importance of intramol. electrostatic interactions in the MAO binding site and provide key information relevant to incorporation of the propargyl moiety into novel multi-target drugs.  Based on the structure, we propose a mechanism of MAO inactivation applicable to all propargylamine inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5rqCMiMig07Vg90H21EOLACvtfcHk0lj-iF5KG13PFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2rtLzI&md5=761e1d3e0bae22bce03bf2eba88d7bb1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00169%26sid%3Dliteratum%253Aachs%26aulast%3DAlbreht%26aufirst%3DA.%26aulast%3DVovk%26aufirst%3DI.%26aulast%3DMavri%26aufirst%3DJ.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26atitle%3DEvidence%2520for%2520a%2520Cyanine%2520Link%2520between%2520Propargylamine%2520Drugs%2520and%2520Monoamine%2520Oxidase%2520Clarifies%2520the%2520Inactivation%2520Mechanism%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D169%26doi%3D10.3389%2Ffchem.2018.00169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span> <span> </span><span class="NLM_article-title">Kinetic and Structural Analysis of the Irreversible Inhibition of Human Monoamine Oxidases by ASS234, a Multi-Target Compound Designed for Use in Alzheimer’s Disease</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1844</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1104</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2014.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.bbapap.2014.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=24642166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntVeqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1844&publication_year=2014&pages=1104-1110&issue=6&author=G.+Estebanauthor=J.+Allanauthor=A.+Samadiauthor=A.+Matteviauthor=M.+Unzetaauthor=J.+Marco-Contellesauthor=C.+Bindaauthor=R.+R.+Ramsay&title=Kinetic+and+Structural+Analysis+of+the+Irreversible+Inhibition+of+Human+Monoamine+Oxidases+by+ASS234%2C+a+Multi-Target+Compound+Designed+for+Use+in+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.bbapap.2014.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease</span></div><div class="casAuthors">Esteban, Gerard; Allan, Jennifer; Samadi, Abdelouahid; Mattevi, Andrea; Unzeta, Mercedes; Marco-Contelles, Jose; Binda, Claudia; Ramsay, Rona R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1844</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1104-1110</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Monoamine oxidases (MAO) and cholinesterases are validated targets in the design of drugs for the treatment of Alzheimer's disease.  The multi-target compd. N-((5-(3-(1-benzylpiperidin-4-yl)propoxy)-1-methyl-1H-indol-2-yl)methyl)-N-methylprop-2-yn-1-amine (ASS234), bearing the MAO-inhibiting propargyl group attached to a donepezil moiety that inhibits cholinesterases, retained activity against human acetyl- and butyryl-cholinesterases.  The inhibition of MAO A and MAO B by ASS234 was characterized and compared to other known MAO inhibitors.  ASS234 was almost as effective as clorgyline (kinact/KI = 3 × 106 min- 1 M- 1) and was shown by structural studies to form the same N5 covalent adduct with the FAD cofactor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqdbntEH0c5rVg90H21EOLACvtfcHk0lghWsQn7AHlQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntVeqtLg%253D&md5=6bb57337217cbf2813593c9cb36eea0f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2014.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2014.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DAllan%26aufirst%3DJ.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DMattevi%26aufirst%3DA.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26atitle%3DKinetic%2520and%2520Structural%2520Analysis%2520of%2520the%2520Irreversible%2520Inhibition%2520of%2520Human%2520Monoamine%2520Oxidases%2520by%2520ASS234%252C%2520a%2520Multi-Target%2520Compound%2520Designed%2520for%2520Use%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2014%26volume%3D1844%26issue%3D6%26spage%3D1104%26epage%3D1110%26doi%3D10.1016%2Fj.bbapap.2014.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of Monoamine Oxidase B in Complex with Four Inhibitors of the <i>N</i>-Propargylaminoindan Class</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1774</span>, <span class="refDoi"> DOI: 10.1021/jm031087c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031087c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1767-1774&issue=7&author=C.+Bindaauthor=F.+Hubalekauthor=M.+Liauthor=Y.+Herzigauthor=J.+Sterlingauthor=D.+E.+Edmondsonauthor=A.+Mattevi&title=Crystal+Structures+of+Monoamine+Oxidase+B+in+Complex+with+Four+Inhibitors+of+the+N-Propargylaminoindan+Class&doi=10.1021%2Fjm031087c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Monoamine Oxidase B in Complex with Four Inhibitors of the N-Propargylaminoindan Class</span></div><div class="casAuthors">Binda, Claudia; Hubalek, Frantisek; Li, Min; Herzig, Yaacov; Sterling, Jeffrey; Edmondson, Dale E.; Mattevi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1767-1774</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoamine oxidase B (MAO B) is an outer mitochondrial membrane enzyme that catalyzes the oxidn. of arylalkylamine neurotransmitters.  The crystal structures of MAO B in complex with four of the N-propargylaminoindan class of MAO covalent inhibitors (rasagiline, N-propargyl-1(S)-aminoindan, 6-hydroxy-N-propargyl-1(R)-aminoindan, and N-methyl-N-propargyl-1(R)-aminoindan) have been detd. at a resoln. of better than 2.1 Å.  Rasagiline, 6-hydroxy-N-propargyl-1(R)-aminoindan, and N-methyl-N-propargyl-1(R)-aminoindan adopt essentially the same conformation with the extended propargyl chain covalently bound to the flavin and the indan ring located in the rear of the substrate cavity.  N-Propargyl-1(S)-aminoindan binds with the indan ring in a flipped conformation with respect to the other inhibitors, which causes a slight movement of the Tyr326 side chain.  Four ordered water mols. are an integral part of the active site and establish H-bond interactions to the inhibitor atoms.  These structural studies may guide future drug design to improve selectivity and efficacy by introducing appropriate substituents on the rasagiline mol. scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkiXn0OI5eubVg90H21EOLACvtfcHk0lghWsQn7AHlQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit70%253D&md5=7b3df3c611e3f0dd59342a59096402dd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm031087c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031087c%26sid%3Dliteratum%253Aachs%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DHubalek%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHerzig%26aufirst%3DY.%26aulast%3DSterling%26aufirst%3DJ.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26aulast%3DMattevi%26aufirst%3DA.%26atitle%3DCrystal%2520Structures%2520of%2520Monoamine%2520Oxidase%2520B%2520in%2520Complex%2520with%2520Four%2520Inhibitors%2520of%2520the%2520N-Propargylaminoindan%2520Class%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D7%26spage%3D1767%26epage%3D1774%26doi%3D10.1021%2Fjm031087c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagide, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mialet-Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span> <span> </span><span class="NLM_article-title">Tight-Binding Inhibition of Human Monoamine Oxidase B by Chromone Analogs: A Kinetic, Crystallographic, and Biological Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4203</span>– <span class="NLM_lpage">4212</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFSnsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4203-4212&issue=9&author=J.+Reisauthor=N.+Manzellaauthor=F.+Cagideauthor=J.+Mialet-Perezauthor=E.+Uriarteauthor=A.+Pariniauthor=F.+Borgesauthor=C.+Binda&title=Tight-Binding+Inhibition+of+Human+Monoamine+Oxidase+B+by+Chromone+Analogs%3A+A+Kinetic%2C+Crystallographic%2C+and+Biological+Analysis&doi=10.1021%2Facs.jmedchem.8b00357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Tight-Binding Inhibition of Human Monoamine Oxidase B by Chromone Analogs: A Kinetic, Crystallographic, and Biological Analysis</span></div><div class="casAuthors">Reis, Joana; Manzella, Nicola; Cagide, Fernando; Mialet-Perez, Jeanne; Uriarte, Eugenio; Parini, Angelo; Borges, Fernanda; Binda, Claudia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4203-4212</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monoamine oxidase B (MAO-B) is a validated drug target for Parkinson's disease.  Chromone derivs. were identified as novel potent and reversible MAO-B inhibitors, and herewith we report on a crystallog. and biochem. anal. to investigate their inhibition mechanism.  The crystal structures of human MAO-B in complex with three chromone analogs bearing different substituents on the exocyclic arom. ring (detd. at 1.6-1.8 Å resoln.) showed that they all bind in the active site cavity of the protein with the chromone moiety located in front of the FAD cofactor.  These inhibitors form two hydrogen bonds with Tyr435 and Cys172 and perfectly fit the hydrophobic flat active site of human MAO-B.  This is reflected in their tight-binding mechanism of inhibition with Ki values of 55, 17, and 31 nM for N-(3',4'-dimethylphenyl)-4-oxo-4H-chromene-3-carboxamide (1), N-(3'-chlorophenyl)-4-oxo-4H-chromene-3-carboxamide (2), and N-(3'-fluorophenyl)-4-oxo-4H-chromene-3-carboxamide (3), resp.  These compds. were also 1000-fold more effective than L-deprenyl in reducing the cellular levels of reactive oxygen species (ROS).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI4_ZAaYfpTbVg90H21EOLACvtfcHk0lglqPs7QO-Thg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFSnsrw%253D&md5=129e0b5bbd744bc3ef74a75bda97a550</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00357%26sid%3Dliteratum%253Aachs%26aulast%3DReis%26aufirst%3DJ.%26aulast%3DManzella%26aufirst%3DN.%26aulast%3DCagide%26aufirst%3DF.%26aulast%3DMialet-Perez%26aufirst%3DJ.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DParini%26aufirst%3DA.%26aulast%3DBorges%26aufirst%3DF.%26aulast%3DBinda%26aufirst%3DC.%26atitle%3DTight-Binding%2520Inhibition%2520of%2520Human%2520Monoamine%2520Oxidase%2520B%2520by%2520Chromone%2520Analogs%253A%2520A%2520Kinetic%252C%2520Crystallographic%252C%2520and%2520Biological%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D9%26spage%3D4203%26epage%3D4212%26doi%3D10.1021%2Facs.jmedchem.8b00357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Frota Junior, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotto-Filho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurer, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpo, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelain, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapczinski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, J. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da
Cruz Fernandes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klamt, F.</span></span> <span> </span><span class="NLM_article-title">Comparison between Proliferative and Neuron-Like SS-SY5Y Cells as an in Vitro Model for Parkinson Disease Studies</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1337</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2010.03.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.brainres.2010.03.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=20380819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslWis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1337&publication_year=2010&pages=85-94&author=F.+M.+Lopesauthor=R.+Schroderauthor=M.+L.+da+Frota+Juniorauthor=A.+Zanotto-Filhoauthor=C.+B.+Mullerauthor=A.+S.+Piresauthor=R.+T.+Meurerauthor=G.+D.+Colpoauthor=D.+P.+Gelainauthor=F.+Kapczinskiauthor=J.+C.+F.+Moreiraauthor=M.+da%0ACruz+Fernandesauthor=F.+Klamt&title=Comparison+between+Proliferative+and+Neuron-Like+SS-SY5Y+Cells+as+an+in+Vitro+Model+for+Parkinson+Disease+Studies&doi=10.1016%2Fj.brainres.2010.03.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies</span></div><div class="casAuthors">Lopes, Fernanda Martins; Schroeder, Rafael; Conte da Frota, Mario Luiz, Jr.; Zanotto-Filho, Alfeu; Mueller, Carolina Beatriz; Pires, Andre Simoes; Meurer, Rosalva Thereza; Colpo, Gabriela Delevati; Gelain, Daniel Pens; Kapczinski, Flavio; Moreira, Jose Claudio Fonseca; Fernandes, Marilda da Cruz; Klamt, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1337</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mol. mechanisms underlying the cellular lost found in the nigrostriatal pathway during the progression of Parkinson's disease (PD) are not completely understood.  Human neuroblastoma cell line SH-SY5Y challenged with 6-hydroxydopamine (6-OHDA) has been widely used as an in vitro model for PD.  Although this cell line differentiates to dopaminergic neuron-like cells in response to low serum and retinoic acid (RA) treatment, there are few studies investigating the differences between proliferative and RA-differentiated SH-SY5Y cells.  Here we evaluate morphol. and biochem. changes which occurs during the differentiation of SH-SY5Y cells, and their responsiveness to 6-OHDA toxicity.  Exponentially growing SH-SY5Y cells were maintained with DMEM/F12 medium plus 10% of fetal bovine serum (FBS).  Differentiation was triggered by the combination of 10 μM RA plus 1% of FBS during 4, 7 and 10 days in culture.  We found that SH-SY5Y cells differentiated for 7 days show an increase immunocontent of several relevant neuronal markers with the concomitant decrease in non-differentiated cell marker.  Moreover, cells became two-fold more sensitive to 6-OHDA toxicity during the differentiation process.  Time course expts. showed loss of mitochondrial membrane potential triggered by 6-OHDA (mitochondrial dysfunction parameter), which firstly occurs in proliferative than neuron-like differentiated cells.  This finding could be related to the increase in the immunocontent of the neuroprotective protein DJ-1 during differentiation.  Our data suggest that SH-SY5Y cells differentiated by 7 days with the protocol described here represent a more suitable exptl. model for studying the mol. and cellular mechanisms underlying the pathophysiol. of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp106_9hpIIu7Vg90H21EOLACvtfcHk0lglqPs7QO-Thg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslWis7s%253D&md5=83c035ab4a0e891f927d0ba073f34a20</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2010.03.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2010.03.102%26sid%3Dliteratum%253Aachs%26aulast%3DLopes%26aufirst%3DF.%2BM.%26aulast%3DSchroder%26aufirst%3DR.%26aulast%3Dda%2BFrota%2BJunior%26aufirst%3DM.%2BL.%26aulast%3DZanotto-Filho%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DC.%2BB.%26aulast%3DPires%26aufirst%3DA.%2BS.%26aulast%3DMeurer%26aufirst%3DR.%2BT.%26aulast%3DColpo%26aufirst%3DG.%2BD.%26aulast%3DGelain%26aufirst%3DD.%2BP.%26aulast%3DKapczinski%26aufirst%3DF.%26aulast%3DMoreira%26aufirst%3DJ.%2BC.%2BF.%26aulast%3Dda%2BCruz%2BFernandes%26aufirst%3DM.%26aulast%3DKlamt%26aufirst%3DF.%26atitle%3DComparison%2520between%2520Proliferative%2520and%2520Neuron-Like%2520SS-SY5Y%2520Cells%2520as%2520an%2520in%2520Vitro%2520Model%2520for%2520Parkinson%2520Disease%2520Studies%26jtitle%3DBrain%2520Res.%26date%3D2010%26volume%3D1337%26spage%3D85%26epage%3D94%26doi%3D10.1016%2Fj.brainres.2010.03.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finberg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabey, J. M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">340</span>, <span class="refDoi"> DOI: 10.3389/fphar.2016.00340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.3389%2Ffphar.2016.00340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=27803666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=340&author=J.+P.+Finbergauthor=J.+M.+Rabey&title=Inhibitors+of+MAO-A+and+MAO-B+in+Psychiatry+and+Neurology&doi=10.3389%2Ffphar.2016.00340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of MAO-A and MAO-B in psychiatry and neurology</span></div><div class="casAuthors">Finberg, John P. M.; Rabey, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">340-354</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Inhibitors of MAO-A and MAO-B are in clin. use for the treatment of psychiatric and neurol. disorders resp.  Elucidation of the mol. structure of the active sites of the enzymes has enabled a precise detn. of the way in which substrates and inhibitor mols. are metabolized, or inhibit metab. of substrates, resp.  Despite the knowledge of the strong antidepressant efficacy of irreversible MAO inhibitors, their clin. use has been limited by their side effect of potentiation of the cardiovascular effects of dietary amines ("cheese effect").  A no. of reversible MAO-A inhibitors which are devoid of cheese effect have been described in the literature, but only one, moclobemide, is currently in clin. use.  The irreversible inhibitors of MAO-B, selegiline and rasagiline, are used clin. in treatment of Parkinson's disease, and a recently introduced reversible MAO-B inhibitor, safinamide, has also been found efficacious.  Modification of the pharmacokinetic characteristics of selegiline by transdermal administration has led to the development of a new drug form for treatment of depression.  The clin. potential of MAO inhibitors together with detailed knowledge of the enzyme's binding site structure should lead to future developments with these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUpMUqQ2oLP7Vg90H21EOLACvtfcHk0ljk5ygyL9IGPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWnu7k%253D&md5=7d7cf400373f86aa87e1147ce52b6d16</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2016.00340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2016.00340%26sid%3Dliteratum%253Aachs%26aulast%3DFinberg%26aufirst%3DJ.%2BP.%26aulast%3DRabey%26aufirst%3DJ.%2BM.%26atitle%3DInhibitors%2520of%2520MAO-A%2520and%2520MAO-B%2520in%2520Psychiatry%2520and%2520Neurology%26jtitle%3DFront.%2520Pharmacol.%26date%3D2016%26volume%3D7%26spage%3D340%26doi%3D10.3389%2Ffphar.2016.00340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shulman, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S. E.</span></span> <span> </span><span class="NLM_article-title">Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1007/s40263-013-0097-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1007%2Fs40263-013-0097-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=23934742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSms73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=789-797&issue=10&author=K.+I.+Shulmanauthor=N.+Herrmannauthor=S.+E.+Walker&title=Current+Place+of+Monoamine+Oxidase+Inhibitors+in+the+Treatment+of+Depression&doi=10.1007%2Fs40263-013-0097-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression</span></div><div class="casAuthors">Shulman, Kenneth I.; Herrmann, Nathan; Walker, Scott E.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">789-797</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  This paper reviews the discovery and history of the use of irreversible monoamine oxidase (MAO) inhibitors (MAOIs) such as phenelzine, tranylcypromine and isocarboxazid, as well as the second generation selective and reversible MAOIs such as the MAO-A inhibitor, moclobemide and the MAO-B inhibitor, selegiline.  Data for review were identified from a literature search of OvidSP Medline and PsycInfo performed in July 2012, using the subject terms and keywords of 'monoamine oxidase inhibitors', 'major depression', 'depressive disorder' and 'depression (emotion)'.  The search was limited to papers published in the English language and from 2007 onward only.  Irreversible MAOIs have the potential to treat the most challenging mood disorder patients including those with treatment-resistant depression, atypical depression and bipolar depression.  Unfortunately, the use of irreversible MAOIs has been declining sharply due to lack of marketing and the excessive fears of clinicians.  Moreover, few clinicians now have any experience, let alone comfort, in prescribing this class of antidepressants.  The newer MAOIs are available as another option for the treatment of major depression but have not replaced the irreversible MAOIs for the specific sub-types of depression for which they are now recommended in most consensus guidelines and treatment algorithms.  The pharmacol., drug interactions and dietary recommendations assocd. with the use of MAOIs are reviewed.  With the appropriate dietary restrictions and attention to potential drug interactions with serotonin and noradrenaline agents this class of drugs can be used effectively and safely.  The MAOIs still represent an important element in our therapeutic armamentarium.  Despite recommendations by opinion leaders and consensus guidelines for the use of MAOIs in specific sub-types of depression, the prescription rate of MAOIs is far less than expected and is decreasing.  The "bad reputation" and the lack of industry support for this class of agents (esp. the irreversible MAOIs) must be overcome in order to continue to provide a potentially useful treatment for a very vulnerable yet substantial sub-population of mood disorder patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9oHuy14vFo7Vg90H21EOLACvtfcHk0ljk5ygyL9IGPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSms73J&md5=f297225f058268df2a6b096e49904715</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs40263-013-0097-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-013-0097-3%26sid%3Dliteratum%253Aachs%26aulast%3DShulman%26aufirst%3DK.%2BI.%26aulast%3DHerrmann%26aufirst%3DN.%26aulast%3DWalker%26aufirst%3DS.%2BE.%26atitle%3DCurrent%2520Place%2520of%2520Monoamine%2520Oxidase%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Depression%26jtitle%3DCNS%2520Drugs%26date%3D2013%26volume%3D27%26issue%3D10%26spage%3D789%26epage%3D797%26doi%3D10.1007%2Fs40263-013-0097-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kircanski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeMoult, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotlib, I. H.</span></span> <span> </span><span class="NLM_article-title">Investigating the Nature of Co-Occurring Depression and Anxiety: Comparing Diagnostic and Dimensional Research Approaches</span>. <i>J. Affective Disord.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.jad.2016.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.jad.2016.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=27554605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BC2szjsFygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2017&pages=123-135&author=K.+Kircanskiauthor=J.+LeMoultauthor=S.+Ordazauthor=I.+H.+Gotlib&title=Investigating+the+Nature+of+Co-Occurring+Depression+and+Anxiety%3A+Comparing+Diagnostic+and+Dimensional+Research+Approaches&doi=10.1016%2Fj.jad.2016.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating the nature of co-occurring depression and anxiety: Comparing diagnostic and dimensional research approaches</span></div><div class="casAuthors">Kircanski Katharina; LeMoult Joelle; Gotlib Ian H; Ordaz Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of affective disorders</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123-135</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Although approximately half of adults diagnosed with a depressive or anxiety disorder exhibit their simultaneous co-occurrence, traditional research has centered on single-target diagnoses, overlooking comorbidities within samples.  In this article, we review and extend the literature that directly investigates co-occurring depression and anxiety, with the goal of shifting the focus from co-occurring diagnoses to symptom dimensions.  METHODS:  First, we review studies that have directly compared psychobiological features (neural, neuroendocrine, autonomic) across depression, anxiety, and their co-occurrence, defined either categorically or dimensionally.  Second, we analyze adults' diurnal cortisol secretion to examine the independent and interactive relations of continuously-assessed depressive and anxiety symptoms to neuroendocrine function.  RESULTS:  Previous findings on the psychobiology of diagnostic co-occurrence are mixed.  While nascent, evidence from dimensionally focused studies suggests that co-occurring levels of depressive and anxiety symptoms can interact with one another, as reflected in a distinct psychobiological profile for individuals with high levels of both symptom dimensions.  Results of our analyses support this formulation: we found that depressive and anxiety symptom dimensions interacted consistently in their relation to the measures of diurnal cortisol.  LIMITATIONS:  The illustrative sample was relatively small and included only women; future research should examine generalizability of these findings.  CONCLUSIONS:  A dimensional approach to investigating the psychobiology of co-occurring depression and anxiety affords both conceptual and practical advantages.  Simultaneously assessing depressive and anxiety symptom dimensions can efficiently capture their unique, shared, and interactive features, thereby identifying targets for intervention across a wide range of symptom presentations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUoeyc0x-yUxwLZxei1HN8fW6udTcc2ealrJDJE29n-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szjsFygtw%253D%253D&md5=2964f6072d83bf3d098b784d6befec58</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2016.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2016.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DKircanski%26aufirst%3DK.%26aulast%3DLeMoult%26aufirst%3DJ.%26aulast%3DOrdaz%26aufirst%3DS.%26aulast%3DGotlib%26aufirst%3DI.%2BH.%26atitle%3DInvestigating%2520the%2520Nature%2520of%2520Co-Occurring%2520Depression%2520and%2520Anxiety%253A%2520Comparing%2520Diagnostic%2520and%2520Dimensional%2520Research%2520Approaches%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2017%26volume%3D216%26spage%3D123%26epage%3D135%26doi%3D10.1016%2Fj.jad.2016.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akimova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanzenberger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, S.</span></span> <span> </span><span class="NLM_article-title">The Serotonin-1A Receptor in Anxiety Disorders</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2009.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.biopsych.2009.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=19423077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWqtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=627-635&issue=7&author=E.+Akimovaauthor=R.+Lanzenbergerauthor=S.+Kasper&title=The+Serotonin-1A+Receptor+in+Anxiety+Disorders&doi=10.1016%2Fj.biopsych.2009.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The Serotonin-1A Receptor in Anxiety Disorders</span></div><div class="casAuthors">Akimova, Elena; Lanzenberger, Rupert; Kasper, Siegfried</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">627-635</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The serotonin system plays an important role in the neural processing of anxiety.  The involvement of the main inhibitory serotonergic receptor, the serotonin-1A (5-HT1A) subtype, in dysfunctional forms of anxiety has been supported by findings from a wide range of preclin. research and clin. trials, including treatment studies, genetic research, and neuroimaging data.  The following article summarizes preclin. results with a focus on 5-HT1A receptor knockout and transgenic mice as genetic models of anxiety.  Behavioral, autonomic, and endocrinol. changes in these mice are reported.  This article also presents genetic polymorphisms in humans assocd. with increased anxiety scores and pharmacol. data focused on 5-HT1A receptor agonists and antagonists.  Furthermore, mol. neuroimaging results are presented.  Recent positron emission tomog. (PET) studies have reported reduced 5-HT1A receptor binding in patients with panic disorder and social anxiety disorder, but not in posttraumatic stress disorder.  In healthy subjects, increased anxiety scores might be assocd. with lower 5-HT1A receptor binding.  This overview of preclin. and clin. data provides strong evidence for the key role of the 5-HT1A receptor in the serotonergic dysregulation of anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6rff9u48uMbVg90H21EOLACvtfcHk0lhS-4TIgQnRiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWqtLbI&md5=2ea0a9d4c1223825478e4263e5062991</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2009.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2009.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DAkimova%26aufirst%3DE.%26aulast%3DLanzenberger%26aufirst%3DR.%26aulast%3DKasper%26aufirst%3DS.%26atitle%3DThe%2520Serotonin-1A%2520Receptor%2520in%2520Anxiety%2520Disorders%26jtitle%3DBiol.%2520Psychiatry%26date%3D2009%26volume%3D66%26issue%3D7%26spage%3D627%26epage%3D635%26doi%3D10.1016%2Fj.biopsych.2009.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasowski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loscalzo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granger, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladini, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marder, M.</span></span> <span> </span><span class="NLM_article-title">Central Nervous System Depressant Action of Flavonoid Glycosides</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>539</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2006.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.ejphar.2006.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=16698011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XltFOqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=539&publication_year=2006&pages=168-176&issue=3&author=S.+P.+Fernandezauthor=C.+Wasowskiauthor=L.+M.+Loscalzoauthor=R.+E.+Grangerauthor=G.+A.+Johnstonauthor=A.+C.+Paladiniauthor=M.+Marder&title=Central+Nervous+System+Depressant+Action+of+Flavonoid+Glycosides&doi=10.1016%2Fj.ejphar.2006.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Central nervous system depressant action of flavonoid glycosides</span></div><div class="casAuthors">Fernandez, Sebastian P.; Wasowski, Cristina; Loscalzo, Leonardo M.; Granger, Renee E.; Johnston, Graham A. R.; Paladini, Alejandro C.; Marder, Mariel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">539</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">168-176</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The pharmacol. effects on the central nervous system (CNS) of a range of available flavonoid glycosides were explored and compared to those of the glycosides 2S-hesperidin and linarin, recently isolated from valeriana.  The glycosides 2S-neohesperidin, 2S-naringin, diosmin, gossypin and rutin exerted a depressant action on the CNS of mice following i.p. injection, similar to that found with 2S-hesperidin and linarin.  We demonstrate in this work that these behavioral actions, as measured in the hole board, thiopental induced sleeping time and locomotor activity tests, are unlikely to involve a direct action on γ-aminobutyric acid type A (GABAA) receptors.  The corresponding aglycons were inactive, pointing to the importance of the sugar moieties in the glycosides in their CNS depressant action following systemic administration.  The pharmacol. properties of the flavonoid glycosides studied here, in addn. to our previous results with hesperidin and linarin, opens a promising new avenue of research in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPw80KbqQYi7Vg90H21EOLACvtfcHk0lhS-4TIgQnRiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltFOqsbs%253D&md5=9c50ee2bcdbecb7b08d1d2bf3b05a128</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez%26aufirst%3DS.%2BP.%26aulast%3DWasowski%26aufirst%3DC.%26aulast%3DLoscalzo%26aufirst%3DL.%2BM.%26aulast%3DGranger%26aufirst%3DR.%2BE.%26aulast%3DJohnston%26aufirst%3DG.%2BA.%26aulast%3DPaladini%26aufirst%3DA.%2BC.%26aulast%3DMarder%26aufirst%3DM.%26atitle%3DCentral%2520Nervous%2520System%2520Depressant%2520Action%2520of%2520Flavonoid%2520Glycosides%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D539%26issue%3D3%26spage%3D168%26epage%3D176%26doi%3D10.1016%2Fj.ejphar.2006.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaggi, A. S.</span></span> <span> </span><span class="NLM_article-title">Preclinical Experimental Stress Studies: Protocols, Assessment and Comparison</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>746</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.ejphar.2014.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=25446911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWisbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=746&publication_year=2015&pages=282-292&author=A.+Baliauthor=A.+S.+Jaggi&title=Preclinical+Experimental+Stress+Studies%3A+Protocols%2C+Assessment+and+Comparison&doi=10.1016%2Fj.ejphar.2014.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical experimental stress studies: Protocols, assessment and comparison</span></div><div class="casAuthors">Bali, Anjana; Jaggi, Amteshwar Singh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">746</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">282-292</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Stress is a state of threatened homeostasis during which a variety of adaptive processes are activated to produce physiol. and behavioral changes.  Preclin. models are pivotal for understanding these physiol. or pathophysiol. changes in the body in response to stress.  Furthermore, these models are also important for the development of novel pharmacol. agents for stress management.  The well described preclin. stress models include immobilization, restraint, elec. foot shock and social isolation stress.  Stress assessment in animals is done at the behavioral level using open field, social interaction, hole board test; at the biochem. level by measuring plasma corticosterone and ACTH; at the physiol. level by measuring food intake, body wt., adrenal gland wt. and gastric ulceration.  Furthermore the comparison between different stressors including elec. foot shock, immobilization and cold stressor is described in terms of intensity, hormonal release, protein changes in brain, adaptation and sleep pattern.  This present review describes these preclin. stress protocols, and stress assessment at different levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx22IsqEcKbbVg90H21EOLACvtfcHk0lhk8cEZt0KmNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWisbfN&md5=7d884e624f69c790bf586cff543aff64</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DBali%26aufirst%3DA.%26aulast%3DJaggi%26aufirst%3DA.%2BS.%26atitle%3DPreclinical%2520Experimental%2520Stress%2520Studies%253A%2520Protocols%252C%2520Assessment%2520and%2520Comparison%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D746%26spage%3D282%26epage%3D292%26doi%3D10.1016%2Fj.ejphar.2014.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraf, S. K.</span></span> <span> </span><span class="NLM_article-title">Privileged Scaffolds as MAO Inhibitors: Retrospect and Prospects</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1016%2Fj.ejmech.2018.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=29335210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVens7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2018&pages=445-497&author=A.+C.+Tripathiauthor=S.+Upadhyayauthor=S.+Paliwalauthor=S.+K.+Saraf&title=Privileged+Scaffolds+as+MAO+Inhibitors%3A+Retrospect+and+Prospects&doi=10.1016%2Fj.ejmech.2018.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged scaffolds as MAO inhibitors: Retrospect and prospects</span></div><div class="casAuthors">Tripathi, Avinash C.; Upadhyay, Savita; Paliwal, Sarvesh; Saraf, Shailendra K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">445-497</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This review aims to be a comprehensive, authoritative, crit., and readable review of general interest to the medicinal chem. community because it focuses on the pharmacol., chem., structural and computational aspects of diverse chem. categories as monoamine oxidase inhibitors (MAOIs).  Monoamine oxidases (MAOs), namely MAO-A and MAO-B represent an enormously valuable class of neuronal enzymes embodying neurobiol. origin and functions, serving as potential therapeutic target in neuronal pharmacotherapy, and hence we have coined the term "Neurozymes" which is being introduced for the first time ever.  Nowadays, therapeutic attention on MAOIs engrosses two imperative categories; MAO-A inhibitors, in certain mental disorders such as depression and anxiety, and MAO-B inhibitors, in neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD).  The use of MAOIs declined due to some potential side effects, food and drug interactions, and introduction of other classes of drugs.  However, curiosity in MAOIs is reviving and the recent developments of new generation of highly selective and reversible MAOIs, have renewed the therapeutic prospective of these compds.  The initial section of the review emphasizes on the detailed classification, structural and binding characteristics, therapeutic potential, current status and future challenges of the privileged pharmacophores.  However, the chem. prospective of privileged scaffolds such as; aliph. and arom. amines, amides, hydrazines, azoles, diazoles, tetrazoles, indoles, azines, diazines, xanthenes, tricyclics, benzopyrones, and more interestingly natural products, along with their conclusive SARs have been discussed in the later segment of review.  The last segment of the article encompasses some patents granted in the field of MAOIs, in a simplistic way.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqYob-n4zgsLVg90H21EOLACvtfcHk0lhk8cEZt0KmNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVens7k%253D&md5=4fa0cc226ee27522671188d0cfe62ab2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DTripathi%26aufirst%3DA.%2BC.%26aulast%3DUpadhyay%26aufirst%3DS.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DSaraf%26aufirst%3DS.%2BK.%26atitle%3DPrivileged%2520Scaffolds%2520as%2520MAO%2520Inhibitors%253A%2520Retrospect%2520and%2520Prospects%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D145%26spage%3D445%26epage%3D497%26doi%3D10.1016%2Fj.ejmech.2018.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holt, A.</span></span> <span> </span><span class="NLM_article-title">On the Practical Aspects of Characterising Monoamine Oxidase Inhibition in Vitro</span>. <i>J. Neural. Transm. (Vienna)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1685</span>– <span class="NLM_lpage">1705</span>, <span class="refDoi"> DOI: 10.1007/s00702-018-1943-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1007%2Fs00702-018-1943-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=30374594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BB3cvks1Glug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1685-1705&issue=11&author=A.+Holt&title=On+the+Practical+Aspects+of+Characterising+Monoamine+Oxidase+Inhibition+in+Vitro&doi=10.1007%2Fs00702-018-1943-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">On the practical aspects of characterising monoamine oxidase inhibition in vitro</span></div><div class="casAuthors">Holt Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission (Vienna, Austria : 1996)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1685-1705</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The development of novel inhibitors of human monoamine oxidase enzymes with improved pharmacodynamic and pharmacokinetic profiles has, in the past, been hampered by limited access to enzyme, by assay protocols offering limited throughput, and by inappropriate analyses of kinetic data.  More recently, high-level expression of human enzymes in yeast has facilitated thorough examinations of steady-state enzyme behaviour that have led to improvements in our understanding of the mathematical underpinnings of kinetic analyses of monoamine oxidases.  However, with these improvements have come a realisation that to be useful, more data points across wider concentration ranges are required.  In turn, many discontinuous assay approaches, such as those involving radiolabelled substrates or chromatographic separation of product from substrate, have been rendered somewhat obsolete.  Justification for the use of a platereader-based approach to assess the effects of novel inhibitors on monamine oxidases is provided, along with details of experimental design optimised to address the unexpectedly complex kinetics followed by these enzymes.  Potential sources of error are discussed, and comments provided on techniques that may enhance the quality of experimental data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLQ9Tr45XEAp0d-O_J5C0AfW6udTcc2eY90CQjccATyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvks1Glug%253D%253D&md5=6c716e83045d9735c4c07ddc1d6c65f9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00702-018-1943-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-018-1943-8%26sid%3Dliteratum%253Aachs%26aulast%3DHolt%26aufirst%3DA.%26atitle%3DOn%2520the%2520Practical%2520Aspects%2520of%2520Characterising%2520Monoamine%2520Oxidase%2520Inhibition%2520in%2520Vitro%26jtitle%3DJ.%2520Neural.%2520Transm.%2520%2528Vienna%2529%26date%3D2018%26volume%3D125%26issue%3D11%26spage%3D1685%26epage%3D1705%26doi%3D10.1007%2Fs00702-018-1943-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonesson, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of a Set of Para-Substituted 4-Phenylpiperidines and 4-Phenylpiperazines as Monoamine Oxidase (MAO) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3242</span>– <span class="NLM_lpage">3249</span>, <span class="refDoi"> DOI: 10.1021/jm201692d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201692d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Srtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3242-3249&issue=7&author=F.+Petterssonauthor=P.+Svenssonauthor=S.+Watersauthor=N.+Watersauthor=C.+Sonesson&title=Synthesis+and+Evaluation+of+a+Set+of+Para-Substituted+4-Phenylpiperidines+and+4-Phenylpiperazines+as+Monoamine+Oxidase+%28MAO%29+Inhibitors&doi=10.1021%2Fjm201692d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of a Set of Para-Substituted 4-Phenylpiperidines and 4-Phenylpiperazines as Monoamine Oxidase (MAO) Inhibitors</span></div><div class="casAuthors">Pettersson, Fredrik; Svensson, Peder; Waters, Susanna; Waters, Nicholas; Sonesson, Clas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3242-3249</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of para-substituted 4-phenylpiperidines/piperazines have been synthesized and their affinity to recombinant rat cerebral cortex monoamine oxidases A (MAO A) and B (MAO B) detd.  Para-substituents with low dipole moment increased the affinity to MAO A, whereas groups with high dipole moment yielded compds. with no or weak affinity.  In contrast, the properties affecting MAO B affinity were the polarity and bulk of the para-substituent, with large hydrophobic substituents producing compds. with high MAO B affinity.  In addn., these compds. were tested in freely moving rats and the effect on the post-mortem neurochem. was measured.  A linear correlation was demonstrated between the affinity for MAO A, but not MAO B, and the levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-methoxytyramine (3-MT) in the striatum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrugvUaJuL0LLVg90H21EOLACvtfcHk0lhsBq1Lh382Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Srtbc%253D&md5=99d694bfa2bb530cbb72c7e7cc7da3e9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm201692d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201692d%26sid%3Dliteratum%253Aachs%26aulast%3DPettersson%26aufirst%3DF.%26aulast%3DSvensson%26aufirst%3DP.%26aulast%3DWaters%26aufirst%3DS.%26aulast%3DWaters%26aufirst%3DN.%26aulast%3DSonesson%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520a%2520Set%2520of%2520Para-Substituted%25204-Phenylpiperidines%2520and%25204-Phenylpiperazines%2520as%2520Monoamine%2520Oxidase%2520%2528MAO%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D7%26spage%3D3242%26epage%3D3249%26doi%3D10.1021%2Fjm201692d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heuson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charmantray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gefflaut, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span> <span> </span><span class="NLM_article-title">Profiling Substrate Specificity of Two Series of Phenethylamine Analogs at Monoamine Oxidase A and B</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">8689</span>– <span class="NLM_lpage">8695</span>, <span class="refDoi"> DOI: 10.1039/C4OB01377H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1039%2FC4OB01377H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=25253656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WitLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=8689-8695&issue=43&author=E.+Heusonauthor=M.+Storgaardauthor=T.+H.+Huynhauthor=F.+Charmantrayauthor=T.+Gefflautauthor=L.+Bunch&title=Profiling+Substrate+Specificity+of+Two+Series+of+Phenethylamine+Analogs+at+Monoamine+Oxidase+A+and+B&doi=10.1039%2FC4OB01377H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling substrate specificity of two series of phenethylamine analogs at monoamine oxidase A and B</span></div><div class="casAuthors">Heuson, Egon; Storgaard, Morten; Huynh, Tri H. V.; Charmantray, Franck; Gefflaut, Thierry; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">8689-8695</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The membrane bound enzyme monoamine oxidase exist in two splice variants designated A and B (MAO-A and MAO-B) and are key players in the oxidative metab. of monoamines in mammalians.  Despite their importance and being a prevalent target for the development of inhibitors as drugs, no systematic study of substrate specificity has been reported.  In this study we present a systematic study of the MAO-A and MAO-B substrate specificity profile by probing two series of phenethylamine analogs.  Km and kcat values were detd. for four N-alkyl analogs 2-5 and four aryl halide analogs 6-9 at MAO-A and MAO-B.  A following in silico study disclosed a new adjacent compartment to the MAO-B substrate pocket defined by amino acids Tyr188, Tyr435, Tyr398, Thr399, Cys172 and Gly434.  This new insight is important for the understanding of the substrate specificity of the MAO-B enzyme and will be relevant for future drug design within the field of monoamines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4EgaQ2sgNq7Vg90H21EOLACvtfcHk0lhPmPUAmp6zDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WitLnN&md5=8c909937cc8c54362c3f8ec01be703e0</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1039%2FC4OB01377H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4OB01377H%26sid%3Dliteratum%253Aachs%26aulast%3DHeuson%26aufirst%3DE.%26aulast%3DStorgaard%26aufirst%3DM.%26aulast%3DHuynh%26aufirst%3DT.%2BH.%26aulast%3DCharmantray%26aufirst%3DF.%26aulast%3DGefflaut%26aufirst%3DT.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DProfiling%2520Substrate%2520Specificity%2520of%2520Two%2520Series%2520of%2520Phenethylamine%2520Analogs%2520at%2520Monoamine%2520Oxidase%2520A%2520and%2520B%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2014%26volume%3D12%26issue%3D43%26spage%3D8689%26epage%3D8695%26doi%3D10.1039%2FC4OB01377H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baboota, S.</span></span> <span> </span><span class="NLM_article-title">Design Expert(®) Supported Optimization and Predictive Analysis of Selegiline Nanoemulsion <i>Via</i> the Olfactory Region with Enhanced Behavioural Performance in Parkinson’s Disease</span>. <i>Nanotechnology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">435101</span>, <span class="refDoi"> DOI: 10.1088/0957-4484/27/43/435101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1088%2F0957-4484%2F27%2F43%2F435101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=27655136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOlt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=435101&issue=43&author=S.+Kumarauthor=J.+Aliauthor=S.+Baboota&title=Design+Expert%28%C2%AE%29+Supported+Optimization+and+Predictive+Analysis+of+Selegiline+Nanoemulsion+Via+the+Olfactory+Region+with+Enhanced+Behavioural+Performance+in+Parkinson%E2%80%99s+Disease&doi=10.1088%2F0957-4484%2F27%2F43%2F435101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Design Expert supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson's disease</span></div><div class="casAuthors">Kumar, Shobhit; Ali, Javed; Baboota, Sanjula</div><div class="citationInfo"><span class="NLM_cas:title">Nanotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">435101/1-435101/24</span>CODEN:
                <span class="NLM_cas:coden">NNOTER</span>;
        ISSN:<span class="NLM_cas:issn">1361-6528</span>.
    
            (<span class="NLM_cas:orgname">IOP Publishing Ltd.</span>)
        </div><div class="casAbstract">Selegiline is a monoamine oxidase B (MAO-B) inhibitor and is used in the treatment of Parkinson's disease.  The main problem assocd. with its oral administration is its low oral bioavailability (10%) due to its poor aq. soly. and extensive first pass metab.  The aim of the present research work was to develop a nanoemulsion loaded with selegiline for direct nose-to-brain delivery for the better management of Parkinson's disease.  A quality by design (QbD) approach was used in a statistical multivariate method for the prepn. and optimization of nanoemulsion.  In this study, four independent variables were chosen, in which two were compns. and two were process variables, while droplet size, transmittance, zeta potential and drug release were selected as response variables.  The optimized formulation was assessed for efficacy in Parkinson's disease using behavioral studies, namely forced swimming, locomotor, catalepsy, muscle coordination, akinesia and bradykinesia or pole test in Wistar rats.  The obsd. droplet size, polydispersity index (PDI), refractive index, transmittance, zeta potential and viscosity of selegiline nanoemulsion were found to be 61.43 ± 4.10 nm, 0.203 ± 0.005, 1.30 ± 0.01, 99.80 ± 0.04%, -34 mV and 31.85 ± 0.24 mPas resp.  Surface characterization studies demonstrated a spherical shape of nanoemulsion which showed 3.7 times enhancement in drug permeation as compared to drug suspension.  The results of behavior studies showed that treatment of haloperidol induced Parkinson's disease in rats with selegiline nanoemulsion (administered intranasally) showed significant improvement in behavioral activities in comparison to orally administered drug.  These findings demonstrate that nanoemulsion could be a promising new drug delivery carrier for intranasal delivery of selegiline in the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY8fTm-JjnlrVg90H21EOLACvtfcHk0lhPmPUAmp6zDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOlt7vE&md5=598c99317c3d81659246509da6cb2e63</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1088%2F0957-4484%2F27%2F43%2F435101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F0957-4484%252F27%252F43%252F435101%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DAli%26aufirst%3DJ.%26aulast%3DBaboota%26aufirst%3DS.%26atitle%3DDesign%2520Expert%2528%25C2%25AE%2529%2520Supported%2520Optimization%2520and%2520Predictive%2520Analysis%2520of%2520Selegiline%2520Nanoemulsion%2520Via%2520the%2520Olfactory%2520Region%2520with%2520Enhanced%2520Behavioural%2520Performance%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DNanotechnology%26date%3D2016%26volume%3D27%26issue%3D43%26spage%3D435101%26doi%3D10.1088%2F0957-4484%2F27%2F43%2F435101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">42717</span>, <span class="refDoi"> DOI: 10.1038/srep42717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1038%2Fsrep42717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=28256516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42717&author=A.+Dainaauthor=O.+Michielinauthor=V.+Zoete&title=SwissADME%3A+A+Free+Web+Tool+to+Evaluate+Pharmacokinetics%2C+Drug-Likeness+and+Medicinal+Chemistry+Friendliness+of+Small+Molecules&doi=10.1038%2Fsrep42717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span></div><div class="casAuthors">Daina Antoine; Michielin Olivier; Zoete Vincent; Michielin Olivier; Michielin Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42717</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.  Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited.  In that context, computer models constitute valid alternatives to experiments.  Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar.  Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch.  Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl_Uk5dOMKs6qcneEtCi92fW6udTcc2ebx3pFltBqOgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D&md5=9715b8cb8a34b17c4c73ff69a5a8cc50</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fsrep42717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42717%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DSwissADME%253A%2520A%2520Free%2520Web%2520Tool%2520to%2520Evaluate%2520Pharmacokinetics%252C%2520Drug-Likeness%2520and%2520Medicinal%2520Chemistry%2520Friendliness%2520of%2520Small%2520Molecules%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42717%26doi%3D10.1038%2Fsrep42717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&issue=7&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lhzokKtLViz8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchuk-Voloshina, N.</span></span> <span> </span><span class="NLM_article-title">A One-Step Fluorometric Method for the Continuous Measurement of Monoamine Oxidase Activity</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>253</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1006/abio.1997.2392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=10.1006%2Fabio.1997.2392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=9367499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;key=1%3ACAS%3A528%3ADyaK2sXnsFahsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1997&pages=169-174&issue=2&author=M.+Zhouauthor=N.+Panchuk-Voloshina&title=A+One-Step+Fluorometric+Method+for+the+Continuous+Measurement+of+Monoamine+Oxidase+Activity&doi=10.1006%2Fabio.1997.2392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A one-step fluorometric method for the continuous measurement of monoamine oxidase activity</span></div><div class="casAuthors">Zhou, Mingjie; Panchuk-Voloshina, Nataliya</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-174</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A 1-step fluorometric method was developed for the measurement of monoamine oxidase (MAO) activity in 96-well microplates with a sensitivity 10-fold higher than the conventional spectrophotometric assay method.  This assay was based on the detection of H2O2 in a horseradish peroxidase-coupled reaction using N-acetyl-3,7-dihydroxyphenoxazine (Amplex Red), a highly sensitive and stable probe for H2O2.  With a single sampling, this assay was useful for performing both end-point and continuous measurements of MAO activity.  Using a com. available enzyme, the assay allowed the detection of MAO B activity as low as 1.2 × 10-5 U/mL.  When applied to crude tissue homogenates, it was possible to selectively detect both MAO A and MAO B from bovine brain tissue with a protein content as low as 200 μg per sample.  The potential applications of this assay include the measurement of MAO activity in normal and diseased tissues, blood samples and other biol. fluids, and the screening of drugs for the treatment of MAO-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql6SqApG0lS7Vg90H21EOLACvtfcHk0lhzokKtLViz8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsFahsr8%253D&md5=b828a3cc40db9fd5b251fd138268b1d7</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1006%2Fabio.1997.2392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1997.2392%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DPanchuk-Voloshina%26aufirst%3DN.%26atitle%3DA%2520One-Step%2520Fluorometric%2520Method%2520for%2520the%2520Continuous%2520Measurement%2520of%2520Monoamine%2520Oxidase%2520Activity%26jtitle%3DAnal.%2520Biochem.%26date%3D1997%26volume%3D253%26issue%3D2%26spage%3D169%26epage%3D174%26doi%3D10.1006%2Fabio.1997.2392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z5X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z5X','PDB','2Z5X'); return false;">PDB: 2Z5X</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FVZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FVZ','PDB','6FVZ'); return false;">PDB: 6FVZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKB','PDB','6RKB'); return false;">PDB: 6RKB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKP','PDB','6RKP'); return false;">PDB: 6RKP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RLE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RLE','PDB','6RLE'); return false;">PDB: 6RLE</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i122"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01886">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_78685"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01886?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01886</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Supplementary figures, supplementary tables, supplementary results and discussion, supplementary methods, HPLC traces for representative final compounds, and <sup>1</sup>H and <sup>13</sup>C NMR spectra for final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Movie for undocking experiment, MAO-A (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_002.mp4">MP4</a>)</p></li><li><p class="inline">Movie for undocking experiment, MAO-B (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_003.mp4">MP4</a>)</p></li><li><p class="inline">Molecular formula strings and activity data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_004.csv">CSV</a>)</p></li><li><p class="inline">Model of undocking in <a id="rightTab-" class=" internalNav" href="#fig3">Figure <a id="rightTab-" class=" internalNav" href="#fig3">3</a></a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Model of undocking in <a id="rightTab-" class=" internalNav" href="#fig3">Figure <a id="rightTab-" class=" internalNav" href="#fig3">3</a></a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Model of undocking in <a id="rightTab-" class=" internalNav" href="#fig3">Figure <a id="rightTab-" class=" internalNav" href="#fig3">3</a></a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_007.pdb">PDB</a>)</p></li><li><p class="inline">Model of undocking in <a id="rightTab-" class=" internalNav" href="#fig3">Figure <a id="rightTab-" class=" internalNav" href="#fig3">3</a></a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_008.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_001.pdf">jm9b01886_si_001.pdf (9.39 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_002.mp4">jm9b01886_si_002.mp4 (214.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_003.mp4">jm9b01886_si_003.mp4 (381.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_004.csv">jm9b01886_si_004.csv (3.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_005.pdb">jm9b01886_si_005.pdb (342.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_006.pdb">jm9b01886_si_006.pdb (342.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_007.pdb">jm9b01886_si_007.pdb (333.29 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01886/suppl_file/jm9b01886_si_008.pdb">jm9b01886_si_008.pdb (333.29 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The coordinates and structure factors have been deposited in the PDB under accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKB">6RKB</a> (compound <b>1</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RKP">6RKP</a> (compound <b>84</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6RLE">6RLE</a> (compound <b>97</b>). Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01886&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-3%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01886%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01886" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991f677d2b3cbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
